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Abstract 
Loss  of  expression  of  the  human  DNA  mismatch  repair  (MMR)  gene,  hMLH1,  is  seen  in  a 
number  of  tumour  cell  lines  resistant  to  a  variety  of  cytotoxic  drugs  (Brown  et  al.,  1997). 
Restoration  of  sensitivity  to  for  example,  cisplatin,  has  been  demonstrated  in  MMR 
deficient  cell  lines,  through  the  transfer  of  hMLH1  on  chromosome  3  into  these  cells 
(Moreland  et  al.,  1999).  MMR  has  been  implicated  in  playing  a  role  in  signalling  apoptotic 
death  pathways,  via  c-Abl,  p53  and  p73,  in  response  to  DNA  damage  (Duckett  et  al.,  1999; 
Gong  et  al.,  1999;  Nehme  et  al.,  1997).  Exactly  how  MMR  couples  to  these  apoptotic 
pathways  is  unclear.  The  aim  of  this  study  was  to  identify  other  proteins  that  interact  with 
hMLH1  to  attempt  to  further  elucidate  its  role  in  MMR  and  the  engagement  of  downstream 
damage  response  pathways. 
A  yeast  two-hybrid  system,  an  in  vivo  system  for  detecting  protein-protein  interactions  was 
utilised  for  this  purpose.  In  this  system,  full  length  hMLH1  and  a  C-terminal  fragment  of 
hMLH1,  amino  acids  514-756,  were  shown  to  interact  with  two  separate  regions  of 
hPMS2,  amino  acids  430-613  and  amino  acids  630-862.  The  hMLH1  hybrid  protein  was 
used  to  screen  yeast  two-hybrid  cDNA  libraries,  from  both  normal  mammary  gland  and 
ovarian  tissue.  Fifteen  known  and  five  unknown  genes  were  identified  as  encoding 
proteins  interacting  with  hMLH1.  These  included  three  known  hMLH1  binding  proteins, 
hMLH3,  hPMS1  and  MED1.  Amongst  the  other  genes  identified  was  the  proto-oncogene 
c-MYC,  a  gene  previously  implicated  in  genetic  instability  and  apoptosis 
Confirmation  of  the  ability  of  MYC  to  interact  with  hMLH1  has  been  shown  with  GST 
pull-down  experiments  of  human  cell  extracts  using  hMLH1  protein  expressed  in  E.  coli. 
Evidence  for  these  proteins  interacting  in  cells,  is  shown  by  c-MYC  co- 
immunoprecipitating  with  hMLH1  from  human  and  avian  cell  extracts.  Using  in  vitro 
derived  mutants  of  c-MYC,  it  has  been  shown  that  hMLH1  interacts  with  the  leucine- 
zipper  domain  of  c-MYC.  This  region  of  c-MYC  is  also  required  for  the  interaction  with 
its  major  binding  partner  MAX.  However  the  affinity  of  hMLH1  for  c-MYC  was  shown 
not  to  be  high  enough  to  disrupt  a  c-MYC-MAX  complex  bound  to  its  DNA  recognition 
binding  site,  as  shown  by  electrophoretic  mobility  shift  assays  (EMSA). 
The  effect  of  elevated  c-MYC  expression  on  functional  MMR  was  examined.  An 
inducible  c-MYC  expression  system,  Rat-1  fibroblasts  expressing  c-MYCERTM,  a  fusion  of 
c-MYC  to  the  hormone  binding  domain  of  the  oestrogen  receptor  was  utilised.  Elevated x 
expression  of  c-MYC  did  not  effect  the  mismatch  specific  binding  complex  activity  in 
these  cells  as  measured  in  EMSA  experiments. 
However  c-MYC  overexpression  utilising  the  Rat-1  c-MYCERTM  system  was  shown  to 
result  in  a  mutator  phenotype  in  these  cells.  This  was  demonstrated  through  measuring  the 
mutation  rate  at  the  selectable  HPRT  gene.  Mutant  clones  were  examined  for  mutations  at 
a  specific  frameshift  mutation  hotspot,  at  a  run  of  six  guanines  in  exon  3  of  the  HPRT  gene, 
previously  associated  with  loss  of  MMR.  No  mutations  were  detected  in  the  22  mutant 
clones  from  cells  grown  in  the  absence  of  elevated  c-MYC  expression.  Four  of  the  25 
mutant  clones  from  cells  grown  in  the  presence  of  elevated  c-MYC  expression,  had  a 
frameshift  mutation  at  this  hotspot,  with  five  instead  or  six  guanines. 
The  results  suggest  there  may  be  a  link  between  the  mutator  phenotype,  induced  through 
overexpression  of  c-MYC,  and  loss  of  MMR.  It  has  been  shown  that  c-MYC  is  capable  of 
interacting  with  hMLH1  using  in  vitro  protein  interaction  assays,  and  that  c-MYC  and 
hMLH1  can  be  co-immunoprecipitated  from  cells.  Overexpression  of  c-MYC,  which  is 
associated  with  many  cancers,  may  result  in  the  sequestration  of  hMLH1  preventing 
functional  MMR.  The  interaction  between  hMLH1  and  c-MYC  is  proposed  to  act  in  a 
DNA  damage  response  pathway  which  is  disrupted  upon  aberrant  c-MYC  expression. xi 
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Introduction 2 
1.1  DNA  Mismatch  Repair 
Mismatch  repair  (MMR)  of  DNA  plays  a  fundamental  role  in  correcting  replication  errors 
i.  e.  mispaired  bases  that  escape  the  proof-reading  activity  of  DNA  polymerases.  MMR 
also  corrects  mispaired  bases  of  recombination  heteroduplexes  that  result  from  strand 
transfer  between  sequences  that  are  related,  but  have  diverged  slightly  at  the  nucleotide 
level.  Mismatched  base  pairs  can  also  arise  through  physical  or  chemical  damage  to  DNA 
such  as  the  deamination  of  5-methylcytosine.  A  fundamental  requirement  of  MMR  is  the 
ability  to  distinguish  the  correct  base  from  the  incorrect  base.  Functional  MMR  is  essential 
to  maintain  genetic  fidelity. 
1.1.1  The  Discovery  of  MMR  in  Prokaryotes 
The  role  of  MMR  was  first  discovered  over  twenty  years  ago  in  bacteria.  Loss  of  MMR 
was  shown  to  produce  increased  spontaneous  mutation  rates  (a  mutator  phenotype) 
(Modrich  and  Lahue,  1996;  Nevers  and  Spatz,  1975).  Escherichia  coli  (E.  coli)  strains  were 
isolated  with  this  mutator,  phenotype  which  led  to  the  discovery  of  four  mutator  genes, 
mutS,  mutL,  mutH  and  mutU/uvrD.  These  MMR  genes  have  been  shown  to  play  a  role  in 
the  correction  of  replication  errors  by  in  vitro  analysis  of  cell  free  eXtracts  (Lu  et  al.,  1983; 
Lu  et  al.,  1984).  Reconstitution  of  this  methyl  directed  system  was  achieved  in  vitro 
(Lahue  et  al.,  1989).  By  mixing  the  purified  proteins,  MutH,  MutL,  MutS,  DNA  helicase 
II,  SSB  (single  stranded  DNA  binding  protein),  exonuclease  I,  DNA  polymerase  III 
holoenzyme,  DNA  ligase  and  co-factors  ATP,  deoxynucleoside-5'-triphosphates,  Mg  2+  and 
the  ligase  co-factor  NAD+  together,  repair  mimicking  that  seen  in  vivo  and  in  cell  extracts 
was  observed  (Grilley  et  al.,  1990;  Lahue  et  al.,  1989). 
Initiation  of  E.  coli  MMR  requires  the  MutS,  MutL  and  MutH  proteins  (Modrich  and 
Lahue,  1996).  In  wild  type  cells  DNA  is  adenine-methylated  at  d(GATC)  sequences  by 
DAM  methylase,  however  newly  synthesised  strands  are  not  methylated  until  modified  by 
this  methylase.  This  allows  the  parent  strand  to  be  distinguished  from  the  newly 
synthesised  daughter  strand  and  directs  =repair  to  the  newly  synthesised  daughter  strand. 
MutS  is  an  ATPase  which  functions  as  a  homodimer.  MutS  recognises  mismatched  base 
pairs  and  insertion  deletion  loops  in  one  DNA  strand.  MutH  is  an  endonuclease  which  is 
both  sequence  and  methylation  specific.  It  acts  by  cleaving  the  DNA  5'  to  the 
unmethylated  d(GATC)  sequence  in  the  hemimethylated  duplex.  The  strand  break  is  the 3 
primary  signal  which  directs  correction  to  the  unmethylated  strand.  MutL,  as  a 
homodimer,  acts  to  mediate  an  interaction  between  the  site  of  the  mismatch  bound  by 
MutS  and  the  d(GATC)  sequence  cleaved  by  MutH. 
MutL  has  been  demonstrated  to  physically  interact  with  both  MutH  and  UvrD  (the  protein 
product  of  mutU)  (Hall  et  al.,  1998;  Hall  and  Matson,  1999).  The  d(GATC)  specific 
endonuclease  activity  of  MutH  is  stimulated  by  MutL,  in  the  absence  of  MutS  and  a 
mismatch,  but  requires  ATP  (Hall  and  Matson,  1999).  However  further  stimulation  was 
observed  with  the  addition  of  MutS  in  the  presence  of  a  mismatch  and  a  hydrolysable  form 
of  ATP.  The  observed  interaction  between  MutL  and  UvrD  (DNA  helicase  II)  led  to  the 
discovery  that  the  helicase  activity  of  this  enzyme  on  incised  duplex  DNA  is  enhanced  by 
MutS  and  MutL  in  a  mismatch  dependent  manner  (Yamaguchi  et  al.,  1998). 
DNA  helicase  II  is  one  of  several  exonucleases  required  to  excise  the  error  carrying  DNA 
strand,  beginning  at  the  nicked  d(GATC)  site.  The  bi-directional  capability  of  the  system 
means  that  the  strand  signal  can  be  either  side  of  the  mismatch  and  explains  why  a  number 
of  exonucleases  function  in  this  repair  process.  The  final  step  of  the  methyl  directed  repair 
reaction  is  the  gap  repair  by  DNA  Polymerase  III  holoenzyme  and  ligation  of  the  repair 
product. 
1.1.2  The  Discovery  of  MMR  in  Eukaryotes 
The  identification  of  MMR  in  yeast  and  fungi  arose  through  observations  of  postmeiotic 
segregation  (the  result  of  un-repaired  heteroduplex  DNA  generated  during  the  process  of 
meiotic  recombination).  Isolation  of  yeast  mutants  that  displayed  elevated  post  meiotic 
segregation  (PMS)  frequencies  led  to  the  discovery  of  MMR  in  Saccharomyces  cerevisiae 
(Kramer  et  al.,  1989;  Williamson  et  al.,  1985).  Mutations  in  three  loci  the  PMS1,  PMS2 
and  PMS3  loci  produced  a  mutator  phenotype,  with  homozygotes  displaying  an  elevated 
post  meiotic  segregation  frequency  and  reduced  spore  viability. 
Evidence  for  the  recognition  and  repair  of  mismatches  in  yeast  also  emerged.  By 
transformation  of  wild-type  cells  with  covalently  closed  heteroduplex  plasmid  substrates  it 
was  shown  that  the  yeast  cells  were  able  to  repair  single  base  substitution  mismatches,  a 
single  base  frameshift  mismatch,  and  small  insertion  deletion  heterologies  (Bishop  et  al., 
1989;  Bishop  and  Kolodner,  1986;  Grilley  et  al.,  1990;  Muster-Nassal  and  Kolodner, 
1986).  However  mismatch  correction  was  greatly  reduced  in  the  pmsl,  pms2,  and  pms3 4 
mutant  strains  (Bishop  et  al.,  1989;  Bishop  and  Kolodner,  1986;  Kramer  et  al.,  1989; 
Muster-Nassal  and  Kolodner,  1986).  Collectively  these  findings  along  with  the 
observation  that  the  PMS1  gene  product  is  homologous  to  the  bacterial  MutL  protein 
provided  strong  evidence  that  these  three  genes  encode  components  of  a  yeast  MMR 
system  and  that  this  process  in  yeast  also  contributes  to  genetic  stability  (Kramer  et  al., 
1989). 
Mutations  in  the  PMS1  gene  result  in  elevated  rates  of  spontaneous  mutation  and  increased 
levels  of  post  meiotic  segregation  (Kramer  et  al.,  1989).  Additional  yeast  MMR  genes 
were  identified  encoding  proteins  homologous  to  bacterial  MütS,  yMshlp  and  yMsh2p  and 
proteins  homologous  to  bacterial  MutL,  yMlhlp  (Prolla  et  al.,  1994;  Reenan  and  Kolodner, 
1992).  As  in  the  case  of  PMS1,  mutations  in  MSH2  and  MLH1  affect  nuclear  mutation 
rates  and  PMS  levels  (Strand  et  al.,  1993).  yMshlp  was  shown  to  play  a  role  in 
mitochondrial  DNA  maintenance. 
It  was  soon  apparent  that  MMR  is  conserved  from  bacteria  to  humans.  The  crucial 
discovery  in  yeast  of  a  mutator  phenotype  associated  with  increased  instability  of  a 
poly(GT)  tract,  due  to  mutations  in  the  MMR  genes  PMS1,  MLH1  and  MSH2  was 
paramount  in  the  elucidation  of  phenotypes  of  human  cells  with  deficient  MMR  (Strand  et 
al.,  1993). 
1.1.3  DNA  Mismatch  Repair  in  Human  Cells 
Microsatellite  instability  (MSI)  was  observed  in  tumour  DNA  from  a  number  of  cancers  at 
dinucleotide  and  trinucleotide  repeat  sequences  (Thibodeau  et  al.,  1993).  The  majority  of 
tumours  displaying  this  observed  somatic  instability,  did  so  at  numerous  unrelated 
microsatellites.  One  study  in  particular  demonstrated  this  MSI  phenotype  in  tumour  DNA 
from  a  familial  colorectal  cancer,  hereditary  nonpolyposis  colorectal  cancer  (HNPCC) 
(Aaltonen  et  al.,  1993).  A  significantly  lower  fraction  of  tumour  DNA  from  sporadic  CRC 
Colorectal  cancer)  examined  showed  this  MSI  phenotype.  These  studies  suggested 
replication  errors  (RER)  had  occurred  in  these  sequences  during  tumour  development. 
Tumours  with  this  associated  replication  error  phenotype  or  microsatellite  instability  are 
designated  RER+  tumours.  Genetic  instability  was  therefore  proposed  to  be  a  component 
of  the  familial  cancer  phenotype.  These  analogies  to  the  yeast  system  led  to  the  suggestion 
that  microsatellite  instability  observed,  for  example  in  HNPCC  tumour  DNA,  could  be  a 5 
consequence  of  a  mutation  in  a  functional  homologue  of  PMS1,  MLH1  or  MSH2  or  another 
component  of  the  MMR  system. 
HNPCC,  a  form  of  colorectal  cancer,  has  been  observed  within  familial  groups.  HNPCC 
kindred  are  defined  as  those  in  which  at  least  three  relatives  in  two  generations  have 
colorectal  cancer,  with  one  of  these  being  diagnosed  under  the  age  of  fifty  (Lynch  et  al., 
1985).  Genetic  linkage  analysis  was  used  to  attempt  to  identify  specific  loci  implicated  in 
HNPCC  families. 
One  gene  localised  to  a  HNPCC  locus  was  a  human  MutS  homologue  hMSH2  on 
chromosome  2  (Fishel  et  al.,  1993;  Leach  et  al.,  1993).  Mutations  in  this  gene  occurred  in 
the  germline  of  patients  with  RER+  tumours,  with  or  without  classical  HNPCC,  and 
additional  somatic  alterations  at  this  gene  occurred  in  tumours.  Results  in  these  studies 
strongly  suggested  hMSH2  mutations  are  responsible  for  HNPCC  and  the  RER+  phenotype 
apparent  in  these  tumours. 
Linkage  analysis  also  provided  evidence  for  strong  linkage  between  a  polymorphic  marker 
on  the  short  arm  of  chromosome  3  and  the  HNPCC  disease  locus  (Lindblom  et  al.,  1993; 
Peltomaki,  1994).  Two  studies  identified  three  human  MutL  homologues,  hMLH1,  hPMS1 
and  hPMS2  (Bronner  et  al.,  1994;  Papadopoulos  et  al.,  1994).  The  first  gene  was  called 
hMLH1  due  to  its  high  level  of  homology  to  the  yeast  MLHI  gene.  The  second  and  third 
gene  were  more  homologous  to  the  yeast  PMS1  gene  and  were  called  hPMS1  and  hPMS2. 
hMLH1  was  mapped'  to  chromosome  3,  hPMS1  to  chromosome  2  and  hPMS2  to 
chromosome  7. 
Mutations  in  hMLHJ  were  identified  in  HNPCC  families.  Following  the  discovery  of 
mutations  in  both  hMSH2  and  hMLH1  in  HNPCC  affected  individuals,  a  proportion  of 
HNPCC  cases  remained  unaccounted  for  (Service,  1994).  Mutation  screening  in  HNPCC 
cases  is  a  demanding  process,  because  the  predisposing  mutations  vary  between  kindreds 
and  are  often  scattered  in  different  positions  in  the  genes.  Approximately  70%  of  HNPCC 
cases  have  mutations  in  hMLH1  or  hMSH2  and  with  roughly  equal  proportions  in  the  two 
genes  (Peltomaki  and  de  la  Chapelle,  1997).  The  other  MutL  homologues,  hPMS1  and 
hPMS2,  represented  good  candidates  to  account  for  the  remainder  of  HNPCC  cases.  The 
discovery  of  an  interaction  between  yeast  Pms1p  and  yMlhlp  was  also  suggestive  of  a  role 
for  a  PMS1  human  homologue  in  HNPCC  (Prolla  et  al.,  1994). 6 
Mutations  were  identified  in  both  hPMS1  and  hPMS2  genes  in  HNPCC  cases  (Nicolaides 
et  al.,  1994).  Microsatellite  instability  was  also  observed  in  the  tumour  cell  DNA  from 
patients  with  these  mutations.  The  somatic  alteration  of  the  remaining  allele,  in  a  tumour 
from  a  patient  with  a  germline  hPMS2  mutation,  supports  the  idea  that  inactivation  of  both 
alleles  of  an  MMR  gene  is  required  for  tumour  formation  (Nicolaides  et  al.,  1994). 
The  inactivation  of  either  yeast  MutL  gene  (yMLH1  and  yPMSJ)  or  the  yeast  MutS  gene 
(yMSH2)  results  in  a  mutator  phenotype  (Strand  et  al.,  1993).  Inactivation  of  any  of  the 
three  human  MutL-related  genes  can  result  in  HNPCC  due  to  a  deficiency  in  MMR  and 
examination  of  tumour  DNA  demonstrates  a  related  MSI  (RER+)  phenotype. 
1.1.4  MutS  and  MutL  Homologues  Involved  in  Eukaryotic  DNA 
Mismatch  Repair. 
The  discovery  of  inherited  mutations  in  a  number  of  human  MMR  genes  in  HNPCC,  has 
led  to  extensive  studies  of  both  the  yeast  and  human  MMR  system.  These  studies  have  led 
to  the  identification  of  a  range  of  MMR  proteins  and  some  understanding  of  how  they 
function  in  this  process  (see  Figure  1  and  Table  1). 
DNA  polymerase  slippage  during  replication  results  in  characteristic  insertion-deletion 
loop-type  (IDL)  mismatched  nucleotides.  In  the  absence  of  a  functional  MMR  system 
these  mismatches  persist  and  following  rounds  of  replication  MSI  results.  In  the  bacterial 
system  it  has  been  demonstrated  that  nucleotide  mismatches  are  recognised  and  bound  by 
the  bacterial  MutS  protein  (Modrich,  1989;  Su  and  Modrich,  1986).  It  was  therefore  of 
interest  to  identify  whether  MutS  homologues  in  yeast  or  human  cells  could  also  recognise 
and  bind  mismatched  DNA. 
1.1.4.1  MutS  Homologues  in  Eukaryotes 
hMSH2  and  its  yeast  homologue,  yMsh2p,  have  also  been  shown  to  bind  with  high 
efficiency  and  specificity  to  single  base  pair  mismatched  nucleotides  (Alani  et  al.,  1995; 
Fishel  et  al.,  1994;  Fishel  et  al.,  1994;  Miret  et  al.,  1993;  Miret  et  al.,  1996).  Gel  shift 
experiments  with  purified  hMSH2  have  also  demonstrated  binding  to  DNA  containing  IDL 
mismatches  (Fishel  et  al.,  1994).  The  specificity  of  this  binding  to  the  mismatch  was 
visualised  through  electron  microscopy.  Further  evidence  for  the  role  of  hMSH2  in  loop 7 
Escherichia  coli  Saccharont  ces  cerevisiae  Homo  sapiens 
Muts  yMsh2p  hMSH2 
Msh6  hMSH6 
Msh3  hMSH3 
yMshlp  - 
yMsh4p  hMSH4 
yMsh5p  hMSH5 
Mutt  Mih  I  hMLH  I 
Pills  I  hPMS2 
yMlh3p  hPMS  I 
MIh?  hMLH3 
MutH  -  - 
MutU  -  - 
Table  1:  MMR  Proteins  Conserved  from  Escherichia  coli  to  Homo  sapiens. 
Yeast  and  human  MutS  and  MutL  homologues  are  listed.  Human  homologues  are  listed 
beside  their  yeast  counterparts.  hMLH3  is  most  closely  related  to  yPMS  l  and  other  non- 
mammalian  MutL  proteins. 
yMutSa  CD  hMutSa 
yMsh2p  +  yMsh6  p  hMSH2  +  hMSH6 
C) 
yMutSß 
C) 
hMutSß 
yMsh2p  +  yMsh3p  hMSH2  +  hMSH3 
0) 
yMutLU 
1) 
hMutLa 
yM1hIp+yPmtiI  p  hMLHI  +  hPMS2p 
yMutLß  hMutLß 
yMlh  Ip+  yMlh3p  hMLHI+hPMSI 
1) 
hMLH  I+  hMLH3 
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repair  and  more  specifically  in  mutation  avoidance  came  from  a  study  utilising  an  in  vitro 
mismatch  repair  assay.  Extracts  from  cells  with  normal  hMSH2  expression  and  from  cells 
with  deletions  in  both  hMSH2  alleles  were  tested  in  this  assay  and  loss  of  repair  for  both 
loops  and  mismatches  was  demonstrated  only  in  the  MSH2  mutant  lines  (Umar  et  al., 
1994). 
hMSH2  was  shown  to  recognise  and  bind  mismatched  DNA,  however  the  form  of  the 
protein  active  in  MMR  was  not  yet  defined.  The  isolation  of  a  hMutS  protein  complex 
from  HeLa  cells,  that  restores  repair  activity  to  the  hMSH2  defective  LoVo  cell  line,  gave 
some  clues  (Drummond  et  al.,  1995).  This  complementing  activity  was  named  hMutSct 
and  consists  of  two  polypeptides  of  105  kDa  (hMSH2)  and  160  kDa.  Restoration  of  repair 
activity  to  another  cell  line  with  defective  MMR,  but  no  mutations  in  hMSH2,  was  also 
achieved,  leading  to  the  hypothesis  that  in  this  cell  line  the  second  polypeptide  component 
of  hMutSa  must  be  mutated. 
This  polypeptide  was  identified  as  GTBP  (for  G/T  binding  protein)  protein  and  is  highly 
homologous  to  the  MSH  family  of  proteins  (Acharya  et  al.,  1996;  Palombo  et  al.,  1995). 
The  GTBP  protein  complexes  with  hMSH2  and  binds  mismatched  DNA.  The  GTBP  gene 
was  also  found  to  be  mutated  in  a  cell  line  which  displayed  no  mismatch  binding  activity 
but  in  which  neither  hMSH2  alleles  were  mutated.  In  addition  GTBP  was  found  to  be 
mutated  in  a  number  of  cell  lines  with  an  MSI  (RER+)  phenotype  (Papadopoulos  et  al., 
1995).  Therefore  suggesting  that  like  hMSH2,  GTBP  is  essential  for  maintaining  the 
fidelity  of  the  human  genome.  The  GTBP  protein  was  found  to  be  homologous  to  yeast 
MSH6  and  is  therefore  now  referred  to  as  hMSH6. 
A  third  human  MutS  homologue  was  identified  as  a  divergently  transcribed  gene  next  to 
the  dihydrofolate  reductase  (DHFR)  gene  (Fujii  and  Shimada,  1989;  Linton  et  al.,  1989). 
Although  the  function  of  this  gene  was  not  immediately  recognised,  it  was  soon  discovered 
to  be  a  homologue  of  yeast  MSH3  and  therefore  named  hMSH3.  hMSH2  also 
heterodimerises  with  hMSH3  forming  the  hMutSß  complex  (Palombo  et  al.,  1996).  This 
hMutS  3  complex  binds  loops  of  one  to  four  nucleotides.  The  discovery  of  this  second 
hMutS  complex  gave  some  explanation  of  how  cells  lacking  GTBP  (hMSH6)  are  partially 
proficient  in  the  repair  of  larger  IDL  mismatches.  It  also  suggested  that  hMSH3  and 
hMSH6  are  redundant  in  loop  repair. 9 
The  role  of  MSH3  and  MSH6  in  MSH2  dependent  mismatch  repair  was  initially  elucidated 
from  genetic  studies  in  the  yeast  Saccharomyces  cerevisiae.  Mutations  in  either  yMSH3  or 
yMSH6  alone  did  not  cause  the  extreme  mutator  phenotype  seen  in  ymsh2  mutants 
(Johnson  et  al.,  1996;  Strand  et  al.,  1995).  However  when  both  genes  together  were 
mutated  a  comparable  mutator  phenotype  to  that  seen  in  ymsh2  mutants  was  observed. 
These  observations  support  the  suggestion  that  yMsh3p  and  yMsh6p  have  overlapping 
functions  in  the  yMsh2p  dependent  repair  pathway  in  yeast. 
Another  study  examining  the  mutation  rates  in  ymsh2,  ymsh3  and  ymsh6  mutants 
demonstrated  the  two  pathways  that  exist  in  yeast  for  yMsh2p-dependent  mismatch  repair 
(Marsischky  et  al.,  1996).  One  pathway  consisting  of  yMsh2p  and  yMsh6p  recognises 
single  base  mispairs  and  the  second  recognises  insertion/deletion  mispairs  (IDIs)  and 
requires  either  yMsh2p  in  combination  with  yMsh3p  or  with  yMsh6p.  This  study  also 
demonstrated  the  ability  of  yMsh2p  to  bind  both  yMsh3p  and  yMsh6p,  suggesting  that 
these  two  complexes  may  specifically  bind  mismatched  DNA. 
yMutSa  was  isolated  in  complex  with  mismatched  DNA  providing  support  for  such  a 
model  (Iaccarino  et  al.,  1996).  The  use  of  purified  proteins,  yMsh2p  and  yMsh6p,  also 
clearly  demonstrated  the  mismatch  specific  binding  of  this  yMutSa  complex,  and  suggest 
that  the  repair  activity  of  the  complex  bound  to  the  mismatch  is dependent  on  its  ability  to 
use,  ATP  hydrolysis  to  activate  downstream  steps  of  the  repair  pathway  (Alani,  1996). 
Purification  of  the  yMsh2p-yMsh3p  heterodimer  to  near  homogeneity  allowed  a 
demonstration  of  the  binding  activity  of  this  complex  as  well  (Habraken  et  al.,  1996).  This 
yMutS  3  complex  has  low  affinity  for  a  G/T  mismatch  but  binds  insertion/deletion 
mismatches  with  high  specificity. 
hMSH2  also  functionally  interacts  with  hMSH3  and  hMSH6  (Acharya  et  al.,  1996). 
hMSH2  was  able  to  associate  with  itself  in  vitro  but  at  a  lower  efficiency  than  that  seen 
with  hMSH3  and  hMSH6.  hMSH2  is  found  in  excess  of  these  two  proteins  in  proliferating 
cells  and  therefore  it  is  possible  that  hMSH3  and  hMSH6  are  mostly  if  not  wholly  in 
complex  with  hMSH2.  The  excess  hMSH2  may  therefore  form  a  homodimer  complex 
active  in  other  cellular  functions.  With  gel  shift  experiments  the  hMSH2-hMSH3  complex 
was  shown  to  recognise  some  +1  IDL  and  larger  IDL  substrates.  The  hMSH2-hMSH6 
complex  also  recognised  some  +1  IDL  substrates  in  addition  to  a  G/T  mismatch  but  failed 
to,  recognise  the  larger  IDL  substrates.  Results  from  this  study  clearly  suggest  an 
overlapping  mismatch  recognition  specificity  of  the  two  complexes. 10 
Further  evidence  for  the  redundant  roles  of  hMSH3  and  hMSH6  in  mismatch  repair  came 
from  a  study  utilising  the  HHUA  endometrial  tumour  cell  line  that  is  mutant  in  both 
hMSH3  and  hMSH6  (Umar  et  al.,  1998).  These  cells  display  elevated  mutation  rates  at  the 
HPRT  locus  and  an  MSI  phenotype  at  a  number  of  loci  examined.  However  microcell- 
mediated  transfer  of  chromosome  5  (hMSH3)  or  2  (hMSH6)  into  these  cells  partially 
corrects  the  MSI  phenotype  seen  in  these  cells  and  also  the  mutator  phenotype  at  the  HPRT 
locus.  By  using  an  in  vitro  mismatch  repair  system,  the  re-introduction  of  chromosome  2 
(hMSH6)  in  the  HHUA  cell  line  was  shown  to  restore  repair  activity  to  the  cell  line, 
specifically  repair  of  single  base  mismatches  or  heteroduplexes  containing  up  to  four  extra 
bases  in  one  strand.  An  earlier  study  also  showed  that  re-introduction  of  hMSH3  on 
chromosome  5  can  restore  repair  activity  in  these  extracts  for  substrates  with  one  to  four 
extra  nucleotide  bases  but  not  for  base:  base  mismatches  (Risinger  et  al.,  1996). 
Clearly  hMSH2  acts  with  hMSH6  and  to  a  lesser  extent  with  hMSH3  to  recognise  and  bind 
mismatched  DNA  at  an  early  stage  of  the  DNA  mismatch  repair  pathway.  hMutSa  has 
previously  been  shown  to  be  in  excess  of  hMutSß  in  proliferating  cells  (Drummond  et  al., 
1997).  90%  of  nuclear  hMSH2  has  also  been  shown  to  be  in  complex  with  hMSH6  in 
mitotically  active  HeLa  cells  (Genschel  et  al.,  1998).  The  binding  specificities  of  the  two 
complexes  observed  are  in  agreement  with  the  information  from  genetic  experiments  that 
the  hMutSa  (hMSH2-hMSH6)  complex  preferentially  recognises  and  binds  base:  base 
mismatches  and  short  IDL  substrates  whereas  the  hMutSß  (hMSH2-hMSH3)  complex 
recognises  and  binds  specifically  IDL  substrates  (Umar  et  al.,  1998).  There  are  clearly 
redundant  roles  for  the  two  individual  complexes  in  the  recognition  and  binding  of 
insertion/deletion  loop  substrates.  In  the  absence  of  detectable  hMSH2  polypeptide  neither 
hMSH3  or  hMSH6  polypeptides  were  detectable  by  western  blot  (Drummond  et  al.,  1997; 
Genschel  et  al.,  1998).  These  results  suggest  that  perhaps  hMSH2  regulates  hMSH3  and 
hMSH6  levels,  perhaps  by  stabilisation  of  the  polypeptides  through  heterodimer  formation. 
The  balance  between  the  MutSa  and  MutSß  complexes  is  apparently  crucial  too. 
Overexpression  of  hMSH3  through  amplification  of  the  DHFR  locus  produced  a 
significant  change  in  the  relative  levels  of  these  two  complexes  (Marra  et  al.,  1998). 
hMSH6  mRNA  levels  have  been  shown  to  be  approximately  four  times  as  high  as  those  of 
hMSH3  (Chang  et  al.,  2000).  It  is  therefore  not  surprising  that  hMSH2  is  found  mainly  in 
complex  with  hMSH6,  and  hMutSa  is  relatively  abundant  compared  to  low  levels  of 
hMutSI.  Overexpression  of  hMSH3  therefore  results  in  an  increased  amount  of  hMutSß 11 
being  formed,  which  means  that  hMSH2  is  sequestered  mainly  into  this  complex  (Marra  et 
al.,  1998).  This  results  in  the  degradation  of  hMSH6  which  does  not  have  a  hMSH2 
partner  and  hence  depletion  of  hMutSa  levels.  Because  of  the  different  roles  of  these  two 
complexes,  a  concomitant  increase  in  the  acquisition  of  transversions  and  transitions  is 
seen.  The  effect  of  the  change  in  balance  between  hMSH6  and  hMSH3  levels  therefore 
can  clearly  effect  functional  MMR. 
Germline  mutations  in  hMSH6  have  also  been  identified  in  a  small  number  of  HNPCC 
families  (Akiyama  et  al.,  1997;  Miyaki  et  al.,  1997).  These  tumours  had  reduced  MSI 
compared  to  tumours  with  mutations  in  hMSH2  or  hMLH1.  The  recent  discovery  of 
mutations  in  yMSH6  that  can  inactivate  both  yMutSa  and  yMutSß  dependent  MMR,  would 
suggest  that  similar  germline  mutations  in  hMSH6  may  be  found  in  some  HNPCC  or 
sporadic  cancers  (Das  Gupta  and  Kolodner,  2000).  Such  mutations  would  result  in 
defective  MMR,  similar  to  that  seen  for  hmsh2  and  hmlhl  mutations,  and  could  be 
responsible  for  MSI'  HNPCC  and  sporadic  cancers. 
1.1.4.2  MutL  Homologues  in  Eukaryotes 
The  yeast  PMS1  gene  product  was  found  to  be  homologous  to  the  bacterial  MutL  protein 
(Kramer  et  al.,  1989).  From  this  initial  discovery  it  soon  became  clear  that  there  are 
multiple  homologues  of  MutL  expressed  in  eukaryotic  cells  (designated  PMS  and  MLH). 
The  existence  of  multiple  MutL  homologues  therefore  mirrors  the  complexity  seen  in 
eukaryotic  mismatch  repair  with  respect  to  the  MSH  proteins 
Isolation  of  yMihlp  another  MutL  homologue  in  Saccharomyces  cerevisiae  demonstrated 
that  unlike  the  bacterial  system  two  MutL  like  proteins  are  required  for  MMR  (Prolla  et  al., 
1994).  The  ymlhl  mutant  displayed  a  mutator  phenotype,  as  well  as  an  overall  inefficient 
repair  of  heteroduplex  DNA,  generated  during  genetic  recombination  (elevated  PMS). 
The  inactivation  of  either  yeast  MutL  gene  (yMLH1  and  yPMS1)  resulted  in  a  mutator 
phenotype  similar  to  that  seen  in  ymsh2  mutants  (Prolla  et  al.,  1994).  ymlhl,  ypmsl  and 
ymlhl  ypmsl  double  mutants  displayed  a  similar  phenotype.  This  would  suggest  that  these 
two  proteins  are  acting  in  the  same  DNA  mismatch  repair  pathway. 
In  Saccharomyces  cerevisiae  genetic  studies  show  mismatch  repair  requires  bacterial  MutS 
homologues  yMsh2p,  yMsh3p  and  yMsh6p  and  two  bacterial  MutL  homologues  yMlhlp 12 
and  yPmslp.  In  the  E.  coli  MMR  pathway,  MutL  forms  a  homodimer  in  solution,  that 
interacts  with  MutS  in  the  presence  of  heteroduplex  DNA  (Grilley  et  al.,  1989).  Therefore 
the  physical  interactions  between  yMsh2p,  yPmslp  and  yMlhlp  were  examined  (Prolla  et 
al.,  1994). 
Initially  a  yeast  two-hybrid  system  was  used  to  examine  in  vivo  interactions  between  these 
proteins.  yMlhlp  and  yPmslp  were  shown  to  interact  using  this  system.  In  vitro  binding 
assays  also  demonstrated  an  interaction  between  yPmslp  and  yMlhlp  but  not  between 
either  of  these  two  proteins  and  yMsh2p  (Prolla  et  al.,  1994). 
In  addition  a  gel  retard  assay  was  used  to  test  the  DNA  binding  properties  of  these  three 
proteins  (Prolla  et  al.,  1994).  A  108bp  homoduplex  and  a  heteroduplex  containing  a  G-T 
mismatch  were  constructed  for  use  in  this  assay.  This  assay  was  used  to  assess  whether 
yMlhlp  and  yPmslp  proteins  interact  with  yMsh2p  bound  to  heteroduplex  DNA.  The 
affinity  of  yMsh2p  binding  for  a  G-T  containing  heteroduplex  was  10-20  times  greater  than 
for  G-C  containing  homoduplex.  Alone  or  together,  both,  yMlhlp  and  yPmslp  showed  low 
affinity  binding  for  either  homoduplexes  or  heteroduplexes.  However  when  all  three 
proteins  were  mixed  together,  the  characteristic  yMsh2p-heteroduplex  band  shift  was 
replaced  by  a  lower  mobility  species.  This  suggested  the  presence  of  a  protein-DNA 
complex  of  a  higher  molecular  weight,  requiring  all  three  proteins  to  be  present.  The 
occurrence  of  this  band  shift  was  more  prevalent  in  the  presence  of  heteroduplex  DNA. 
yMLH1  and  yPMS1  genes  were  over-expressed  in  yeast,  and  the  yMlhlp-yPmslp  complex 
that  resulted  purified  (Habraken  et  al.,  1997).  The  purified  yMlhlp-yPmslp  complex  was 
examined  for  DNA  mismatch  recognition  activity  but  no  stable  nucleoprotein  complex 
formed.  A  yMsh2p-yMsh3p  complex  was  also  purified,  which  is  known  to  bind 
specifically  to  DNA  fragments  containing  extra-helical  loops.  Subsequently  it  was 
examined  whether  addition  of  yMlhlp-yPmslp  would  affect  the  mismatch  recognition 
properties  of  this  second  complex.  yMlhlp-yPmslp  was  discovered  to  specifically 
enhance  the  mismatch  binding  ability  of  yMsh2p-yMsh3p. 
A  second  study  utilising  purified  yMlhlp-yPmslp  and  yMsh2p-yMsh6p  complexes 
demonstrated  that  these  two  MMR  complexes  could  form  a  ternary  complex  on 
mismatched  DNA  (Habraken  et  al.,  1998).  The  yMsh2p-yMsh6p  complex  had  been 
previously  shown  to  bind  a  DNA  substrate  with  a  G/T  mismatch  and  also  to  IDL 
mismatches,  with  decreasing  affinity  as  the  size  of  the  extra-helical  loop  increases  (Alani, 13 
1996;  laccarino  et  al.,  1996).  Addition  of  ATP  or  a  non-hydrolysable  form  of  ATP  led  to  a 
significant  decrease  in  binding  of  this  yMutSa  complex  to  the  mismatched  substrate. 
Formation  of  this  ternary  complex  between  yMutSa  and  the  yMlhlp-yPmslp  complex,  on 
a  mismatch  containing  DNA  substrate,  however  required  ATP,  which  can  also  be 
substituted  by  a  non  hydrolysable  form  of  ATP.  It  is  proposed  that  ATP  binding  by  the 
yMutSa  complex  induces  a  conformation  allowing  an  interaction  with  the  yMlhlp-yPmslp 
complex,  which  results  in  the  formation  of  the  ternary  complex. 
Two  additional  yeast  MutL  homologues,  yMlh2p  and  yMlh3p,  were  identified  from  the 
Saccharomyces  cerevisiae  genome  sequence  project.  A  C-terminal  yMlh3p  fragment  was 
also  identified  as  interacting  with  yMlhlp  from  a  yeast  two-hybrid  library  screen  with 
yMlhip  as  bait  (Pang  et  al.,  1997).  This  interaction  would  suggest  a  role  for  yMlh3p  in  a 
yMlhlp-dependent  reaction  of  some  sort.  ymlh3  mutants  displayed  a  mutator  phenotype. 
ymlh3  ymsh6  double  mutants  had  a  synergistic  effect  on  the  mutator  phenotype  observed 
whereas  the  ymlh3  ymsh3  double  mutants  had  the  same  mutation  rates  as  seen  in  the  single 
mutants.  These  observations  would  suggest  that  a  proportion  of  the  repair  of  specific  IDL 
mismatches,  by  the  yMsh3p-dependent  MMR  pathway,  utilises  a  heterodimeric  yMlhlp- 
yMlh3p  complex  instead  of  yMlhlp-yPmslp  (Flores-Rozas  and  Kolodner,  1998). 
Three  separate  yMlhlp  based  heterocomplexes  are  now  known  to  form.  Using  yMlhlp  as 
a  bait  in  a  yeast  two-hybrid  screen,  interactions  were  identified  between  yMlhip  and  three 
other  MutL  homologues  yPmslp,  yMlh2p  and  yMlh3p  (Wang  et  al.,  1999).  These 
interactions  were  confirmed  using  co-immunoprecipitation  experiments. 
An  interaction  between  hMLH1  and  hPMS2  was  discovered  in  human  cells  (Li  and 
Modrich,  1995).  The  hypermutable  H6  colorectal  tumour  cell  line  is  defective  in  strand 
specific  mismatch  repair,  and  both  alleles  of  the  hMLHl  gene  are  mutated.  A  specific 
activity  was  purified  from  HeLa  cells  that  complements  H6  nuclear  extracts  to  restore 
repair  efficiency  to  a  set  of  heteroduplex  DNAs.  This  activity  fractionated  as  a  single 
species  and  co-purified  with  proteins  of  85  and  110  kDa.  Sequencing  allowed  the 
identification  of  these  two  proteins  to  be  hMLH1  and  hPMS2.  The  1:  1  stoichiometry  of 
the  two  polypeptides  indicate  they  form  a  heterodimer,  hMutLa. 
A  single  individual  from  a  family  with  a  clear  cancer  predisposition  was  shown  to  carry  a 
mutation  in  the  human  mutL  homologue  hPMS1  gene  (Nicolaides  et  al.,  1994).  However 
this  mutation  could  not  be  shown  to  segregate  with  the  disease  as  clinical  samples  were  not 14 
available  from  the  other  family  members.  Therefore  it  is  not  clear  whether  this  mutation  is 
causative,  but  this  discovery  does  suggest  hPMS1  may  play  a  role  in  MMR.  Support  for 
this  hypothesis  has  come  from  the  discovery  that  in  yeast,  yMlh3p,  the  closest 
Saccharomyces  cerevisiae  homologue  of  hPMS1,  interacts  with  yMlhlp.  Further  evidence 
for  such  a  role  has  come  from  the  identification  of  the  human  MutLß  (hMutLß) 
heterodimer  which  consists  of  hMLH1  and  hPMS1  in  complex  (Leung  et  al.,  2000; 
Raschle  et  al.,  1999).  However  unlike  the  hMutLa  complex,  the  hMutL  3  complex  was 
unable  to  complement  extracts  of  MMR  deficient  cell  lines  lacking  hMLH1in  an  in  vitro 
MMR  assay.  Therefore  a  direct  role  for  the  hMutLß  complex  in  MMR  is  yet  to  be 
demonstrated. 
Interestingly,  although  not  proving  a  role  for  this  hMutL(3  complex  in  MMR,  two 
complexes  between  hMutSa  and  hMutLa  and  between  hMutSa  and  hMutLß  have  been 
identified  from  HeLa  nuclear  extracts  (Matton  et  al.,  2000).  The  interactions  between  these 
complexes  occurred  without  the  addition  of  ATP  and  the  complexes  were  shown  to 
specifically  bind  to  heteroduplex  DNA  but  not  to  a  similar  homoduplex  oligonucleotide. 
Upon  addition  of  ATP  the  interaction  between  hML  1  and  hPMS2  and/or  hPMS1  or  with 
the  hMutSa  complex  is  no  longer  seen. 
A  new  MMR  protein,  human  MLH3,  has  recently  been  identified  (Lipkin  et  al.,  2000). 
This  hMLH3  protein  has  been  shown  to  be  most  closely  related  to  yMlh3p  protein  and 
other  non-mammalian  MutL  homologues.  Similar  to  other  MutL  homologues  the  N- 
terminal  of  the  protein  has  a  putative  ATPase  domain  and  the  C-terminal  has  a  predicted 
hMLH1  interaction  domain.  The  hMLH3  mRNA  was  found  to  be  ubiquitously  expressed. 
An  interaction  between  hMLH1  and  hMLH3  was  demonstrated  in  a  mammalian  two- 
hybrid  system.  Expression  of  a  dominant  negative  form  of  hMLH3  in  cultured  cells 
resulted  in  microsatellite  instability. 
How  this  protein  functions  in  MMR  is  yet  to  be  discovered.  By  analogy  to  the  yMlh3p 
protein,  hMLH3  could  act  in  complex  with  hMLH1,  and  with  the  hMutSß  complex,  play  a 
role  in  the  repair  of  IDL  mismatches.  MSI  in  MMR  knockout  mice  is  lower  in  PMS2-'" 
mice  than  in  MLH1-1-  mice,  even  though  both  mice  lack  the  hMLH1/hPMS2  complex  (Yao 
et  al.,  1999).  hMLH3  could  be  responsible  for  this  residual  IDL  repair  activity. 
Many  HNPCC  cancers  and  sporadic  colon  cancers  have  no  identifiable  mutations  in  MMR 
genes  that  have  been  implicated  in  these  diseases  previously.  A  group  of  patients 15 
displaying  characteristics  of  hereditary  colorectal  cancer  but  without  any  mutations 
identified  in  MMR  genes  were  tested  for  germline  mutations  in  hMLH3  (Loukola  et  al., 
2000).  None  were  found.  A  group  of  MSI-positive  tumours  were  also  examined  for 
somatic  mutations  in  eight  exonic  mononucleotide  repeats  of  hMLH3,  to  test  for  somatic 
inactivation  as  is  seen  for  hMSH3  and  hMSH6,  but  none  were  seen.  Therefore  from  this 
study  hMLH3  mutations  and  hence  inactivation,  does  not  seem  to  be  selected  for  in  MSI- 
positive  tumours. 
Little  is  known  of  the  functional  domains  of  MMR  proteins.  The  yMlhlp  and  hPmslp 
protein  domains  required  for  them  to  interact  with  each  other  have  been  described  (Pang  et 
al.,  1997).  This  study  identified  the  yMlhlp-interactive  domain  of  hPmslp  as  a  260  amino 
acid  domain  located  at  the  carboxyl  terminus  of  the  protein.  The  hPmslp-interactive 
domain  of  yMlhlp  is  within  its  final  212  amino  acids.  These  domains  are  sufficient  for 
yMlhlp-hPmslp  interactions.  No  interaction  is  seen  when  deletions  are  located  within 
these  domains.  Some  ymlhl  and  ypmsl  mutant  alleles  caused  a  dominant  negative  mutator 
effect  when  over-expressed.  This  observation  was  particularly  important  as  mutations  in 
homologues  of  these  genes  in  humans  have  been  shown  to  abolish  functional  MMR  and 
have  been  implicated  in  HNPCC.  This  may  occur  in  a  dominant  negative  manner  leading 
to  early  tumour  development.  For  example  expression  of  a  mutant  form  of  hPMS2  which 
can  still  bind  hMLH1,  could  result  in  complexes  between  these  two  proteins  that  are  not 
functional.  This  complex  formation,  by  sequestering  the  majority  of  hMLH1  in  the  cell, 
may  also  result  in  the  loss  of  interactions  between  hMLH1  and  other  proteins  such  as 
hPMS1  and  hMLH3  which  may  play  a  role  in  MMR. 
The  interaction  domains  of  the  hMutLa  complex  components  has  also  been  examined.  In 
hMLH1  the  interaction  region  has  been  shown  to  lie  between  amino  acids  506  and  675  and 
in  hPMS2  between  amino  acids  675  and  850  (Guerrette  et  al.,  1999).  The  majority  of 
mutations  associated  with  HNPCC  examined  in  hMLH1  lead  to  a  decreased  ability  to  bind 
hPMS2.  This  finding  confirms  that  functional  deficiencies  in  the  interaction  of  these  two 
proteins  are  associated  with  HNPCC.  Interestingly  there  have  been  no  reports  of  single- 
amino  acid  substitutions  in  hPMS2  located  within  this  interaction  domain  (Guerrette  et  al., 
1999).  Perhaps  as  in  the  hMutS  system  hMLH1  can  function  with,  for  example  hPMS1,  in 
MMR,  such  that  hPMS1  has  a  redundant  function  with  hPMS2. 16 
1.1.4.3  How  Does  MutS  Function? 
In  the  bacterial  system  it  has  been  demonstrated  that  nucleotide  mismatches  are  recognised 
and  bound  by  the  bacterial  MutS  protein  (Modrich,  1989;  Su  and  Modrich,  1986). 
However  the  exact  function  and  the  dependence  on  ATP  of  this  reaction  remains  a 
contentious  issue.  It  is  accepted  that  MutS  recognises  and  binds  heteroduplex  DNA 
leading  to  downstream  events  resulting  in  repair  of  the  heteroduplex. 
MutS  homologues  (MSH)  have  all  been  identified  on  the  basis  that  they  carry  a  highly 
conserved  region  incorporating  a  Walker-A  adenine  nucleotide  binding  motif.  This 
conserved  region  encompasses  approximately  150  amino  acid  residues  which  includes  a 
helix-turn-helix  domain  associated  with  the  Walker  A  type  adenine  nucleotide  binding 
motif  and  a  Walker  B  type  magnesium  binding  motif  (Walker  et  al.,  1982).  This  Walker-A 
box  represents  over  80%  of  identifiable  homology  between  MutS  homologues  (Fishel  and 
Wilson,  1997). 
Both  purified  bacterial  and  yeast  MutS  homologues  have  been  shown  to  possess  an 
intrinsic  low  level  ATPase  activity  (Alani  et  al.,  1997;  Chi  and  Kolodner,  1994;  Haber  and 
Walker,  1991).  This  ATPase  function  is  likely  to  be  important  for  MutS  homologue 
function,  as  mutation  of  these  conserved  amino  acid  residues  in  the  adenine  nucleotide 
binding  domain  result  in  a  dominant  mutator  phenotype  in  both  bacteria  and  yeast  (Alani  et 
al.,  1997;  Haber  and  Walker,  1991).  The  precise  function  and  dependence  on  ATP  of  the 
MutS  complex  is  unclear.  A  range  of  studies  with  bacterial  MutS  and  also  eukaryotic 
MutS  homologues  have  given  some  clues.  A  number  of  models  have  been  proposed  to 
explain  how  this  complex  functions. 
In  both  bacteria  and  eukaryotes  MutS  homologues  fail  to  form  a  specific  complex  with  a 
mismatch  containing  oligonucleotide  in  the  presence  of  ATP  (Alani,  1996;  Iaccarino  et  al., 
1996;  Marsischky  and  Kolodner,  1999).  For  example  in  a  study  utilising  purified  yeast 
proteins,  yMutSa  was  shown  to  bind  a  G/T  mismatch,  but  this  ability  was  lost  upon 
addition  of  ATP  (Habraken  et  al.,  1998).  However  formation  of  a  ternary  complex 
between  yeast  MutLa  and  MutSa  was  also  demonstrated  and  requires  the  addition  of  ATP 
analogous  to  the  observations  in  bacteria  (Allen  et  al.,  1997;  Habraken  et  al.,  1998). 
However  ATP  hydrolysis  is  not  required.  No  such  complex  was  formed  in  the  presence  of 
ADP  and  it  has  been  previously  shown  that  yMutSß  forming  a  ternary  complex  with 
yMutLa  does  not  require  ATP  to  be  present. 17 
It  has  been  proposed  by  Modrich  et  al  that  MutS  recognises  and  binds  the  heteroduplex, 
initiating  downstream  events,  which  results  in  repair  of  the  mismatch  and  ATP-dependent 
translocation  of  MutS  away  from  the  site.  This  complex  is  proposed  to  dissociate  from  the 
DNA  until  it  again  encounters  and  binds  another  mismatch.  E.  coli  MutS  incubated  with 
heteroduplex  DNA  has  been  shown  to  form  cc-loop  shaped  structures,  with  the  mismatch  in 
most  cases  localised  within  the  loop  structure  (Allen  et  al.,  1997).  This  structure  is  only 
formed  upon  addition  of  ATP  to  the  reaction,  as  visualised  by  electron  microscopy.  The 
MutS  protein  was  found  to  localise  most  probably  as  a  dimer  at  the  base  of  the  loop.  MutL 
co-localised  to  the  base  of  the  loop  with  MutS.  Once  the  loop  had  formed  no  ATP  was 
required.  MutL  binding  was  shown  to  enhance  the  rate  of  loop  formation  and  the  loop  size 
increased  with  time.  These  observations  led  to  the  proposal  that  ATP  activates  the 
formation  of  secondary  DNA  binding  sites,  used  for  the  movement  of  the  complex  along 
the  helix  by  a  translocation  mechanism,  which  would  require  ATP  hydrolysis. 
A  second  study  supporting  this  model  came  from  observations  of  nucleotide  promoted 
release  of  human  MutSa  from  heteroduplex  DNA  (Blackwell  et  al.,  1998).  In  this 
experiment  a  blocked  end  heteroduplex  substrate  was  utilised.  Addition  of  ATP  to  these 
blocked  end  substrates  in  complex  with  hMutSa  did  not  result  in  dissociation  of  hMutSa 
from  these  substrates.  When  ATP  hydrolysis  is  prevented  either  by  the  omission  of 
magnesium  ions  or  by  using  a  non-hydrolysable  form  of  ATP,  addition  of  ATP  or  these 
analogues  still  induces  the  dissociation  of  the  complex  from  the  heteroduplex.  This  would 
imply  that  hydrolysis  of  ATP  by  at  least  one  subunit  of  the  complex,  must  be  necessary  to 
allow  resistance  of  the  complex  to  ATP  induced  dissociation  from  the  heteroduplex. 
Therefore  a  model  was  proposed  whereby  each  component  of  hMutSa  has  two  sites  that 
function  in  the  movement  of  the  complex  along  the  DNA.  Movement  of  the  complex 
along  the  DNA  is  restricted  by  the  ATP  or  ADP  occupancy  of  the  hMutSa  subunit 
nucleotide  binding  site.  This  study  argues  that  ADP  is  not  actually  required  for  mismatch 
recognition  but  changes  the  dynamics  of  formation  of  complex  versus  dissociation  of  the 
complex  from  DNA. 
The  hMutSa  complex  (hMSH2-hMHS6)  has  been  shown  to  have  an  intrinsic  ATPase 
activity  (Gradia  et  al.,  1997).  This  along  with  the  associated  adenine  nucleotide  binding 
domain,  function  to  regulate  mismatch  binding,  and  are  proposed  to  act  as  a  molecular 
switch  (Fishel,  1998;  Gradia  et  al.,  1997;  Gradia  et  al.,  2000).  Using  purified  hMSH2  and 
hMSH6  protein  which  form  a  stable  complex,  the  intrinsic  DNA-dependent  ATpase 18 
activity  of  this  heterodimer  was  demonstrated  and  shown  to  require  magnesium  as  a  co- 
factor.  It  was  also  observed  that  this  ATPase  function  was  most  active  in  the  presence  of  a 
G/T  mismatch. 
In  this  study  hMutSa  was  released  upon  addition  of  ATP  to  the  reaction  but  the  specific 
binding  affinity  of  the  complex  for  the  mismatch  was  restored  gradually  upon  addition  of 
ADP  (Gradia  et  al.,  1997).  ATP  hydrolysis  by  the  hMutSa  complex  also  resulted  in  the 
recovery  of  the  binding  activity  of  the  complex.  Binding  of  the  hMutSa  complex  to  a  G/T 
mismatch  was  found  to  stimulate  the  exchange  of  ADP--ATP  resulting  in  release  from  the 
mismatch  and  recycling  of  the  protein  complex. 
The  molecular  switch  model  proposes  that  this  switch  is  'ON'  when  the  complex  is  in  an 
ADP  bound  form  and  is  able  to  bind  the  mismatch  and  'OFF'  when  in  an  ATP  bound  form 
which  prevents  mismatch  binding  (Gradia  et  al.,  1997).  How  exactly  this  switch  model 
signals  downstream  repair  events  is  not  known.  Two  possibilities  were  proposed.  The  first 
proposes  that  when  hMutSa  is  in  its  active  ADP  bound  form  and  binds  the  mismatched 
DNA,  this  triggers  the  assembly  of  the  required  repair  machinery  in  close  proximity  to  the 
mismatch,  followed  by  ADP-.  ATP  exchange  leading  to  release  of  the  hMutSa  complex 
from  the  DNA.  The  latter  proposes  that  mismatch  recognition  and  binding  triggers 
ADP-ATP  exchange,  which  results  in  hydrolysis  independent,  DNA  associated  diffusion 
of  the  complex  away  from  the  mismatch,  concomitant  with  assembly  of  the  repair 
components,  which  upon  binding  by-the  hMutSa  complex  engages  repair.  In  both  cases 
the  common  end  point  is  the  release  of  the  hMutSa  complex  which  hydrolyses  the  ATP 
and  therefore  the  'complex  is  recycled. 
As  in  the  study  by  Modrich  and  colleagues  (Blackwell  et  al.,  1998)  this  study  has 
demonstrated  the  requirement  for  magnesium  ions  for  the  formation  of  a  stable  complex  of 
hMutSa  on  heteroduplex  DNA  in  the  presence  of  ATP  (Gradia  et  al.,  1999).  'Dissociation 
induced  by  the  addition  of  a  poorly  hydrolysable  form  of  ATP  in  the  absence  of  magnesium 
would  suggest  that  specifically  magnesium  and  not  ATP  hydrolysis  is  required  for 
formation  of  this  stable  complex.  It  was  also  shown  that  ADP-ATP  exchange  is  normal 
where  these  blocked  end  substrates  are  utilised.  However  the  hMutSa  ATPase  levels  are 
reduced  to  levels  seen  in  the  absence  of  DNA.  This  strengthens  the  molecular  switch 
model  whereby  MutSu  binds  the  mismatch,  which  leads  to  ADP-"ATP  exchange,  but 
because  this  complex  is  blocked  in  an  ATP  bound  form  due  to  the  blocked  ends  of  the 19 
heteroduplex  substrate,  no  dissociation  and  reduced  ATP  hydrolysis  are  observed,  as  would 
be  seen  if  the  ends  were  free. 
A  circular  heteroduplex  substrate  was  also  utilised  to  examine  these  effects  (Gradia  et  al., 
1997).  With  this  substrate  the  same  binding  patterns  are  seen.  Upon  addition  of  ATP 
however  a  number  of  more  slowly  migrating  species  were  seen  by  gel  shift  assays 
suggesting  a  number  of  complexes  bound  to  the  substrate.  Electron  microscopy  (EM) 
showed  a  number  of  MutSa  protomers  bound  on  the  DNA  upon  addition  of  ATP.  Upon 
addition  of  ATP  this  group  proposes  MutSa  forms  a  clamp  on  the  DNA.  When  the 
circular  DNA  substrate  is  nicked  by  addition  of  an  endonuclease  i.  e.  producing  a  free  end, 
dissociation  of  the  complex  from  the  DNA  is  seen.  It  is  proposed  that  this  is  by  diffusion 
as  translocation  would  require  ATP  hydrolysis  which  has  been  shown  to  be  decreased. 
Also  a  number  of  forms  of  the  complex  bound  to  DNA  were  observed  by  EM.  The 
majority  of  which  were  either  pac-man  ('C')  shaped  (open)  or  doughnut  shaped  (closed). 
By  EM  it  is  shown  that  addition  of  ATP  to  hMutSa  produces  a  mixture  of  this  closed  and 
open  forms  but  addition  of  a  poorly  hydrolysable  form  of  ATP  produces  mostly  closed 
forms.  Addition  of  the  circular  heteroduplex  DNA  produces  no  binding  of  the  heteroduplex 
in  the  presence  of  the  non-hydrolysable  form  of  ATP  which  this  group  argues  gives  further 
credence  to  the  molecular  switch  model. 
hMutSß  was  also  demonstrated  by  this  group  to  dissociate  from  DNA  upon  addition  of 
ATP,  an  effect  which  does  not  require  ATP  hydrolysis  (Wilson  et  al.,  1999).  Limited 
proteolysis  also  demonstrated  conformational  changes  induced  by  binding  of  the  complex 
to  ATP  and  ADP.  This  supports  the  idea  that  conformational  transitions  are  associated 
with  adenosine  nucleotide  binding. 
To  attempt  to  define  the  role  of  the  ATP  binding  domains  conserved  in  MutS  homologues, 
a  number  of  studies  were  carried  out  utilising  mutated  purified  proteins,  with  a  range  of 
mutations,  which  are  still  capable  of  forming  stable  MutSa  complexes..  Yeast  Msh2p  and 
yMsh6p  proteins  with  mutations  in  the  conserved  C-terminal  region,  which  includes  a 
helix-turn-helix  (HTH)  domain  and  an  ATP  binding  motif,  were  produced  (Alani  et  al., 
1997).  From  experiments  with  these  purified  mutant  yMutSa  complexes,  it  was  proposed 
that  both  the  ATP  binding  and  hydrolysis  modulation  of  mismatch  recognition,  and  the 
interaction  between  the  two  sub-units  of  the  yMutSa  complex,  is  crucial  for  the  ATPase 
role  of  the  complex.  Also  ATP  binding,  ATP  hydrolysis  or  both  resulted  in  a 20 
conformational  change  in  the  complex  which  was  mediated  through  a  domain  that  is 
clearly  important  for  yMsh2p-yMsh6p  interactions. 
Yeast  msh2  and  ymsh6  mutants  were  made  by  mutating  a  conserved  phosphate  loop  (p- 
loop)  which  is  also  conserved  in  purine  nucleotide  binding  proteins  and  predicted  from 
studies  with  prokaryote  MutS  protein  to  disrupt  ATP  binding  or  ATP  hydrolysis  or  both 
(Studamire  et  al.,  1998).  Studies  with  these  mutants  in  yMutSa  complexes  have 
demonstrated  the  requirement  for  both  sub-units  through  their  ATP  binding  domains  in 
mediating  ATP-dependent  conformational  changes  in  the  complex.  Upon  addition  of  ATP 
to  these  complexes  bound  to  heteroduplex  DNA,  no  dissociation  of  the  mutant  yMutSa 
complexes  is  seen.  These  observations  would  support  an  equivalent  role  for  the  two  sub- 
units  of  the  yMutSa  in  ATP  dependent  release  from  the  mismatch  site. 
yMutSa  with  these  mutations  in  yMsh6p  has  a  lower  ATPase  activity  than  with  a  mutated 
yMsh2p.  Apparently  only  the  yMsh6p  ATPase  is  responsive  to  the  presence  of 
heteroduplex  substrate.  An  analogous  study  with  the  purified  human  proteins  utilised  a 
lysine  to  arginine  mutation  in  yMsh2p  and  yMsh6p  (laccarino  et  al.,  1998).  Mutation  of 
this  conserved  residue  in  the  Salmonella  typhimurium  MutS  homologue  inactivated  the 
ATP  binding  but  not  the  ATPase  activity  of  the  protein.  UV  crosslinking  experiments  with 
the  hMutSa  complex  with  a  heteroduplex  substrate  showed  that  hMSH2,  hMSH6  and 
DNA  were  present  in  the  complex  but  that  hMSH6  alone  was  covalently  bound  to  the 
mismatch.  Mutation  of  hMSH6  led  to  a  decreased  ATPase  activity  of  the  hMutSa 
complex,  whereas  mutation  of  the  hMSH2  protein  had  little  effect  on  the  ATPase  activity 
of  the  complex.  These  results  along  with  those  in  the  yeast  study  would  suggest  a  role  for 
the  MSH6  protein  in  steps  prior  to  the  proposed  release  of  the  complexes  from  the 
mismatch  site 
As  shown  in  the  study  by  Gradia  et  al  (Gradia  et  al.,  1999)  ATP  binding  and  not 
hydrolysis  is  shown  to  be  required  for  the  dissociation  of  hMutSa  from  DNA.  The  lysine 
to  arginine  mutation  analogous  to  -the  yeast  mutation  described  by,  Studamire  et  al 
(Studamire  et  al.,  1998)  in  the  hMutSa  components  also  led  to  severe  attenuation  of  the 
ATP-dependent  dissociation  of  these  complexes  from  heteroduplex  oligonucleotides.  This 
must  be  due  to  a  reduced  affinity  of  the  mutant  proteins  for  ATP.  Contrary  to  expectations 
based  upon  the  results  with  the  Salmonella  mutants  this  mutation  apparently  effects  ATP 
binding  of  hMutSa.  The  addition  of  the  double  mutant  hMutSa  complex  to  cell  extracts 
proficient  for  MMR  led  to  a  decreased  ability  of  these  extracts  for  MMR  using  an  in  vitro 21 
MMR  assay.  Overexpression  of  the  mutant  yeast  proteins  in  wild  type  yeast  also  produced 
a  dominant  negative  phenotype  (Studamire  et  al.,  1998). 
Overall  the  combination  of  the  two  studies  with  mutant  yeast  and  human  MutSa  would 
suggest  that  the  ATPase  activity  is  not  required  for  mismatch  binding  but  for  mismatch 
correction  and  that  ATP  binding  is  required  for  displacement  of  MutSa  from  mismatched 
DNA. 
Another  mutation  utilised  was  seen  in  an  MMR  deficient  cell  line  MT1  which  has  an 
aspartate  (D)--ývaline  (V)  mutation  in  the  Walker  B  motif  of  hMSH6  (laccarino  et  al., 
2000).  This  Walker  B  motif  has  been  seen  in  GTPases  to  play  a  role  in  co-ordinating 
divalent  metal  ions  into  the  catalytic  site  of  the  GTPases  with  Walker  A  and  B  motifs.  The 
D---V  msh6  mutant  in  complex  with  hMSH2  showed  the  same  binding  and  specificity  for 
heteroduplex  DNA.  ATP  induced  dissociation  of  this  hMutSa  complex  from  heteroduplex 
was  also  still  seen  and  at  even  lower  concentrations  of  ATP  than  seen  for  the  wild  type 
complex.  Where  the  ends  of  the  heteroduplex  were  blocked,  and  this  mutant  hMutSa 
complex  bound  to  the  heteroduplex,  addition  of  ATP  in  the  presence  or  absence  of 
magnesium  led  to  dissociation  of  the  complex  from  the  DNA.  This  has  led  to  the  proposal 
of  two  different  methods  of  dissociation  of  the  complex  from  DNA.  The  first  method  is 
dissociation  by  translocation  where  hMutSa  requires  the  occupancy  of  both  the  Walker  A 
and  B  sites  by  ATP  and  magnesium  ions  respectively.  The  second  method  is  by  direct 
dissociation  as  in  the  case  where  the  ends  of  the  oligo  are  blocked  and  this  requires  only 
nucleotide  binding.  Limited  proteolysis  experiments  also  demonstrated  two  distinct 
conformations  of  hMutSa,  `dissociation  prone'  and  `translocation  prone'.  The  latter  only 
apparent  where  both  ATP  and  magnesium  or  manganese  are  present. 
Another  yeast  mutant  examined  utilised  a  phenylalanine  (F)  to  alanine  (A)  mutation  in 
yMsh6p  (Bowers  et  al.,  1999).  The  mutation  of  this  conserved  residue  F--P-A  in  MutS  from 
Thermus  aquaticus  had  been  shown  to  terminate  the  crosslinking  of  MutS'  to  DNA.  The 
F---A  mutation  in  yMsh6p  and  the  over-expression  of  this  mutated  protein  in  a  wild  type 
yeast  background  gave  a  dominant  negative  phenotype  in  yeast.  It  also  led  to  defective 
MMR  by  the  wild  type  yMsh2p-yMsh3p  and  yMsh2p-yMsh6p  complexes  probably  through 
sequestering  yMsh2p.  Both  crosslinking  and  gel  shift  experiments  demonstrated  that  this 
msh6  mutant  protein  could  not  bind  a  DNA  heteroduplex  in  a  stable  manner. 22 
An  analogous  F--)-A  N-terminus  mutation  to  that  described  by  Bowers  et  al  was  utilised  in 
hMSH6  and  hMSH2  (Dufner  et  al.,  2000).  Loss  of  mismatch  binding  was  observed  only 
for  the  msh6  and  double  mutants  with  loss  of  the  binding  affinity  for  either  homoduplex  or 
heteroduplex.  The  msh6  mutant  complex  has  a  normal  ATPase  activity  but  upon  addition 
of  homo  or  heteroduplex  DNA  the  ATPase  activity  of  the  msh6  mutant  unlike  that  of  the 
msh2  or  wild  type  complex  does  not  increase.  Neither  of  these  two  mutants  can  restore 
MMR  activity  to  MMR  deficient  extracts.  In  yeast  the  double  mutant  can  still  be 
crosslinked  to  DNA,  but  unlike  the  human  protein  which  cannot,  it  has  a  second  conserved 
phenylalanine  closeby. 
The  structure  of  co-crystals  of  Thermus  aquaticus  MutS  proteins  with  DNA  shows  this 
phenylalanine  residue  is  located  on  an  alpha  helix  which  contacts  DNA  in  the  vicinity  of 
the  structural  distortion  and  the  phenylalanine  residue  partially  intercalates  into  the  DNA  at 
the  site  of  the  mismatch  (Obmolova  et  al.,  2000).  This  explains  the  key  role  of  the  residue 
in  mismatch  recognition.  Again  only  one  subunit  contacts  the  substrate  DNA  via  its  N- 
terminal  alpha-helix  while  the  equivalent  alpha  helix  of  the  second  subunit  is  turned  away 
from  the  DNA.  Also  in  the  absence  of  DNA,  much  of  the  protein  is  unstructured,  but 
mismatch  recognition  induces  formation  of  a  dimeric  clamp  on  the  substrate. 
The  way  in  which  MutS  functions  remains  controversial,  yet  is  key  to  understanding  the 
MMR  pathway.  In  summary,  Modrich  et  al  suggest  MutS  complexes  act  to  recognise  and 
bind  heteroduplex  DNA  and  subsequently  signal  downstream  events,  leading  to  repair  of 
the  mismatch  and  ATP-hydrolysis  dependent  translocation  of  the  complex  away  from  the 
mismatch  (2000;  Allen  et  al.,  1997;  Blackwell  et  al.,  1998).  Fishel  et  al  argue  against  this 
model  suggesting  instead  a  `sliding  clamp'  model,  whereby  a  mismatch  provokes 
ADP-.  ATP  exchange  within  the  MutS  complex.  Binding  of  ATP  by  this  complex  is 
proposed  to  induce  a  conformational  change  in  the  MutS  complex,  followed  by 
translocation  in  an  ATP-hydrolysis-independent  manner  away  from  this  mismatch  and 
signals  to  the  repair  machinery  (Fishel,  1998;  Gradia  et  al.,  1997;  Gradia  et  al.,  2000; 
Gradia  et  al.,  1999). 
Recent  crystal  structure  studies  of  prokaryote  MutS  complexes  propose  yet  another 
alternative  model  for  how  MutS  functions  (Lamers  et  al.,  2000;  Obmolova  et  al.,  2000).  A 
model  proposed  from  the  results  of  the  elucidation  of  the  crystal  structure  of  Thermus 
aquaticus  (TAQ)  argue  against  the  `translocation  model'.  Structural  observations  suggest 
that  the  MutS  dimer  proposed  to  facilitate  this  `translocation  model'  actually  represents  a 23 
tetramer  which  is  not  believed  to  be  the  functionally  relevant  form  of  MutS  and  which  does 
not  occur  often  under  physiological  conditions.  Biochemical  and  crystal  structure  studies 
both  suggest  that  in  fact  it  is  a  MutS  dimer  that  recognises  a  mismatch.  These  crystal 
structure  studies  also  argue  against  the  `sliding  clamp'  model.  This  model  proposed  a 
conformational  change  induced  through  ADP-ATP  exchange.  However  the  mobility  of  a 
number  of  domains  of  MutS  increases  when  the  complex  is  not  bound  to  DNA  which  is 
proposed  therefore  to  make  interpretation  of  conformational  changes  difficult.  Also  the 
MutS  complex  is  believed  to  be  tightly  bound  to  the  heteroduplex,  arguing  against  sliding. 
The  crystal  structure  studies  suggest  that  MutS  needs  to  remain  bound  to  a  mismatch  site  to 
invoke  MMR.  It  is  proposed  that  this  complex  is  unable  to  retain  the  mismatch-bound 
conformation  upon  leaving  the  mismatch.  Both  studies  propose  that  stabilisation  of  MutS 
binding  to  DNA  by  addition  of  MutL  is  facilitated  by  binding  of  MutL  to  a  specific  domain 
of  the  MutS  protein  (Lamers  et  al.,  2000;  Obmolova  et  al.,  2000).  They  also  propose  an 
allosteric  interaction  between  the  distant  ATP-  and  DNA-binding  sites  on  MutS  which  acts 
as  a  `transmitter'  of  information  between  the  two  sites. 
Overall  the  precise  function  and  ATP-dependence  of  the  MutS  complex  remains  unclear. 
However  with  further  study  a  more  unified  model  may  emerge  providing  a  fuller 
understanding  of  how  MutS  functions. 
1.1.4.4  How  Does  MutL  Function? 
The  E.  coli  MutL  gene  product  MutL  was  isolated,  purified  and  shown  to  exist  in  solution 
as  a  homodimer  (Grilley  et  al.,  1989).  This  MutL  protein  was  able  to  complement  the 
defective  MMR  activity  of  MutL  deficient  cell  extracts  in  an  in  vitro  MMR  assay.  The 
MutS  protein  as  described  earlier,  has  been  shown  to  bind  DNA  in  the  vicinity  of 
mismatched  DNA  (Su  et  al.,  1988;  Su  and  Modrich,  1986).  Using  DNAase  I  protection 
experiments  the  level  of  protection  of  the  mismatch  containing  DNA  was  shown  to 
decrease  significantly  in  the  presence  of  ATP  or  ATPyS.  In  this  study,  only  in  the  presence 
of  ATP,  the  MutL  complex  has  been  demonstrated  to  interact  with  these  MutS- 
heteroduplex  complexes  (Grilley  et  al.,  1989). 
Members  of  the  MutL  family  have  been  found  to  have  a  conserved  region  of  about  300bp 
at  the  N-terminus  of  the  protein  and  more  diverse  C-termini.  Most  mutations  producing  a 
dominant  mutator  phenotype  in  E.  coli  MutL  as  well  as  greater  than  50%  of  missense 24 
mutations  in  the  human  homologue  hMLH1  of  HNPCC  patients  are  found  within  this  N- 
terminus.  The  E.  coli  MutL  protein  is  cleaved  by  thrombin  into  an  N-terminal  40  kDa  (LN- 
40)  and  a  C-terminal  30Kd  fragment  (LC30)  (Ban  and  Yang,  1998).  The  LN40  fragment 
contains  the  conserved  residues  of  the  MutL  family.  Unlike  MutL,  LN40  is  monomeric  in 
solution  which  is  consistent  with  reports  that  the  C-terminal  is  required  for  dimerisation  of 
MutL  and  its  eukaryotic  homologues.  In  an  in  vitro  assay  for  E.  coli  MutH  activity,  LN40 
is  able  to  induce  MutH  activity  in  the  presence  of  MutS  and  DNA  heteroduplex  with  a 
GATC  site,  in  place  of  MutL  (Ban  and  Yang,  1998). 
MutL  has  also  been  shown  to  be  a  member  of  an  emergent  ATPase,  the  GHL  family 
(Bergerat  et  al.,  1997;  Dutta  and  Inouye,  2000).  Members  of  the  family  are  identified  by 
their  conserved  ATP-binding  domains,  characterised  by  three  conserved  sequence  motifs, 
and  this  family  includes  DNA  gyrase,  HSP90,  type  II  topoisomerases  and  MutL.  The 
crystal  structure  of  the  LN40  fragment  was  elucidated  and  found  to  be  homologous  to  the 
structure  of  the  ATPase  of  DNA  gyrase  (Ban  and  Yang,  1998). 
Both  MutL  and  LN40  have  been  shown  to  bind  ATP.  MutL  is  also  demonstrated  to  have 
ATPase  activity.  However  the  LN40  fragment  does  not  have  this  ATPase  activity  which 
would  suggest  that  the  C-terminal  half  of  MutL  plays  a  role  in  this  function,  possibly 
through  dimerisation  of  the  protein.  Site  directed  mutagenesis  of  MutL,  based  on 
homology  to  other  members  if  this  superfamily,  of  regions  required  for  their  ATPase 
function  have  eliminated  the  ATPase  function  of  MutL  (Ban  and  Yang,  1998).  From  this 
study  it  is  proposed  that  ATP  binding  but  not  hydrolysis  is  required  for  activation  of  MutH 
by  MutL  but  that  ATP  hydrolysis  is  required  for  mismatch  dependent  activation  of  MutH 
by  MutS  and  MutL.  ATP  binding  by  the  N-terminus  of  MutL  also  induced  conformational 
changes  in  the  protein. 
A  further  study  with  this  N-terminal  LN40  fragment  of  MutL  has  given  further  clues  to 
how  it  functions  (Ban  et  al.,  1999).  Crystal  structures  of  this  fragment  in  complex  with 
ADP  demonstrated  that  LN40  does  have  a  weak  ATP  hydrolysis  activity.  Pure  LN40  had 
been  incubated  with  ATP  but  as  ADP  was  discovered  in  the  final  refined  crystal,  hydrolysis 
must  have  occurred.  Also  crystals  of  ADPnP  complexed  with  LN40  were  made.  Studies 
with  these  crystals  demonstrated  a  change  in  MutL  conformation  upon  binding  ATP,  which 
together  with  the  weak  ATPase  activity  (stimulated  by  DNA)  of  this  protein,  are 
hypothesised  to  act  as  a  switch  involved  in  co-ordinating  DNA  mismatch  repair. 25 
Functional  requirements  for  this  ATPase  activity  of  MutL  were  identified  (Spampinato  and 
Modrich,  2000).  A  mutation  in  the  N-terminal  conserved  nucleotide  binding  motif  had 
previously  been  shown  to  produce  a  dominant  negative  phenotype  in  E.  coli.  Using  in  vitro 
assays  this  mutant  was  shown  to  be  defective  in  the  ATPase  activities,  and  the  MutS  and 
MutL  dependent  activation  of  the  MutH  endonuclease,  seen  with  the  wild  type  MutL 
protein.  The  dominant  negative  effect  of  the  mutation  results  from  inhibition  of  the  MutL 
mediated  signal  from  MutS  mismatch  recognition  to  the  MutH  endonuclease  activation 
through  the  formation  of  inactive  ternary  complexes  with  the  mutant  protein. 
The  requirement  for  this  ATPase  activity  in  eukaryotes  was  elucidated  through  the  use  of 
mutant  yeast  MutLa  components.  The  importance  of  the  N-termini  of  MutL  homologues 
in  yeast  have  been  previously  demonstrated  (Pang  et  al.,  1997).  Two  sets  of  mutations  of 
conserved  residues  of  the  nucleotide  binding  motif  in  the  yMlhip  and  yPmslp  were  made 
which  eliminated  ATP  binding  and  ATP  hydrolysis  in  the  MutL  protein  respectively  (Tran 
and  Liskay,  2000).  The  double  hydrolysis  and  ATP  binding  mutants  gave  the  same 
mutator  phenotype  observed  for  a  double  ymlhl'  ypmsl"  mutant  suggesting  that  these 
mutations  eliminated  functional  MMR.  The  individual  ATP  binding  mutants  had  a 
stronger  effect  on  mutation  avoidance  than  the  individual  ATP  hydrolysis  mutants. 
Limited  proteolysis  experiments  were  utilised  to  demonstrate  that  the  amino  terminus  of 
yMlhlp  in  yMutLa  undergoes  an  ATP-binding-dependent  conformational  change  (Tran 
and  Liskay,  2000).  Yeast  two-hybrid  analysis  has  previously  shown  that  the  N-termini  of 
yMlhlp  and  yPmslp  cannot  interact  (Pang  et  al.,  1997).  Mutations  of  the  ATP  binding 
motif  have  been  identified  in  other  GHL  family  members  which  eliminate  the  ATP 
hydrolysis  function  of  the  protein  but  not  the  ATP  binding  function.  Based  on  the  idea  that 
hydrolysis  mutations  in  the  yeast  MutL  homologues  may  act  to  prolong  the  double  ATP- 
bound  state  in  vivo,  and  allow  interaction  of  the  N-termini  of  the  two  proteins,  a  yeast  two- 
hybrid  system  was  utilised  to  examine  the  interactions  of  mutant  N-terminal  fragments  of 
yMlhlp  and  yPmslp  (Tran  and  Liskay,  2000).  These  N-terminal  mutant  fragments  clearly 
interacted  in  this  system.  However  by  repeating  this  assay  with  either  of  the  two  proteins 
expressing  a  mutant  ATP  binding  domain  in  addition  to  the  double  ATPase  mutations  no 
interaction  between  the  two  proteins  was  observed.  These  observations  suggest  that  the 
ATP  binding  function  of  both  proteins  but  not  hydrolysis  is  required  for  this  interaction 
between  the  amino  termini  of  the  two  proteins. 26 
1.1.5  Other  Proteins  Involved  in  MMR. 
In  E.  coli,  MutL  acts  to  mediate  an  interaction  between  the  site  of  the  mismatch  bound  by 
MutS  and  the  d(GATC)  sequence  cleaved  by  the  endonuclease  MutH.  MutL  is  known  to 
activate  this  endonuclease  activity  of  MutH  and  the  helicase  activity  of  UvrD  (MutU)  (Hall 
et  al.,  1998;  Hall  and  Matson,  1999;  Yamaguchi  et  al.,  1998).  MutL  and  its  eukaryotic 
homologues  are  also  known  to  enhance  -  the  binding  of  MutS  proteins  to  DNA 
(Drotschmann  et  al.,  1998;  Habraken  et  al.,  1997).  Little  else  is  understood  of  the  function 
of  MutL. 
In  the  eukaryotic  MMR  system  there  is  some  evidence  to  suggest  that  a  single-strand  nick 
either  3'  or  5'  to  the  mispair  determines  strand  discrimination  in  eukaryotic  cells  (Holmes 
et  al.,  1990;  Thomas  et  al.,  1991).  Eukaryotic  cells  do  not  have  the  d(GATC)  methylation 
signal  seen  in  E.  coli  nor  has  there  been  a  MutH  homologue  identified.  As  eukaryotic 
MMR  proteins  act  in  complexes,  a  number  of  groups  searched  for  proteins  interacting  with 
known  MMR  proteins,  with  the  aim  of  identifying  potentially  novel  proteins  involved  in 
this  repair  pathway.  For  example  no  MutH  homologue  has  been  identified  in  eukaryotic 
cells.  Therefore  using  MutL  (known  to  interact  with  MutH)  homologues  for  interaction 
studies  could  potentially  lead  to  the  discovery  of  a  MutH  homologue  in  eukaryotic  cells. 
Saccharomyces  cerevisiae  Exo1p  has  been  shown  to  interact  with  yMsh2p  protein  in  a 
yeast  two-hybrid  study  (Tishkoff  et  al.,  1997).  This  is  a  homologue  of  Saccharomyces 
pombe  Exo1p,  which  is  a  double-stranded  DNA  specific  5'-º3'  exonuclease. 
Saccharomyces  cerevisiae  exol  mutant  strain  had  a  moderate  mutator  phenotype.  Epistasis 
experiments  with  an  exol  mutant  and  mutations  in  yMSH2,  yMLH1  and  yPMS1  showed 
that  these  genes  encode  products  that  act  in  the  same  pathway,  as  no  difference  was  seen  in 
the  mutation  rate  of  the  double  mutants  compared  to,  the  single  exol  mutants.  These 
observations  would  suggest  a  possible  role  for  hEXO1  in  MMR.  An  interaction  between 
hMSH2  and  hEXO1  a  human  homologue  has  also  been  demonstrated  (Schmutte  et  al., 
1998). 
In  E.  coli,  a  number  of  exonucleases  (Exol,  ExoVII  or  RecJ)  act  with  the  helicase  UvrD  in 
the  excision  step  of  bacterial  MMR.  In  yeast  a  number  of  candidate  exonucleases  have 
been  suggested  to  act  in  this  pathway,  including  yExolp.  A  second  exonuclease  proposed 
to  function  in  this  pathway  is  the  Saccharomyces  cerevisiae  Rad27p  (FEN1  in  humans) 
5'-ý3'  exonuclease  and  flap  endonuclease,  known  to  play  a  role  in  processing  Okazaki 27 
fragments.  Once  again  mutations  in  RAD27  produce  a  moderate  mutator  phenotype 
(Johnson  et  al.,  1995;  Tishkoff  et  al.,  1997).  Mutations  in  both  genes,  i.  e.  rad27  exol 
double  mutations  are  lethal  (Tishkoff  et  al.,  1997).  These  genetic  results  with  RAD27  and 
EXO1  support  the  possibility  that  they  act  as  redundant  5'-3-3'  endo/exonucleases  in  the 
MMR  pathway.  No  3'--'5'  exonucleases  have  yet  been  implicated  in  eukaryotic  MMR. 
Proliferating  cell  nuclear  antigen  (PCNA)  plays  a  role  in  both  replication  and  repair. 
PCNA,  encoded  by  the  POL30  gene,  is  a  homotrimeric  sliding  clamp  which  is  loaded  onto 
primer-template  junctions  in  an  ATP-dependent  manner  by  the  RFC  (replication  factor  C) 
complex  (Kelman,  1997;  Lee  and  Hurwitz,  1990;  Tsurimoto  and  Stillman,  1990).  '  PCNA 
acts  as  a  processivity  factor  for  both  DNA  polymerase  S  and  E.  It  acts  to  harness  the 
catalytic  unit  of  the  polymerase  to  the  DNA  template  allowing  rapid  and  processive  DNA 
synthesis  (Kelman,  1997).  PCNA  has  been  shown  to  interact  with  a  number  of  proteins 
involved  in  replication  and  repair  including,  the  CDK  inhibitor  p21,  a  protein  which  can 
block  entry  into  S-phase  of  the  cell  cycle  and  hence  replication.  This  role  of  p21  is 
believed  to  be  partially  facilitated  through  its  interaction  with  PCNA  (Flores-Rozas  et  al., 
1994;  Kelman,  1997).  Using  an  in  vitro  repair  system  the  selective  effect  of  p21  on  PCNA 
was  demonstrated  (Li  et  al.,  1994).  -  p21  can  arrest  DNA  replication  while  permitting  active 
DNA  repair.  This  supports  the  proposal  that  DNA  damage  leads  to  inactivation  of 
chromosomal  replication,  but  allows  damage  repair.  PCNA  has  also  been  shown  to 
interact  with  and  activate  FEN1(Li  et  al.,  1995).  However  p21  inhibits  binding  of  FEN1  to 
PCNA  (Chen  et  al.,  1996;  Gomes  and  Burgers,  2000).  Whether  p21  inhibits  PCNA- 
dependent  FEN1  activity  is  yet  to  be  established. 
A  yeast  two-hybrid  library  screen  identified  interactions  between  yPcnap  and  the  two  yeast 
MMR  proteins  yMlhlp  and  yMsh2p  (Umar  et  al.,  1996).  A  yeast  strain  with  a  PCNA 
mutation  has  an  elevated  mutation  rate  at  a  dinucleotide  repeat.  The  mutation  rate  at  this 
repeat  did  not  increase  further  upon  introduction  of  mutations  into  yMLH1,  suggesting  the 
two  proteins  act  in  the  same  pathway.  These  observations  were  supported  by  epistasis 
experiments  with  another  pcna  mutant  and  mutations  in  yMSH2,  yMLH1  and  yPMS1 
(Johnson  et  al.,  1996).  The  requirement  for  PCNA  in  MMR  was  demonstrated  more 
directly  utilising  an  in  vitro  MMR  assay  that  does  not  require  DNA  repair  synthesis.  Upon 
addition  of  p21  protein,  known  to  bind  and  inhibit  PCNA  activity,  MMR  activity  as 
measured  by  this  assay  was  inhibited.  However  on  the  introduction  of  excess  PCNA, 
MMR  activity  was  restored. 28 
Human  MSH2,  hMLH1  and  hPMS2  have  been  shown  to  form  a  ternary  complex  on 
heteroduplex  DNA  (Gu  et  al.,  1998).  Formation  of  this  complex  requires  the  addition  of 
exogenous  ATP.  hPCNA  was  also  found  to  specifically  co-immunoprecipitate  with  this 
complex  (Gu  et  al.,  1998).  In  agreement  with  earlier  studies  this  group  found  hPCNA  to  be 
required  for  repair  initiation  but  also  in  the  repair  DNA  re-synthesis  step.  Affinity  binding 
studies  using  purified  proteins  demonstrated  the  ability  of  yPcnap  to  bind  the  yMsh3p- 
yMsh2p  complex  but  not  with  yMsh2p  alone  (Johnson  et  al.,  1996).  As  yMsh2p 
heterodimerises  with  yMsh3p  or  yMsh6p  and  acts  in  these  complexes  in  MMR  this  result 
supports  a  role  for  yPcnap  in  MMR.  hPCNA  has  also  been  shown  to  bind  a  number  of 
proteins  involved  in  replication  and  repair  such  as  FEN1,  UDG,  XPG,  p21  and  DNA  ligase 
1  (Kelman,  1997).  These  proteins  share  a  conserved  amino  acid  motif.  This  consensus 
sequence  has  recently  been  identified  in  the  N-terminal  of  both  MSH3  and  MSH6  proteins 
in  yeast  and  humans  but  not  in  MSH2  (Clark  et  al.,  2000).  Human  PCNA  has  been  shown 
using  GST  pull-down  assays  to  bind  short  peptide  sequences  with  this  consensus  sequence 
from  hMSH3,  hMSH6,  yMsh3p  and  yMsh6p.  An  interaction  between  yPcnap  and  the 
yMsh2p-yMsh6p  complex  was  also  observed.  Introduction  of  mutations  into  this 
consensus  binding  sequence  in  yMsh3p  and  yMsh6p  generated  a  mutator  phenotype  in 
these  strains.  These  observations  suggest  that  these  interactions  between  PCNA  and 
MSH3  and  MSH6  play  a  role  in  maintaining  genomic  stability.  Further  support  came  from 
in  vitro  MMR  assays,  where  N-terminal  MSH3  and  MSH6  peptides  with  this  consensus 
binding  sequence  were  added  to  the  reaction,  and  inhibited  the  repair  process  at  a  point 
prior  to  DNA  re-synthesis.  These  proteins  are  predicted  to  compete  with  the  native  MSH3 
and  MSH6  proteins  for  binding  to  PCNA,  preventing  functional  repair. 
Most  recently  a  complex  formed  between  yPcnap  and  the  yMsh2p-yMsh6p  complex  has 
been  identified  and  implicated  in  playing  a  role  in  mismatch  recognition  (Flores-Rozas  et 
al.,  2000).  This  interaction  was  found  to  be  mediated  through  a  specific  binding  site  on 
yMsh6p.  Mutation  of  this  site  results  in  defective  binding  to  yPcnap  and  also  produces  a 
mutator  phenotype.  Specific  binding  of  the  yMutSa  complex  to  mismatched  DNA  was 
demonstrated  upon  addition  of  yPcnap.  It  has  been  proposed  from  these  studies  that 
yPcnap  plays  a  role  in  mispair  recognition  with  yMutSa. 
With  the  aim  of  identifying  novel  eukaryotic  MMR  genes,  another  yeast  two-hybrid  screen 
was  utilised  to  identify  proteins  interacting  with  the  hMLH1  protein  (Belläcosa  et  al., 
1999).  From  this  screen,  hMLH1  was  shown  to  interact  with  the  newly  cloned  MED1 
(methyl-CpG  binding  endonuclease  1)  protein.  MED1  (or  MBD4)  structure  was  predicted 29 
from  the  protein  sequence  to  include  an  amino  terminal  methyl-CpG-binding  domain 
(MBD),  a  carboxy-terminal  catalytic  domain  with  homology  to  bacterial  DNA  damage- 
specific  glycosylase/lyases,  and  a  central  region  with  five  putative  nuclear  localisation 
signals.  In  this  study,  the  MED1  protein  was  shown  to  be  capable  of  binding  both 
hemimethylated  and  fully  methylated  DNA  and  also  to  have  a  weak  endonuclease  activity. 
Transfection  of  an  MMR  proficient  cell  line  with  a  mutant  form  of  MED1  (with  a  deleted 
MBD  domain,  AMBD)  which  acts  in  a  dominant  negative  manner  produced  an  MSI 
(microsatellite  instability)  phenotype  in  these  cells.  This  would  suggest  MED1  plays  a  role 
in  DNA  repair. 
MSI  is  detected  in  HNPCC  tumours  as  well  as  in  many  sporadic  tumours.  The  MSI 
phenotype  (RER+)  is  associated  with  loss  of  functional  MMR.  The  MED1  coding 
sequences  contains  four  potential  hypermutable  tracts.  A  number  of  studies  have  identified 
mutations  in  the  polyadenine  microsatellites  in  the  central  region  of  the  coding  sequence  of 
MED1  in  human  endometrial,  colon  and  pancreatic  carcinomas  defective  for  the  MMR 
genes  hMLH1  and  hMSH2  (Bader  et  al.,  1999;  Riccio  et  al.,  1999).  These  mutations  are 
predicted  to  result  in  the  synthesis  of  truncated  proteins  lacking  the  C-terminal  catalytic 
domain. 
Further  studies  with  the  MED1  protein  have  disputed  the  weak  endonuclease  activity  of 
this  protein  and  instead  shown  it  to  be  a  mismatch  specific  TIU  DNA  glycosylase 
(Hendrich  et  al.,  1999;  Petronzelli  et  al.,  2000).  Cytosine  methylation  in  a  CpG  context  is  a 
common  cause  of  mutations.  This  mutability  arises  through  hydrolytic  deamination  of 
cytosine.  Cytosine  deamination  produces  a  guanine-uracil  mismatch  whereas  deamination 
of  methylated  (m)  cytosine  produces  a  guanine-thymine  mismatch.  The  mismatched 
uracil  can  be  removed  by  uracil  glycosylase.  The  latter  mismatches,  m5CpG.  TpG 
mismatches  may  be  corrected  by  a  second  enzyme,  thymine  DNA  glycosylase,  TDG. 
MED1  has  been  shown  in  vitro  to  remove  both  thymine  or  uracil  from  a  mismatched  CpG 
site  (Hendrich  et  al.,  1999;  Petronzelli  et  al.,  2000).  The  MED1  protein  like  a  number  of 
other  DNA  glycosylases,  such  as  TDG  and  the  adenine  glycosylase  have  been  shown  to 
exhibit  single  turnover.  That  is  each  active  enzyme  molecule  is  proposed  to  remove  one 
mismatched  thymine  and/or  adenine  from  mismatch  containing  substrates  (Petronzelli  et 
al.,  2000).  They  also  exhibit  pre-steady  state  kinetics  due  to  the  fact  that  they  tightly  bind 
the  apurinic/apyrimidinic  (AP)  site  and  slowly  release  the  reaction  product  (Petronzelli  et 
al.,  2000).  This  tight  binding  is  believed  to  allow  protection  of  the  AP  site  from  non- 
specific  processing  until  repair  activities  are  recruited  to  the  lesion. 30 
Although  the  MBD  domain  is  not  required  for  removal  of  these  thymine  or  uracil  bases  by 
MED1,  it  is  proposed  that  it  may  act  to  direct  the  protein  to  m5CpG  rich  regions  of  the 
genome.  These  are  sites  where  deamination  of  m5C  may  be  more  frequent.  Hence 
providing  MED1  with  a  more  distinct  function  in  the  repair  of  G'T  mismatches  compared 
to  TDG  which  does  not  have  such  an  MBD  domain.  Some  of  the  proteins  involved  in 
MMR  are  described  in  a  schematic  of  the  MMR  pathway  (see  Figure  2). 
1.1.6  MMR  Knockout  Mice 
To  further  understand  the  role  of  DNA  mismatch  repair  in  maintaining  genome  stability 
and  tumorigenesis  MMR  deficient  mice  were  generated  and  studied. 
msh2"1"  embryonic  stem  (ES)  cells  were  generated  (de  Wind  et  al.,  1995).  Extracts  of  these 
MSH2  deficient  cell  lines  were  used  in  gel  shift  assays  and  the  characteristic  binding  of 
proteins  to  mismatched  DNA  described  earlier  had  been  lost.  This  supported  the  idea  that 
MSH2  is  required  for  heteroduplex  recognition  and  binding.  These  msh1l"  ES  cells  grew 
normally  compared  to  wild  type  cells.  Microsatellite  instability  at  two  loci  was  detected  in 
genomic  DNA  extracts  from  these  cells.  The  cells  also  displayed  a  mutator  phenotype  as 
measured  by  mutation  frequencies  at  the  HPRT  locus  in  response  to  selection  with  6- 
thioguanine  compared  to  wild  type  cells.  The  cells  were  tolerant  to  treatment  with  MNNG 
(N-Methyl-N'-Nitro-Nitrosoguanidine).  Treatment  of  cells  with  methylating  agents  such 
as  MNNG  produces  DNA  adducts  such  as  06-methyl  guanine.  MMR  has  been  proposed  to 
recognise  the  06-methyl  guanine"T  mispair  that  occurs  after  the  mis-incorporation  of  a 
thymidine  nucleotide  opposite  this  damaged  base  during  replication.  The  msh2""  mice 
generated  transmitted  the  mutant  allele  through  the  germline  so  mice  with  a  homozygous 
loss  of  MSH2  could  be  examined.  The  heterozygotes  were  healthy  at  8  months  however 
30%  of  the  homozygous  mice  developed  metastasising  lymphomas  at  an  average  of  2 
months.  These  results  along  with  the  studies  of  the  MSH2  deficient  cell  lines  established  a 
role  for  MSH2  in  mammalian  MMR  and  also  that  MMR  deficiency  can  lead  to  the 
accelerated  malignant  transformation  of  rapidly  expanding  cell  populations. 
MSH2  expression  has  also  been  shown  to  play  a  role  in  the  control  of  apoptosis  and 
genomic  stability  in  the  cells  of  the  murine  small  intestine.  Once  again  knockout  msh1l' 
mice  have  been  utilised  (loft  et  al.,  1999).  The  mutation  frequency  at  the  DLB1  locus  was 
measured  in  wild  type  mice  versus  MSH2  knockout  mice  in  response  to  endogenous  levels 
of  DNA  damage  and  also  in  response  to  damage  after  treatment  with  the  chemotherapeutic 31 
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Figure  2:  Schematic  Describing  the  Proteins  Involved  in  the  Eukaryotic  1)NA 
Mismatch  Repair  Pathway. 
This  figure  describes  the  interactions  between  MutS  and  MutL-related  proteins  during 
MMR.  The  protein  names  used  are  for  Sac  charoirrvices  cerevi.  Siue.  The  closest  human 
homologues  of  yPms  lp  and  yMlh3p  are  hPMS2  and  hPMSI  respectively.  MutSa  and 
MutLa  both  can  play  a  role  in  the  repair  of  IDL  mispairs.  Human  MutL(3  has  not  been 
shown  to  play  a  role  in  MMR  as  yet. 32 
drug  temozolomide.  Loss  of  MSH2  expression  in  both  cases  led  to  a  significant  increase  in 
the  mutation  frequency  at  this  locus.  This  effect  however  was  found,  using  an  in  vitro 
model  of  msh1l'  ES  cells,  to  result  partially  from  an  increased  clonogenicity.  Apoptosis 
within  the  murine  small  intestine  has  been  well  characterised,  therefore  the  MSH2- 
dependence  of  apoptosis  in  the  crypts  of  the  small  intestine  was  examined  in  response  to 
treatment  with  three  agents,  MNNG,  temozolomide,  and  cisplatin.  Resistance  to  each  has 
been  associated  with  loss  of  functional  MMR.  Apoptosis  levels  measured  histologically 
were  shown  to  be  significantly  decreased  in  the  msh2""  mice.  Analysis  of  mice  deficient 
for  both  p53  and  MSH2  demonstrated  that  this  MSH2  dependent  apoptotic  response  was 
mediated  primarily  through  a  p53  dependent  pathway.  However  MSH2  was  also  found  to 
play  a  role  in  a  delayed  p53  independent  apoptotic  pathway.  This  study  provides  evidence 
suggesting  loss  of  MSH2  predisposes  to  malignancy  through  a  lack  of  functional  repair  but 
also  through  loss  of  the  ability  to  engage  apoptosis. 
Germline  mutations  in  hMSH6  but  not  hMSH3  have  been  associated  with  HNPCC  in  a 
small  number  of  cases.  The  loss  of  both  proteins  together  in  mice  produced  a  HNPCC-like 
cancer  predisposition  (de  Wind  et  al.,  1999).  Embryonic  stem  (ES)  cells  from  msh1l'  mice 
displayed  very  low  MSH6  and  MSH3  protein  expression.  However  MSH2  protein 
expression  levels  were  also  reduced  in  msh6""  cells  and  further  reduced  in  msh3"l'  msh6l' 
cells.  These  observations  would  suggest  that  stability  of  these  three  proteins  depends  on 
their  interaction  with  each  other.  Like  msh2"1"  mice,  msh6'1'  mice  presented  with  both 
lymphomas  and  epithelial  cancer  of  the  uterus  and  skin,  but  unlike  msh2'1"  mice  did  not 
present  with  intestinal  tumours.  However  in  a  separate  study,  mice  deficient  for  MSH6, 
with  a  different  mouse  genetic  background,  were  shown  to  develop  intestinal  tumours 
which  would  suggest  that  genetic  or  environmental  factors  can  play  a  role  in  determining 
the  consequences  of  MMR  defects  (Edelmann  et  al.,  1997).  In  this  second  study  of  MSH6 
defective  mice,  extracts  from  the  msh6"''  ES  cells  were  defective  for  repair  of  single 
nucleotide  mismatches  but  repair  of  1,2,  or  4  IDL  mismatches  was  unaffected.  In 
agreement  with  this  observation  there  was  no  MSI  phenotype  observed  in  DNA  from 
tumour  cells  from  such  mice. 
MSH3  deficiency  did  not  predispose  the  mice  to  cancer,  but  in  combination  with  MSH6 
deficiency  i.  e.  in  mshYl'  msh6+  mice,  intestinal  tumours  did  develop  (de  Wind  et  al., 
1999).  In  these  knockout  mice  the  role  of  MSH6  in  MMR  directed  anti-recombination 
effects  were  demonstrated,  however  MSH3  does  not  seem  to  play  such  a  role.  MSH6  but 
not  MSH3  deficiency  was  also  shown  to  result  in  resistance  to  N-methyl-N'-nitro-N- 33 
nitrosoguanidine.  These  differences  in  effect  are  most  likely  related  to  the  functional 
redundancy  between  MutSa  and  MutS  3. 
Mice  defective  in  the  PMS2  gene  were  generated,  which  also  supported  a  role  for  PMS2  in 
DNA  mismatch  repair  (Baker  et  al.,  1995).  A  fraction  of  pms2"-  mice  developed  either  a 
lymphoma  or  a  sarcoma.  No  tumours  were  seen  in  the  wild  type  or  the  pms2+'"  mice. 
Microsatellite  instability  was  observed  in  tumour  DNA,  germline  and  tail  DNA 
demonstrating  a  role  for  PMS2  in  MMR  in  a  range  of  tissue  types  (Baker  et  al.,  1995; 
Narayanan  et  al.,  1997).  Male  pms2"'"  mice  were  infertile  which  is  due  to  abnormal 
spermatogenesis  resulting  from  defective  chromosome  synapsis  during  meiosis.  Once 
again  providing  evidence  for  a  link  between  MMR,  recombination  and  chromosome 
synapsis  in  meiosis. 
mlhl  "'"  mice  initially  generated,  once  again  like  the  msh2"1"  and  pms2"l"  mice  are  also 
defective  for  MMR  as  illustrated  by  a  microsatellite  instability  phenotype  (Edelmann  et  al., 
1996).  Extracts  from  mlhl  "''  mouse  embryonic  fibroblasts  (MEF)  were  demonstrated  to 
have  impaired  MMR  using  an  in  vitro  MMR  assay.  As  in  the  pms2"'  mice  the  male  mice 
are  infertile  although  in  this  case  no  spermatozoa  are  made.  However  mlhl""  female  mice 
are  also  infertile. 
The  tumour  susceptibility  of  mlhl  "'"  mice  was  examined  in  another  study  and  compared  to 
that  of  mice  deficient  in  PMS2  and  mice  deficient  in  PMS1  (Prolla  et  al.,  1998).  Unlike 
the  pms2"'"  mice,  mlhl  ""  mice  develop  as  well  as  lymphomas,  intestinal  adenomas  and 
adenocarcinomas  and  to  a  lesser  extent  skin  tumours  and  sarcomas.  pmsl"'  mice  did  not 
develop  tumours.  These  results  suggest  distinct  roles  for  the  three  proteins  in  tumour 
prevention.  MEF  cells  deficient  for  MLH1  and  PMS2  showed  frequent  microsatellite 
instability  at  di-  and  mono-nucleotide  repeats  unlike  PMS1  deficient  MEF  cells  which 
specifically  showed  increased  MSI  at  only  mono-nucleotide  repeats.  Similarly  the  MEF 
cells  deficient  for  MLH1  and  PMS2  showed  a  mutator  phenotype  (increased  mutation  rate) 
as  measured  by  resistance  to  oubain  which  was  not  observed  in  the  PMS1  deficient  MEF 
cells. 
These  results  suggest  MLH1  and  PMS2  function  in  a  similar  way  in  the  maintenance  of 
genetic  fidelity.  This  is  consistent  with  the  observation  that  homologues  of  these  two 
proteins  heterodimerise  in  human  and  yeast  cells.  The  mononucleotide  repeat  mutation 
frequency  in  DNA  from  mlhl  ""  mice  was  found  to  be  2-3  fold  higher  than  that  seen  in 34 
pms2"1"  mice  (Yao  et  al.,  1999).  Therefore  making  it  possible  that  some  residual  repair 
capacity  is  existent  in  the  pms2"1"  mice.  MLH1  protein  expression  was  normal  in  pms1' 
mice,  however  in  mlhl""  mice  no  PMS2  protein  expression  was  detected.  The  mlhl  "''  mice 
had  a  similar  mutator  phenotype  to  the  double  knockout  mice.  The  difference  in  tumour 
development  in  the  MLH1  and  PMS2  knockout  mice  may  reflect  this  difference  in  mutator 
phenotype.  Possibly  the  absence  of  one  protein  in  comparison  to  the  absence  of  both 
MLH1  and  PMS2  in  the  mlhl  "-  mice  determines  the  tumour  spectra  observed. 
The  stable  expression  of  human  MLH1  in  MLH1-deficient  MEF  cells  was  shown  to 
complement  a  number  of  phenotypes,  already  described  that  result  from  loss  of  functional 
MMR  (Buermeyer  et  al.,  1999).  By  transfecting  hMLH1  cDNA  into  mlhl"'  MEF  cells, 
mouse  PMS2  protein  expression  was  restored  to  normal  levels,  MSI  was  reduced, 
restoration  of  sensitivity  to  6-TG  was  seen  and  restoration  of  6-TG-induced  cell  cycle  arrest 
also  resulted.  These  observations  along  with  those  from  the  MLH1  knockout  mice  support 
a  role  for  MLH1  in  maintaining  genomic  stability  and  in  mediating  sensitivity  to  6-TG. 35 
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A  larger  number  of  mutations  are  seen  in  tumour  cells,  than  can  be  accounted  for  by  the 
spontaneous  mutation  rate  in  somatic  cells  (Loeb,  1991).  Loeb  proposed  that  if  these 
multiple  mutations  observed  in  tumours  actually  play  a  role  in  tumorigenesis,  rather  than 
just  accompanying  cancer,  then  perhaps  an  early  step  in  tumour  progression  is  the 
induction  of  this  observed  mutator  phenotype.  A  clear  relationship  between  this  mutator 
phenotype  and  tumour  progression  soon  emerged. 
The  observation  of  the  expansion  or  contraction  of  microsatellite  (tandem  repeat  nucleotide 
sequences)  in  human  tumour  cells  but  not  in  non-malignant  cells  provided  the  first  strong 
evidence  to  support  a  mutator  phenotype  in  cancer  (Peinado  et  al.,  1992).  This  change  in 
microsatellite  length  is  believed  to  result  from  DNA  polymerase  slippage  during 
replication.  A  subset  of  sporadic  colorectal  tumours  as  well  as  tumours  from  HNPCC 
cancer  patients  were  both  shown  to  display  this  MSI  or  replication  error  positive  (RER+) 
phenotype  (Aaltonen  et  al.,  1993;  Ionov  et  al.,  1993;  Thibodeau  et  al.,  1993). 
The  biochemical  basis  of  this  MSI  phenotype  soon  became  apparent.  The  mutation  rate  at 
dinucleotide  repeat  sequences  in  RER+  cells  were  shown  to  be  significantly  higher  than 
those  seen  in  RER'  cells  (Parsons  et  al.,  1993).  Importantly  it  was  found  that  these  RER+ 
cells  were  deficient  in  functional  MMR  as  demonstrated  using  an  in  vitro  MMR  assay. 
The  loss  of  MMR  leading  to  genomic  instability  was  consistent  with  studies  in  bacteria  and 
yeast.  This  RER+  phenotype  in  particular  was  observed  in  yeast  cells  in  which  genes 
known  to  play  a  role  in  yeast  MMR  (yMLH1,  yPMS1  and  yMSH2)  had  been  mutated 
(Strand  et  al.,  1993).  The  identification  of  the  human  MutS  homologue,  hMSH2,  as  a  gene 
mutated  in  some  HNPCC  families,  gave  further  credence  to  the  proposal  that  loss  of 
functional  MMR  was  in  fact  the  cause  of  this  RER+  phenotype  (Leach  et  al.,  1993).  The 
hMSH2  gene  was  shown  to  be  heterozygous  for  the  mutation  observed  in  the  somatic  tissue 
of  HNPCC  patient  but  in  tumour  RER+  cells  an  acquired  mutation  in  the  second  hMSH2 
allele  was  observed  (Leach  et  al.,  1993). 
Methylating  agents  such  as  MNU  and  MNNG  are  mutagenic  and  cytotoxic.  O6- 
methylguanine  (06-meG)  is  the  lesion  produced  in  DNA  by  treatment  with  these  agents 
(Karran  and  Bignami,  1994;  Karran  et  al.,  1990).  Under  normal  circumstances  06-meG- 
DNA  methyltransferase  (MGMT),  a  repair  enzyme,  repairs  this  lesion  directly.  However  in 36 
many  transformed  cells  this  gene  is  not  functionally  expressed  due  to  epigenetic  silencing. 
In  the  absence  of  MGMT,  cells  are  hypersensitive  to  killing  by  treatment  with  these 
methylating  agents.  This  sensitivity  is  believed  to  be  a  direct  consequence  of  the 
persistence  of  unrepaired  06-meG  in  DNA.  However  tolerance  to  treatment  with 
methylating  agents  like  MNU  and  MNNG  has  also  been  observed.  This  tolerance  or 
resistance  was  found  in  both  human  and  hamster  cell  lines  to  be  associated  once  again  with 
defective  MMR  (Branch  et  al.,  1993).  Loss  of  MMR,  known  to  be  associated  with  a 
mutator  phenotype,  was  also  shown  in  these  methylation  tolerant  cell  lines  to  result  in 
increased  mutation  rates,  as  measured  by  increased  rates  of  spontaneous  mutations  at 
selectable  genes. 
A  recent  study  demonstrated  an  increase  in  hMSH2  and  hMSH6  protein  levels  and  G/T 
mismatch  binding  activity  in  the  nucleus,  in  response  to  treatment  with  alkylating  agents 
which  produce  an  06-alkyl  guanine  adduct,  such  as  MNU,  ENU  and  MNNG,  due  to  the  re- 
localisation  of  these  proteins  to  the  nucleus  (Christmann  and  Kaina,  2000).  This  intriguing 
response  was  dose  and  time  dependent.  Treatment  of  cells  lacking  functional  MGMT,  with 
doses  of  alkylating  agents  which  did  not  trigger  cell  death,  resulted  in  increased 
translocation  of  pre-formed  hMutSa  complexes  from  the  cytoplasm  into  the  nucleus.  The 
translocation  mechanism  is,  proposed  to  involve  a  putative  nuclear  localisation  signal 
encoded  by  hMSH6.  The  results  suggest  that  06-meG  adducts  are  the  main  trigger  of  this 
translocation  of  hMutSa  into  the  nucleus.  This  discovery  supports  the  idea  that  the  loss  of 
functional  MMR  can  have  a  major  impact  on  the  response  of  cells  to  alkylating  agents. 
Another  hypermutable  cell  line  was  identified  that  was  also  tolerant  to  treatment  with  such 
methylating  agents  (Kat  et  al.,  1993).  Once  again,  the  role  for  MMR  in  mediating 
methylating  agent  cytotoxicity  was  demonstrated,  as  these  cells  were  shown  using  an  in 
vitro  MMR  assay,  to  be  defective  in  functional  MMR.  This  MT1  lymphoblastoid  B-cell 
line  had  a  different  mutation  pattern  to  its  alkylation  sensitive  parental  line  in  response  to 
treatment  with  MNNG  and  also  in  its  spontaneous  mutation  spectrum.  In  particular  a 
specific  frameshift  mutation  hotspot  in  exon  3  of  the  HPRT  gene  was  identified  in  the  MT1 
cell  line  in  response  to  treatment  with  MNNG. 
This  hotspot  at  a  run  of  six  guanines  in  exon  3  was  observed  in  a  second  study  utilising  a 
colorectal  carcinoma  cell  line  (Bhattacharyya  et  al.,  1994).  This  particular  cell  line  was 
again  shown  to  be  defective  in  MMR,  had  a  RER+  phenotype  and  an  increased-  mutation 
rate  at  the  selectable  (on  the  basis  of  resistance  to  6-thioguanine)  HPRT  gene.  The 37 
mechanism  of  6-TG  cytotoxicity  begins  by  the  metabolic  processing  of  6-TG  by  HPRT  the 
product  of  the  HPRT  gene,  to  yield  6-thioguanosine  monophosphate.  This  product  is  then 
phosphorylated  to  give  6-thioguanosine  triphosphate  which  can  be  incorporated  into 
genomic  DNA.  This  incorporation  step  is  the  key  to  the  cytotoxicity  induced  by  this  agent. 
After  incorporation  into  DNA  the  thioguanine  is  methylated  by  S-adenosylmethionine  to 
give  S6-methylthioguanine  (Swann  et  -  al.,  1996).  S6-methylthioguanine  directs 
incorporation  of  thymine  or  cytosine  into  the  newly  made  DNA  strand  during  replication 
and  the  S6-methylthioguanine-thymine  pairs  that  result  have  been  shown  to  be  recognised 
by  the  MMR  system.  From  these  observations  it  was  proposed  that  this  frameshift 
mutation  hotspot  in  exon  3  of  the  HPRT  gene  specifically  arises  due  to  defective  MMR 
(Bhattacharyya  et  al.,  1994). 
Overall  it  was  clear  from  these  studies  that  functional  mismatch  repair  is  required  to 
maintain  genomic  stability.  Loss  of  MMR  leads  to  increased  microsatellite  instability, 
increased  mutation  rates  at  selectable  gene  (e.  g.  HPRT  gene)  but  most  intriguingly  to 
resistance  to  treatment  of  cells  with  methylating  agents  such  as  MNNG.  This  resistance 
phenotype  is  also  seen  in  mice  which  have  defective  MMR  (de  Wind  et  al.,  1995;  Prolla  et 
al.,  1998).  How  exactly  functional  MMR  mediates  sensitivity  to  these  methylating  agents 
is  not  understood. 
One  model  proposed  to  explain  how  functional  MMR  mediates  sensitivity  to  these  agents 
suggests  that  methylated  bases  such  as  06-meG  do  not  actually  block  replication  (Karran 
and  Hampson,  1996).  Rather,  this  model  proposes  that  DNA  polymerase  inserts  a  base 
opposite  the  methylated  guanine,  which  is  the  best  match  'resulting  in  the  least  distortion  to 
the  DNA.  In  the  case  of  06-meG,  06-meG'T  introduces  the  least  amount  of  distortion  into 
the  DNA  (Wood  and  Shivji,  1997).  This  base  pair  is  proposed  to  be  recognised  by  the 
MMR  system  as  a  mismatch.  Support  for  this  idea  came  from  the  discovery  using  in  vitro 
gel  shift  assays  that  06-meG  base  pairs  are  recognised  by  mismatch  binding  activities 
(hMutSa)  (Duckett  et  al.,  1996;  Karran  et  al.,  1993).  hMutSa  recognises  and  binds  O6- 
meG"T  slightly  less  efficiently  than  a  G"T  mismatch.  Repair  synthesis  is  induced  in  the 
newly  made  strand  i.  e.  opposite  the  06-meG  but  as  no  suitable  complementary  base  is 
available,  it  is  proposed  that  these  lesions  lead  to  repeated  attempts  to  repair  this  mismatch 
which  somehow  triggers  cell  death.  Therefore  in  the  absence  of  functional  MMR  no  such 
attempts  to  repair  these  methylated  bases  are  instigated,  so  the  cells  survive. 38 
This  resistant  phenotype  seen  in  tumour  cells  to  treatment  with  MNU  and  MNNG  and  their 
clinical  counterparts,  such  as  temozolomide,  is  clearly  associated  with  the  loss  of  a 
functional  MMR  pathway.  The  possibility  that  this  RER+  phenotype  associated  with  loss 
of  MMR  could  be  associated  with  resistance  of  tumour  cells  to  a  wider  range  of  DNA 
damaging  agents  was  next  considered.  From  a  number  of  studies  it  soon  became  apparent 
that  functional  MMR  is  essential  to  mediate  sensitivity  to  a  wide  variety  of  clinically 
important  chemotherapeutic  agents.  ` 
The  chemotherapeutic  drug  cis-diamminedichloroplatinum  (II),  or  cisplatin  (CDDP)  is 
widely  used  and  is  effective  against  a  variety  of  tumour  types.  CDDP  exerts  its  cytotoxic 
effect  by  covalently  binding  DNA.  This  results  in  the  formation  of  a  range  of  adducts 
including  intra-strand  cross-links  and  inter-strand  cross-links.  The  majority  of  adducts  are 
believed  to  be  intrastrand  cross-links  at  the  N-7  positions  of  adjacent  guanine  bases  (1,2 
d(GpG)  adduct).  Tumour  cells  selected  for  resistance  to  cisplatin  were  discovered  to  have 
an  associated  loss  of  hMLH1  protein  expression  (Anthoney  et  al.,  1996).  These  cells  had  a 
concomitant  RER+  phenotype  and  an  increased  mutation  rate  at  the  HPRT  locus.  This 
cisplatin  resistance  phenotype  was  again  demonstrated  in  isogenic  pairs  of  cell  lines 
proficient  or  defective  for  MMR  as  determined  by  hMLH1  or  hMSH2  expression  or  lack 
thereof  (Aebi  et  al.,  1996;  Anthoney  et  al.,  1996).  In  the  absence  of  either  hMLH1  or 
hMSH2  gene  expression,  cells  were  shown  to  be  resistant  to  treatment  with  cisplatin. 
Restoration  of  sensitivity  in  these  cells  was  seen  with  chromosome  transfer  experiments, 
transferring  the  respective  wild  type  MMR  gene  back  into  these  cells. 
Sensitivity  of  cells  to  treatment  with  a  number  of  cisplatin  analogues  was  tested  in  an 
MMR  proficient  versus  deficient  background  again  using  isogenic  tumour  cell  lines  (Fink 
et  al.,  1996).  Platinum  drug  resistance  associated  with  loss  of  functional  MMR  was  shown 
to  be  specific  for  cisplatin  and  carboplatin.  No  MMR  associated  resistance  was  seen  with 
oxaliplatin,  tetraplatin  or  transplatin.  From  this  study  it  became  apparent  that  the  reason 
for  this  difference  is  due  to  the  ability  of  MMR  proteins  to  bind  the  adduct  produced  by 
treatment  with  each  drug.  Using  gel  shift  assays,  nuclear  extracts  incubated  with  cisplatin 
but  not  oxaliplatin  formed  protein  DNA  complexes  which  contained  both  hMLH1  and 
hMSH2. 
Sensitivity  of  a  wide  range  of  chemotherapeutic  agents  was  shown  to  be  dependent  on 
functional  MMR.  For  example  a  similar  study  to  those  described  above  was  carried  out 
again  using  isogenic  tumour  cells  and  demonstrated  the  acquired  resistance  to  doxorubicin 39 
(a  topoisomerase  II  inhibitor)  in  cells  where  functional  MMR  was  lost  (Drummond  et  al., 
1996).  A  summary  of  the  various  agents,  sensitivity  to  which  is  dependent  on  functional 
MMR,  is  listed  in  Table  2. 
hMutSa  binds  lesions  resulting  from  treatment  with  methylating  agents  such  as  O6- 
methylguanine  or  04-methylthymine  and  binds  platinated  adducts  such  as  the  cisplatin 
induced  1,2  d(GpG)  adduct  (Duckett  et  al.,  1996).  The  hMutSa  complex  has  been  shown 
to  have  different  levels  of  affinity  for  different  adducts  depending  on  the  base-pairing  with 
the  alkylated  or  platinated  base  (Yamada  et  al.,  1997).  hMutSa  binds  the  1,2  d(GpG) 
adduct  with  the  highest  affinity  when  it  is  opposite  non-complementary  bases  i.  e.  when  the 
complementary  strand  has  aT  opposite  the  3',  and  aC  opposite  the  5'  guanine.  When  the 
1,2  d(GpG)  adduct  or  the  06-methylguanine  is  base-paired  with  a  C,  recognition  by 
hMutSa  is  poor,  compared  to  when  they  are  base-paired  with  a  non-complementary  base 
such  as  T.  This  would  suggest  that  damaged  DNA  which  has  undergone  replication  is 
most  likely  to  be  recognised  by  the  hMutSa  complex.  Recent  studies  of  crystal  structures 
of  TAQ  MutS  bound  to  heteroduplex  DNA  suggest  kinked  DNA  is  a  general  feature  of 
these  complexes  (Obmolova  et  al.,  2000).  Base  stacking  is  less  stable  at  a  mismatch  site 
and  is  therefore  more  susceptible  to  deformation.  Therefore  as  DNA  effected  by  cisplatin 
treatment  is  kinked,  this  in  combination  with  the  mismatch  resulting  from  a  round  of  DNA 
replication  may  aid  binding  of  the  adduct  by  hMutSa.  Rapid  induction  of  apoptosis  in 
immature  rat  thymocytes  in  response  to  treatment  with  cisplatin  was  seen  in  proliferating 
cells  (Evans  et  al.,  1994).  However  in  purified  non-proliferating  cells  apoptosis  levels  in 
response  to  treatment  with  cisplatin  were  nominal.  These  two  studies  would  suggest  that 
the  induction  of  apoptosis  in  sensitive  cells  in  response  to  treatment  with  cisplatin  requires 
the  cells  to  be  proliferating  and  therefore  undergoing  replication. 
A  model  to  explain  how  resistance  arises  due  to  loss  of  functional  MMR  must 
accommodate  the  different  methods  of  action  of  the  various  DNA  damaging  agents 
described.  The  discovery  of  a  range  of  agents,  sensitivity  to  which  is  mediated  through  the 
MMR  pathway,  has  led  to  a  second  model  being  proposed  to  explain  how  resistance 
occurs.  This  model  proposes  that  enhanced  replicative  bypass,  which  is  defined  as  the 
ability  of  the  replicative  complex  of  a  cell  to  synthesise  DNA  past  the  DNA  adduct,  gives 
rise  to  the  resistant  phenotype  (Mamenta  et  al.,  1994).  This  process  has  also  been  referred 
to  as  postreplication  repair  because  bypassing  the  adduct  during  S  phase  will  allow  survival 40 
Table  2:  Mismatch  Repair  Defects  Mediate  Cellular  Drug  Response. 
Taken  from  Sedwick  et  al  (Sedwick,  1999). 
Drug  or  Agent  Response  Probable  or  Possible  Mechanism 
ALKYLATING  AGENTS  Resistance  Prevents  apoptotic  signalling 
SN-1  Alkylators  Critical  proteins  for  apoptosis  may  not  be 
expressed  in  some  MMR  defective  cells. 
MNNG 
Prevents  toxicity  from  futile  DNA  repair  cycling 
MNU  Mutation  in  response  to  miscoding  during  DNA  polymerase 
bypass  synthesis. 
Temozolomide 
With  MMS,  apurinic  sites  may  be  recognised  as 
SN-2  Alkylators  miscoding  lesions  similar  to  base  modifications 
MMS 
Cisplatin  Resistance  Allows  lesion  by-pass  to  occur  preventing  toxicity 
at  DNA  segregation. 
Carboplatin 
Blocks  recombination-dependent  DNA  repair. 
Doxorubicin  Resistance  Unknown,  may  be  similar  to  alkylator  resistance 
mechanism. 
6-Thioguanine  Resistance  Tolerance  to  mispairs  from  drug  mis-incorporation 
mediated  by  same  mechanisms  as  those  seen  for 
alkylating  agents. 
5-Fluoruracil  (5-FU)  Resistance  Allows  lesion  by-pass,  prevents  apoptosis 
signalling. 
X-irradiation  Accumulation  of  toxic  oxidative  lesions  and/or 
lesion  leading  to  double  strand  break  repair  may 
Low  dose  rate  Sensitivity  kill  cells. 
Interference  with  recombinational  repair  may 
predominate  over  other  repair  processes  in 
response  to  low  levels  of  toxic  lesions. 
High  dose  rate  Resistance 
Mixed  results  may  reflect  differing  capacities  of 
or 
Sensitivity  cells  for  repair  of  oxidative  or  recombinagenic 
lesions. 41 
Acridine  compounds  Sensitivity  Prevents  lesion  repair  leading  to  toxic  levels  of 
frameshift  events 
Mutation 
Temozolomide  +  Benzimide  Sensitivity  3-aminobenzamide  may  alter  capacity  for  lesion 
by-pass  or  affect  other  co-operating  repair 
systems. 
Cisplatin  +  Aphidicolon  Sensitivity  Aphidicolon  prevents  lesion  by-pass  at  cisplatin 
lesions  in  MMR-defective  cells. 42 
of  the  cell  into  G2  where  cell  cycle  arrest  can  occur  allowing  repair  of  the  damage  before 
entering  mitosis  (Karran  and  Marinus,  1982). 
Utilising  parental  and  resistant  human  ovarian  carcinoma  cell  lines  the  relationship 
between  resistance  and  replicative  bypass  was  analysed  further  (Mamenta  et  al.,  1994).  In 
the  cisplatin-resistant  cell  lines  replicative  bypass  of  the  platinated  adducts  was  specifically 
observed.  These  observations  suggest  that  this  replicative  bypass  mechanism  contributes 
in  part  to  the  resistant  phenotype  observed  in  these  cells.  This  proposal  is  further  supported 
by  another  study  which  utilised  an  in  vitro  system  to  look  at  steady-state  replication  which 
measures  the  rate  of  DNA  synthesis  across  DNA  lesions  (Vaisman  et  al.,  1998). 
Specifically  the  rate  of  bypass  of  cisplatin  adducts  in  cells  with  defects  in  either  hMLH1  or 
hMSH6  was  significantly  increased  compared  to  MMR  proficient  cells. 
The  sensitivity  of  MMR  defective  cells  to  cisplatin  and  MNU  has  been  shown  to  increase 
upon  treatment  of  the  cells  with  the  polymerase  inhibitor  aphidicolin  (inhibits  polymerase 
a,  c  and  S)  to  a  greater  extent  than  seen  in  MMR  proficient  cells  (Moreland  et  al.,  1999). 
Polymerase  c  and  S  have  been  shown  to  bypass  cisplatin  induced  1,2  crosslinks  in 
structures  that  resemble  replication  forks.  Treatment  with  aphidicolin  also  partially 
restored  the  cisplatin  induced  G2  arrest  absent  in  MMR  deficient  cells  compared  to 
proficient  cells.  These  observations  are  consistent  with  the  model  proposed  above  whereby 
aphidicolin  is  inhibiting  replicative  bypass  preferentially  in  cells  with  defective  MMR. 
1.2.1  MMR  Mediated  Sensitivity  to  DNA  Damaging  Agents:  Possible 
Pathways 
Overall  a  number  of  models  have  been  proposed  to  explain  how  loss  of  functional  MMR 
leads  to  a  resistant  phenotype.  One  model  suggests  that  the  lesion  produced  in  response  to 
treatment  with  e.  g.  methylating  agents  persists  in  the  template  leading  to  futile  rounds  of 
repair.  This  abortive  repair  produces  excision  intermediates  which  are  proposed  to 
somehow  activate  the  damage  response  pathway.  Therefore  in  the  absence  of  functional 
MMR  no  such  excision  intermediates  will  arise.  A  second  model  proposes  that  due  to  the 
fact  that  MMR  proteins  recognise  and  bind  these  lesions  this  leads  to  the  assembly  of  a 
signalling  complex  which  directly  triggers  the  damage  response.  Again  in  the  absence  of 
MMR  the 
, 
signalling  to  these,  downstream  pathways  will  be  lost.  Finally  another  model 
suggests  the  mechanism  of  resistance  involves  enhanced  replicative  bypass  of  the  lesion,  in 
the  absence  offunctional  MMR  which  allows  the  damage  to  persist.  The  models  proposed 43 
to  explain  how  these  resistant  phenotypes  arise  suggest  that  a  functional  MMR  pathway  is 
required  to  trigger  downstream  cellular  responses  which  result  in  an  apoptotic  response  to 
treatment  with  these  agents.  How  exactly  MMR  transduces  signals  leading  to  apoptosis  is 
not  clear. 
Alterations  in  the  p53  gene  are  frequently  observed  in  human  neoplasia.  p53  levels  are 
elevated  in  the  cisplatin  resistant,  MMR  deficient  A2780/CP70  ovarian  carcinoma  cell  line 
compared  to  the  parental  cisplatin  sensitive,  MMR  proficient  A2780  cell  line  (Brown  et  al., 
1993).  Elevated  expression  of  p53  is  often  associated  with  mutations  in  conserved 
domains  of  the  protein.  However  p53  in  the  A2780/Cp70  cell  line  was  shown  to  be  wild 
type,  i.  e.  no  mutations  were  found  upon  sequencing.  These  cells  also  had  a  decreased 
apoptotic  response  to  treatment  with  cisplatin  compared  to  the  parental  cell  line  (Anthoney 
et  al.,  1996).  In  addition  the  p53  dependent  Gl  arrest  in  response  to  ionising  radiation  (IR) 
was  also  significantly  reduced  in  these  cells  compared  to  the  parental  cell  line.  This 
demonstration  of  loss  of  p53  functions  was  corroborated  by  the  reduced  amount  of  p21 
mRNA  expressed  in  these  cells,  a  gene  known  to  be  partially  regulated  by  p53  and  required 
for  the  p53  dependent  Gl  arrest  in  response  to  IR.  Introduction  of  a  dominant  negative 
mutant  form  of  p53  into  the  A2780  parental  cell  line  or  inactivation  of  p53  function  in 
these  cells  using  genetic  suppressor  elements  results  in  acquired  resistance  to  cisplatin 
(Anthoney  et  al.,  1996;  Gallagher  et  al.,  1997).  Restoration  of  functional  MMR  to  these 
MMR  deficient  cells  restores  sensitivity  to  drugs  such  as  cisplatin,  but  does  not  restore  p53 
function.  From  these  studies  a  direct  role  for  MMR  in  signalling  to  p53  has  not  been 
established  in  this  model.  Instead  it  is  possible  that  both  functional  MMR  and  p53  are 
required  for  sensitivity  to  cisplatin  but  are  not  mutually  exclusive  as  is  suggested  by  other 
studies  (Branch  et  al.,  2000). 
Phosphorylation  of  Ser-15  and  Ser-392  of  p53  has  been  implicated  in  playing  a  role  in 
cellular  responses  to  different  types  of  DNA  damage.  Therefore  p53  was  used  in  another 
study  as  an  in  vivo  substrate,  to  test  whether  damage-signalling  kinases  are  activated  in 
response  to  treatment  with  MNU  or  MNNG,  in  an  MMR  dependent  manner  (Duckett  et  al., 
1999).  Loss  of  hMutSa  or  hMutLa,  in  cells  results  in  loss  of  G2  arrest  and  apoptosis  in 
response  to  treatment  with  methylating  agents  or  the  anti-metabolite  6-thioguanine  (Hawn 
et  al.,  1995;  Kat  et  al.,  1993).  This  G2  arrest  occurs  in  the  second  cycle  after  drug  exposure 
in  MMR  proficient  cells.  This  suggests  that  a  round  of  replication  is  required,  allowing 
incorporation  of  an  incorrect  base  opposite  e.  g.  the  06-methylguanine  or  the  S6- 
methylthioguanine  adducts  that  result  from  treatment  with  such  agents,  forming  a  mispair 44 
recognised  by  the  MMR  system.  The  MMR  system  is  proposed  to  recognise  these  adducts 
and  signal  downstream  cellular  responses.  This  observation  further  supports  the 
requirement  for  translesion  synthesis  for  sensitivity  to  these  agents,  i.  e.  to  trigger  cell  death. 
Functional  MMR,  in  particular  both  hMutSa  and  hMutLa,  were  found  to  also  be  required 
for  phosphorylation  of  p53  in  response  to  treatment  with  these  methylating  agents  (MNU 
or  MNNG)  (Duckett  et  al.,  1999).  These  results  clearly  implicate  MMR  as  playing  a  role 
in  signalling  cellular  responses  to  methylator  damage  through  a  p53.  dependent  pathway. 
Analysis  of  mice  deficient  for  both  p53  and  MSH2  demonstrated  that  MSH2  dependent 
apoptotic  response  to  treatment  with  temozolomide  (a  methylating  agent)  is  also  mediated 
primarily  through  a  p53  dependent  pathway  (loft  et  al.,  1999).  However  MSH2  was  also 
found  to  play  a  role  in  a  delayed  p53  independent  apoptotic  pathway. 
The  c-ABL  protein  tyrosine  kinase  and  the  c-JUN  NH2-terminal  kinase  (JNK)  are  activated 
in  cells  in  response  to  treatment  with  the  DNA-damaging  agent  cisplatin  (Nehme  et  al., 
1997).  In  MMR  deficient  cells  the  activation  of  the  c-ABL  kinase  in  response  to  treatment 
with  cisplatin  is  completely  lost.  Activation  of  JNK  has  also  been  shown  to  be  weaker  in 
MMR  deficient  cells  compared  to  proficient  cells  in  response  to  treatment  with  cisplatin. 
However  JNK  activation  by  cisplatin  was  not  seen  in  cells  deficient  for  hMSH2  suggesting 
that  JNK  is  not  essential  for  activation  of  apoptosis  in  response  to  cisplatin.  c-ABL 
activation  is  seen  in  response  to  a  number  of  different  forms  of  DNA  damage.  For  example 
c-ABL  contributes  to  the  Gl  arrest  of  cells  in  response  to  IR  in  a  p53-dependent  manner 
(Yuan  et  al.,  1996).  c-ABL  interacts  with  p53  in  irradiated  cells  but  does  not  phosphorylate 
the  p53  protein.  c-ABL  can  regulate  DNA-damage  induced  apoptosis  through  a  p53  - 
independent  mechanism  (Yuan  et  al.,  1997).  Theses  observations  have  led  to  the  proposal 
that  c-ABL  may  act  to  couple  damage  detection,  such  as  recognition  of  adducts  by  the 
MMR  system,  to  an  apoptotic  response. 
Further  evidence  for  this  proposed  role  for  c-ABL  has  come  from  studies  of  the  p53-related 
gene  p73.  The  p73  gene  like  p53  encodes  a  protein  with  a  transactivation,  DNA-binding 
and  oligomerisation  domain  and  is  significantly  homologous  to  p53  (Clurman  and 
Groudine,  1997).  Different  isoforms  of  p73  are  expressed  due  to  alternative  splicing,  some 
of  which  can  transactivate  p53  target  genes,  induce  cell  cycle  arrest  and  apoptosis  (White 
and  Prives,  1999).  A  number  of  studies  have  demonstrated  that  p73  is  a  target  of  the  non- 
receptor  protein  tyrosine  kinase  c-Abl. 45 
A  cell  line  deficient  for  hMLH1  expression  was  utilised  in  one  study  (Gong  et  al.,  1999). 
Restoration  of  MMR  activity  in  these  cells  and  hence  sensitivity  to  cisplatin  was  seen  upon 
transfer  of  chromosome  3  (carries  hMLHJ)  into  these  cells.  Chromosome  transfer  of 
chromosome  2  into  these  cells  had  no  such  effect,  these  cells  like  the  parent  line  remained 
resistant  to  treatment  with  cisplatin.  However  p53  induction  on  treatment  with  cisplatin 
was  the  same  in  each  of  these  three  cell  types.  Interestingly  p73  was  induced  only  in  the 
chromosome  3  transfer  line  i.  e.  where  there  was  proficient  MMR  upon  treatment  with 
cisplatin.  In  this  cell  line  sensitivity  correlates  with  the  induction  of  both  p53  and  p73. 
p73  mRNA  expression  levels  did  not  increase,  instead  the  half-life  of  the  protein  was  seen 
to  increase. 
This  induction  of  p73  in  response  to  treatment  with  cisplatin  and  the  stabilisation  of  this 
protein  in  these  cell  lines  was  found  to  be  dependent  on  the  kinase  activity  of  c-ABL. 
Using  mouse  embryonic  fibroblasts  deficient  for  c-ABL,  hMLH1  and  p53  it  was  found  that 
although  p73  is  expressed  in  the  absence  of  these  proteins  induction  upon  treatment  with 
cisplatin  requires  both  hMLH1  and  c-ABL.  p53  induction  does  not  require  expression  of 
either  hMLH1  or  c-ABL.  In  the  p53  deficient  cells  some  killing  by  cisplatin  is  apparently 
mediated  via  p73. 
Induction  of  apoptosis  by  p73  specifically  requires  c-ABL,  in  particular  the  kinase  activity 
of  this  protein  (Agami  et  al.,  1999).  p73  and  c-ABL  were  shown  to  interact,  via  the  SH3 
domain  of  c-ABL  and  a  PXXP  domain  within  the  linker  region  between  the  DNA-binding 
and  oligomerisation  domains  of  p73.  Under  physiological  conditions  these  two  proteins 
were  shown  to  co-immunoprecipitate  in  untreated  cells  and  in  cells  after  y-irradiation 
(Agami  et  al.,  1999;  Yuan  et  al.,  1999).  p73  was  also  shown  to  be  a  substrate  for  c-ABL 
mediated  phosphorylation.  c-ABL  induced  the  transactivation  function  of  p73  by 
phosphorylation  of  tyrosine  at  position  99  of  this  protein. 
However  this  phosphorylation  of  p73  decreased  in  AT  cells  (ATM  deficient)  (Yuan  et  al., 
1999).  ATM  is  known  to  interact  with  and  phosphorylate  both  c-ABL  and  p53  (Banin  et 
al.,  1998;  Shafman  et  al.,  1997).  The  activation  of  both  proteins  by  ATM  probably 
represents  two  separate  pathways.  Overall  the  c-ABL  mediated  phosphorylation  of  p73 
results  in  increased  apoptosis  in  response  to  DNA  damage  caused  by  IR,  treatment  with 
cisplatin,  but  not  UV  (Gong  et  al.,  1999).  c-ABL  induction  in  response  to  cisplatin  relies 
upon  functional  MMR.  These  studies  together,  provide  some  evidence  for  a  role  for 
mismatch  repair  proteins  in  the  signalling  of  downstream  responses  to  DNA  damage. 46 
1.2.2  Significance  of  MSI  and  Resistance. 
Functional  MMR  is  clearly  required  to  mediate  sensitivity  to  a  range  of  clinically  important 
anti-cancer  agents  such  as  cisplatin.  However  in  the  studies  described  the  resistance  to 
cisplatin  is  relatively  low,  about  2  fold,  in  the  absence  of  functional  MMR.  The  question 
of  whether  this  level  of  resistance  is  clinically  relevant  must  be  asked. 
Experiments  with  mixed  populations  of  cells,  with  a  minority  of  MMR  deficient  cells 
which  are  constitutively  expressing  GFP  (green  fluorescent  protein),  exposed  a  number  of 
times  to  either  cisplatin  or  oxaliplatin  were  carried  out  (Fink  et  al.,  1998;  Fink  et  al.,  1997). 
Treatment  with  cisplatin  but  not  oxaliplatin  resulted  in  the  gradual  enrichment  for  MMR 
deficient  cells.  When  grown  as  xenografts,  cisplatin  treatment  of  the  tumours  again 
resulted  in  significant  enrichment  for  MMR  deficient  cells  (Fink  et  al.,  1998).  These 
results  would  suggest  that  treatment  with  the  DNA-damaging  agent  cisplatin  results  in 
selection  of  MMR  deficient  cells.  The  lack  of  enrichment  by  oxaliplatin  for  MMR 
deficient  cells  is  in  agreement  with,  observations  that  MMR  does  not  seem  to  play  a  role  in 
mediating  sensitivity  to  this  agent  (Fink  et  al.,  1996). 
Xenografts  were  also  utilised  to  test  whether  loss  of  MMR  causes  resistance  to  cisplatin  in 
vivo.  MSH2+'+  and  msh2"l'  ES  cells  were  established  as  xenografts  in  nude  mice  and 
treated  with  either  cisplatin  or  oxaliplatin  after  tumour  implantation  (Fink  et  al.,  1997). 
The  msh2'l'  mice  were  considerably  less  sensitive  to  treatment  with  cisplatin  compared  to 
the  MSH2+1+  mice,  whereas  there  was  no  difference  in  sensitivity  to  oxaliplatin.  This 
provides  evidence  for  in  vivo  resistance  to  cisplatin  in  MMR  deficient  cells. 
Collectively  these  observations  suggest  that  although  the  level  of  resistance  to  these  drugs 
is  quite  modest  in  the  absence  of  MMR,  exposure  to  e.  g.  cisplatin  can  produce  a  significant 
enrichment  for  MMR  deficient  cells  both  in  vitro  and  in  vivo.  It  is  proposed  that  this 
enrichment  could  foster  additional  mutations  that  underlie  tumour  progression. 
This  proposal  is  supported  by  the  fact  that  loss  of  functional  MMR  is  also  associated  with 
the  emergence  of  microsatellite  instability,  an  RER+  phenotype.  For  example  cancers 
associated  with  HNPCC,  a  hereditary  cancer  linked  to  loss  of  functional  MMR,  are 
characterised  by  instabilities  of  these  simple  repeat  sequences  (Aaltonen  et  al.,  1993).  This 
microsatellite  instability  (MSI)  is  not  only  observed  in  colorectal  cancer  but  in  a  wide  range 
of  cancers  including  sporadic  breast  and  ovarian  cancers. 47 
An  RER+  phenotype  has  been  seen  in  a  proportion  of  sporadic  colorectal  cancer  tumours  to 
be  associated  with  good  prognosis  (Bubb  et  al.,  1996).  However  this  association  of  an 
RER+  phenotype  with  good  prognosis  is  not  seen  in  all  cancers  with  this  phenotype.  For 
example  this  RER+  phenotype  has  also  been  shown  to  correlate  with  poor  disease  free  and 
overall  survival  in  sporadic  breast  cancers  (Paulson  et  al.,  1996).  This  difference  in  the 
effect  of  an  RER+  phenotype  on  prognosis  between  colon  and  breast  cancer  may  reflect  the 
different  impact  of  this  phenotype  on  these  tumours.  For  example  the  RER+  phenotype 
seen  in  these  sporadic  colon  cancers  may  select  for  mutations  in  genes  that  normally 
facilitate  tumour  progression.  In  the  case  of  these  breast  cancers  the  effect  of  the  RER+ 
phenotype  may  have  more  to  do  with  the  chemotherapeutic  treatment  administered,  as  loss 
of  MMR  and  an  RER+  phenotype  are  associated  with  resistance  to  drugs  such  as  cisplatin, 
which  are  commonly  used  in  the  treatment  of  sporadic  breast  cancer. 
If  cisplatin  or  other  similar  anti-cancer  agents  enrich  tumour  populations  for  cells  deficient 
for  MMR  this  may  have  important  implications  other  than  just  the  emergence  of  drug 
resistance.  MMR  deficient  cells  have  a  mutator  phenotype  which  is  indicative  of  increased 
mutation  rates  at  a  variety  of  alleles  including  e.  g.  transforming  growth  factor  ß  receptor  II, 
which  can  influence  the  tumour  phenotype  (Markowitz  et  al.,  1995).  This  mutator 
phenotype,  identified  in  a  range  of  HNPCC  and  sporadic  cancers  has  been  attributed  in 
many  cases  to  mutations  in  MMR  genes.  In  MSI-positive  tumours,  from  HNPCC  and 
sporadic  cancers,  somatic  frameshift  mutations  have  been  detected  in  the  repeat  tracts  of  a 
range  of  genes  including  the  MMR  genes,  hMSH3  and  hMSH6,  the  pro-apoptotic  gene  BAX 
and  more  recently  the  repair  gene  MED1  (Riccio  et  al.,  1999;  Yamamoto  et  al.,  1997; 
Yamamoto  et  al.,  1998).  These  observations  support  the  model  of  mutators  mutations 
(Malkhosyan  et  al.,  1996;  Perucho,  1996).  This  model  proposes  that  the  mutator  phenotype 
emerges  through  a  number  of  steps.  The  primary  step  is  a  homozygous  mutation  in  for 
example  an  MMR  gene  such  as  hMLH1  or  hMSH2,  which  results  in  mutations  in 
secondary  mutator  genes,  such  as  other  MMR  genes.  As  there  is  a  higher  occurrence  of 
these  somatic  frameshift  mutations  in  the  repeat  tracts  of  such  genes,  compared  to  other 
genes  with  these  repeat  sequences,  a  positive  selective  pressure  for  mutations  in  these 
specific  genes  appears  to  exist  in  tumorigenesis.  This  enrichment  effect  could  therefore 
result  in  the  accumulation  of  additional  mutations  in  genes  that  underlie  tumour 
progression  and/or  drug  resistance. 
Paired  tumour  samples  from  38  ovarian  cancer  patients  who  had  undergone  at  least  three 
rounds  of  cisplatin  or  carboplatin  based  chemotherapy  were  examined  histologically  for 48 
hMLH1  expression  (Fink  et  al.,  1998).  In  a  large  proportion  of  cases  following  treatment 
with  either  drug,  the  level  of  hMLH1  expressed  in  the  tumour  cells  had  decreased 
significantly.  In  a  number  of  small  retrospective  studies  looking  at  hMLH1  expression  in 
breast  and  ovarian  tumour  samples,  pre  and  post  cisplatin-based  chemotherapy,  hMLH1 
was  also  shown  to  be  significantly  reduced  and  this  was  associated  with  poor  disease  free 
survival  (Mackay  et  al.,  2000).  Evidence  for  loss  of  hMLH1  expression  other  than  through 
mutation  has  also  emerged.  Loss  of  hMLH1  in  colon  and  ovarian  tumour  cells  and  also 
colon,  ovarian  and  endometrial  tumour  cell  lines  arose  through  cytosine  methylation  of  the 
hMLH1  promoter  (Kane  et  al.,  1997;  Strathdee  et  al.,  1999). 49 
1.3  MMR  and  the  Cell  Cycle 
A  role  for  MMR  in  cell  cycle  regulation  has  been  suggested  from  a  number  of  studies.  Re- 
introduction  of  chromosome  3  (carries  hMLH1)  into  a  hMLH1  deficient  cell  line  produced 
increased  cell  cycle  arrest  at  G2  in  response  to  treatment  with  the  antimetabolite  6- 
thioguanine  compared  to  the  parent  cell  line  (Hawn  et  al.,  1995).  hMLH1  has  also  been 
implicated  in  regulating  a  G2-M  arrest  in  response  to  treatment  with  IR  (Davis  et  al.,  1998). 
Once  again,  using  chromosome  3  transfer  into  a  hMLH1  deficient  parental  cell  line, 
enhanced  G2-M  arrest  was  demonstrated  in  response  to  IR  compared  to  the  MMR  deficient 
parental  cell  line.  However  as  seen  in  studies  utilising  established  mouse  embryonic 
fibroblasts  deficient  for  PMS2,  MLH1  or  MSH2  expression,  these  cells  deficient  for 
functional  MMR  did  not  show  much  difference  in  survival  after  IR  compared  to  the  MMR 
proficient  cells  (Fritzell  et  al.,  1997). 
Cell  cycle  expression  of  MMR  genes  was  examined.  In  yeast  mRNA  expression  of 
yMSH2,  yMSH6  and  yPMS1  were  each  found  to  increase  at  the  GI-S  boundary  compared  to 
other  points  in  the  cycle  (Kramer  et  al.,  1996).  Expression  levels  of  yMLH1  and  yMSH3 
were  shown  to  be  constitutive  throughout  the  cell  cycle. 
Expression  of  human  MMR  genes  has  also  been  studied.  One  study  of  hMSH2  expression 
in  resting  versus  proliferating  blood  lymphocytes  and  thymocytes  demonstrated  that 
hMSH2  protein  levels  increased  12  fold  upon  induction  of  proliferation  (Marra  et  al., 
1996).  However  throughout  the  cell  cycle  only  minor  variations  in  hMSH2  protein 
expression  were  observed,  in  particular  a  slight  increase  in  expression  was  seen  at  the 
G2/M  replicative  and  post-replicative  phases.  A  second  study  also  reported  little  variation 
in  hMSH2  mRNA  or  protein  levels  throughout  the  cell  cycle  (Meyers  et  al.,  1997). 
Expression  levels  of  hMLH1  showed  a  similar  pattern,  although  as  for  hPMS2,  protein 
levels  did  increase  slightly  at  the  G1/S  transition  phase. 
Steady  state  levels  of  the  human  MMR  proteins  were  also  examined  (Chang  et  al.,  2000). 
Utilising  competitive  quantitative  reverse  transcription-polymerase  chain  reaction  and 
western  blotting.  Results  with  both  measurements  gave  similar  ratios  of  expression  levels 
between  the  different  gene  products.  The  hMutS  homologues  were  found  to  be  the  most 
abundantly  expressed  proteins.  In  particular  hMSH2  was  expressed  at  approximately  3-5 
times  the  level  of  hMLH1.  hMSH6  was  more  highly  expressed  than  hMSH3  but  the 
combined  abundance  of  the  two  proteins  was  about  equal  to  that  of  hMSH2.  hMLH1  was 50 
about  twice  as  abundant  as  hPMS2.  In  agreement  with  the  earlier  study  with  hMSH2 
alone,  expression  levels  of  all  the  MMR  genes  examined  increased  in  highly  proliferative 
cells. 
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1.4  Transcription  Coupled  Repair  and  MMR 
DNA  repair  and  transcription  are  not  two  completely  separate  processes  as  demonstrated 
by  the  discovery  that  in  E.  coli,  Saccharomyces  cerevisiae  and  human  cells,  DNA  damage  is 
repaired  more  rapidly  in  the  transcribed  strand  than  from  the  non-transcribed  strand  in 
expressed  genes  (Hanawalt,  1994).  This  phenomenon  has  been  called  transcription- 
coupled  repair  (TCR).  It  is  proposed  that  the  presence  of  a  bulky  lesion  in  response  to 
treatment  with  e.  g.  ultraviolet  light  (UV)  leads  to  the  stalling  of  RNA  polymerase  at  this 
lesion,  somehow  signalling  repair  to  this  strand  (Leadon,  1999;  Mellon  et  al.,  1987). 
Nucleotide  excision  repair  (NER)  acts  to  repair  bulky  helix  distorting  lesions,  such  as 
cyclobutane  pyrimidine  dimers  that  result  from  UV  exposure,  or  thymine  glycols  that  result 
from  oxidative  DNA  damage  (Wood,  1997).  Such  bulky  lesions  can  obstruct  transcription 
and  replication  processes.  A  key  part  of  the  NER  pathway  is  the  incision  of  the  damaged 
strand  on  both  sides  of  the  lesion  and  consequent  removal  of  the  damage  site.  It  is  believed 
that  a  proportion  of  NER  is  coupled  to  transcription  (Leadon,  1999).  A  number  of  gene 
products  involved  in  this  TCR  process  have  been  found  to  be  mutated  in  three  human 
hereditary  disorders,  xeroderma  pigmentosum  (XP),  Cockayne's  syndrome  (CS),  and 
trichothiodystrophy  (TTD).  Two  helicases,  encoded  by  XPB  and  XPD  which  play  a  role  in 
NER  are  also  known  to  be  components  of  TFIIH,  a  transcription  initiation  factor  complex 
NER  repairs  bulky  adducts  as  described  above.  MMR  functions  to  repair  single  base 
mismatches  and  small  heteroduplexes.  MMR  proteins  have  been  discovered  to  also  play  a 
role  in  TCR,  which  has  led  to  the  proposal  that  MMR  may  act  to  couple  NER  to 
transcription.  Initial  observations  in  E.  co1i  demonstrated  that  mutations  in  MutS  or  MutL 
resulted  in  the  abolition  of  TCR  of  cyclobutane  pyrimidine  dimers  (CPD)  in  the  induced 
lactose  operon  of  cells  treated  with  UV  (Mellon  and  Champe,  1996).  However  the  addition 
of  MutL  or  MutS  to  an  in  vitro  NER  system  did  not  have  any  effect  on  the  efficiency  of 
lesion  removal  (Leadon,  1999;  Selby  and  Sancar,  1995). 
Mutations  in  the  yeast,  Saccharomyces  cerevisiae,  yMSH2,  yMLHJ,  yPMS1  and  yMSH3 
genes  had  no  effect  on  TCR  of  UV  induced  DNA  damage  (Sweder  et  al.,  1996).  However 
the  TCR  of  thymine  glycols  in  response  to  oxidative  damage  was  found  to  require  yMsh2p, 
yMlhlp  and  yPmslp  (Leadon  and  Avrutskaya,  1998).  Interestingly  in  the  single  mlhl  and 
pmsl  mutants  no  effect  on  TCR  was  observed.  However  loss  of  TCR  of  thymine  glycols 52 
was  observed  in  the  double  mlhl  pmsl  mutants  which  would  suggest  that  unlike  for  their 
role  in  MMR  these  two  proteins  act  independently  but  have  overlapping  roles  in  TCR. 
In  contrast  with  these  observations  in  yeast,  hMLH1,  hMSH2  and  hPMS2  were  each  shown 
to  play  a  role  in  TCR  of  cyclobutane  pyrimidine  dimers  which  arise  in  response  to  UV 
treatment  (Mellon  et  al.,  1996).  However  in  the  case  of  TCR  of  oxidative  damage  in 
human  cells,  hMSH2  was  required,  but  hMLH1  was  not  required  for  the  preferential 
removal  of  oxidative  DNA  damage  from  the  transcribed  strand  of  the  active  gene  (Leadon 
and  Avrutskaya,  1997).  The  human  MutSu  complex  has  also  been  shown  to  specifically 
bind  such  adducts  (Wang  et  al.,  1999).  This  differential  involvement  of  the  two  proteins 
was  the  first  example  of  a  protein  absolutely  required  for  TCR  of  UV-induced  damage  of 
DNA  but  not  for  TCR  of  oxidative  DNA  damage.  Recent  observations  of  interaction 
between  yeast  Msh2p  and  a  number  of  NER  proteins  suggests  these  proteins  could  act  in 
complex  (Bertrand  et  al.,  1998). 53 
1.5  Aims  of  the  Thesis 
The  initial  aim  of  the  work  in  this  thesis  was  to  set  up  a  functional  yeast  two-hybrid  system. 
In  particular  it  was  hoped  to  construct  a  yeast  two  hybrid  vector  expressing  a  hMLH1 
hybrid  protein.  Utilising  this  hMLH1  yeast  two-hybrid  construct  the  aim  was  to  identify 
novel  proteins  involved  in  DNA  mismatch  repair.  hMLH1  has  been  implicated  in  playing 
a  role  in  signalling  downstream  cellular  pathways  in  response  to  DNA  damage.  Screening 
a  yeast  two-hybrid  cDNA  library  could,  also  therefore  potentially  identify  novel  protein- 
protein  interactions  between  hMLH1  and  other  proteins  involved  in  these  pathways. 
From  these  studies  an  intriguing  interaction  between  hMLH1  and  c-MYC  was  observed. 
This  particular  protein-protein  interaction  has  been  further  characterised,  and  attempts  to 
elucidate  the  functional  significance  of  this  interaction  have  been  made.  Therefore  a  brief 
introduction  to  c-MYC  follows. 54 
1.6  The  c-Myc  Oncogene 
The  proto-oncogene  c-MYC  was  first  discovered  through  its  homology  with  the 
transforming  gene,  v-MYC,  of  avian  myelocytomatosis  virus,  MC29  (Ryan  and  Birnie, 
1996;  Vennstrom  et  al.,  1982).  Members  of  the  MYC  oncogene  family  include,  c-MYC,  N- 
MYC  and  L-MYC.  The  latter  two  genes  were  discovered  again  through  their  homology 
with  v-MYC,  as  amplified  genes  in  neuroblastoma  cells  (N-MYC)  and  a  small  cell  lung 
tumour  cells  (L-MYC)  (Nesbit  et  al.,  1999).  The  oncogenic  activation  of  the  c-MYC,  N- 
MYC  and  L-MYC  genes  has  been  implicated  in  the  establishment  of  a  range  of  human 
neoplasias  (Hayward  et  al.,  1981;  Nesbit  et  al.,  1999).  The  most  ubiquitous  and  best 
studied  of  the  group,  the  c-MYC  gene  is  associated  with  a  range  of  cancers. 
The  c-MYC  gene  is  found  on  chromosome  8  and  consists  of  three  exons  (Battey  et  al., 
1983;  Dang,  1999).  Exon  I  is  a  long  untranslated  exon,  and  Exon  II  and  III  encompass  the 
protein  coding  sequences.  Transcription  initiates  from  two  major  promoters  P1  and  P2, 
found  in  Exon  I  with  a  gap  of  174  nucleotides  between  them.  Most  transcript  in  tissues  and 
cell  lines  examined  originate  from  P2.  Both  P1  and  P2  have  a  consensus  TATA  box 
element,  and  P2  also  has  a  strong  consensus  initiator  element  (Inr).  The  major  c-MYC 
protein  (c-MYC  2)  is  translated  from  the  AUG  start  codon  in  exon  2,  and  produces  a  64 
kDa  protein.  A  second  67  kDa  (c-MYC  1)  protein  is  produced  by  translation  from  an 
alternative  CUG  codon  in  exon  1,15  codons  upstream  of  the  AUG  (Dang,  1999;  Hann  et 
al.,  1992).  The  expression  from  the  upstream  start  codon  is  inefficient  compared  to  that 
from  the  major  AUG  start  codon.  However  upon  increased  cell  density  in  culture, 
initiation  from  this  CUG  upstream  start  codon  increases,  which  is  specifically  due  to  amino 
acid  deprivation  in  particular  through  lower  availability  of  methionine  (Hann  et  al.,  1992). 
A  more  recently  identified  45  kDa  polypeptide,  c-MYC  short  (c-MYC  S)  results  from 
translation  from  an  internal  AUG  initiation  site  (Spotts  et  al.,  1997). 
Expression  of  the  c-myc  gene  is  closely  related  to  cellular  proliferation  (Obaya  et  al.,  1999; 
Ryan  and  Birnie,  1996).  In  quiescent  cells  c-MYC  expression  is  absent.  Upon  mitogen 
stimulation  i.  e.  the  addition  of  serum  containing  growth  factors,  c-MYC  expression  is 
rapidly  induced  (Cole,  1986;  Eilers  et  al.,  1989).  c-MYC  is  an  immediate  early  gene,  as 
shown  by  the  fact  that  c-MYC  levels  peak  between  2  and  4  hours  after  serum  stimulation 
of  expression  (Persson  et  al.,  1985).  Levels  of  c-MYC  subsequently  decrease  to  a  lower 
constitutive  level,  which  is  maintained  throughout  the  rest  of  the  cell  cycle  (Rabbitts  et  al., 
1985).  Removal  of  serum  containing  growth  factors,  from  cells  at  any  point  during 55 
progress  through  the  cell  cycle  leads  to  the  down-regulation  of  c-MYC  expression  (Dean  et 
al.,  1986). 
Altered  c-MYC  expression  is  associated  with  many  cancers.  c-MYC  is  capable  of 
transforming  cells  in  vitro  and  mouse  xenografts  with  cells  expressing  activated  c-MYC 
(i.  e.  increased  c-MYC  expression)  from  tumours  (Keath  et  al.,  1984).  How  c-MYC  induces 
neoplastic  transformation  however  is  not  fully  understood.  The  observation  that  c-MYC 
could  affect  gene  expression  led  to  the  idea  that  this  protein  may  play  a  role  in  transcription 
control  (Kaddurah-Daouk  et  al.,  1987). 56 
1.7  c-Myc  Protein  Structure 
The  c-MYC  protein  in  avian  and  human  cells  was  found  to  localise  to  the  nucleus  by 
immunofluorescence  analysis  (Dang  and  Lee,  1988;  Eisenman  et  al.,  1985).  Further 
examination  of  the  c-MYC  protein  revealed  a  number  of  motifs  that  were  previously 
identified  in  a  number  of  known  transcription  factors  (see  Figure  3).  Immunofluorescence 
experiments  with  mutants  of  c-MYC,  examining  the  subcellular  localisation  of  these 
proteins,  demonstrated  the  role  of  this  conserved  region  in  the  nuclear  localisation  of  c- 
MYC  (Stone  et  al.,  1987).  c-MYC  was  also  found  to  be  a  phosphoprotein,  phosphorylated 
by  kinases  such  as  casein  kinase  II  (CKII)  (Luscher  et  al.,  1989). 
Amino  acid  sequence  similarity  was  recognised  between  c-MYC  and  two  other 
transforming  proteins,  JUN  and  FOS  (Landschulz  et  al.,  1988;  Vogt  et  al.,  1987).  Periodic 
repeats  of  leucine  residues  were  observed  in  the  C-terminal  sequences  of  each  of  these 
proteins  (Landschulz  et  al.,  1988).  It  was  proposed  that  these  repeated  leucine  residues 
extend  from  an  extra  long  a-helix.  These  leucine  residues  were  proposed  to  establish 
amphipathy  which  aids  the  stabilisation  of  this  long  a-helix.  c-MYC  has,  beginning  at  a 
position  32  amino  acids  from  the  C-terminus,  leucine  residues  at  every  seventh  position 
over  8  proposed  turns  of  the  a-helix.  This  motif  is  conserved  in  the  N-MYC  protein  and 
also  in  three  of  the  four  positions  in  L-MYC.  This  proposed  conserved  motif  structure  is 
seen  in  other  proteins  including  FOS,  JUN  and  C/EBF.  Only  the  leucine  amino  acids  are 
conserved  between  these  proteins.  The  leucine  side  chains  (which  are  long,  symmetrical 
and  bulky)  of  one  helix  were  proposed  to  `interdigitate'  with  those  of  a  matching  helix 
from  a  second  polypeptide,  to  allow  stable  non-covalent  linking  of  the  proteins. 
Another  structural  motif  found  in  the  DNA  binding  domain  of  bacterial  repressors  and 
activators  was  identified  in  mammalian  proteins.  This  DNA  binding  motif  elucidated 
through  X-ray  crystallography  is  called  a  `helix-turn-helix'  motif.  The  characteristics  of 
this  motif  are  two  consecutive  amphipathic  a-helices  juxtaposed  at  approximately  90°  by  a 
turn  or  `loop'  of  four  amino  acids  (Landschulz  et  al.,  1988;  Steitz  et  al.,  1982).  This  helix- 
loop-helix  (HLH)  motif  was  soon  identified  in  a  range  of  mammalian  proteins  including  c- 
MYC  (Luscher  and  Eisenman,  1990).  Proteins  involved  in  transcription  regulation  have 
also  been  shown  to  carry  this  motif  e.  g.  the  transcription  factors  USF  and  MYOD1.  This 
motif  facilitates  protein  oligomerisation. 57 
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Figure  3:  c-MYC  Structure 
Structural  domains  of  the  c-MYC  protein,  amino  acids  (a(x)  1-439,  are  illustrated. 58 
Examination  of  the  MYOD1  protein  also  led  to  the  discovery  of,  in  addition  to  this  HLH 
domain,  a  group  of  basic  residues  adjacent  to  the  HLH  motif  (Davis  et  al.,  1990).  This 
basic  region  was  found  to  be  required  for  sequence  specific  binding  of  DNA.  The  c-MYC 
HLH  motif  located  directly  upstream  of  the  C-terminus  leucine  zipper  domain  was  flanked 
on  its  amino-terminal  side  by  a  `basic  region'  (see  Figure  3)  (Luscher  and  Eisenman,  1990; 
Ryan  and  Birnie,  1996). 
These  common  motifs  found  in  c-MYC  and  a  number  of  other  transcription  factors 
indicated  the  possible  role  of  c-MYC  in  transcriptional  regulation.  The  C-terminal  half  of 
c-MYC  was  predicted  to  play  a  role  in  protein  oligomerisation  and  binding  to  DNA.  The 
amino  terminal  half  of  c-MYC  however  has  a  number  of  short  regions  rich  in  glutamine, 
proline,  and  acidic  residues  ,  which  are  associated  with  a  number  of  transactivation 
domains  (Kato  et  al.,  1990).  GAI4-c-MYC  fusion  proteins  were  expressed  in  cells  to  test 
the  ability  of  this  protein  to  activate  transcription.  Fusion  proteins  consisting  of  the  N- 
terminal  region  of  c-MYC  and  the  GAI4  binding  domain  of  the  yeast  GAL4  transcription 
factor  were  demonstrated  to  have  transactivation  ability.  By  transient  co-transfection  of  a 
vector  expressing  this  fusion  protein  and  a  reporter  construct  consisting  of  the  GAL4  DNA 
binding  site  upstream  of  a  chloramphenicol  acetyltransferase  (CAT)  reporter  gene, 
transactivation  was  easily  measured.  This  experiment  clearly  demonstrated  the  specific 
transactivation  potential  of  the  c-MYC  protein.  Three  independent  regions  were  identified, 
that  lie  between  amino  acids  1-143  of  c-Myc,  and  are  capable  of  activating  transcription 
from  the  CAT  reporter  gene. 
Multiple  oncogenes  are  required  to  mediate  the  transformation  of  normal  cells  into 
tumorigenic  cells  (Land  et  al.,  1983).  Expression  of  either  c-MYC  or  activated  RAS  alone 
does  not  lead  to  transformation  of  primary  cells,  but  together  can  do  so  (Land  et  al.,  1986; 
Lee  et  al.,  1985).  The  transformation  of  rat  embryo  fibroblasts  through  both  aberrant  c- 
MYC  expression  and  expression  of  a  mutant  ras  gene  serves  as  a  classical  example  of 
cooperation  between  oncogenes  (Lee  et  al.,  1985).  By  utilising  in  frame  insertion  or 
deletion  mutants  of  c-myc  expressed  from  a  retroviral  promoter-enhancer,  the  regions  of  c- 
MYC  required  for  co-transformation  of  rat  embryo  fibroblasts  with  a  mutant  ras  gene  were 
elucidated  (Stone  et  al.,  1987).  This  oncogenic  activity  of  c-MYC  was  shown  to  depend  on 
two  specific  regions  of  the  protein,  amino  acids  105-143  and  321-439.  The  region  between 
amino  acids  1-104  could  tolerate  small  insertions  or  deletions  and  the  region  between 
amino  acids  144-320  was  dispensable  for  this  oncogenic  role  of  c-myc.  A  number  of 
conserved  blocks  of  amino  acids  are  found  within  the  N-terminus  of  the  c-MYC  protein. 59 
The  most  critical  for  the  oncogenic  transformation  role  of  c-MYC  is  MYC  Box  II  (MBII) 
which  centres  around  amino  acid  135  (see  Figure  3)  (Cole  and  McMahon,  1999;  Stone  et 
al.,  1987). 
The  N-MYC  and  L-MYC  genes  also  have  the  three  exon  structure  of  c-MYC  with  coding 
sequences  in  exons  II  and  III.  Both  proteins  encoded  by  these  genes,  N-MYC  and  L-MYC 
have  a  number  of  domains  with  at  least  80%  amino  acid  sequence  homology  to  the  c-MYC 
protein.  These  highly  conserved  regions  include  the  N-terminal  MYC  Box  I  (MbI)  and 
MYC  Box  II  (MbII)  domains  and  the  basic  helix-loop-helix  and  leucine  zipper  domains. 
The  conservation  of  these  domains  between  these  three  proteins  and  with  homologous 
proteins  from  other  species  suggest  they  play  and  important  functional  role. 60 
1.8  The  MYC/MAX/MAD  Family  of  Proteins 
Evidence  was  accumulating  in  the  early  1990s  to  suggest  that  c-MYC  is  a  transcription 
factor.  However  it  was  discovered  that  c-MYC  could  only  oligomerise  and  bind  DNA 
when  expressed  at  high  concentrations,  suggesting  these  observations  are  not 
physiologically  relevant  (Dang  et  al.,  1989;  Ryan  and  Birnie,  1996).  The  conserved  bHLH- 
Zip  (basic-helix-loop-helix-leucine  zipper)  domain  of  c-MYC  was  used  to  screen  a  cDNA 
expression  library  derived  from  a  baboon  lymphoblastoid  cell  line  (Blackwood  and 
Eisenman,  1991).  This  resulted  in  the  identification  of  MAX,  a  protein  that  can 
specifically  bind  to  c-MYC,  L-MYC  and  N-MYC,  in  in  vitro  binding  assays.  The  HLH- 
Zip  domain  of  c-MYC  was  required  for  this  interaction  which  supports  the  models 
proposed  for  how  c-MYC  exerts  its  function  through  oligomerisation  and  DNA  binding. 
Examination  of  MAX  sequence  suggested  it  also  contains  a  putative  C-terminal  bHLH-Zip 
domain  as  well  as  a  basic  region.,  The  basic  region  of  c-MYC  was  found  not  to  be  required 
for  this  interaction.  However  the  c-MYC-MAX  heterocomplex  was  found  to  be  able  to 
bind  to  an  oligonucleotide  containing  the  sequence  CACGTG,  and  this  binding  required 
the  basic  region'of  c-MYC.  This  confirms  the  hypothesis  that  this  domain  is  required  for 
specific  binding  of  this  protein  to  DNA. 
MAX  encodes  two  major  polypeptides  p21  (21  kDa)  and  p22  (22  kDa)  that  differ  by  the 
addition  of  9  amino  acids  amino  terminal  to  the  basic  region  of  the  protein  sequence 
(Blackwood  et  al.,  1992).  MAX  is  a  highly  stable  nuclear  protein  and  like  c-MYC  is 
phosphorylated  by  CKII  (casein  kinase  II).  Co-immunoprecipitation  studies  demonstrated 
an  in  vivo  interaction  between  c-MYC  and  MAX  (Blackwood  et  al.,  1992).,  Under  these 
conditions  of  immunoprecipitation  most  of  c-MYC  was  found  to  be  in  complex  with 
MAX.  Formation  of  the  complex  did  not  effect  the  short  half-life  of  the  c-MYC  protein. 
These  immunoprecipitated  complexes  were  also  found  to  be  capable  of  binding  specifically 
to  an  oligonucleotide  with  the  CACGTG  sequence.  Unlike  c-MYC,  MAX  is  expressed  at 
constant  levels  when  cells  are  quiescent,  after  mitogenic  stimulation  and  in  cycling  cells 
(Berberich  et  al.,  1992;  Blackwood  et  al.,  1992). 
The  MAX  interaction  with  c-MYC  was  found  to  depend  on  functional  HLH-Zip  domains 
on  both  proteins  (Kato  et  al.,  1992).  This  supports  the  role  of  these  domains  in 
oligomerisation.  Like  c-MYC,  MAX  has  a  nuclear  localisation  signal  but  does.  not  have 
any  domains  capable  of  transcriptional  activation.  The  transcriptional  activation  abilities 61 
of  MAX  were  tested  for  in  the  same  way  as  c-MYC  previously  described,  utilising  GAL4 
fusion  proteins.  The  C-terminal  half  of  the  c-MYC  protein  expressed  as  a  recombinant 
protein  was  shown  to  be  capable  of  binding  the  consensus  E-box  recognition  binding 
sequence  (CACG/ATG)  in  DNA.  MAX  dimers  or  c-MYC-MAX  heterodimers  also  bind 
this  E-box  sequence,  and  bind  with  it  specifically  when  mixed  with  a  pool  of  random 
oligonucleotides  (Berberich  et  al.,  1992;  Kato  et  al.,  1992;  Littlewood  et  al.,  1992). 
The  interaction  between  c-MYC  and  MAX  was  a  very  interesting  observation.  The  C- 
terminal  bHLH-Zip  domain  of  c-MYC  has  been  shown  to  be  essential  for  the  oncogenic 
activity  of  c-MYC  (Stone  et  al.,  1987).  Some  suggestions  of  a  link  between  this 
transforming  ability  of  c-MYC  and,  its  potential  role  in  transcriptional  activation  had  also 
been  proposed  through  the  discovery  -  of  a  requirement  for  the  N-terminal  conserved 
domains  of  c-MYC  for  both  activities.  The  discovery  of  an  interaction  between  MAX  and 
c-MYC  which  facilitates  binding  of  the  c-MYC  protein  to  the  E-box  derivative  consensus 
sequence  as  part  of  this  complex,  led  to  the  proposal  that  MAX  could  be  mediating  these 
functions  of  c-MYC. 
An  in  vivo  expression  system  in  yeast  was  utilised  to  test  the  transcriptional  activation 
ability  of  c-MYC  and  MAX  (Amati  et  al.,  1992).  This  system  involved  the  expression  of 
c-MYC,  MAX  or  both  proteins  in  yeast  which  had  a  LACZ  gene  with  an  E-box  sequence 
upstream  of  the  promoter  sequence.  MAX  homodimers  and  c-MYC-MAX  heterodimers 
could  both  bind  this  recognition  sequence.  However  by  measuring  ß-galactosidase  activity 
from  the  reporter  gene,  it  was  shown  that  only  the  c-MYC-MAX  heterodimers  could 
activate  transcription  of  this  gene.  Through  using  mutants  of  c-MYC  in  this  system,  it  was 
shown  that  the  basic  region  of  this  protein  is  required  for  binding  to  DNA  and  hence 
transactivation  of  the  LACZ  gene.  The  dimerisation  ability  is  also  required  for 
transcactivation  as  mutations  in  the  HLH-Zip  domain  also  resulted  in  the  loss  of 
transactivation  function.  Mutants  in  the  N-terminal  transactivation  domain  (TAD)  of  c- 
MYC  also  led  to  loss  of  transactivation  function.  Through  these  studies,  the  HLH-Zip 
domain  of  MAX  was  found  to  have  higher  affinity  for  the  HLH-Zip  domain  of  c-MYC 
than  for  itself  and  preferably  formed  heterodimers  with  c-MYC  than  forming  homodimers 
with  itself. 
A  similar  in  vivo  reporter  system  in  yeast  was  used  to  characterise  the  regions  of  c-MYC 
required  -  for  binding  to  MAX  and  subsequent  transactivation  functions  (Crouch  et  äl., 
1993).  By  utilising  c-MYC  mutants  in  this  system  both  the  HLH  and  the  leucine  zipper 62 
domains  were  shown  to  be  required  for  MAX-dependent  DNA  binding  and  transactivation 
by  c-MYC.  In  particular  helix  2  of  the  HLH  and  the  leucine  zipper  are  required  for  the  c- 
MYC-MAX  interaction,  whereas  helix  1  of  the  HLH  is  required  for  the  sequence  specific 
DNA  binding  of  the  heterodimer.  These  mutants  had  been  previously  tested  for  their 
ability  to  transform  higher  eukaryotic  cells.  Comparison  of  the  effect  of  c-MYC  mutations 
on  the  transforming  ability  and  'on  the  transactivation  role  of  the  protein  revealed  a  close 
correlation  between'  the  regions  of  c-MYC  required  for  these  functions  (Crouch  et  al., 
1993;  Crouch  et  al.,  1990). 
Another  reporter  system,  a  CAT  reporter  gene  expressed  in  fibroblast  or  epithelial  cell 
lines,  was  used  with  a  fourfold  repeat  of  an  E-box  sequence  upstream  of  the  promoter 
(Kretzner  et  al.,  1992).  This  system  demonstrated  that  overexpression  of  the  MAX  protein 
leads  to  repression  of  transcription  from  the  reporter  gene,  in  contrast  to  overexpression  of 
c-MYC  which  led  to  activation  of  expression.  This  overexpression  of  c-MYC  can 
specifically  release  the  repressive  effect  of  overexpressed  MAX. 
In  summary  c-MYC  in  complex  with  MAX  can  activate  reporter  gene  expression  through 
binding  of  this  complex  to  a  specific  DNA  recognition  sequence  CACG/ATG,  the  E-box 
sequence.  MAX  homodimers  can  also  bind  this  sequence  and  have  a  repressive  effect  on 
transcription  of  the  reporter  gene.  As  stated  above  the  MAX  protein  was  not  found  to 
encode  a  TAD  domain.  However  MAX  forms  heterodimers  with  c-MYC  preferably  to 
homodimers.  These  heterodimers  are  more  stable  than  the  homodimers  and  have  a  higher 
affinity  for  the  E-box  sequence  than  the  MAX-MAX  dimers.  This  would  therefore  suggest 
that  putative  genes  regulated  by  c-MYC  are  also  dependent  on  the  levels  of  MAX  being 
expressed.  The  oligomerisation  of  the  two  proteins  via  their  respective  HLH-Zip  domains 
produces  a  protein  structure  capable  of  binding  DNA  through  the  basic  domains  of  the 
proteins.  This  binding  of  c-MYC-MAX  to  the  E-box  derivative  sequence,  CACG/ATG, 
facilitates  the  transactivation  abilities  of  the  c-MYC  protein. 
Further  studies  with  mutants  of  c-MYC  and  MAX  suggest  that  only  the  HLH-Zip  domain 
of  MAX  is  required  for  the  transactivation  function  of  c-MYC  (Amati  et  al.,  1993).  This 
supports  the  proposal  that  the  TAD  of  c-MYC  is  sufficient  to  drive  the  transactivational 
activity  of  the  DNA  bound  c-MYC-MAX  complex.  MAX  and  its  mouse  homologue  MYN 
were  both  found  to  be  able  to  inhibit  the  transforming  effect  of  MYC  and  RAS  together 
when  expressed  at  high  levels  (Amati  et  al.,  1993; 
. 
Prendergast  et  al.,  1991).  The 
possibility  that  MAX  could  heterodimerise  with  other  proteins  that  could  bind  the  same 63 
recognition  binding  sequence  and  compete  with  MYC-MAX  as  do  MAX  homodimers  was 
proposed  from  these  observations.  MAX  therefore  plays  a  role  in  mediating  both  the 
transactivation  and  oncogenic  roles  of  c-MYC.  However  interestingly  MAX  can  act  as 
both  suppressor  and  activator  of  these  functions. 
Evidence  soon  emerged  for  a  network  of  transcription  regulators  with  MAX  acting  as  a 
central  component  (see  Figure  4).  To  test  for  the  possibility  that  MAX  can  interact  with 
other  HLH-Zip  proteins,  a  similar  cDNA  expression  library  screen  was  carried  out,  to  that 
which  originally  identified  the  c-MYC-MAX  interaction  (Ayer  et  al.,  1993).  This  led  to 
the  identification  of  MAD,  also  a  HLH-Zip  protein.  MAD,  through  its  C-terminal  half  was 
shown  to  bind  MAX  in  vitro.  However  MAD  did  not  bind  c-MYC,  and  like  c-MYC, 
formed  homodimers  poorly.  Also  in  common  with  c-MYC-MAX  heterodimers,  the  MAD- 
MAX  heterodimers  are  favoured  over  MAX  homodimers.  MAD  and  c-MYC  can  compete 
for  binding  to  MAX  to  form  DNA  binding  complexes  with  the  derivative  E-box  sequence 
CACG/ATG.  MAD  alone  did  not  bind  this  DNA  binding  sequence.  Utilising  the  CAT- 
reporter  assay  described  earlier,  the  transcriptional  activity  of  the  MAD-MAX  heterodimer 
was  also  examined  (Ayer  et  al.,  1993;  Kretzner  et  al.,  1992).  This  assay  demonstrated  the 
opposing  functions  of  the  MAD-MAX  and  c-MYC-MAX  heterodimers.  In  contrast  to  c- 
MYC-MAX,  MAD-MAX  acts  like  MAX  homodimers  to  repress  transcription  of  the 
reporter  gene. 
Other  MAD  family  proteins  were  identified  that  can  also  interact  with  MAX.  These 
include  MXI1  another  bHLH-Zip  protein,  which  in  complex  with  MAX  can  bind  the  c- 
MYC-MAX  consensus  recognition  site  (Zervos  et  al.,  1993).  Two  more  MAD  family 
members  MAD3  and  MAD4  also  bind  MAX,  and  show  similar  characteristics  to  the 
MAD-MAX  complex  (Hurlin  et  al.,  1995).  However  these  complexes  act  to  repress 
transcription  at  the  same  sites  as  c-MYC-MAX  complexes  activate  transcription.  This 
repression  activity  is  facilitated  through  an  association  with  the  mSIN3  co-repressor 
complex,  which  includes  for  example  histone  deacetlyases  (Alland  et  al.,  1997;  Ayer  et  al., 
1995;  Schreiber-Agus  et  al.,  1995).  Unlike  c-MYC-MAX  the  formation  of  these  MAD- 
MAX  complexes  is  closely  linked  to  terminal  differentiation  (Ayer  and  Eisenman,  1993). 
MAD  and  MAD4  have  been  demonstrated  to  interact  with  MLX  (_Max  Like  protein  X)  a 
MAX  related  protein  (Billin  et  al.,  1999).  These  dimers  also  have  transcriptional 
repression  activity.  Two  additional  bHLH-Zip  proteins,  MNT  (also  known  as  ROX)  and 
MGA  have  been  shown  to  interact  with  MAX  (Hurlin  et  al.,  1999;  Meroni  et  al.,  1997). 64 
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Figure  4:  MAX  Interacting  Proteins. 
Schematic  describing  the  different  protein-protein  interactions  involving  MAX  and  MAX- 
like  proteins. 65 
MNT-MAX  acts  to  repress  transcription  in  a  similar  manner  to  the  other  heterodimers 
described  above.  MNT  also  heterodimerises  with  MLX  (Meroni  et  al.,  2000).  MGA  has 
an  additional  T-box  DNA  binding  domain  through  which  it  represses  transcription  from 
specific  sites  including  the  c-MYC-MAX  recognition  binding  site.  However  upon  binding 
by  MAX  this  transcriptional  repression  effect  of  MGA  is  converted  to  transcriptional 
activation  from  these  sites  (Hurlin  et  al.,  1999). 66 
1.9  c-MYC  Function 
The  identification  of  an  N-terminal  transactivation  domain  and  also  a  C-terminal  bHLH- 
Zip  domain  (which  is  commonly  found  in  a  number  of  transcription  factors)  in  the  c-MYC 
protein  suggested  a  role  for  this  protein  in  transcriptional  control.  c-MYC  through  its 
interaction  with  MAX  can  bind  a  consensus  DNA  recognition  binding  sequence  and 
activate  transcription  of  a  reporter  gene  in  a  number  of  in  vivo  reporter  gene  expression 
systems  (Amati  et  al.,  1992;  Kretzner  et  al.,  1992).  The  description  of  a  number  of  novel 
protein-protein  interactions  between  c-MYC  and  proteins  known  to  play  a  role  in 
transcription  regulation  gives  further  support  to  the  model  of  c-MYC  as  a  transcription 
factor  (Sakamuro  and  Prendergast,  1999).  In  particular  the  discovery  of  an  interaction 
between  c-MYC  and  TRRAP  with  the  subsequent  recruitment  of  the  histone 
acetlytransferase  GCN5  provided  a  direct  link  between  c-MYC  and  modes  of 
transcriptional  activation  (McMahon  et  al.,  1998;  McMahon  et  al.,  2000).  The  diversity  of 
these  interactions  as  well  as  their  effects  suggest  that  c-MYC  does  not  conform  to  the 
classical  model  of  a  transcription  factor. 
The  ability  of  c-MYC  to  activate  transcription  from  both  reporter  genes  and  also  putative 
endogenous  genes  is  relatively  weak.  It  has  been  proposed  that  the  transactivation  function 
of  c-MYC-MAX  perhaps  through  its  association  with  proteins  such  as  TRRAP  is  indirect. 
It  may  instead  act  to  make  target  genes  more  accessible,  through  interactions  with  TRRAP 
and  GCN5,  to  other  transcription  factors  such  as  USF  which  are  also  capable  of  binding  the 
E-box  recognition  sequence.  c-MYC  has  also  been  implicated  in  repression  of  the 
expression  of  a  number  of  genes.  Again  this  function  of  c-MYC  is  believed  to  be  mediated 
through  its  interactions  with  a  number  of  different  proteins.  For  example  c-MYC  somehow 
activates  the  repression  function  of  the  POZ  domain  of  MIZ-1,  a  protein  known  to  interact 
with  the  HLH  domain  of  c-MYC,  and  inhibits  the  normal  transactivation  function  of  MIZ- 
1.  Whether  these  two  roles  of  c-MYC  are  separable  or  are  required  to  act  in  concert  to 
exert  overall  c-MYC  function  has  not  yet  been  elucidated. 
Elevated  expression  of  c-MYC  can  inhibit  differentiation  in  some  cell  types  whereas  in  cell 
culture  inhibition  of  c-MYC  expression  can  lead  to  induction  of  differentiation  (Facchini 
and  Penn,  1998).  Competition  for  c-MYC-MAX  binding  sites  by  for  example  the  MNT- 
MAX  and  MAD.  MAX  complexes  is  central  to  their  antagonistic  roles  in  transcription 
activation  versus  repression.  A  switch  from  c-MYC-MAX  to  these  alternative  complexes 
accompanies  the  switch  from  proliferation  to  differentiation  (Ayer  and  Eisenman,  1993; 67 
Hurlin  et  al.,  1997).  This  switch  leads  to  the  sequential  expression  of  the  MAD  family  of 
transcription  repressors  during  this  differentiation  process  (Queva  et  al.,  1998).  c-MYC  is 
also  found  to  repress  the  expression  of  a  number  of  genes  involved  in  differentiation 
(Claassen  and  Hann,  1999).  Therefore  by  blocking  differentiation  aberrant  expression  of  c- 
MYC  can  keep  cells  proliferating  and  predispose  the  cells  to  transformation. 
c-MYC  is  an  immediate  early  gene  suggesting  that  it  plays  a  critical  role  in  signalling  a 
number  of  growth  signal  response  pathways.  c-MYC  apparently  plays  a  role  in  regulation 
of  the  cell  cycle.  The  deletion  of  c-MYC  through  homologous  recombination  in  Ratl  cells 
results  in  a  longer  cell  cycle  (Mateyak  et  al.,  1997).  Cell  cycle  regulation  is  through 
cyclins,  cyclin  dependent  kinases  and  their  target  genes,  which  act  as  key  players  in 
inducing  DNA  synthesis.  Induction  of  c-MYC  expression  e.  g.  through  the  addition  of 
growth  factors  to  quiescent  cells,  can  drive  cells  into  the  cell  cycle  (Cole,  1986;  Eilers  et 
al.,  1989).  A  number  of  candidate  c-MYC  target  genes  play  a  role  in  the  cell  cycle 
progression  and  may  explain  how  c-MYC  can  influence  this  process. 
The  role  of  c-MYC  in  proliferation  is  unlikely  to  be  restricted  to  the  regulation  of  the  cell 
cycle.  An  important  aspect  of  the  proliferative  process  is  the  ability  of  cells  to  increase  in 
size  and  also  to  co-ordinate  this  growth  with  division.  Cell  growth  regulation  operates  at  a 
number  of  levels,  as  dictated  by  for  example  nutrient  availability  or  changes  in  protein 
synthesis  with  progression  through  the  cell  cycle  (Schmidt,  1999).  Protein  synthesis  is 
itself  regulated  at  two  stages,  ribosomal  synthesis  and  translation  initiation.  The 
transcription  factor  YY1  which  is  known  to  interact  with  c-MYC,  plays  a  major  role  in 
transcription  of  ribosomal  protein  mRNA  (Chung  and  Perry,  1993).  Translation  initiation 
factors  are  then  required  for  the  assembly  of  ribosomes  into  active  translation  complexes. 
These  factors  are  rate  limiting  due  to  the  fact  that  they  are  not  as  abundant  as  the  ribosomal 
components  of  these  complexes.  c-MYC  has  been  previously  implicated  in  the  regulation 
of  the  translation  initiation  factor  eIF4E  (Jones  et  al.,  1996).  Both  these  roles  of  c-MYC 
although  not  yet  directly  tested  could  potentially  implicate  c-MYC  as  playing  a  role  in 
regulation  of  protein  synthesis  and  explain  the  growth  phenotype  of  the  c-MYC  null  cells. 
c-MYC  gene  expression  is  clearly  required  for  proliferation  and  downregulation  of  this 
gene  results  in  growth  arrest  and  differentiation.  The  discovery  that  the  constitutive 
expression  of  c-MYC  in  both  rat  embryonic  fibroblasts  and  established  Ratl  fibroblasts 
grown  in  low  serum  can  trigger  apoptosis,  places  c-MYC  protein  at  a  cross-roads  between 
two  opposing  pathways,  proliferation  versus  cell  death  (Askew  et  al.,  1991;  Evan  et  al., 68 
1992).  Apoptosis  by  c-MYC  was  shown  to  be  activated  by  a  number  of  signals,  for 
example  amino  acid  deprivation,  suggesting  that  in  fact  the  combination  of  the  signal  for 
growth  and  the  conflicting  signal  for  arrest  could  be  the  major  determinant  of  the  death 
signal.  In  normal  cells  the  withdrawal  of  growth  factors  is  accompanied  by  downregulation 
of  c-MYC  expression  leading  to  exit  from  the  cell  cycle,  but  in  cells  where  c-MYC 
expression  is  constitutive,  apoptosis  occurs.  The  domains  of  c-MYC  required  for  its  co- 
transformation,  transactivation  and  repression  functions  are  also  required  for  this  role  in 
apoptosis. 
The  requirement  for  c-MYC  for  signalling  both  proliferation  and  apoptosis,  two  opposing 
pathways,  has  been  demonstrated.  A  `dual  signal  model'  has  been  proposed  to  explain 
these  paradoxical  roles  for  the  protein  (Harrington  et  al.,  1994;  Prendergast,  1999).  This 
model  proposes  that  c-MYC  acts  to  regulate  both  cell  division  and  cell  death.  However 
these  functions  of  c-MYC  cannot  be  separated  as  distinct  entities.  Therefore  this  model 
has  been  re-modelled  to  suggest  that  c-MYC  can  co-ordinately  prime  both  cell  death  and 
drive  proliferation  (see  Figure  5)  (Prendergast,  1999).  Priming  of  cell  death  for  example 
could  involve  the  transcriptional  regulation  of  c-MYC  target  genes.  Triggering  of  cell 
death  is  proposed  to  subsequently  act  through  an  additional  pathway. 
c-MYC  can  sensitise  cells  to  the  death  receptor  signals  from  the  Tumour  Necrosis  Factor 
(TNF)  transmembrane  receptor  family,  which  includes  the  CD95/Fas  receptor  (Prendergast, 
1999).  Evidence  for  the  model  proposed  above,  come  from  studies  reporting  the 
observation  that  inhibition  of  CD95/Fas  signalling  blocks  apoptosis  in  Rat1  fibroblasts  but 
proliferation  induced  by  c-MYC  continues.  Likewise  the  interaction  between  c-MYC  and 
the  BIN1  protein  is  required  to  trigger  apoptosis  but  is  not  necessary  to  drive  proliferation 
or  transformation  (Prendergast,  1999;  Sakamuro  and  Prendergast,  1999).  The  transition 
from  `priming'  cell  death  to  actually  `triggering'  cell  death  could  involve  for  example 
interactions  between  BIN1  and  the  c-MYC  target  gene  products  (Prendergast,  1999). 69 
Dual  Control  Model 
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Figure  5:  Dual  Control  Model 
This  model  proposes  that  c-MYC  can  co-ordinately  prime  both  cell  death  and  drive 
proliferation  (Prendergast,  1999).  Priming  of  cell  death  for  example  could  involve  the 
transcriptional  regulation  of  c-MYC  target  genes.  Triggering  of  cell  death  is  proposed  to 
subsequently  act  through  an  additional  pathway. 70 
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2.1  -  Materials 
2.1.1  Equipment 
Routine  equipment  which  would  be  an  integral  part  of  any  laboratory  is  not  listed. 
Coulter  Electronics  Cell Counter 
Millipore  Electroblotting  System 
Kodak  Film  Processor 
Applied  Biosystems  Sequencer 
Hybaid  Touchdown  PCR  Thermal  Cycler 
Hybaid  Omnigene  PCR  Thermal  Cycler 
Innova  4300  Incubator  shaker,  New  Brunswick  Scientific 
Innova  4000  Incubator  shaker,  New  Brunswick  Scientific 
Omega  Prestige  Medicäl  Autoclave 
Flow  laboratories  CO2  Incubator  220 
Voss  Eppendorf  Rotator 
MixiMatic  Shaker,  Jencons  Scientific  Ltd 
MSE  Soniprep  150  Sonicator 
IEC  Centra-7R  Refrigerated  Centrifuge 
Sorvall  Instruments  -  Dupont  RC3C  Refrigerated  Centrifuge 
Sorvall  Instruments  -  Dupont  RC5B  Refrigerated  Superspeed  Centrifuge 72 
IEC  Micromax  Centrifuge 
Hybaid  Electroporator 
Invitrogen  Novex  Gel  Apparatus 
Luckham  4RT  Rocking  Table 
Corning  pH  meter  240 
Pharmacia  Biotech  Electrophoresis  Power  Pack  Supply  EPS  600 
MPH  Multipurpose  Gel  Electrophoresis  Chamber 
Bio-Rad  Gel  Doc  1000  UV  box 
Applied  Biosystems  392  DNA/RNA  Oligonucleotide  Synthesiser 
Pharmacia  Biotech  GeneQuant  RNA/DNA  Calculator 
Synoptics  Protos  Colony  Counter,  Don  Whitley  Scientific 
2.1.2  Chemicals 
All  chemicals  were  of  the  highest  available  quality  and  were  supplied  by: 
Gibco  BRL  Life  Technologies,  Paisley,  Renfrewshire,  UK. 
Transgenomic  Ltd.,  Crewe,  Cheshire,  UK. 
BDH  Limited  Chemicals,  Supplied  by  McQuilken  &  Co.,  Glasgow,  UK. 
Fisher  Chemicals,  Fisher  Scientific,  Loughborough,  UK. 
Sigma-Aldrich  Company  Ltd.,  Poole,  Dorset,  UK. 
Roche  Molecular  Biochemicals,  Lewes,  East  Sussex,  UK. 73 
2.1.3  Kits 
Material 
Plasmid  Maxi  Kit; 
Qiaprep  Spin  Miniprep  Kit; 
Qiaquick  PCR  Purification  Kit 
RNeasy  Kit 
Supplier 
Qiagen  Ltd.,  Dorking,  Surrey 
England. 
Promega  Wizard  DNA  Clean-Up  System  Promega  Ltd,  Chilworth  Research  Centre, 
Southampton,  England 
Nucleon  Kit  for  Yeast  DNA  Extraction 
SUPERSCRIPT  TM  Preamplification 
System  for  First  Stand  cDNA  Synthesis 
2.1.4 
Material 
Falcon  tubes 
General  Plasticware 
5m1  Bijous;  20m1  Universals; 
Scotlab  Bioscience,  Coatbridge,  Lanarkshire, 
Scotland 
Gibco  BRL  LifeTechnologies,  Paisley,  UK. 
Supplier 
Becton  Dickinson  Labware,  Plymouth,  UK. 
Bibby-Sterilin  Ltd.,  Stone,  UK. 
Microcentrifuge  tubes;  Pipette  tips  Elkay,  Galway,  Ireland. 
2.1.5  Microbial  Host,  Media  and  Supplies 
Material 
Bactotryptone;  BactoAgar; 
Yeast  Extract 
Competent  E.  coli  DH5a  cells; 
ElectroMAX  Cells  DH1OB; 
Select  Peptone 
Supplier 
Difco,  Becton  Dickinson,  UK. 
Gibco  BRL  LifeTechnologies,  Paisley,  UK. 74 
Petri  dishes 
Ampicillin;  Kanamycin 
Nitrogen  Base  w/o  Amino  Acids 
Amino  Acids 
Bibby-Sterilin  Ltd.,  Stone,  UK 
Sigma-Aldrich  Company  Ltd.,  Dorset,  Yeast 
England 
Human  Mammary  Gland 
MATCHMAKER  cDNA  Library; 
Pretransformed  Human  Ovary 
MATCHMAKER  cDNA  Library; 
KC8  Electro-competent  Cells 
CLONTECH 
Hampshire,  UK 
2.1.6  Electrophoresis  Gels 
Material 
Agarose,  electrophoresis  grade; 
Tris  Base; 
Hae  III  digested  4X174  DNA 
Hind  III  digested  bacteriophage  A.  DNA 
1Kb  DNA  Ladder 
Supplier 
Laboratories  UK  Ltd., 
Gibco  BRL  Life  Technologies,  Paisley,  UK 
SequaGel,  19:  1  acrylamide:  bisacrylamide  National  Diagnostics,  Hull,  UK 
Novex  Gels 
RainbowT  coloured  protein  molecular 
markers 
Invitrogen  BV,  Gronigen,  The  Netherlands. 
Amersham,  International  plc.,  Amersham, 
Bucks,  England. 
Redivue  [y32P]dATP 
2.1.7  Western  Blots  and  Autoradiography 
Material  Supplier 
3MM  Filter  Paper  Whatman  International,  Maidstone,  UK. 
Immobilon-P  Transfer  Membrane  Millipore  Corporation,  USA. 75 
ECL  Western  Detection  Agent  Amersham,  International  plc.,  Amersham, 
Bucks,  England. 
Fuji  Super  RX,  X-Ray  Film  Fuji  Photo  Film  (Europe),  H.  A.  West, 
Clydebank,  Glasgow,  UK. 
2.1.8  Antibodies 
Antibody  Isotvne  Supplier 
MLH1(Ab-1)  Mouse  Monoclonal  IgGI  Oncogene  Research  Products 
MLH1  (Ab-2)  Rabbit  Polyclonal  IgG  Calbiochem,  UK 
MSH2  (Ab-2)Mouse  Monoclonal  IgGI 
PMS2  (Ab-1)  Mouse  Monoclonal  IgGI 
c-myc  (Ab-2)  Mouse  Monoclonal  IgG2a 
c-MYC  (C-8)  Mouse  Monoclonal  IgG2a  Santa  Cruz  Biotechnology, 
c-MYC  (C-19)  Rabbit  Polyclonal  IgG  Autogen  Bioclear,  Wiltshire,  UK. 
3/23,  an  anti-human  c-MYC  Monoclonal  Made  by  Karin  Moelling,  gift  from 
D.  Gillespie 
237-6,  an  anti-human  c-MYC  Polyclonal  Made  by  D.  Gillespie,  against 
bacterially  produced  full  length  c- 
MYC 
Anti-mouse  IgG-horseradish  Santa  Cruz  Biotechnology, 
peroxidase  conjugate  (from  goat)  Autogen  Bioclear,  Wiltshire,  UK. 
2.1.9  Tissue  Culture  Media  and  Supplies 
Material  Supplier 
Foetal  Bovine  Serum 
L-Glutamine 
Trypsin  (2.5%) 
Penicillin-Streptomycin 
RPMI  1640 
Autogen  Bioclear,  Wiltshire,  UK. 
Gibco  BRL  Life  Technologies,  Paisley,  UK. 
Dulbecco's  Modified  Eagle  Medium, 76 
(with  sodium  pyruvate,  w/o  L-glutamine, 
with  pyridoxine) 
25,75  and  150  cm2  flasks 
6  and  96  well  plates 
9  cm  Plates 
Iwaki,  Scitech,  Japan 
Becton  Dickinson  Labware,  Plymouth,  UK. 
2.1.10  Buffers,  Solutions  and  Media 
Luria-Bertani  (LB)  broth 
10  g/L  Bacto-tryptone 
5  g/L  Bacto-yeast  extract 
5  g/L  NaCl 
Double  distilled  water  was  added  to  the  mixture  to  a  final  volume  of  M.  The  pH  was 
adjusted  to  7  with  NaOH  and  the  mixture  autoclaved  and  then  allowed  to  cool  and  stored  at 
4°C. 
S.  O.  C.  Medium 
2.0%  Bactotryptone 
0.5%  Yeast  Extract 
lo  mm  NaC1 
2.5  mM  KCl 
lo  mm  MgC12 
lo  mm  MgSO4 77 
20  mM  Glucose 
A  50X  stock  solution  of  the  sodium,  potassium  and  magnesium  salts  in  distilled  water  was 
prepared.  The  Bactotryptone/Yeast  Extract  solution  was  prepared  and  the  pH  was  adjusted 
to  7.  The  three  solutions  were  autoclaved  separately  and  allowed  to  cool.  Appropriate 
volumes  of  the  salts  solution  and  glucose  solution  were  added  to  the  Bactotryptone/Yeast 
Extract  solution. 
S.  O.  B.  Medium 
SOB  contains  the  same  nutrients  and  salts  as  SOC,  but  it  lacks  glucose. 
M9  Minimal  Medium 
200  ml  5X  M9  Salts 
100  ml  of  the  appropriate  sterile  1OX  dropout  solution  (Leu) 
18  g/L,  Bacto-agar 
The  solution  was  made  up  to  a  final  volume  of  980m1  with  sterile  double  distilled  water 
and  autoclaved.  20m1  of  sterile  20%  Glucose  solution  was  added  to  the  medium. 
M9  Salts 
64  g/L  Na2HPO4.7H20 
15  g/L  KH2PO4 
2.5  g/L  NaCl 
5  g/L  NH4CI 
The  salts  were  dissolved  in  a  final  volume  of  1L  of  double  distilled  water  and  autoclaved. 
YPD  Medium 
20  g/L  Difco  Peptone 78 
10  g/L  Yeast  Extract 
18  g/L  Bacto-Agar  (for  plates  only) 
Distilled  water  was  added  to  the  mixture  to  950  ml.  The  pH  was  adjusted  to  5.8  using  HCl 
and  the  mixture  autoclaved  and  then  allowed  to  cool  to  approximately  55°C.  Glucose  was 
added  to  2%  before  use. 
lOX  Dropout  Solution 
Dropout  solution  was  made  up  with  the  following  concentrations  of  amino  acids.  When 
yeast  were  grown  under  nutrient  selection,  the  appropriate  amino  acids  were  left  out  of  the 
mixture. 
Amino  acids  M&L  Sigma  Catalogue  No. 
L-Adenine  hemisulfate  salt  200  A-9126 
L-Arginine  200  A-5131 
L-Histidine  HC1  monohydrate  200  H-9511 
L-Leucine  1000  L-1512 
L-Lysine  HC1  300  L-1262 
L-Methionine  200  M-9625 
L-Phenylalanine  500  P-5030 
L-Threonine  2000  T-8625 
L-Tryptophan  200  T-0254 
L-Tyrosine  300  T-3754 
L-Uracil  200  U-0750 79 
L-Isoleucine 
L-Valine 
SD  Medium 
6.7g/L 
18g/L 
Yeast  Nitrogen  Base 
Bacto-Agar 
300  1-7383 
1500  V-0500 
850  ml  H2O 
100  ml  of  the  appropriate  sterile  10X  dropout  solution 
The  pH  was  adjusted  to  5.8  using  NaOH  and  the  mixture  autoclaved  and  then  allowed  to 
cool  to  approximately  55°C.  Glucose  was  added  to  2%  before  use. 
1OX  TE  Buffer 
0.1  M  Tris-  HCl 
lo  mm  '  EDTA 
The  pH  of  the  solution  was  adjusted  to  7.5  and  the  solution  autoclaved. 
10x  LiAc 
1M  Lithium  Acetate. 
The  pH  of  the  solution  was  adjusted  to  7.5  and  the  solution  autoclaved. 
1X  TE/LiAc  Solution 
Prepared  fresh  immediately  prior  to  use  from  stocks  of  10X  TE  buffer  and  1OX  LiAc 
diluted  in  sterile  water. 
PEG/LiAc  Solution 80 
8  ml  50%  PEG4000 
1  ml  1OX  TE 
1  ml  1OX  LiAc 
Z  buffer 
16.1  g/L  Na2HPO47H2O 
5.5  g/L  NaH2PO4H2O 
0.75  g/L  KCl 
0.246  g/L  MgSO47H2O 
The  pH  of  the  solution  was  adjusted  to  7  and  autoclaved. 
X-gal  Stock  Solution 
5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside  (X-GAL,  Sigma  #8060-1)  was  re- 
suspended  in  N,  N-dimethylformamide  (DMF)  at  a  concentration  of  20mg/ml.  The  solution 
was  stored  in  the  dark  at  -20°C. 
Z  buffer/X-gal  Solution 
100  ml  Z  buffer 
0.27  ml  ß-mercaptoethanol 
1.67  ml  X-gal  stock  solution 
Whatman  #5  Filters 
75  mm  diameter  filters  were  used. 81 
Yeast  Protein  Extraction  Buffer 
50  mm  Tris-HC1  pH7.4 
loo  mm  NaC1 
2  mM  EDTA 
Protease  Inhibitor  Cocktail 
0.1  mg/ml  Chymostatin 
0.1  mg/ml  Leupeptin 
0.05  M  PMSF 
0.1  mg/ml  Pepstatin 
0.05  M  Benzamidine 
0.1  mg/ml  Aprotonin 
DNA  Loading  Buffer 
30%  w/v  Glycerol 
0.25%  w/v  Bromophenol  blue 
0.25%  w/v  Xylene  cyanol 
1OX  TBE 
108  g/L  Tris 
55  g/L  Boric  Acid 
8.45  g/L  EDTA 82 
Phosphate  Buffered  Saline  (PBS) 
0.8%  w/v  NaC1 
0.115%  w/v  Na2HPO4 
0.02%  w/v  KCl 
0.02%  w/v  KH2PO4 
3X  Protein  Sample  Buffer 
1  ml  1M  Tris  (pH8) 
20%  w/v  SDS 
0.5  ml  ß-mercaptoethanol 
1  ml  Glycerol 
0.25%  w/v  Bromophenol  blue 
10X  Blotto 
500  mM  Tris  pH7.5 
500  mM  NaC1 
lo  mm  EDTA 
Blocking  Solution 
1X  Blotto 
5%  w/v  Marvel 
0.01%  v/v  Tween-20 83 
5X  Annealing  Buffer 
335  mM  Tris  pH  7.6 
65  mM  MgC12 
33.5  mM  DTT 
6.5  mM  Spermidine 
6.5  mM  EDTA  pH  8 
2X  Salt  Binding  Buffer 
1.12  ml  4M  NaCI 
1  ml  1M  Tris  pH7.9 
3  ml  Glycerol  (100%) 
16  ml  250  mM  EDTA 
20  ml  1M  DTT 
4.88  ml  dH2O 
2X  No  Salt  Binding  Buffer 
1  ml  im  Tris  pH  7.9 
3  ml  Glycerol  (100%) 
0.5  ml  Salmon  Sperm  DNA  (2.5mg/ml  sonicated) 
16  ml  250  mM  EDTA 
20  ml  1M  DTT 84 
5.5  ml  dH2O 
lOX  Binding  Buffer 
100  mm  Hepes  pH  7.9 
2  mM  EDTA 
1  mg/ml  BSA 
40%  Glycerol 
Gel  Fix  Solution 
10%  Methanol 
10%  Glacial  Acetic  Acid 
Made  up  to  a  final  volume  of  100  ml  with  ddH2O 
Non-Denaturing  Polyacrylamide  Gels  for  EMSA 
8  ml,  30%  Acrylamide/Bisacrylamide  (19:  1  sequencing  grade) 
6  ml  1OX  TBE 
46  ml  ddH2O 
300  µl  10%  APS  (freshly  made) 
30  µl  TEMED 
Low  Stringency  Lysis  Buffer 
1%  v/v  NP40 
0.2  mM  PMSF 85 
0.7  mg/ml  Pepstatin 
0.5%  w/v  Aprotonin 
lo  mm  NaF 
50  mM  ß-glycerophosphate 
Nuclear  Extraction  Buffer 
25  mM  Hepes.  KOH  pH  8.0 
1  mm  EDTA 
1  mm  Benzamidine 
2  mM  ß-mercaptoethanol 
0.5  mm  Spermidine 
0.1  mm  Spermine 
Mismatch  Retard  Buffer 
25  mM  Hepes.  KOH  pH8 
0.5  mM  EDTA 
10%  v/v  Glycerol 
0.1  mm  ZnC12 
0.5  mM  DTT 
Complete  Mismatch  Gel  Retard  Mix 
200  ml  Mismatch  Retard  Buffer 86 
10  µl  (10mg)  Poly  (dI.  dC)2  (Sigma)  -1mg/ml  in  TE  or  ddH2O 
4  ml  G:  C  34mer  @100fmol/ml  (40fmol/tube)  ds  complementary 
oligo  competitor 
6%  Polyacrylamide  Non-denaturing  Gel 
6  ml  30%  Acrylamide/Bisacrylamide  (19:  1  sequencing  grade) 
20.4  ml  ddH2O 
600  µl  10%  ammonium  persulphate  solution  (fresh  made) 
3  ml  1OX  TBE 
15  µl  TEMED 
Reagent  B 
400  mM  Tris-HCI  pH8.0 
60  mM  EDTA 
150  mm  NaCI 
1%  w/v  SDS  (added  after  the  solution  is  autoclaved) 
20X  MOPS  SDS  Running  Buffer 
1M  MOPS 
1M  Tris  Base 
69.3  mM  SDS 
20.5  mM  EDTA 87 
20X  MES  SDS  Running  Buffer 
im  MES 
1M  Tris  Base 
69.3  mM  SDS 
20.5  mM  EDTA 
2.1.11  Oligonucleotides 
Oligonucleotides  for  Electrophoretic  Mobility  Shift  Assays 
Myc  oligo  with  the  `E  box'  sequence. 
GATCAATTCGACCACGTGGTCGGATC  MycF-band 
CTAGTTAAGCTGGTGCACCAGCCTAG  MycR-band 
EMSA  Mismatch  Substrate  Oligonucleotide 
5'-AGCTTGGCTGCAGGTNGACGGATCCCCGGGAATT-3' 
EMSA  SP1  Consensus  Binding  Site  Oligonucleotide 
5'  -ATTCGATCG  GGG  CG  GGG  CGAG  C-3' 
Oligonucleotide  Primers  for  PCR  and  Sequencing 
PMS2-F1:  5'-CTAGGTGAATTCATGGAGCGAGCTGAG-3' 
PMS2-R1:  5'-ACCTAGGGATCCTTAATGCAGAGCATCCGAACAGCT-3' 
PMS2-F2:  5'-TCGCCGGAATTCCCTAGTGACTCCGTGTGT-3' 
PMS2-R2:  5'-TCGCCGGGATCCTTATCCTAGAGGGCTCCTTCT-3' 88 
PMS2-F3:  5'-TCGCCGGAATTCGAGAACAAGCCTCACAGC-3' 
PMS2-R3:  5'-TCGCCGGGATCCTTACTTCCTGTAATTCTGTTCCCC-3' 
PMS  2-F4:  5'  -TCG  CCG  GAATTC  CAGTTACATCATGAAG  CACAG  CAA-3' 
PMS2-R4:  5'-ACCTAGGGATCCTCAGTTCTGAGAAATGACACC-3' 
PMS2-R3-9:  5'-TCGCCGGGATCCTTAATTCTGTTCCCCTTCACT-3' 
PMS2-R3-24:  5'-TCGCCGGGATCCTTAACT'ITGCTGTGCTTCATG-3' 
PMS2-R3-51:  5'-TCGCCGGGATCCTTAC  TFATTCGTTTAGCTAA-3' 
PMS2-R3-102:  5'-TCGCCGGGATCCTTACTTATTAATTITCAC-3' 
PMS2-R3-300:  5'-TCGCCGGGATCCTTATGAAAAAGAGTCGTCAGT-3' 
pGAD424-PMS2-F3:  5'-GAGATCGAATTCGAGAACAAGCCTCACAGC-3' 
pGBT9-PMS2-F3:  5'-TCGCCGGAATTCGAGAACAAGCCTCACAGC-3' 
MLH1-Fl:  5'-TCGCCGGAATTCATGTCGTTCGTGGCAGGG-3' 
MLH1-Rl  :  5'-AGGATGGATCCTTACAGTTCTCGACTAACAGCATTTCC-3' 
MLH1-F2:  5'-TCGCCGGAATTCGGCAGGTATTCAGTACAC-3' 
MLH1-R2:  5'-AGGATGGATCCTTACATCCTGGAGGAATTGGA-3' 
MLH1-F3:  5'-TCGCCGGAATTCCCCACAAAGCATGAAGTTCAC-3' 
MLH1-R3:  5'-AGGATGGATCCTTATGGCTCCGATAACCTGAG-3' 
MLH1-F4:  5'-TCGCCGGAATTCGAGCAGGGACATGAGGTT-3' 89 
MLH1-R4:  5'-AGGATGGATCCTTAACACCTCTCAAAGAUITTGTATAG-3' 
pGBT9-F:  5'-GCATTGTTAACAGGATTATTTGTAC-3' 
pGBT9-R:  5'  -TACAG  GAAAGAGTTACTCAAGAA-3' 
pGAD424-F:  5'-ACCAAACTGCGTATAACGCGTTT-3' 
pGAD424-R:  5'-TGGCCAAGATTGAAACTTAGAGG-3' 
pACT2-F-LAST:  5'-CGATGCACAGTTGAAGTGAACTTG-3' 
pACT2-F-LAST:  5'  -ACGATGTTCCAGATTACG  CTAG  CT-3' 
pGBKT7-F:  5'-TCATCGGAAGAGAGTAG-3' 
pGBKT7-R:  5'-TAAAACCTAAGAGTCACT-3' 
myc-F:  5'-GCATACATCCTGTCCGTC-3' 
myc-R:  5'-GACGGACAGGATGTATGC-3' 
Ml:  5'  -ATCG  CGAATTCCG  CCCACGACCAG  CAG  CGAC-3' 
M2:  5'-ACGTCTCGAGCTATGCACGAGAGTTCCTTAG-3' 
HP  RT-F:  5'  -GACTGAACGTCTTG  CTCGAGATG-3' 
HPRT-R:  5'-AATCTACAGTCATAGGAATGGA-3' 90 
2.1.12  Cell  Lines 
A2780 
A  human  ovarian  adenocarcinoma  cell  line  derived  from  an  untreated  patient  received  from 
R.  F.  Ozols  and  T.  C.  Hamilton,  Fox  Chase  Cancer  Centre,  Philadelphia. 
K562 
Human  erythroleukaemia  cell  line,  derived  from  Chronic  Myeloid  Leukaemia  in  blast 
crisis. 
Rat-1 
Rat  fibroblast  cell  line. 
Rat-i  MYCER1' 
Rat-1  fibroblasts  expressing  c-MYCERTM  (Littlewood  et  al.,  1995). 
2.1.13  Yeast  Strains 
Y190 
Genotype  MATa,  gal4A,  gal80A,  NO,  trpl  -901,  ade2-101,  ura3-52, 
leu2-3,112,  URA3::  GAL-lacZ,  LYS::  GAL(u  s)-HIS3, 
cyh.  r 
Reporters  HIS3,  lacZ 
Transformation  Markers  trpl,  leu2 91 
PJ69-2A 
Genotype  MATa,  trpl-901,  leu2-3,112,  ura3-52,  his3-200,  gal4A, 
gal80A,  LYS2::  GAL1  uAS-GALITATA-HIS3,  GAL2uAs- 
GAL2TATA  ADE2 
Reporters 
Transformation  Markers 
Y187 
HIS3,  ADE2 
trpl,  ura3,  leu2 
Genotype  MATa,  ura3-52,  his3-200,  ade2-101,  trpl-901,  leu2-3, 
112,  gal4A,  gal800,  mef,  URA3::  GAL1  UAS-GAL1  TATA-lacZ 
Reporters  lacZ 
Transformation  Markers  trpl,  leu2 
2.1.14  Plasmids 
GAIA  DNA-BD  Vectors  Description  Size  Unique  Cloning  Sites 
pGBT9  GAL4(1-147)  DNA-BD,  5.4  Kb  BamHI,  EcoRI,  Pstl, 
TRP1,  amp`  Sall,  Smal,  XmaI 
pGBKT7 
GAL4(1-147: 
762-1202)  7.3  Kb  Ndel,  Ncol,  Sf  II,  EcoRI, 
DNA-BD,  TRP1,  kan`  Smal,  Xmal,  BamHI, 
Sall,  Pst! 92 
GAL4  DNA-AD  Vectors  Description  Size  Unique  Cloning  Sites 
pGAD424  GAI4(768_881)  DNA-AD,  6.6  Kb  EcoRI,  Smal,  BamHI, 
LEU2,  amp`  Sall,  PstI 
pACT2  Gß(768-881:  5081-5419)  8.1  Kb  NcoI,  Sf  I,  Smal,  Xmal, 
DNA-AD,  LEU2,  amp`  BamH1,  EcoRI,  Sad, 
Xhol,  BgIII 
Control  Plasmids  Description  Size 
pCL1  wild-type  full  length  GAL4  gene  in  a  Ycp50  derivative, 
LEU2,  amp` 
15.3  Kb 
pVA3  murine  p53(72_390)  in  pGBT9,  TRP1,  amp`  6.4  Kb 
p'ID1  SV40  large  T-antigen(g¢7o8)  in  pGAD3F,  LEU2,  amp`  15  Kb 
pLAM5'  Human  lamin  C(66-230)  in  pGBT9,  TRP1,  amp`  6.0  Kb 93 
2.2  Methods 
2.2.1  Bacterial  Protocols 
2.2.1.1  Bacterial  Culture 
Bacteria  were  maintained  either  in  Luria-Bertani  (LB)  broth  liquid  culture  or  on  LB  agar 
plates  under  selective  conditions.  Cells  were  stored  for  long  periods  in  15%  glycerol  in  LB 
broth  at  -70°C. 
2.2.1.2  Preparation  of  Electrocompetent  Bacterial  Cells. 
50  ml  of  S.  O.  B.  media  was  inoculated  with  a  freshly  grown  single  colony  of  the  KC8 
bacterial  strain.  The  culture  was  incubated  overnight  (12-16  hours)  at  37°C  in  a  shaking 
incubator.  5  ml  of  the  overnight  culture  was  used  to  inoculate  500  ml  of  S.  O.  B  media  in  a 
2L  flask..  This  culture  was  incubated  at  37°C  in  a  shaking  incubator  until  the  cell  density 
reached  an  optical  density  of  0.8  at  550  nm  (2-3  hours).  The  culture  was  transferred  into 
chilled  centrifuge  bottles  and  the  cells  collected  by  centrifugation  in  the  Sorvall  RC3C,  H- 
6000A  rotor  at  1000  g.  The  cell  pellet  was  re-suspended  in  ice-cold  sterile  distilled  water 
to  wash  the  cells  and  collected  again  by  centrifugation.  This  wash  step  was  repeated.  The 
cells  were  then  washed  twice  in  ice-cold  sterile  10%  glycerol.  The  cell  pellet  was  re- 
suspended  in  10%  glycerol  and  aliquots  were  dispensed  into  chilled  microcentrifuge  tubes 
and  stored  at  -70°C. 
2.2.1.3  Transformation  of  Bacterial  Cells  with  Plasmid  DNA  by 
Electroporation 
10-50  ng  of  plasmid  DNA  was  added  to  40  µl  of  electrocompetent  bacterial  cells  in  pre- 
chilled  microcentrifuge  tubes.  This  mixture  was  then  transferred  into  a  standard 
electroporation  cuvette  witha  1mm  gap.  The  loaded  cuvette  was  placed  into  the  Hybaid 
electroporator  cuvette  holder  and  the  safety  cover  closed.  A  pulse  was  delivered  through 
the  cuvette  and  1  ml  of  S.  O.  C  media  was  added  immediately  to  the  cuvette  to  wash  the 
cells  out  of  the  electrode  gap  and  transferred  to  a  culture  tube.  The  cells  were  incubated  at 
37°C  in  a  shaking  incubator  for  1  hour.  Appropriate  dilutions  were  plated  on  selective 94 
medium  (1.5%  LB-agar  plates,  100  µg/ml  ampicillin  or  50  µg/ml  kanamycin)  using  a 
sterile  glass  loop.  Plates  were  incubated  overnight  at  37°C. 
2.2.1.4  Transformation  of  Bacterial  Cells  with  Plasmid  DNA 
10-20  ng  of  plasmid  DNA  was  added  to  50  µl  of  Library  Efficiency  DH5a  competent  cells 
(Gibco)  and  left  on  ice  for  30  minutes.  After  a  45  sec  heat-shock  at  42°C,  900  µl  of  S.  O.  C 
media  was  added  and  the  samples  vortexed  before  incubation  at  37°C  for  1  h..  Appropriate 
dilutions  were  plated  on  selective  medium  (1.5%  LB-agar  plates,  100  µg/ml  ampicillin  or 
50  µg/ml  kanamycin)  using  a  sterile  glass  loop.  Plates  were  incubated  overnight  at  37°C. 
2.2.1.5  Plasmid  DNA  Mini-Preparation. 
Cultures  for  plasmid  preparation  were  grown  from  a  single  colony  picked  with  a  sterile 
loop  from  a  freshly  streaked  selective  plate.  This  single  colony  was  used  to  inoculate  5  ml 
of  Luria-Bertani  (LB)  broth  and  the  culture  incubated  overnight  at  37°C  in  a  shaking 
incubator.  Antibiotic  selection  was  used  at  every  stage  of  growth,  ampilcillin  100  mg/ml 
or  kanamycin  50  mg/ml  depending  on  the  plasmid  being  used.  The  Qiaprep  Spin  Miniprep 
kit  was  used  according  to  the  manufacturers  recommendations  to  obtain  plasmid  DNA. 
2.2.1.6  Plasmid  DNA  Maxi  Preparation. 
A5  ml  culture  was  used  to  inoculate  500  ml  of  LB-broth  in  a1L  flask  containing  100 
µg/ml  ampicillin  or  50  µg/ml  kanamycin  (for  selection)  and  this  culture  was  grown  to 
stationary  phase  overnight  in  a  37°C  shaking  incubator.  The  Qiagen  Maxi  Preparation  kit 
was  used  according  to  the  manufacturers  recommendations  to  obtain  plasmid  DNA.  Both 
Qiagen  Mini  and  Maxi  Preparation  Kits  utilise  a  modified  alkaline  lysis  protocol.  The 
lysate  is  then  cleared  by  centrifugation  and  the  plasmid  DNA  bound  to  an  anion-exchange 
resin.  Any  RNA,  protein  etc.  are  removed  by  a  medium-salt  wash  through  this  resin. 
Plasmid  DNA  is  subsequently  eluted  from  the  resin  in  a  high  salt  buffer  and  concentrated 
and  desalted  by  isopropanol  precipitation. 95 
2.2.2  Yeast  Protocols 
2.2.2.1  Yeast  Culture. 
Yeast  were  maintained  either  in  YPD  liquid  culture  or  on  YPD  agar  plates.  Cells  were 
stored  for  long  periods  in  15%  glycerol  in  YPD  at  -70°C. 
Synthetic  dropout  (SD)  minimal  medium  was  used  for  yeast  transformations  to  select  and 
test  for  specific  phenotypes.  SD  medium  was  prepared  with  a  minimal  SD  base  with  a 
stock  of  `dropout'  solution  containing  a  specific  mixture  of  amino  acids  and  nucleosides. 
2.2.2.2  Yeast  Strain  Phenotype  Testing 
The  phenotypes  of  each  yeast  strain  were  verified  before  any  experiments  were  carried  out. 
Yeast  strains  used  were  supplied  as  frozen  glycerol  stocks.  Fresh  working  stock  plates 
were  prepared  for  each,  by  scraping  a  small  amount  of  cells  with  a  sterile  loop  from  the 
frozen  stock  and  streaking  these  onto  YPD  plates.  The  yeast  strains  used  in  these  studies 
are  all  deficient  for  Leu  and  Trp  i.  e.  they  cannot  grow  on  SD  minimal  medium  lacking 
these  nutrients.  Therefore  the  phenotype  of  the  yeast  strains  was  tested  by  streaking  them 
out  onto  SD  medium  plates  selecting  for  a  number  of  different  essential  amino  acids. 
2.2.2.3  Preparation  of  Yeast  Competent  Cells 
A  single  yeast  colony  was  inoculated  into  20  ml  of  YPD  medium  (adenine  supplemented  2 
g/L).  The  inoculates  were  incubated  at  30°C  for  16-18  hours  or  until  the  culture  was  at 
stationary  phase  (OD600>1.5).  This  overnight  culture  was  transferred  into  a  final  volume  of 
300  ml  YPD.  This  was  incubated  at  30°C  with  shaking  for  3  hours.  The  cells  were 
collected  by  centrifugation  in  the  Sorvall  RC3C,  H-6000A  rotor  at  1000  g  for  5  min  at 
room  temperature  (20-21°C).  The  supernatant  was  discarded  and  the  cell  pellet  was  re- 
suspended  in  50  ml  of  water.  The  cells  were  centrifuged  again  for  5  min  at  1000  g  at  room 
temperature.  The  pellet  was  re-suspended  in  1.5  ml  of  freshly  prepared,  sterile  1X 
TE/LiAc.  Competent  cells  were  stored  at  -70°C  in  15%  glycerol. 96 
2.2.2.4  Lithium/Acetate  Transformation  of  Yeast  Cells  with  Plasmid  DNA 
1.5  µg  of  each  plasmid  DNA  was  mixed  together  with  100  µg  of  herring  testes  DNA  (20 
µg/µ1,  denatured  by  placing  on  a  100°C  heating  block  for  20  min  and  cooling  rapidly  on 
ice)  in  a  1.5  ml  microcentrifuge  tube.  100  µl  of  yeast  competent  cells  was  added  to  the 
DNA  and  mixed  well.  600  µl  of  sterile  PEG/LiAc  solution  was  added  to  each  tube  and 
vortexed  to  mix.  The  tubes  were  incubated  at  30°C  for  30  min,  with  shaking  (200  rpm). 
70  µl  of  DMSO  was  added  and  mixed  gently  by  inversion.  The  cells  were  heat  shocked  for 
15  min  in  a  42°C  water  bath.  To  pellet  the  cells,  the  tubes  were  chilled  on  ice  and 
centrifuged  for  5  sec  at  18,300  g  in  a  microcentifuge.  The  supernatant  was  removed  and 
the  cells  were  re-suspended  in  0.5  ml  of  1X  TE  buffer.  100  µl  of  the  transformation 
mixture  was  spread  onto  each  10  cm  plate  containing  the  appropriate  selection  medium. 
The  plates  were  incubated  at  30°C  for  2-4  days  (until  colonies  appeared).  Master  plates 
were  sealed  with  parafilm  and  stored  at  4°C  for  3-4  weeks. 
2.2.2.5  Large  Scale  Transformation  Protocol  for  Library  Screen  1 
A5  ml  culture  of  Trp  SD  liquid  media  was  inoculated  with  a  single  colony  of  Y190 
transformed  with  pGBT9  MLH1.  This  was  allowed  to  grow  at  30°C  for  8  hours.  The  5ml 
culture  was  made  up  to  a  50  ml  culture  and  was  grown  overnight  in  Trp  dropout  media. 
One  litre  of  cells  was  grown  by  adding  half  of  this  overnight  culture  to  each  of  two  flasks 
with  500  ml  YPD  in  each.  These  cells  were  allowed  to  grow  at  30°C  with  shaking  for  4 
hours.  The  cells  were  collected  by  centrifugation  at  1000  g  for  5  min  at  room  temperature. 
The  supernatant  was  decanted  and  the  pellet  re-suspended  in  500  ml  sterile  water  and 
centrifuged  as  above.  The  supernatant  was  decanted  and  the  pellet  re-suspended  in  8  ml 
PEG/LiAc  solution.  The  library  DNA  (Human  Mammary  Gland  MATCHMAKER  cDNA 
Library,  Clontech  Cat.  #HL4036AH)  was  mixed  with  0.25  ml  of  20  mg/ml  denatured 
herring  testes  DNA  and  30  µg  of  library  DNA.  This  mixture  was  then  added  to  the  cell 
suspension  and  mixed.  60  ml  of  PEG/LiAc  solution  was  also  added  and  this  mixture  was 
incubated  at  30°C  for  30  mins  with  shaking.  7.6  ml  of  DMSO  was  then  added  and  swirled 
to  mix.  This  mixture  was  heat  shocked  for  15  min  at  42°C  with  occasional  swirling  to 
facilitate  heat  transfer.  The  cells  were  collected  by  centrifugation  at  1000  g  for  5  min  at 
room  temperature.  The  pellet  was  re-suspended  in  50  ml  of  TE  buffer  and  centrifuged  as 
above.  The  supernatant  was  decanted  and  the  pellet  re-suspended  in  10  ml  of  TE  buffer. 97 
500  µl  of  this  mixture  was  plated  out  onto  Leu-/Trp"/His"  23  cm  x  23  cm  plates  with  25  mM 
3-AT  (3-amino-1,2,4-triazole,  SIGMA). 
2.2.2.6  Large  Scale  Transformation  Protocol  for  the  Yeast  Two-Hybrid 
Pretransformed  Library  Mating  Screen 
hMLH1  was  cloned  into  a  GAL  4  binding  domain  (BD)  vector,  pGBKT7  and  transformed 
into  the  PJ69-2A  strain.  The  pGBKT7  hMLH1  construct,  like  pGBT9  MLH1  did  not 
autonomously  activate  the  reporter  genes,  was  not  toxic  when  expressed  in  yeast  and  gave  a 
positive  interaction  when  co-transformed  into  Y190  with  pGAD424  PMS2  F3.  One  large 
pGBKT7  hMLH1  transformed  PJ69-2A  colony  was  used  to  inoculate  50  ml  of  Trp  SD 
liquid  media.  This  culture  was  incubated  at  30°C  with  shaking  for  24  hours.  The  cells 
were  collected  by  centrifugation  at  1000  g  for  5  minutes.  The  supernatant  was  decanted  off 
and  the  pellet  re-suspended  in  the  residual  liquid  by  vortexing.  A1  ml  aliquot  of  the  pre- 
transformed  library  was  allowed  to  thaw  in  a  room  temperature  water  bath.  10  [.  1  of  this 
aliquot  was  set  aside.  The  bait  containing  cells  and  the  1  ml  library  aliquot  were  mixed 
with  45  ml  YPDA/Kanamycin  (15  mg/L  Kanamycin)  in  a2L  conical  flask  and  mixed 
gently  by  swirling.  The  flask  was  incubated  at  30°C  in  a  shaking  incubator  (50  rpm)  for  24 
hours.  This  mating  culture  was  transferred  into  two  50  ml  Falcon  tubes  and  the  cells 
collected  by  centrifugation  at  1000  g  for  10  minutes.  The  pellet  was  re-suspended  in  10  ml 
of  YPDA/Kan  giving  a  total  volume  of  11  ml.  100  µl  of  a  1:  10,1:  100,1:  1000  and  a 
1:  10000  dilution  of  this  mixture  was  plated  out  on  10  cm  Leu",  Trp"  and  Leu  iTrp"  SD 
plates.  200  µl  of  the  remaining  mixture  was  plated  out  onto  52  QDO  (quadruple  dropout) 
plates  and  incubated  at  30°C  for  16  days. 
2.2.2.7  Library  Titre 
The  10  µl  aliquot  of  the  library  set  aside  was  mixed  with  1  ml  YPDA/Kan  in  a  1.5  ml 
microcentrifuge  tube.  This  was  labelled  dilution  A  (dilution  factor  of  10"2).  10  µl  of 
dilution  A  was  mixed  with  1  ml  YPDA/Kan  and  labelled  dilution  B  (dilution  factor  10-4). 
10  µl  of  dilution  A  was  mixed  with  50  µl  YPDA/Kan  and  plated  out  onto  a  Leu  SD  plate. 
50  µl  and  100  µl  of  dilution  B  was  plated  out  onto  Leu  SD  plates.  The  plates  were 
incubated  at  30°C  until  colonies  appeared. 98 
2.2.2.8  Colony  Lift  Filter  Assay 
The  colony  lift  filter  assay  can  be  performed  at  any  time  after  colonies  are  visible.  A  sterile 
Whatman  #5  filter  was  placed  over  the  surface  of  the  agar  plate  with  the  transformant 
colonies.  To  orient  the  filter  on  the  agar,  holes  were  poked  through  the  filter  into  the  agar, 
in  three  asymmetric  locations,  with  a  sterile  needle.  The  filter  was  carefully  lifted  off  the 
agar  plate  with  a  sterile  forceps  and  transferred  (colonies  facing  up)  to  a  pool  of  liquid 
nitrogen.  Using  the  forceps,  the  filters  were  completely  submerged  for  10  sec.  After  the 
filter  had  frozen  completely,  it  was  removed  from  the  liquid  nitrogen  and  allowed  to  thaw 
at  room  temperature.  This  freeze/thaw  treatment  serves  to  permeabilise  the  cells.  The 
filter  was  carefully  placed,  colony  side  up,  on  another  filter  that  had  been  pre-soaked  in  Z 
buffer/X-gal  solution.  The  filters  were  incubated  at  30°C  and  checked  periodically  for  the 
appearance  of  blue  colonies.  The  time  for  blue  colonies  to  appear  varied  between  30mins 
and  up  to  8  hours  (blue  colonies  after  8  hours  taken  as  false  positives).  Certain  strains,  e.  g. 
those  transformed  with  pCL1  (a  wild-type  GAI4  control),  turned  blue  more  quickly  (20-30 
min).  For  the  c-DNA  library  screen  ß-galactosidase-producing  colonies  were  identified  by 
aligning  the  filter  to  the  agar  plate  using  the  orienting  marks.  Positives  were  isolated  by 
picking  the  corresponding  colonies  from  the  original  plates  to  fresh  media. 
2.2.2.9  Plasmid  DNA  Isolation  from  Yeast 
Cultures  for  plasmid  preparation  were  grown  from  a  single  colony,  picked  from  a  freshly 
streaked  selective  plate,  with  a  sterile  loop.  A  single  colony  was  used  to  inoculate  5  ml  of 
the  appropriate  SD  medium  and  allowed  to  grow  overnight  in  a  30°C  shaking  incubator. 
The  Nucleon  Biosciences  Mini  Preparation  (Scotlab  Biosciences)  kit  was  used  according  to 
the  manufacturers  recommendations  to  obtain  plasmid  DNA. 
2.2.2.10  Preparation  of  Protein  Extracts  from  Yeast 
Fresh  single  yeast  colonies  were  used  to  grow  up  300  ml  yeast  cultures  as  described  above. 
The  yeast  cells  were  collected  by  centrifugation  at  1000  g  and  the  pellet  washed  in  sterile 
distilled  water.  The  cell  pellet  was  re-suspended  in  10  ml  of  sterile  distilled  water  and 
transferred  to  a  15  ml  Falcon-2059  tube.  The  cells  were  again  collected  by  centrifugation 
and  the  pellet  re-suspended  in  0.5  ml  of  ice  cold  yeast  protein  extraction  buffer  which 
contains  a  protease  inhibitor  cocktail.  Glass  beads  (  425-600  microns,  Sigma)  were  added 
to  two  thirds  the  height  of  the  meniscus.  The  tubes  were  vortexed  at  4°C  for  10  min.  The 99 
cell  extract  was  recovered  from  the  glass  beads  using  a  fine-tipped  plastic  Pasteur  pipette. 
To  recover  as  much  extract  as  possible  the  beads  were  re-extracted  with  0.5  ml  of  buffer. 
Total  protein  concentration  was  estimated  for  the  extracts  using  the  BCA  method. 
2.2.3  DNA  Protocols 
2.2.3.1  Preparation  of  Herring  Testes  Carrier  DNA 
Herring  testes  DNA  for  use  as  a  carrier  DNA  in  yeast  transformations  was  prepared  by 
dissolving  herring  testes  DNA  in  1X  TE  buffer  and  sonicating  the  mixture  to  reduce  its 
viscosity.  The  DNA  was  extracted  with  phenol/chloroform,  and  precipitated  with  ethanol. 
The  DNA  was  re-suspended  at  a  concentration  of  20  mg/ml  in  1X  TE  buffer.  The  DNA 
was  placed  in  a  tube  in  a  boiling  water  bath  for  20  min  and  immediately  cooled  on  ice.  The 
carrier  DNA  was  re-denatured  just  prior  to  use. 
2.2.3.2  Phenol/Chloroform  Extraction  of  DNA 
An  equal  volume  of  phenol:  chloroform  was  added  to  the  nucleic  acid  sample  in  a 
polypropylene  tube.  The  contents  of  the  tube  were  mixed  until  an  emulsion  formed.  The 
mixture  was  centrifuged  at  2000  g  in  a  Sorvall  RC3C,  H-6000A  rotor  for  3  min  at  room 
temperature.  A  pipette  was  used  to  transfer  the  aqueous  phase  to  a  fresh  tube.  The 
interface  and  organic  phase  were  discarded.  -  An  equal  volume  of  chloroform  was  added  to 
this  and  again  the  mixture  was  centrifuged  at  2000  g  for  3  min  at  room  temperature.  The 
nucleic  acid  was  recovered  by  precipitation  with  ethanol. 
2.2.3.3  Ethanol  Precipitation  of  DNA 
3M  Na  Acetate  (pH  8)  was  added  to  the  DNA  sample  (final  concentration  of  0.3  M  i.  e.  a 
1/10  volume)  followed  by  2i  volumes  of  ice-cold  ethanol.  The  mixture  was  placed  at  - 
20°C  for  30  min  to  allow  the  DNA  precipitate  to  form.  The  samples  were  centrifuged  at 
15,800  g  for  15  min  in  a  microcentrifuge.  The  supernatant  was  removed,  1  ml  of  70% 
ethanol  was  added  to  wash  the  pellet  and  the  tube  was  placed  at  -20°C  for  30  minutes.  The 
tubes  were  again  centrifuged  at  15,800  g  for  15  min.  The  supernatant  was  removed  and  the 
pellet  was  allowed  to  air  dry  before  re-suspending  in  sterile  water. 100 
2.2.3.4  Oligonucleotide  Synthesis 
Oligonucleotides  were  synthesised  by  the  Beatson  Institute  technical  services  staff  on  an 
Applied  Biosystems  392  DNA/RNA  oligonucleotide  synthesiser,  using  the  manufacturers 
protocol  and  Cruachem  reagents.  After  de-protection  in  ammonia  at  55°C  overnight,  the 
oligonucleotides  were  precipitated  and  used  without  further  purification. 
2.2.3.5  Quantitation  of  DNA  Concentrations 
DNA  was  quantified  by  spectrophotometric  determination  of  its  UV  light  absorbency.  A 
Pharmacia  Biotech  GeneQuant  machine  was  used  for  this  measurement.  This  instrument 
measures  absorbency  of  the  input  solution  at  260  nm  and  280  nm  in  a  quartz  capillary  tube. 
dH2O  was  used  as  a  blank.  Calculation  of  the  solution  concentration  utilises  de  Beer's  law 
which  takes  an  optical  density  of  1.0  at  260  nm  as  corresponding  to  a  concentration  of  50 
µg/ml  for  double  stranded  DNA  and  37  µg/ml  for  single  stranded  oligonucleotides. 
A260/A28o  ratios  are  1.8  and  2.0  for  pure  DNA  and  RNA  preparations  respectively.  The 
GeneQuant  gives  out  a  direct  concentration  reading  for  the  DNA. 
2.2.3.6  Restriction  Digests 
All  restriction  endonucleases  used  were  supplied  by  Gibco  BRL  Life  Technologies. 
Restriction  digests  were  carried  out  according  to  the  manufacturer's  instructions,  with  the 
total  enzyme  concentration  in'the  reaction  not  exceeding  10%.  50  µl  reactions  were  used 
with  500-750  ng  of  plasmid  DNA  per  reaction.  Reactions  were  incubated  on  a  37°C 
heating  block  for  1-2  hours.  When  a  double  digest  was  required  with  two  enzymes  that 
required  different  enzyme  buffers,  sequential  digestions  were  carried  out.  The  first  enzyme 
digestion  was  completed.  This  reaction  was  cleaned  up  using  a  Promega  Wizard  DNA 
Clean-Up  System  according  to  the  manufacturers  recommendations  to  remove  the  first 
enzyme  used  and  small  nucleotides  resulting  from  digestion.  This  cleaned  up  linear  DNA 
was  subsequently  digested  with  the  second  enzyme. 
2.2.3.7  De-Phosphorylation  Reactions 
De-phosphorylation  of  restriction  digested  plasmids  was  performed  with  CIP  (calf 
intestinal  phosphatase).  The  protocol  detailed  in  Maniatis  suggests  the  use  of  1  unit  of  CIP 
per  100  pmoles  of  DNA,  however  CIP  was  used  in  excess  of  this  concentration.  In  the  case 101 
of  double  digests  CIP  was  added  in  excess  to  the  second  digest  reaction  and  incubated  with 
this  reaction  at  37°C  on  a  heating  block  for  1-2  hours.  The  digested  DNA  was  again 
cleaned  up  using  the  Promega  Wizard  DNA  Clean-Up  System. 
2.2.3.8  Ligation  Reactions 
Ligation  reactions  were  carried  out  in  a  final  volume  of  no  greater  than  15  µl  so  as  to 
maintain  a  high  concentration  of  5'  and  3'  DNA  ends.  T4  DNA  Ligase  (Promega) 
catalyses  the  joining  of  two  strands  of  DNA  between  the  5'-phosphate  and  the  3'-hydroxyl 
groups  of  adjacent  nucleotides  in  either  a  sticky-ended  or  blunt-ended  configuration  The 
reactions  were  performed  using  a  1:  1  and  1:  3  molar  ratio  of  vector:  insert  DNA  when 
cloning  a  fragment  into  a  plasmid  vector.  Plasmid  DNA  was  treated  with  CIP  before  the 
ligation  reactions  were  carried  out.  Reactions  consisted  of  100  ng  of  plasmid  DNA,  insert 
DNA,  1  Weiss  Unit  of  T4  DNA  ligase  in  1X  ligase  buffer  (300  mM  Tris-HCI,  pH  7.8,100 
mM  MgCl2.100  mM  DTT  and  10  mM  ATP)  in  a  final  volume  of  10-15  µl.  The  ligated 
products  were  used  to  transform  DH5ct  library  efficiency  competent  cells  as  described. 
2.2.3.9  Preparation  of  cDNA 
RNA  was  prepared  from  1x  107  A2780  cells  using  a  Qiagen  RNeasy  Kit  according  to  the 
manufacturers  protocol.  cDNA  was  subsequently  prepared  from  this  using  a 
SUPERSCRIPTTM  Preamplification  System  kit  for  first  strand  cDNA  synthesis  (Gibco 
BRL)  again  according  to  the  manufacturers  protocol. 
2.2.3.10  Polymerase  Chain  Reaction  (PCR) 
The  following  conditions  were  used  to  perform  the  majority  of  PCR  amplifications.  Slight 
alterations  were  made  to  the  annealing  temperature  or  concentration  of  magnesium  ions 
where  required  for  optimal  results.  Each  standard  PCR  reaction  consisted  of  100-300  ng 
template  'DNA,  1X  PCR  reaction  buffer  (contains  MgC12),  0.18  mM  dNTP,  0.16  µM  of 
each  primer,  2.5  U  Taq  DNA  polymerase  (Roche)  or  1.75  U  Expand  Taq  (Roche)  with  the 
volume  adjusted  to  50  µl  with  ddH2O.  ddH2O  instead  of  template  was  added  to  control 
reactions.  The  thermal  cycling  parameters  consisted  of  30  cycles  of  1  min  denaturation  at 
94°C,  1  min  annealing  at  55°C,  and  1  min  extension  at  72°C  using  a  Hybaid  Touchdown  or 
Omnigene  PCR  Thermal  Cycler. 102 
2.2.3.11  Removal  of  Primers  from  PCR  Products 
Primer  dimers  were  removed  from  PCR  products  using  the  Qiaquick  PCR  Purification  Kit 
(Qiagen). 
2.2.3.12  Automated  DNA  Sequencing 
Samples  were  sequenced  using  the  PRISM  BigDyeTM  terminator  cycle  sequencing  ready 
reaction  kit  (ABI)..  Purified  PCR  products  were  mixed  with  3.2  pmoles  of  primer  and  the 
volume  made  up  to  6  µl  with  H2O.  4  µl  of  the  BigDyeTM  terminator  ready  reaction  mix 
was  added  to  each  sample  before  undergoing  the  following  PCR  protocol  with  Perkin 
Elmer  9600.  Preheat  to  96°C  followed  by  25  cycles;  96°C  for  15  sec,  50°C  for  1  sec,  60°C 
for  4  min,  and  left  to  soak  at  4°C. 
Excess  dye  terminators  were  removed  using  ethanol  precipitation  and  samples  were  loaded 
in  appropriate  buffer  on  an  automated  DNA  sequencer  and  run  overnight.  Sequence 
information  was  examined  using  an  ABI  data  analysis  program  (version  1.2.1)  by  technical 
services  staff  of  the  Beatson  Institute. 
2.2.3.13  Isolation  of  Genomic  DNA  from  Cells 
The  cell  pellet  (1.5  x  106  cells)  was  re-suspended  in  340  µl  Reagent  B.  100  µl  of  5M 
sodium  perchlorate  was  added  to  this  mixture.  The  tubes  were  incubated  at  37°C  for  20 
minutes  followed  by  a  20  min  incubation  on  a  70°C  heating  block.  The  DNA  was 
extracted  using  a  phenol/chloroform  extraction  procedure  and  precipitated  with  ethanol,  in 
the  absence  of  salt. 
2.2.3.14  Agarose  Gel  Electrophoresis 
DNA  samples  and  size  markers,  both  in  DNA  loading  buffer,  were  electrophoresed  through 
1-2%  agarose  gels  containing  0.5  mg/ml  ethidium  bromide.  Gels  were  made  by  dissolving 
the  appropriate  amount  of  electrophoresis  grade  agarose  in  1X  TBE.  The  gels  were 
submerged  in  TBE  and  run  at  3  V/cm.  Electrophoresed  DNA  was  visualised  using  a  UV 
transilluminator  and  a  record  of  the  gel  was  made  using  a  digital  imaging  system. 103 
2.2.4  Electrophoretic  Mobility  Shift  Assays 
2.2.4.1  Annealing  Reaction  for  Re-annealing  of  Complementary 
Oligonucleotides 
Equal  amounts  of  oligonucleotides  were  incubated  together  with  20  µl  of  5X  Annealing 
Buffer,  1.4  µl  of  0.5  M  DTT  and  made  up  to  100  µl  total  volume  with  ddH2O.  The 
annealing  reaction  was  incubated  in  a  boiling  water  bath  (95°C)  for  two  minutes  and  then 
left  in  the  water  until  the  water  bath  had  reached  room  temperature. 
2.2.4.2  y32P-dATP  Labelling  Reaction  for  Double  Stranded  Oligonucleotide 
Approximately  200  ng  of  the  re-annealed  oligonucleotide  was  mixed  with  2  µl  kinase 
buffer  (Transgenomic),  5  µl  y32P-dATP  (specific  activity  10  mCi/ml)  and  2  µl  T4 
polynucleotide  kinase  (Transgenomics)  made  up  to  20  µl  total  volume  with  ddH2O.  The 
reaction  was  incubated  at  37°C  for  60  min  after  which  time  the  volume  of  the  reaction  was 
made  up  to  100  µl  with  ddH2O.  This  100  µl  was  put  through  a  Biorad  Micro  Bio-Spin 
chromatography  column  to  clean  up  and  purify  the  double  stranded  labelled  oligo. 
For  the  mismatch  gel  retards  the  probes  were  gel  purified  by  resolving  the  labelling 
reaction  on  a  15%  acrylamide/TBE  gel.  The  bromophenol  blue  dye  band  was  allowed  to 
run  half  way  down  the  gel.  The  DNA  was  located  by  autoradiography  of  the  wet  gel  (film 
exposed  for  2  minutes)  and  the  band  excised.  The  DNA  was  eluted  by  soaking  the 
macerated  gel  slice  in  TE  (200  µl)  overnight  at  room  temperature.  The  eluate  was  filtered 
through  glass  wool  and  stored  at  -20°C. 
2.2.4.3  MYC/MAX/MLH1  Electrophoretic  Mobility  Shift  DNA 
Binding  Assays. 
The  binding  reaction  included  extract  at  a  range  of  concentrations  (purified  GST-MYC, 
GST-MLH1  and  HIS-MAX),  8  µl  of  no  salt  binding  buffer,  2  µl  salt  binding  buffer,  and  1 
µl  of  the  probe  (added  later),  made  up  to  a  final  volume  of  20  µi.  The  reaction  was  pre- 
incubated  for  10  min  at  30°C.  Probe  was  added  to  each  reaction  and  incubated  at  30°C  for 
another  10  min.  Samples  were  loaded  onto  a  non-denaturing  polyacrylamide  gel  and  run  at 
150  V  for  1.5  hours.  The  gels  were  fixed  in  gel  fix  solution  for  30  min  with  gentle  shaking 
and  dried  using  a  vacuum  pump  system.  The  gel  was  exposed  to  film  overnight  at  -70°C. 104 
2.2.4.4  Preparation  of  Nuclear  Cell  Extracts 
2x  108  cells  were  grown  up  in  T150  flasks  and  collected  by  centrifugation  at  700  g.  The 
pellet  was  washed  in  PBS  and  re-suspended  in  1  ml  of  freshly  made  extraction  buffer  (25 
mM  Hepes.  KOH  pH  8.0,1  mM  EDTA,  1  mM  Benzamidine,  2  mM  ß-mercaptoethanol, 
0.5  mM  Spermidine,  0.1  mM  Spermine).  The  extraction  procedure  was  carried  out  as 
described  previously  (Jiricny  et  al.,  1988;  Stephenson  and  Karran,  1989).  50  µl  aliquots  of 
extract  were  placed  in  pre-cooled  microcentrifuge  tubes  and  stored  at  -70°C. 
2.2.4.5  SPl  Electrophoretic  Mobility  Shift  DNA  Binding  Assays. 
These  gel  shift  assays  were  carried  out  as  for  the  MYC/MAX/MLH1  assays  except  for  the 
binding  reaction  which  varied  slightly.  A  binding  master  mix  was  prepared,  45  µl  10X 
Binding  Buffer,  7.5  µl  poly  dI.  dC  (1  mg/ml),  2  µl  DTT  (1  M),  320  µl  ddH2O.  25  µl  of 
master  mix  was  put  in  each  reaction  tube  on  ice  followed  by  the  addition  of  20  µg  of 
nuclear  extract  and  made  up  to  a  final  volume  of  30  µl  with  ddH2O.  The  binding  assay  was 
initiated  by  addition  of  the  32P  labelled  oligo  probe  and  incubated  on  ice  for  30  min. 
Reaction  samples  were  treated  as  before. 
2.2.4.6  EMSA  with  Mismatched  Substrate 
Experiments  were  performed  using  34mer  oligonucleotides: 
5'-AGCTTGGCTGCAGGTNGACGGATCCCCGGGAATT-3' 
where  N=G,  annealed  to  a  complementary  strand  which  was  either  an  exact  match  or 
contained  a  single  non-complementary  T  base  at  the  position  corresponding  to  N  (position 
16)  (Jiricny  et  al.,  1988;  Stephenson  and  Karran,  1989).  Reactions  were  carried  out  at 
20°C  in  a  total  volume  of  30  µl  with  20  µl  of  Complete  Mismatch  Gel  Retard  Mix  which 
contains  poly  (dl.  dC).  poly(dI.  dC)  at  a  concentration  of  50  µg/ml.  In  this  standard  assay, 
cell  extracts  (30  µg  of  protein  in  s5  µl)  were  pre-incubated  for  5  minutes  with  200  fmol  of 
standard  duplex  34-mer  oligonucleotide  containing  a  G.  C  base  pair  at  position  16  (included 
in  the  Complete  Mismatch  Gel  Retard  Mix)  before  addition  of  the  radioactive  substrate. 
Incubation  with  the  radioactive  substrate  (20  fmol)  was  for  20  min  at  20°C.  Samples  were 
loaded  onto  6%  polyacrylamide  gels  (2  mm  thick).  Electrophoresis  was  carried  out  at  150 
V  in  1X  TBE  buffer.  The  gels  were  dried  and  exposed  to  X-ray  film. 105 
2.2.5  Protein  Protocols 
2.2.5.1  Protein  Concentration  Estimation 
Estimation  of  protein  concentrations  was  performed  using  the  bicinchoninic  acid  (BCA) 
method.  BCA  reagent  (Sigma)  was  prepared  fresh  by  the  addition  of  0.02  volumes  of  4% 
(w.  v)  copper  (II)  sulphate  (Sigma)  to  BCA  solution.  Protein  standards,  10µ1  of  80- 
2000  tg/ml  BSA,  were  added  to  200µ1  of  BCA  reagent  per  well  of  a  96  well  micro-titre 
plate.  l0µ1  of  extract  was  also  added  to  200µ1  of  the  BCA  reagent  in  triplicate.  The  plate 
was  incubated  at  37°C  for  45  min  and  then  the  absorbance  at  562  nm  read  using  a  micro- 
titre  plate  reader.  From  this  reading  the  average  concentration  for  each  sample  was 
calculated. 
2.2.5.2  Co-immunoprecipitation  Assays 
Low-stringency  immunoprecipitations  were  carried  out  as  described  previously 
(Blackwood  et  al.,  1992).  Cells  (1  X  10)  were  lysed  in  low  stringency  lysis  buffer  (1% 
NP-40,0.2  mM  PMSF,  0.7  mg/ml  Pepstatin,  0.5%  Aprotonin,  10  mM  NaF,  50  mM  ß- 
glycerophosphate),  sonicated  on  ice,  clarified  by  ultracentrifugation  (twice  at  304,000  g) 
and  subjected  to  immunoprecipitation  with  saturating  amounts  of  antibody  (all  steps  at 
4°C).  Immunoprecipitates  were  collected  on  protein  A-Sepharose  CL4B  (Sigma)  beads. 
Low  stringency  buffer  was  used  to  wash  the  precipitate  three  times.  All  samples  were  re- 
suspended  in  sample  buffer  and  resolved  on  10%  SDS  PAGE  and  western  blotted. 
2.2.5.3  Polyacrylamide  Gel  Electrophoresis  (PAGE)  for  Protein  Samples 
All  PAGE  for  Western  blots  was  carried  out  using  the  Novex  NUPAGE  Bis-Tris  system. 
Samples  were  loaded  onto  10%  or  4-12%  acrylamide  pre-poured  polyacrylamide  gels  in  1X 
sample  buffer.  The  gels  were  run  with  either  1X  MES  SDS  or  MOPS  SDS  running  buffer 
with  NuPAGE  Running  Buffer  Antioxidant  added  to  the  buffer  in  the  upper  chamber  for 
reducing  conditions. 
2.2.5.4  Western  Transfer  of  Proteins  by  Electroblotting 
Electroblotting  was  performed  using  a  semi-dry  electroblotter  (Millipore).  Immobilin-P 
membrane  was  immersed  in  methanol  and  then  Transfer  Buffer.  Six  sheets  of  3M 106 
Whatman  filter  paper  pre-soaked  in  transfer  buffer  was  sandwiched  adjacent  to  the  anode 
and  cathode  with  the  membrane  and  gel  layered  in  between.  Transfer  took  place  over  45 
min  at  30  mA  (0.65  mA  per  cm2  of  the  gel).  The  gel  was  stained  in  Coomasie  stain 
overnight  and  destained  as  described.  This  allowed  a  visual  assessment  to  be  made  of  the 
integrity  of  the  proteins  and  how  well  they  transferred  onto  the  membrane. 
2.2.5.5  Coomassie  Staining  of  Acrylamide  Gels 
Gels  were  stained  with  Coomasie  stain  (0.2%  Coomasie  brilliant  blue  R250  in  a  50:  50:  7 
v/v  ratio  of  methanol:  H20:  glacial  acetic  acid)  for  4  hours  and  then  de-stained  using  a 
25:  68:  7  v/v  ratio  of  methanol:  H20:  glacial  acetic  acid  overnight. 
2.2.5.6  Immunological  Detection  of  Protein 
Membranes  were  incubated  with  blocking  solution  at  4°C  for  4  hours,  probed  overnight  in 
the  same  buffer  with  primary  antibody  and  washed  with  0.1%  Tween-20  in  PBS.  Blots 
were  incubated  in  blocking  solution  with  anti-mouse  IgG  HRP-linked  rabbit  antibody 
(Santa-Cruz),  then  washed  again  in  0.1%  Tween-20  in  PBS,  after  which  bound  complexes 
were  visualised  by  enhanced  chemiluminescence  (Amersham). 
2.2.5.7  Autoradiography 
Membranes  and  gels  were  exposed  to  X-ray  film  (Fuji)  and  were  developed  using  a  Kodak 
X-ray  developer.  Radioactive  gels  were  exposed  to  X-ray  film  for  a  few  hours  or  overnight 
in  a  -70°C  freezer. 
2.2.5.8  GST  Fusion  Proteins  (work  done  in  collaboration  with  Dr.  E.  Homer) 
Full  length  and  the  four  overlapping  fragments  of  hMLH1  (described)  were  cloned  into 
pGex4T.  From  these  plasmids,  the  proteins  are  expressed  as  fusion  proteins  with  GST 
(glutathione  S-transferase).  GST-MAX  (expressing  full  length  MAX)  was  also  used,  a  gift 
from  Prof.  D.  Gillespie  (Beatson  Labs,  Glasgow).  The  pGEX  constructs  were  transformed 
into  BL21  DE3,  E.  coli  competent  cells.  The  transformants  were  grown  up  in  10  ml  of  LB 
media  with  ampicillin  selection  overnight  at  37°C  overnight  in  a  shaking  incubator.  1  ml 
of  this  overnight  culture  was  added  to  100  ml  LB  media  with  ampicillin  and  incubated  in  a 
shaking  incubator  for  3  hours,  Abdo  0.5-2.  Expression  of  the  fusion  proteins  was  induced 107 
by  addition  of  100  µl  IPTG  (100  mM)  to  this  culture.  The  culture  was  incubated  for  1.5 
hours  at  30°C.  The  cells  were  collected  by  centrifugation  at  4°C  for  10  mins  at  2000  g. 
The  pellets  were  re-suspended  in  5  ml  of  ice  cold  PBS  and  this  mixture  was  sonicated 
appropriately  to  disrupt  the  bacteria  but  not  destroy  the  proteins,  ten  second  pulses  twice 
with  a  probe  sonicator  was  sufficient.  250  p1  of  20%  Triton  X100  in  PBS  was  added  to 
every  5m1  of  sonicate  (i.  e.  1%).  This  was  mixed  at  room  temperature  for  30  minutes.  The 
mixture  was  then  centrifuged  at  4°C  for  10  min  at  9300  g  The  supernatant  was  collected. 
The  GST  fusion  proteins  were  collected  from  the  supernatant  using  glutathione  sepharose 
beads.  250  µl  of  50%  glutathione  sepharose  bead  slurry  was  added  to  each  5  ml  of 
sonicate.  This  mixture  was  placed  on  a  gently  moving  rocking  table  to  mix  for  30  min  at 
room  temperature.  The  mixture  was  subsequently  centrifuged  at  2000  g  for  10  min  and  the 
supernatant  carefully  removed.  The  pellet  was  washed  in  PBS.  The  spin  was  repeated  and 
the  supernatant  discarded.  This  wash  step  was  repeated  twice.  The  final  pellet  with  GST- 
fusion  protein  linked  to  beads  was  stored  at  -20°C  in  PBS  20%  glycerol. 
2.2.5.9  GST  Pull  Down  Assay  (work  done  in  collaboration  with  Dr.  E.  Homer) 
Mammalian  cell  extracts  were  prepared  as  described  for  the  co-immunoprecipitation 
assays.  The  stored  GST-fusion  protein  linked  to  beads  was  thawed  and  washed  twice  in 
PBS  and  re-suspended  in  the  same  extract  buffer  used  for  making  the  mammalian  cell 
extracts.  1  µg  of  fusion  protein  was  added  to  500  pg  of  cell  extract.  These  mixtures  were 
placed  on  a  rotating  wheel  for  1  hour  at  4°C.  The  beads  were  precipitated  by  centrifugation 
for  5  min  at  21,000  g  at  4°C  and  washed  six  times  in  500  µl  wash  buffer.  The  final  pellet 
of  beads  plus  proteins  bound  to  the  beads  was  re-suspended  in  sample  buffer,  denatured, 
and  resolved  by  SDS-PAGE.  Proteins  bound  to  the  various  GST  fusion  proteins  were 
detected  by  western  blot. 
2.2.6  General  Tissue  Culture  Techniques 
2.2.6.1  Cell  Culture 
Aseptic  manipulations  were  performed  using  sterilised  glassware  in  a  class  II 
microbiological  safety  cabinet  with  vertical  airflow.  Cells  were  grown  in  25,75  or  150  cm2 
flasks  (Iwaki)  or  9  cm  dishes  (Falcon)  at  37°C  as  monolayers  in  supplemented  RPMI  or 108 
DMEM  medium  (Rosswell  Park  Memorial  Institute)  in  the  presence  of  5%  or  10%  CO2 
respectively. 
Cells  were  frozen  at  a  concentration  of  1x  106/ml  with  10%  di-methyl  sulphoxide  (DMSO) 
at  -70°C.  After  24  h,  samples  were  transferred  to  liquid  nitrogen. 
2.2.6.2  Cell  Line  Maintenance 
Cell  Line  Growth  Conditions 
A2780  RPMI  (500  ml),  10%  FCS,  5  ml,  2  mM  L-Glutamine, 
1  mM  Sodium  Pyruvate,  500  iu/ml/500  µg/m1 
Pen.  /Strep.,  5%  CO2 
K562  RPMI  (500  ml),  10%  FCS,  1  ml  1M  NaOH,  2  mM 
L-Glutamine,.  500  iu/ml/500  µg/ml  Pen.  /Strep.,  5%  CO2 
Rat-1  DMEM  (500  ml),  2  mM  L-Glutamine,  500  iu/ml/500µg/ml 
Pen.  /Strep,  10%  CO2 
Rat-1  MYCERTh  DMEM  (500  ml),  2  mM  L-Glutamine,  500  iu/ml/500µg/m1, 
2.5  µg/ml  Puromycin,  10%  CO2 
2.2.6.3  Treatment  of  Cells  with  Cisplatin 
Cell  cultures  were  treated  with  cisplatin  from  a  stock  dissolved  in  DMSO.  The  final 
concentration  of  DMSO  in  culture  was  0.01%.  Cells  were  treated  for  one  hour  with 
cisplatin  and  then  incubated  for  24  hours  in  media  without  cisplatin  and  harvested. 
2.2.6.4  Staining  Colonies  on  Culture  Dishes 
PBS  was  added  to  the  media  on  the  culture  plates  and  this  mixture  was  poured  off.  A 
50:  50  mix  of  methanol  and  PBS  was  poured  onto  the  plates  and  left  for  10  minutes.  This 
mixture  was  poured  off  the  plates  and  methanol  was  poured  onto  the  plates.  Again  the 
plates  were  left  in  methanol  for  10  minutes  and  poured  off.  The  plates  were  allowed  to  dry 
for  1  hour  at  37°C.  Crystal  violet  stain  was  poured  onto  the  plates  and  left  on  for  10 
minutes.  The  crystal  violet  was  poured  off  and  the  plates  gently  rinsed  with  tap  water.  The 109 
plates  were  allowed  to  dry  at  room  temperature  overnight  and  the  stained  colonies  were 
counted  using  a  colony  counter. 110 
Chapter  3 
Results 111 
3.1  Introduction 
Mismatch  Repair  (MMR)  recognises  and  repairs  mismatched  nucleotides  that  result  from 
the  mis-incorporation  of  bases  during  replication,  recombination  between  partially 
homologous  sequences  and  physical  damage  to  DNA.  hMLH1  protein  co-purifies  with 
another  MMR  protein,  hPMS2,  as  a  heterodimer  (Umar  et  al.,  1996).  Their  exact  function 
in  MMR  is  unknown,  although  they  have  been  shown  to  be  essential  for  in  vitro  MMR 
activity.  Loss  of  hMLH1  expression  is  seen  in  a  number  of  tumour  cell  lines  resistant  to 
the  cytotoxic  drug  cisplatin,  and  restoration  of  MMR  leads  to  restoration  of  drug  sensitivity 
(Brown  et  al.,  1997).  This  has  led  to  the  hypothesis  that  MMR  is  involved  in  coupling 
DNA  damage  to  an  apoptotic  response.  Indeed  loss  of  apoptotic  signalling  responses  (c- 
Abl,  p53  and  p73)  to  DNA  damage  is  seen  in  MMR  deficient  cells  (Duckett  et  al.,  1999; 
Gong  et  al.,  1999;  Nehme  et  al.,  1997).  Exactly  how  MMR  couples  to  these  apoptotic 
pathways  is  unclear.  The  aim  of  this  study  was  to  identify  other  proteins  that  interact  with 
hMLH1  to  attempt  to  further  elucidate  its  role  in  MMR  and  the  engagement  of  downstream 
damage  response  pathways. 
The  yeast  two-hybrid  system  was  used  to  identify  proteins  interacting  with  hMLH1.  This 
is  an  in  vivo  system  to  identify  protein-protein  interactions  (Fields  and  Song,  1989).  The 
yeast  two-hybrid  system  utilises  the  fact  that  transcription  factors  have  two  physically 
separable  modular  domains,  a  DNA  binding  domain  and  a  transcription  activation  domain. 
The  DNA  binding  domain  targets  the  transcription  factor  to  specific  promoter  sequences 
(UAS,  upstream  activator  sequence),  and  the  activation  domain  facilitates  the  assembly  of 
the  transcription  complex  allowing  transcription  initiation  (see  Figure  6).  Therefore  the 
basis  of  the  yeast  two-hybrid  system  is  that,  through  the  non-covalent  interaction  of  two 
independent  hybrid  proteins  containing  either  the  DNA-binding  domain  or  activation 
domain,  a  functional  transcription  factor  can  be  reconstituted. 112 
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Figure  6:  Schematic  diagram  demonstrating  the  basis  of  the  two-hybrid  system. 
The  hybrid  of  the  GAL4  DNA-binding  domain  (bd)  and  protein  X  binds  to  the  GALT  UAS 
(upstream  activating  sequence)  but  cannot  activate  transcription  without  the  activation 
domain  (ad).  Likewise  the  hybrid  of  the  activation  domain  and  protein  Y  cannot  localise 
to  the  UAS  and  therefore  does  not  activate  transcription.  When  the  X  and  Y  parts  of  the 
hybrid  proteins  interact  in  vivo,  e.  g.  hMLH  I  and  hPMS2,  this  reconstitutes  the  GAL4 
function  and  results  in  expression  of  the  reporter  gene.  The  various  yeast  strains  used  for 
the  two-hybrid  analysis  carry  LAC/,  and/or  the  nutritional  reporters  HIS3  and  AI)L2  under 
the  control  of  GAL4-binding  sites. 113 
3.2  The  Interaction  of  hMLH1  and  hPMS2  in  the  Yeast  Two- 
Hybrid  System. 
The  initial  aim  of  the  project  was  to  set  up  a  functional  yeast  two-hybrid  system  for  routine 
screening  of  proteins  that  could  interact  with  hMLH1.  Full  length  hMLH1  and  full  length 
hPMS2  were  both  expressed  as  hybrid  proteins  with  either  the  GAL4  activation  domain 
(AD)  or  the  GAL4  binding  domain  (BD)  in  yeast  two-hybrid  vectors.  In  addition  four 
overlapping  fragments  of  each  protein  were  also  expressed  as  hybrid  proteins  with  either 
the  GAL4  AD  or  BD.  Each  construct  was  individually  tested  for  autonomous  activation  of 
the  GAL4  controlled  LACZ  reporter  gene  in  the  yeast  system.  From  these  initial  assays  it 
was  determined  that  the  hMLH1  bait  construct  was  functional  in  a  yeast  two-hybrid  system 
and  did  not  autonomously  activate  the  reporter  system  (see  Table  7).  Details  of  these 
observations  are  discussed  later. 
Full  length  and  fragments  of  hMLH1  and  hPMS2  were  amplified  from  A2780  cDNA  by 
PCR  and  cloned  in  frame  into  yeast  two-hybrid  vectors  (see  Table  3;  Figure  7).  The 
sequences  of  the  hMLH1  and  hPMS2  genes.  and  the  primers  used  for  the  PCR  reactions  are 
listed  in  Appendix  1-4.  The  oligo  primers  used  for  PCR  are  listed  in  section  2.1.11,  the 
forward  primers  (5'end  of  fragment)  used  had  an  EcoRI  site  at  the  5'  end  of  the  sequence 
and  the  reverse  primers  (3'end  of  the  fragment)  had  a  BamHI  site  allowing  restriction 
digestion  of  the  ends  of  the  PCR  products.  This  allowed  cloning  of  the  product  into  the 
yeast  two-hybrid  vectors  which  both  have  unique  EcoRI  and  BamHI  sites  within  their 
multiple  cloning  sites.  The  yeast  two-hybrid  plasmids  utilised  were  the  Clontech  plasmid 
vectors,  pGAD424  (carries  the  GAI4  activation  domain)  and  pGBT9  (carries  the  GAI4 
DNA-binding  domain).  These  plasmids  were  subsequently  transformed  into  E.  coli,  DH5a 
competent  cells  and  the  plasmid  DNA  prepared  from  the  transformant  colonies. 
Each  insert  was  checked  by  restriction  enzyme  digestion  and  also  by  sequencing  of  the 
inserts  using  vector  primers  for  both  vectors  (pGAD424-F,  pGAD424-R,  pGBT9-F, 
pGBT9-R)  and  internal  primers  (those  used  to  clone  the  fragments  of  hMLH1  and  hPMS2). 
The  restriction  enzyme  digestions  were  carried  out  utilising  the  Spel,  C1aI  and  HindIIl 
restriction  enzymes.  The  digestion  products  were  examined  on  an  agarose  gel.  The 
predicted  fragment  sizes  for  digestion  of  both  full  length  and  fragments  of  hMLH1  and 
hPMS2  expressed  in  pGAD424  and  pGBT9  were  observed  (see  Table  4  and  Table  5). 114 
Gene  Fragment  Region  (bp)  Size  (bp)  Region  (act)  Size  (aa) 
hMLH1  F1  42-725  683  1-228  228 
F2  582-1067  485  180-342  163 
F3  966-1777  811  308-579  272 
F4  1584-2309  725  514-756  243 
Full  Gene  42  (start  codon)-2309  2267  1-756  756 
hPMS2  F1  3-794  791  1-264  264 
F2  741-1346  605  246-448  203 
F3  1293-1943  650  430-647  218 
F4  1893-2588  695  630-862  233 
Full  Gene  3  (start  codon)-2588  2585  1-862  862 
Table  3:  hMLH1  and  hPMS2  sequences  cloned  into  pGBT9  and  pGAD424 
Full  length  and  four  overlapping  fragments  of  hMLH1  and  hPMS2  were  cloned  into  both 
pGBT9  and  pGAD424.  This  table  lists  the  regions  of  the  genes  included  in  each  fragment 
and  the  size  of  each  fragment  in  both  bp  (base  pairs)  and  as  (amino  acids). 115 
hhlLH  I  Constructs:  lull  l.  en  th  and  Fragments 
Full  Length  MLHI  (amino  arils  I-756) 
I-I  ('1111111o  acid;  I  »,  S)  1  (amino  acids  308-57')) 
F2  (amino  acids  180-342)  F4  (aminoacids  5I4-756) 
hPN1S2  Constructs:  Full  Length  and  Fragments 
Full  I.  enn'th  l  MS_2  (amino  acid;  1  -86_'  ) 
II  (uiuilli)  J.,,  1-204)  1  (;  inniii  acids  430-647) 
1  .2  (jiiiiinu  arils  246-448)  F4  (aminoacids  030-862) 
Figure  7:  Schematic  diagram  representing  the  fragments  of  hMLHI  and  hPMS2 
cloned  into  p(',  B'I'9  and  pGAD424 
This  diagram  represents  the  overlapping  nature  of  hMLH  I  and  hPMS2  protein  fragments 
expressed  as  hybrid  proteins  with  the  GAL4  DNA  binding  domain  and  activation  domain. 116 
Vector  Insert  Spei  Cal  HindIII 
pGAD424-hMLH1  Full  length  1300bp,  7.7  Kb  Linear  450  bp,  700  bp 
900  bp,  1  Kb, 
5.4  Kb 
F1  Linear  Linear  1  Kb,  5.4  Kb 
F2  -  Linear  1.2  Kb,  5.4  Kb 
F3  Linear  Linear  300  bp,  450  bp, 
1  Kb,  5.4  Kb 
F4  -  Linear  1.4  Kb,  5.4  Kb 
pGBT9-hMLH1  Full  length  1.3  Kb,  7  Kb  -  450  bp,  700  bp, 
900  bp,  1.3  Kb, 
4.6  Kb 
F1  Linear  -  700  bp,  900  bp, 
4.6  Kb 
F2  -  -  1.4Kb,  4.6Kb 
F3  Linear  -  500  bp,  600  bp, 
700  bp,  4.6  Kb 
F4  -  -  1.4  Kb,  4.6  Kb 
Table  4:  Predicted  Restriction  Fragments  from  Digesting  pGAD424-hMLH1  and 
pGBT9-hMLH1  Constructs 
Digestion  with  Spel,  CIA  and  HindIII  of  the  various  pGBT9  and  pGAD424  hMLH1 
constructs  gave  the  fragment  sizes  listed  when  digest  were  run  out  on  agarose  gels. 117 
Vector  Insert  Spel  Clal  HindIIl 
pGAD424-hPMS2  Full  length  Linear  1  Kb,  7.3  Kb  600  bp,  875  bp, 
1.9  Kb,  5.9  Kb 
F1  -  Linear  613  bp,  869  bp, 
5.9  Kb 
F2  -  Linear  540  bp,  750  bp, 
5.9  Kb 
F3  -  Linear  1.35  Kb,  5.9  Kb 
F4  Linear  Linear  1.9  Kb,  5.9  Kb 
pGBT9-hMLH1  Full  length  Linear  -  850  bp,  880  bp, 
1.7  Kb,  4.6  Kb 
F1  -  -  643  bp,  1  Kb,  4.6 
Kb 
F2  -  -  720  bp,  890  bp, 
4.6  Kb 
F3  -  -  1.5Kb,  4.6Kb 
F4  Linear  -  1.5  Kb,  4.6  Kb 
Table  5:  Predicted  Restriction  Fragments  from  Digesting  pGAD424-hPMS2  and 
pGBT9-hPMS2  Constructs 
Digestion  with  Spel,  C1aI  and  HindIIl  of  the  various  pGBT9  and  pGAD424  hPMS2 
constructs  gave  the  fragment  sizes  listed  when  digest  were  run  out  on  agarose  gels. 118 
Construct  Fragment  Region  Mutations  Amino  Acid  ((xa) 
(bp)  Change 
pGAD424  F1  42-725  AAC-*AGC  @154  bp  Asn-ºSer  @  aa38 
-hMLH1 
GTC-ýATC  @  696  bp  Val-'Ile  @  aa219 
F2  582-1067  GGA-GGG  @  635  bp  G1y--ºG1y  @  aa198 
GTC-ýATC  @  696  bp  Val--,  -Ile  @  aa219 
TCA-*TCG  @  797  bp  Ser--'Ser  @  aa252 
F3  966-1777  - 
F4  1584-  - 
2309 
Full  42  -2309  GTC-*ATC  @  696  bp  Val-'Ile  @  aa219 
Length 
pGBT9-  F1  42-725  GAG-,  -AAG  @  198  bp  Glu-Lys  @  aa53 
hMLH1 
GTC-->ATC  @  696  bp  Val-ºI1e  @  aa219 
F2  582-1067  GTC-->ATC  @  696  bp  Val--p-Ile  @  aa219 
GCC-ýGTC  @  865  bp  Ala-bVal  @  aa275 
F3  966-1777  - 
F4  1584-  - 
2309 
pGBT9-  Full  42-2309  ATC-i-ATT  @116  bp  Ile-*Ile  @  aa25 
hMLH1  Length 
GGA-GGG  @  203  bp  Gly-*Gly  @  aa54 
GTC-ýATC  @  696  bp  Val-Ile  @  aa219 
AGA-'GGA  @  858  bp  Arg--ºGly  @  aa273 
Table  6:  Summary  of  Sequencing  of  pGAD424-hMLH1  and  pGBT9-hMLH1 
constructs.  (-  =  no  changes) 119 
Construct  Fragment  Region 
(bp) 
Mutations  Amino  Acid  (act) 
Change 
pGAD424- 
hPMS2 
Fl  3-794  - 
F2  741-1346  - 
F3  1293-1943  AAA-->AGA@  1615  Lys-Arg  @  aa538 
F4  1893-2588  AAG-ºAGG  @  1954  Lys-->Arg  @  aa651 
pGBT9- 
hPMS2 
Fl  3-794  - 
F2  741-1346  - 
F3  1293-1943  TCT-ºCCT  @  1410  Ser-->Pro  @  aa470 
F4  1893-2588  - 
Table  7:  Summary  of  Sequencing  of  pGAD424-hPMS2  and  pGBT9-hPMS2 
constructs.  (-  =  no  changes) 120 
Sequencing  of  the  different  construct  inserts  demonstrated  a  number  of  mutations  in  some 
of  the  constructs  (see  Table  6  and  Table  7).  A  single  mutation  at  base  pair  696  was  seen 
consistently  in  hMLH1,  leading  to  a  neutral  amino  acid  change.  It  is  assumed  this  is  a 
polymorphism  as  the  various  hMLH1  fragments  were  cloned  individually  by  PCR  from 
A2780  cDNA.  This  mutation  was  also  seen  in  pGBKT7-hMLH1  (used  later)  which  was 
cloned  from  a  completely  different  source.  No  mutations  were  seen  in  fragment  3  or  4  of 
hMLH1.  No  mutations  were  seen  in  F1  and  F2  of  hPMS2  either.  Two  neutral  amino  acid 
changes  were  shown  in  both  F3  and  F4  of  pGAD424-hPMS2  which  would  suggest  this 
should  not  effect  these  fragments,  which  will  be  borne  out  by  the  demonstration  of  an 
interaction  between  these  fragments  and  hMLH1  later.  The  original  full  length  hPMS2 
constructs  had  too  many  point  mutations  to  be  used  in  this  system.  Recently  new 
constructs  were  made  and  sequenced.  No  mutations  were  found  in  the  sequence  examined. 
The  Y190  yeast  strain  was  used  for  the  yeast  two-hybrid  analysis.  Before  starting  any  of 
the  transformations  the  nutritional  requirement  phenotype  of  Y190  was  checked.  The 
Y190  yeast  strain  is  auxotrophic  for  Trp  (tryptophan)  and  Leu  (leucine),  allowing 
transformation  selection,  and  has  two  reporter  genes  LACZ  and  HIS3  both  of  which  are 
under  the  control  of  GAL4-responsive  sequences  (UAS).  The  hMLH1  and  hPMS2 
constructs  were  transformed  into  Y190  competent  cells  using  a  lithium  acetate  based 
transformation  protocol. 
Yeast  protein  extracts  were  made  from  Y190  yeast  and  from  Y190  transformed  with  the 
hMLH1  and  hPMS2  constructs  alone  or  from  co-transformations  of  hMLH1  and  hPMS2. 
These  extracts  were  denatured  and  loaded  onto  SDS-polyacrylamide  gels  which  were 
subsequently  western  blotted  and  probed  with  anti-hMLH1  and  anti-hPMS2  antibodies  (see 
Figure  8).  In  western  blot  A.  a  hPMS2  hybrid  protein  has  been  clearly  detected  by  probing 
with  anti-hPMS2.  These  extracts  were  prepared  from  Y190  cells  co-transformed  with  a 
full  length  hMLH1  yeast  two-hybrid  vector  (pGAD424-hMLH1  or  pGBT9-hMLH1). 
However,  in  un-transformed  Y190  extracts  or  extracts  from  Y190  transformed  with  vectors 
expressing  only  hPMS2  no  hPMS2  was  detected  (lanes  not  shown).  This  suggests  that 
when  transformed  alone  into  Y190  the  hPMS2  hybrid  protein  is  not  stable.  The  hPMS2 
protein  is  not  detected  in  human  cells  defective  for  hMLH1  expression.  It  has  been 
suggested  that  hMLH1  binding  to  hPMS2  is  required  to  stabilise  the  hPMS2  protein.  The 
lack  of  detectable  hPMS2  when  transformed  alone  into  yeast,  but  presence  when  co- 
transformed  with  hMLH1  is  consistent  with  these  observations.  In  western  blot  B.  hMLH1 
hybrid  protein  is  also  clearly  expressed  from  both  pGBT9-hMLH1  and  pGAD424-hMLH1. 121 
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Figure  8:  anti-hPMS2  (A)  and  anti-hMLHI  (B)  Western  Blots  of  Transformed  Yeast 
Extracts 
Protein  extracts  were  prepared  from  Y  190  yeast  alone  and  Y190  transformed  with 
constructs  expressing  both  hMLH  I  and  hPMS2  hybrid  proteins  and  analysed  by  SDS- 
PAGE.  The  gels  were  western  blotted  and  probed  with  antibodies  against  both  hPMS2  (A) 
and  hMLH  I  (B). 122 
These  extracts  again  are  from  Y190  co-transformed  with  vectors  expressing  both  hMLH1 
and  hPMS2.  However  unlike  hPMS2,  hMLH1  is  detected  in  extracts  from  Y190 
transformed  with  either  pGAD424-hMLH1  or  pGBT9-hMLH1  alone  (data  not  shown). 
The  difference  in  size  between  the  hybrid  proteins  expressed  in  Y190  and  the  A2780 
human  ovarian  carcinoma  cell  extract  (positive  control)  is  due  to  either  the  AD  (pGAD424) 
or  BD  (pGBT9)  part  of  the  hybrid  proteins  which  are  approximately  12  kDa  and  16  kDa 
respectively.  From  these  western  blots  it  is  concluded  that  the  hybrid  proteins  are  being 
expressed  at  detectable  levels  and  in  a  form  recognised  by  the  anti-hPMS2  and  anti- 
hMLH1  antibodies. 
Interactions  between  yeast  two-hybrid  expressed  proteins  are  detected  using  a  ß- 
Galactosidase  assay  detecting  LACZ  expression.  Positive  control  plasmids  known  to 
activate  LACZ  expression  -were  also  transformed  into  the  Y190  yeast  strain  and  give  blue 
colonies  in  the  ß-Galactosidase  assay  (where  permeabilised  cells  are  exposed  to  buffer 
containing  X-GAL)  denoting  a  positive  interaction.  These  plasmids  included  pCL1, 
pLAM5',  pTD1  and  pVA3  (see  Table  8).  pCL1  expresses  a  wild-type  full  length  GAL4 
gene,  and  therefore  yeast  transformed  with  this  plasmid  alone  will  express  a  full  length 
GAL4  transcription  factor,  capable  of  activating  transcription  of  the  LACZ  gene  which  is 
under  transcriptional  control  of  a  GAL4  UAS.  Transformation  of  Y190  with  this  plasmid 
therefore  provides  an  excellent  positive  control  for  the  ß-Galactosidase  assay.  Co- 
transformation  of  pCL1  with  pLAM5'  (Lamin  C  protein  expressed  in  pGBT9)  allows 
growth  of  these  transformed  cells  on  Leu"/Trp"  selection  plates,  so  the  yeast  are  growing 
under  the  same  conditions  as  Y190  co-transformed  with  pGBT9  and  pGAD424  constructs. 
Lamin  C  has  been  found  not  to  interact  with,  or  form  complexes  with  most  proteins  (Bartel 
et  al.,  1993).  pVA3  expresses  a  murine  p53  hybrid  protein  in  pGBT9  and  pTD1  expresses 
an  SV40  T-antigen  hybrid  protein  in  pGAD3F.  Both  these  proteins  are  known  to  interact 
with  each  other  and  therefore,  upon  co-transformation  of  these  two  constructs  into  Y190, 
activation  of  transcription  of  the  LACZ  gene  is  achieved.  Together  transformation  of  Y190 
with  these  combinations  of  plasmids  serve  as  strong  positive  controls  for  GAL4  mediated 
activation  of  transcripiton  of  the  LACZ  gene. 
hMLH1  and  hPMS2  constructs  were  transformed  into  Y190  alone  and  also  co-transformed 
in  a  variety  of  combinations.  None  of  the  constructs  autonomously  activated  LACZ 
expression.  From  these  transformations  it  was  shown  that  hMLH1  full  length  and  fragment 
4  both  clearly  interact  with  hPMS2  fragment  3  and  4  as  shown  by  the  ß-Galactosidase 
assay  (see  Table  9;  Figure  9).  Full  length  hMLH1  encodes  amino  acids  1-756  and 123 
Table  8:  Control  Transformations  with  Various  Combinations  of  Plasmids 
no  DNA  pLAMS'  pVA3  pGBT9 
no  DNA  -  -  -  - 
pCL1  +  +  +  + 
pTD1  -  -  +  - 
pGAD424  -  -  -  - 
+  denotes  blue  colonies  in  ß-Galactosidase  assay  =  proteins  interact 
-  denotes  white  colonies  in  ß-Galactosidase  assay  =  no  interaction 
Table  9:  Transformation  of  pGAD424  and  pGBT9  expressing  hMLH1  and  hPMS2 
hybrid  proteins  in  various  combinations. 
Full  length  and  fragment  4  of  hMLH1  clearly  interact  with  fragments  3  and  4  of  hPMS2. 
PMS2  PMS2  F1  PMS2  F2  PMS2  F3  PMS2  F4  no  DNA 
no  DNA  -  -  -  -  -  - 
MLH1  -  -  -  +  +  - 
MLH1  F1  -  -  -  -  -  - 
MLH1F2  -  -  -  -  -  - 
MLH1  F3  -  -  -  -  -  - 
MLH1  F4  -  -  -  +  +  - 
+  denotes  blue  colonies  in  ß-Galactosidase  assay  =  proteins  interact 
-  denotes  white  colonies  in  ß-Galactosidase  assay  =  no  interaction 124 
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Figure  9:  GAL4  Activation.  Blue  colonies  in  the  (3- 
G.  pGAD424  MLH  I  F2+  galactosidase  assay  denote  a  positive  interaction 
pGBT9  PMS2  F4  I  (A-F),  white  colonies  denote  no  interaction  (G). 125 
fragment  4  of  hMLH1  encodes  amino  acids  514-756.  Both  bind  to  fragment  3  and  4  of 
hPMS2  which  encode  amino  acids  430-647  and  amino  acids  630-862  respectively.  These 
results  localise  the  interaction  regions  of  hMLH1  and  hPMS2  to  the  C-termini  of  both 
proteins.  The  interaction  regions  of  the  yeast  homologues  of  these  proteins,  yMlhlp  and 
yPmsip,  have  previously  been  localised  to  the  C-termini  of  these  proteins  (Pang  et  al., 
1997).  Subsequent  to  our  studies,  the  hMLH1  interaction  with  hPMS2  has  been  shown  to 
occur  through  the  C-termini  of  both  proteins  (Guerrette  et  al.,  1999).  Overall  the  regions  of 
interaction  between  hMLH1  and  hPMS2  localise  to  the  C-termini  of  both  proteins  and 
these  interaction  domains  are  conserved  from  yeast  to  humans. 
None  of  the  hMLH1  or  hPMS2  constructs  gave  positives  in  the  ß-Galactosidase  assay 
when  transformed  alone  into  Y190.  No  positive  activation  of  LACZ  was  seen  when  these 
constructs  were  co-transformed  into  Y190  with  the  empty  reciprocal  yeast  two-hybrid 
plasmid,  with  constructs  expressing  regions  of  the  ATR  kinase  gene  or  the  RPA70  gene 
and  finally  with  the  pLAM5'  plasmid.  More  specifically  pGBT9  constructs  were  co- 
transformed  into  Y190  with  pACT2  (an  AD  expressing  yeast  two-hybrid  vector) 
expressing  RPA70.  The  pGAD424  constructs  were  co-transformed  into  Y190  with  both 
pLAM5'  and  pAS2-1  (a  BD  expressing  yeast  two-hybrid  vector)  expressing  hybrid  proteins 
encoding  regions  of  ATR.  No  interactions  were  seen  between  the  hMLH1  and  hPMS2 
hybrid  proteins  and  any  of  these  hybrid  proteins  described.  Therefore  it  is  concluded  that 
the  interactions  between  hMLH1  and  hPMS2  observed  are  true  positive  interactions. 126 
3.3  Deletion  Analysis  of  hPMS2  Fragment  3. 
hMLH1  full  length  (amino  acids  1-756)  and  fragment  4  (amino  acids  514-756)  hybrid 
proteins  both  interacted  with  hPMS2  fragment  3  (F3,  amino  acids  430-647)  and  4  (F4, 
amino  acids  630-862)  in  the  yeast  two-hybrid  system.  Because  of  the  overlapping  nature  of 
hPMS2  F3  and  F4,  deletion  analysis  of  the  3'  end  of  F3  was  carried  out,  to  further  define 
the  hMLH1  interaction  domain  of  hPMS2.  Constructs  were  made  as  before,  by  PCR  from 
the  PMS2  F3  previously  cloned  into  pGAD424  and  pGBT9.  pGAD424-F3  and  pGBT9-F3 
along  with  PMS2-R3-9,  -24,  -51,  -102,  and  -300  primers  were  used  for  the  PCR.  The 
different  products  expressing  F3  of  hPMS2  with  gradual  deletions  from  its  3'  end,  of  9,24, 
51,102  and  300  bp  were  cloned  into  both  pGAD424  and  pGBT9.  These  fragments  of 
hPMS2  were  each  sequenced  and  found  not  to  carry  any  point  mutations  (other  than  those 
listed  in  F3  earlier)  and  are  expressed  in  frame  with  the  activation  or  binding  domain  of 
GAL4.  Once  again  these  constructs  were  transformed  alone  into  Y190  competent  cells  and 
also  co-transformed  with  both  full  length  hMLH1  and  hMLH1  F4  (see  Table  10). 
hPMS2  F3  constructs  with  between  9  and  102  bp  deleted  from  the  3'  end  of  hPMS2 
fragment  3  gave  positive  interactions  with  both  full  length  and  F4  of  hMLH1.  However 
with  300bp  deleted  from  the  3'  end  of  F3  a  loss  of  interaction  was  seen  with  both  full 
length  and  F4  of  hMLH1.  This  demonstrates  that  a  crucial  domain  of  hPMS2  for  the 
interaction  with  hMLH1  lies  between  amino  acids  547  and  613.  The  interaction  of  the 
overlapping  fragments  of  hPMS2  F3  and  F4  was  not  further  characterised  as  these  two 
deletion  fragments  of  F3  encode  a  region  of  hPMS2  upstream  of  the  overlapping  region  of 
F3  and  R.  Therefore  in  addition  to  this  defined  region  of  hPMS2  required  for  the 
interaction  with  hMLH1,  additional  regions  of  hPMS2  involved  in  the  hPMS2-hMLH1 
interaction  could  lie  between  amino  acids  613-862.  In  the  study  mentioned  above,  the 
hPMS2  interaction  region  of  hMLH1  has  been  shown  to  lie  between  amino  acids  506  and 
675,  and  in  hPMS2,  the  hMLH1  interaction  region  was  shown  to  lie  between  amino  acids 
675  and  850  (Guerrette  et  al.,  1999). 
From  these  studies  of  the  interaction  between  hMLH1  and  hPMS2,  the  C-termini  of  both 
proteins  are  clearly  responsible  for  this  protein-protein  interaction.  In  particular  the  C- 
terminal  243  amino  acids  of  hMLH1  can  facilitate  an  interaction  with  the  C-terminal 
fragments  of  hPMS2  encoding  amino  acids  430-647  and  amino  acids  630-862.  A  specific 127 
Region  of  PMS2  Full  Length  MLH1  MLH1-F4 
as  =amino  acids  as  1-756  act  514-756 
PMS2-F3 
as  430-647 
hPMS2-F3-9 
act  430-644 
hPMS2-F3-24 
as  430-639 
hPMS2-F3-51 
+  + 
as  430-630 
hPMS2-F3-102 
as  430-613 
hPMS2-F3-300 
as  430-547 
Table  10:  Deletion  analysis  of  the  3'  end  of  hPMS2  fragment  3. 
hPMS2  F3  constructs  with  between  9  and  102  bp  deleted  from  its  3'  end  gave  positive 
interactions  with  both  full  length  and  F4  of  hMLH1  (blue  colonies  in  the  ß-Gal  assay). 
However  with  300bp  deleted  from  the  3'  end  of  F3  this  interaction  was  lost. 128 
domain  on  hPMS2  that  lies  between  amino  acids  547  and  613  is  required  for  the  interaction 
of  this  F3  fragment  of  hPMS2  with  hMLH1.  This  has  been  demonstrated  by  the 
examination  of  interactions  between  hMLH1  and  fragments  of  hPMS2  which  are  derived 
from  gradual  deletions  of  amino  acids  from  the  C-terminal  end  of  hPMS2-F3.  hPMS2-F3- 
102  (aa  430-613)  and  hPMS2-F3-300  (act  430-547)  differ  by  only  66  amino  acids  at  their 
C-termini.  Only  hPMS2-F3-102  interacts  with  hMLH1  demonstrating  that  a  domain 
facilitating  this  interaction  lies  within  this  66  amino  acid  sequence.  Overall  the 
demonstration  of  interactions  between  hMLH1  and  hPMS2  in  the  yeast  two-hybrid  system 
suggests  the  constructs  made  and  utilised  are  suitable  for  looking  for  new  proteins 
interacting  with  full  length  hMLH1  utilising  this  system. 129 
3.4  Yeast  Two-Hybrid  cDNA  Library  Screen  with  pGBT9 
hMLH1 
As  described  in  the  previous  sections,  the  yeast  two-hybrid  system  was  fully  operational; 
with  the  transformation  and  ß-galactosidase  assay  protocols  optimised.  A  number  of 
problems  had  materialised  when  setting  up  the  system.  For  example  a  higher  concentration 
of  DNA  was  used  in  each  transformation  than  proposed  in  the  Clontech  manufacturers 
protocol.  This  may  be  due  to  the  fact  that  Y190  competent  cells  were  made  in  bulk  batches 
and  stored  at  -70°C.  The  volume  of  transformation  mixtures  was  also  adjusted,  so  that  not 
too  much  liquid  culture  was  left  on  the  plate  surface,  giving  rise  to  a  higher  probability  of 
contamination.  ß-galactosidase  assays  were  also  performed  on  colonies  that  were  not 
overgrown  as  Y190  has  an  adel  mutation.  This  means  that  after  a  few  days  growth  as 
nutrients  are  depleted  these  colonies  turn  pink-red  which  makes  the  blue  colour  of  positive 
colonies  more  difficult  to  decipher.  Overall  the  system  was  now  optimised  for 
characterisation  of  any  positive  interactions  resulting  from  a  library  screen  with  pGBT9- 
hMLH1. 
pGBT9-hMLH1  has  been  shown  not  to  autonomously  activate  transcription  from  the  LACZ 
gene  when  transformed  into  Y190.  This  plasmid,  when  co-transformed  into  Y190  with 
pGAD424  or  with  pACT2-RPA70  did  not  activate  transcription  of  this  gene  either.  These 
results  suggested  that  this  construct  is  suitable  for  use  in  the  yeast  two-hybrid  system. 
pGBT9-hMLH1  also  gave  a  clearly  positive  interaction  with  fragments  of  hPMS2  in  the 
yeast  two-hybrid  system.  This  would  suggest  that  this  hybrid  hMLH1  protein  is  still  able 
to  participate  in  protein-protein  interactions  inherent  to  the  naturally  expressed  protein. 
Finally  protein  extracts  made  from  Y190  transformed  with  pGBT9-hMLH1  were  shown  by 
western  blot  to  express  a  hMLH1  protein  detectable  by  probing  with  an  anti-hMLH1 
antibody.  It  was  concluded  therefore  that  pGBT9-hMLH1  is  suitable  for  use  in  a  yeast 
two-hybrid  cDNA  library  screen.  Therefore  this  construct  was  used  as  the  bait  hybrid 
protein  in  a  yeast  two-hybrid  cDNA  library  screen  to  identify  new  proteins  that  interact 
with  this  hMLH1  protein. 
A  pre-made  Clontech  MATCHMAKER  Normal  Mammary  Gland  cDNA  library  was  used 
in  this  screen.  A  cDNA  library  made  from  normal  tissue  was  chosen,  rather  than  one  from 
a  tumour  tissue  source,  as  it  was  hoped  to  identify  proteins  interacting  with  hMLH1  that 
are  either  involved  in  MMR  or  play  a  role  in  mediating  signals  from  the  MMR  system  to 130 
other  cellular  response  pathways.  -  If  a  library  from  tumour  tissue  was  used  it  is  possible 
that  normal  protein-protein  interactions  involving  hMLH1  could  be  disrupted  through 
down-regulation  or  amplified  expression  of  certain  proteins  associated  with  tumour 
development.  The  library  is  built  into  the  GAL4  activation  domain  vector  pACT2  (priming 
method:  Xhol-(dT)15)  such  that  random  proteins  fused  to  the  activation  domain  will  be 
expressed. 
pGBT9  MLH1  full  length  was  transformed  into  Y190  competent  cells  (see  Figure  10).  A 
single  transformed  colony  was  grown  and  prepared  for  large  scale  transformation  with  the 
yeast  two-hybrid  library  DNA.  The  co-transformed  Y190  was  subsequently  plated  out  on 
Leu%Trp-/His  plates.  The  basal  level  of  HIS3  expression  from  the  reporter  construct  in 
which  the  HIS3  UAS  sequence  has  been  replaced  by  the  GAL4  UAS  is  sufficient  to  allow 
growth  on  His  media.  Therefore  3-AT  (3-amino-1,2,4-triazole,  SIGMA),  an  inhibitor  of 
HIS3-encoded  IGP-dehydratase  was  also  added  to  the  plates  at  a  concentration  sufficient  to 
inhibit  low  levels  of  His3p  expressed  in  a  leaky  manner  and  suppress  background  growth 
on  media  lacking  His  (Durfee  et  al.,  1993).  By  testing  different  concentrations  of  3-AT  it 
was  found  that  25mM  3-AT  was  sufficient  for  this  purpose. 
The  plates  were  incubated  at  30°C  for  eight  days.  At  this  point,  the  number  of  colonies  on 
each  plate  were  counted.  1x  105  colonies  were  counted  in  total.  A  ß-Galactosidase  assay 
was  carried  out  using  a  colony  lift  protocol  from  each  plate.  Any  colonies  that  gave  a  blue 
positive  result  in  this  assay  were  re-streaked  out  on  Leu7Frp"/His"  plates.  131  colonies 
were  blue  in  the  initial  ß-Galactosidase  assay.  The  131  colonies  were  once  again  tested  for 
LACZ  activity  utilising  the  ß-Galactosidase  assay.  Of  these,  39  confirmed  positives  (blue 
colonies)  were  identified. 
These  39  clones  that  gave  a  positive  interaction  in  both  assays  were  grown  and  yeast  DNA 
mini  preps  were  performed  using  a  Nucleon  Kit  (Scotlab  Bioscience).  The  yeast  DNA  was 
subsequently  transformed  by  electroporation  into  KC8  endA+  E.  coli  electro-competent 
cells.  Up  to  50  ng  of  DNA  was  required  for  these  transformations  as  the  transformation 
efficiency  into  the  KC8  cells  was  not  very  high.  KC8  cells  have  a  defect  in  leuB  which  can 
be  complemented  by  LEU2  from  yeast.  Therefore  through  transformation  into  these  KC8 
cells  the  library  plasmids  pACT2-X  (which  carry  LEU2)  can  be  directly  rescued  from  the 
yeast  DNA  mixture  by  plating  transformants  onto  M9  minimal  medium  lacking  leucine. 
DNA  was  prepared  from  these  transformants  with  a  mini-prep  kit  following  the 
manufacturers  directions  for  preparing  DNA  from  endA+  bacterial  cells. 131 
Figure  10:  Schematic  describing  the  Methods  for  the  Yeast  Two-Hybrid  Normal 
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Plasmid  DNA  was  prepared  from  the  39  clones  and  transformed  into  KCK,  a  leuB-  Ex  oll' 
strain  to  allow  selection  for  bacteria  transformed  with  the  library  plasmid  pACT2-X 
1 
pACT2-X  plasmid  DNA  was  prepared  from  colonies  that  grew  on  M9  minimal  medium 
plates  and  was  co-transformed  into  Y  190  with  pGBT9-hMLH  1.  followed  by  a  (3-Gal  assay 
1 
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as  demonstrated  by  blue  colonies  in  this  assay. 
1 
These  25  `True  Positives'  were  identified  by  sequencing 132 
This  DNA  was  subsequently  transformed  into  DH5a  competent  cells  and  plasmid  DNA 
prepared  from  the  transformants.  This  is  because  the  DNA  prepared  from  endA+  cells  is 
more  difficult  to  use  for  PCR  and  sequencing.  Library  plasmid  insert  sizes  were  checked 
by  PCR. 
The  plasmid  DNA  from  the  39  clones  was  co-transformed  into  Y190  with  pGBT9-hMLII1 
to  confirm  the  positive  interaction.  Each  library  plasmid  was  also  transformed  alone,  and 
co-transformed  with  pGBT9  and  with  pLAM5'  into  Y190.  Any  clone  which  gave  blue 
colonies  in  a  ß-Galactosidase  assay  when  co-transformed  into  Y190  with  pGBT9-hMLH1, 
but  not  when  transformed  alone,  with  pGBT9  or  pLAMS',  was  designated  a  true  positive 
interactor.  25  `true  positive'  clones  were  identified  and  these  clones  were  sequenced  to 
identify  the  proteins  interacting  with  hMLH1.  These  clones  were  identified  as  true  positive 
interacting  proteins  with  hMLH1(see  Table  11). 133 
Positive  Interacting 
Clone 
Identity  Accession 
Number 
9131;  13C1  c-Myc  V00568 
14E1  Polypeptide  chain  elongation  factor  1-alpha  X16869 
3H1;  16B23;  16A21  Ribosomal  protein  L26  X69392 
3D1  U4/U6  small  nuclear  ribonucleoprotein 
(hPrp3) 
AF016370 
14G21;  19A21;  18B23  Protein  phosphatase  methylesterase  1  (PME1)  AF157028 
3C2;  5A1;  11D21  Endothelial  PAS  domain  protein  1  (EPAS1)  U81984 
9C1  Alpha-L-iduronidase  gene  M95740 
4A21  DO  AF201938 
13E1  RIGUI  putative  mammalian  ortholog  of  PER  AF022991 
4C21;  15D23  Uncoupling  protein  2  (UCP2)  AF208500 
8D1  KIAA09134  AB020721 
8131;  18C1  KIAA0167  D79989 
7C1  mRNA  from  chromosome  5q  21-22  AB002439 
4A22;  2K1  mRNA  full  length  insert  cDNA  clone  AL079296 
12A1  cDNA  DKFZp434E2321  HSM80144 
Table  11:  Positive  Interacting  Clones  from  a  Yeast  Two-Hybrid  Screen  with  pGBT9- 
hMLH1  as  bait  and  a  Clontech  Matchmaker  Normal  Mammary  Gland  cDNA  library 134 
3.5  Yeast  Two-Hybrid  Library  Screen  with  hMLH1  using  a 
Pre-transformed  cDNA  Library. 
A  second  yeast  two-hybrid  screen  was  performed  using  hMLH1  as  the  bait.  Because  of  the 
relatively  low  number  of  clones  screened  in  the  original  screen  (1  x  105)  it  was  decided  that 
to  carry  out  a  more  representative  screen  would  be  useful.  This  in  no  way  invalidates  the 
first  screen  but  merely  adds  to  it  as  a  method  of  identification  of  new  protein-protein 
interactions  between  hMLH1  and  other  proteins.  The  development  of  a  new  system  by 
Clontech,  MATCHMAKER  III,  made  the  second  screen  much  easier,  with  a  substantially 
lower  level  of  false  positives  allowing  rapid  analysis  of  results. 
A  Clontech  pre-transformed  MATCHMAKER  III  Ovarian  cDNA  library  was  utilised. 
This  is  a  high  complexity  cDNA  library  cloned  into  a  yeast  GALA  activation  domain  (AD) 
vector,  pACT2,  (priming  method:  XhoI-(dT)15)  and  pre-transformed  into  the 
Saccharomyces  cerevisiae  host  strain  Y187.  Y187  is  transformed  with  an  entire  pre-made 
MATCHMAKER  library  (>1  x  106  independent  clones).  This  library  is  screened  by  yeast 
mating  rather  than  library-scale  transformation.  The  yeast  mating  partner  for  Y187 
(MATa)  used  was  the  PJ69-2A  (MATa)  strain.  PJ69-2A  unlike  most  other  reporter  strains 
contains  two  nutritional  reporter  genes,  HIS3  and  ADE2  which  both  carry  a  GAL4  UAS. 
This  additional  selection  forADE2  allows  a  more  stringent  selection  for  false  positives. 
hMLH1  was  cloned  into  a  GAL  4  binding  domain  (BD)  vector,  pGBKT7  and  transformed 
into  the  PJ69-2A  strain.  pGBKT7  was  used  this  time,  instead  of  pGBT9,  because  it  carries 
a  kanamycin  selection  gene  which  will  allow  easier  isolation  of  the  pACT2  library  plasmid 
later,  which  has  ampicillin  selection.  The  pGBKT7-hMLH1  construct  did  not 
autonomously  activate  the  reporter  genes,  was  not  toxic  when  expressed  in  yeast  and  gave  a 
positive  interaction  when  co-transformed  into  Y190  with  pGAD424-PMS2-F3  and 
pGAD424-PMS2-F4.  PJ69-2A  transformed  with  this  pGBKT7-hMLH1  construct  was  also 
mated  with  Y187  transformed  with  pTD1.  The  mating  efficiency  with  the  two  strains  was 
not  effected  by  the  pGBKT7-hMLH1  construct  and  no  LACZ  activation  was  seen  in  the 
diploid  yeast  that  resulted.  Therefore  it  was  concluded  that  this  pGBKT7-hMLH1 
construct  is  suitable  for  use  in  this  system. 
To  screen  the  pre-transformed  library,  it  was  simply  mated  with  the  bait  strain,  pJ69-2A 
transformed  with  pGBKT7-hMLH1,  for  24  hours  and  the  mixture  plated  onto  quadruple 
drop  out  (QDO)  selection  media  (Leu-/Trp-/His%Ade").  The  double  nutritional  selection 135 
results  in  fewer  false  positives  than  seen  with  the  earlier  screen  which  used  only  a  single 
reporter  gene  (see  Figure  11).  The  plates  were  incubated  at  30°C  for  21  days.  The  29  large 
colonies  growing  on  the  QDO  media  were  streaked  out  onto  fresh  QDO  plates  and 
incubated  for  3  days  at  30°C.  A  ß-Galactosidase  assay  was  performed  on  these  plates 
using  a  filter  lift  assay.  After  lifting  the  colonies  for  the  ß-Galactosidase  assay  the  master 
plates  were  placed  at  30°C  for  2  days  to  allow  the  colonies  to  re-grow.  The  master  plates 
were  wrapped  in  parafilm  and  incubated  at  4°C.  The  positive  colonies  were  re-streaked  on 
Leu"/Trp"  plates  three  times  to  allow  segregation  of  some  of  the  AD/library  plasmids  to  take 
place  while  maintaining  selective  pressure  on  the  two  plasmid  types  (i.  e.,  DNA-BD/target, 
and  AD/library).  Single  colonies  from  these  plates  were  re-streaked  onto  QDO  medium  to 
verify  the  correct  growth  phenotype  is  maintained  and  the  colonies  re-assayed  for  ß-Gal 
activity  using  the  colony  lift  filter  assay. 
The  viability  (colony  forming  units  (cfu)/ml)  of  the  Y187  partner,  the  PJ69-2A  partner,  and 
the  viability  of  the  diploids  was  calculated  from  control  plates  (100µl  of  a  1:  10,1:  100, 
1:  1000,1:  10000  on  10cm  plates)  set  up  by  spreading  dilutions  of  the  library  mixture  onto 
Leu-,  Trp"  and  Leu"/Trp"  plates.  An  estimate  of  the  number  of  clones  screened  was  made: 
#  cfu/ml  of  diploids  x  re-suspended  volume  =#  of  clones  screened 
An  estimated  5.3  x  106  clones  were  screened. 
Yeast  plasmid  DNA  mini-preps  were  performed  on  the  29  clones.  This  DNA  was 
transformed  into  electro-competent  DH10B  cells  (Gibco  BRL)  and  plated  onto  LB-broth 
plates  with  100  µg/ml  ampicillin  therefore  selecting  specifically  for  cells  transformed  with 
the  library  plasmid  (pACT2  has  an  amps  marker,  PGBKT7  has  a  kan`  marker).  These 
transformations  and  the  subsequent  selection  were  more  efficient  than  utilising  the  KC8 
strain  used  in  the  previous  screen.  Plasmid  DNA  was  prepared  from  the  transformants  and 
duplicates  identified  by  digesting  the  DNA  with  Alu  1. 
False  positives  were  eliminated  by  co-transforming  the  newly  isolated  library  plasmid 
DNA  with  pGBKT7-hMLH1  into  Y190  and  performing  a  ß-Galactosidase  assay  on  the 
transformants.  Additionally  both  plasmids  were  also  co-transformed  into  PJ69-2A  and 
plated  out  onto  QDO  plates  testing  for  the  correct  growth  phenotype.  Library  plasmids 
were  co-transformed  with  pLAM5'  and  also  pGBKT7  into  Y190  and  tested  for  LACZ 
activation  and  into  PJ69-2A  and  tested  for  the  ability  to  grow  on  QDO  plates.  It  was  found 
that  23/29  clones  were  `true  positives'. 136 
Figure  11:  Schematic  for  Yeast  Two-Hybrid  Pre-Transformed  Library  Screen 
pGBKT7-hMLH  l+  Pre-transformed  Ovarian  Yeast  Two- 
in  PJ69-2A,  MATa  Hybrid  cDNA  library,  in  Y  187,  MATcx 
Mating  Assay 
1 
29  large  colonies  had  grown  after  three  weeks  on  L.  eu-/Trp-/His  /Ade 
, 
QDO  plates.  The  29 
colonies  were  re-streaked  out  onto  QDO  plates  and  a  colony  lift  filter  13-Galactosidase 
assay  carried  out  on  these  plates.  29/29  plates  gave  blue  colonies. 
O 
I 
Positive  clones  were  streaked  out  onto  consecutive  Leu-/Trp-  plates  three  times  and  then 
onto  QDO  plates.  Colony  lift  filter  (3-Galactosidase  assays  were  carried  out  on  these 
plates.  29/29  plates  gave  blue  colonies 
Plasmid  DNA  was  prepared  from  the  29  clones  and  transformed  into  DH  I  OB  E.  coli,  the 
transformations  were  plated  onto  plates  with  ampicillin  to  allow  specific  selection  of  cells 
with  the  library  pACT2-X  plasmids  as  pGBKT7  does  not  have  an  ampicillin  marker. 
I 
pACT2-X  plasmid  DNA  was  prepared  from  these  colonies  and  was  co-transformed  into 
Y  190  with  pGBKT7-hMLH  1,  followed  by  a  (3-Gal  assay 
23/29  plates  gave  blue  colonies  6/29  plates  gave  white  colonies 
e""  ""  oo  o0 
""""°o00 
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These  23  `True  Positives'  were  identified  by  sequencing  6  'H'alse  Positives' 137 
The  inserts  of  all  true  positive  interacting  clones  were  amplified  by  PCR  and  sequenced  to 
identify  the  interacting  proteins  (see  Table  12).  In  summary  `true  positives'  are  defined  as 
proteins  expressed  from  the  library  constructs  that  interact  with  the  hMLH1  protein  in  the 
yeast  two-hybrid  system  to  give  blue  colonies  in  a  ß-galactosidase  assay.  Subsequent  re- 
isolation  of  these  plasmids  from  the  yeast  leads  to  further  verification  of  a  `true  positive'. 
These  plasmids  do  not  activate  LACZ  or  ADE2  activity  autonomously  or  when  co- 
transformed  into  yeast  (Y190  or  PJ629A  respectively)  with  control  plasmids  such  as 
pLAM5'  or  pGBKT7.  Upon  co-transformation  of  the  `true  positives'  into  Y190  with 
pGBT9-hMLH1  or  pGBKT7-hMLH1  LACZ  expression  is  clearly  activated.  In  the  latter 
screen,  mating  of  PJ69-2A  transformed  with  pGBKT7-hMLH1  and  Y187  with  the  library 
plasmid  allowed  the  growth  phenotype  of  the  diploids  to  be  tested.  Once  again,  only  `true 
positives'  were  able  to  grow  on  QDO  plates. 138 
Positive  Interacting- 
Clone 
Identity  Accession 
Number 
2.1.1  Polypeptide  chain  elongation  factor  1-alpha  E02628 
13.1.1;  20.1.1  Polypeptide  chain  elongation  factor  1-alpha  E02628 
8.2.1;  6.3.1;  3.1.1 
19.2.1;  10.1.3; 
15.1.1;  14.1.3 
Polypeptide  chain  elongation  factor  1-alpha  E02628 
18.1.1;  14.1.3  Polypeptide  chain  elongation  factor  1-alpha  E02628 
12.1.1  ELPIN  AF198455 
7.2.2;  7.1.1;  21.3.1 
9.2.1;  20.2.1;  11.1.1 
PMS1  U13695 
6.2.1  MLH3  AB039667 
14.3.1  MED1  AF114784 
1.1.1  FHL2  U29332 
Table  12:  Positive  Interacting  Clones  from  a  Yeast  Two-Hybrid  Screen  with  pGBKT7 
hMLH1  as  bait  and  pre-transformed  MATCHMAKER  Ovarian  cDNA  library 139 
3.6  c-MYC-hMLH1  Yeast  Two-Hybrid  Interaction. 
Further  examination  of  the  c-MYC-hMLH1  interaction  identified  from  the  first  yeast  two- 
hybrid  library  screen  was  carried  out.  The  particular  aim  of  this  project  was  to  identify 
novel  protein-protein  interactions,  between  hMLH1  and  other  cellular  proteins,  to  help 
further  elucidate  the  role,  of  hMLH1  and  the  MMR  system  in  signalling  cellular  DNA 
damage  response  pathways.  Because  of  the  role  of  c-MYC  in  a  variety  of  cellular 
processes,  including  signalling  progression  through  the  cell  cycle  and  apoptosis,  this 
represented  the  most  intriguing  of  the  interactions  identified.  A  specific  link  between  DNA 
damage  recognition  by  the  MMR  system  to  possible  downstream  pathways  represents  the 
`holy  grail'. 
From  the  yeast  two-hybrid  library  screen  with  the  mammary  gland  cDNA  library  it  has 
been  shown  that  hMLH1  interacts  with  the  C-terminal  half  of  c-MYC  (aa245-439,  stop 
codon).  The  full  sequence  of  the  insert  (1291-1878bp)  was  established  by  sequencing 
(myc-F  and  myc-R  primers  were  used).  This  region  of  c-MYC  includes  a  basic/helix-loop- 
helix/leucine  zipper  domain.  MAX  a  c-MYC  binding  partner  is  known  to  bind  to  this 
region  of  c-MYC.  The  yeast  two-hybrid  system  was  further  utilised  to  verify  whether  this 
interaction  between  c-MYC  and  hMLH1  is  real.  Elucidation  of  domains  facilitating  this 
interaction  could  perhaps  hint  at  the  functional  significance  of  this  protein-protein 
interaction. 
The  construct  pulled  out  of  the  yeast  two-hybrid  library  screen  expressing  the  C-terminal 
half  of  c-MYC  was  co-transformed  into  Y190  with  pGBT9  expressing  fragments  of 
hMLH1  (Fl-F4).  From  this  it  is  clear  that  c-MYC  specifically  interacts  with  fragment  4 
(aa514-756)  of  hMLH1,  which  also  includes  the  hPMS2  interaction  domain  of  this  protein 
(see  Table  13).  To  further  elucidate  the  hMLH1  interaction  domains  of  c-MYC  the 
interaction  of  avian  c-MYC  mutants  with  hMLH1  was  examined,  again  using  the  yeast 
two-hybrid  system  (see  Table  14).  The  C-terminal  half  of  avian  c-MYC  is  highly 
homologous  to  that  of  human  c-MYC  and  therefore  deemed  suitable  for  use  in  this 
experiment  (see  Figure  12).  These  mutants  were  available  from  Dr.  D.  Crouch  (University 
of  Dundee)  and  had  also  been  previously  characterised  in  terms  of  their  effect  on  the 
interaction  of  c-MYC  with  MAX  (Crouch  et  al.,  1993;  Crouch  et  al.,  1990).  Full  length  c- 
MYC  was  not  used  in  the  two-hybrid  system  to  further  verify  this  interaction  as  it  has  an 
N-terminal  transactivation  domain  making  it  unsuitable  for  use  in  this  system. 140 
pACT2  c-MYC 
aa245-stop  codon 
MLH1  Full  Length  aal-756  + 
MLH1  F1  aal-228  - 
MLH1  F2  aa180-342 
MLH1  F3  aa308-579  - 
MLH1  F4  aa514-756  + 
Table  13:  Interactions  of  the  9111  (c-MYC  =245-stop  codon)  clone  identified  from 
the  yeast  two-hybrid  library  screen  with  full  length  and  fragments  1-4  of  pGBT9- 
MLH1. 
Both  full  length  and  fragment  4  of  hMLH1  interact  with  the  C-terminal  half  of  c-MYC 
expressed  by  the  9B1  plasmid  identified  from  the  first  two-hybrid  library  screen. 141 
Mutant  Domain  Amino  Mutation  MYC-MAX 
Mutated  Acids  Interaction 
Mutated 
C/T  Basic  Region  aa339  L-*FR  + 
H1  Helix  1  a(x353  A--,  -P  + 
H2  Helix  2  aa377  T-i-P  - 
C810  Leucine  Zipper  deleted  N-)-STOP  - 
aa407-416 
C628  Leucine  Zipper  deleted  R-'STOP  - 
aa389-416 
Table  14:  List  of  mutants  of  avian  c-MYC  used  to  localise  the  region  of  interaction  of 
c-MYC  with  hMLH1. 
The  C-terminal  half  of  avian  C-MYC,  V-MYC  and  the  mutants  listed  were  cloned  into  the 
yeast  two-hybrid  vector  pACT2  and  tested  for  an  interaction  with  pGBT9-MLH1.  This 
table  also  lists  the  effect  of  these  mutations  on  the  c-MYC-MAX  interaction. 142 
human  1  MPLNVSFTNRNYDLDYDSVQPYFYC.  DEEENFY..  QQQQQSELQPPAPSEDIWKKFELLP 
Chick  1  MPLSASLPSKNYDYDYDSVQPYFYFEEEEENFYLAAQQRGSELQPPAPSEDIWKKFELI,  P 
human  58  TPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMVTELLGGDMVNQSFIC 
chick  61  TPPLSPSRRSSLAAAS...  CFP 
.............. 
STADQLEMVTELLGGDMVNQSFIC 
human  118  DPDDETFIKNIIIQDCMWSGFSAAAKL 
...  VSEKLASYQAARKD  .............  SGS 
chick  104  DPDDESFVKSIIIQDCMWSGFSAAAKLEKVVSEKLATYQASRREGGPAAASRPGPPPSGP 
human  162  PNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSPSSD 
chick  164  PPPPAGPA..  ASAGLYLHDLGAAAADCIDPSVVFPYPLSE.  RAPR 
............... 
human  222  SLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKRSESGS 
chick  206 
....... 
AAPPGANPAALLGVDTPPTTSSDSEEEQEEDEEIDVVTLAEANESESSTESST 
human  282  PSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLRQISNNRK 
Chick  259  EASEEHCKPHHSPLVLKRCHVNIHQHNYAAPPSTKVEYPAAKRLKLDSGRVLKQISNNRK 
human  342  CTSPRSSDTEENV  RRTHNVLERQRRN  LKRSFFALRDQI  ELE[\INFKAP?,  ',  T  TILKKATA 
Chick  319  CSSPRTSDSEEND  RRTHNVLERQRRN  LKLSFFALRD, 
=  .  lE:  VA[INEKAPK'v'V  LF"1":  1,  TE 
Basic  Region  H1  LOOP  H2 
human  402  YILS  QAEEQKLISEEDLLRKRREQLKHKLEQLRNS  A 
Chick  379  YVLS  QSDEHRLIAEKEQLRRRREQLKHYLEQLPNri 
H2  Leucine  Zipper 
Figure  12:  Alignment  of  Human  and  Avian  (chicken)  c-MYC  proteins. 
This  alignment  demonstrates  the  high  homology  between  human  and  avian  c-MYC. 
HI=  helix  I  and  H2  =  helix  2  of  the  Helix  Loop  Helix  domain.  The  sequences  of  (he 
human  and  avian  c-MYC  gene  and  c-MYC  protein  are  listed  in  Appendix  5  and  6 
respectively. 143 
From  these  constructs  the  C-terminal  half  (equivalent  to  the  C-terminal  region  of  human  c- 
MYC  identified  in  the  Y2H  library  screen)  of  each  was  amplified  by  PCR  (using  primers 
M1  and  M2)  and  cloned  into  the  yeast  two-hybrid  vector  pACT2.  The  C-terminal  half  of 
avian  c-MYC  includes  a  number  of  defined  motifs  (see  Figure  13).  The  vector  inserts  were 
checked  by  sequencing  and  each  was  found  to  be  in  frame  and  no  point  mutations  had  been 
incurred.  Each  of  these  constructs  were  co-transformed  with  pGBT9  hMLH1  (full  length 
and  fragment  4),  with  pGBT9  alone  and  also  transformed  alone  into  Y190  (see  Table  15). 
ß-Galactosidase  assays  were  again  performed  on  the  transformant  colonies  (see  Figure  14). 
None  of  the  MYC-hybrid  proteins  activated  LACZ  alone  or  when  co-transformed  with 
pGBT9. 
Initial  results  suggested  the  leucine  zipper  domain  of  c-MYC  was  required  for  the 
interaction  with  hMLH1.  However  these  results  were  initially  somewhat  complicated.  The 
C810  mutant  of  c-MYC  did  not  interact  with  hMLH1,  but  the  C828  mutant  retained  the 
ability  for  this  interaction.  Thus  it  appeared  that  deleting  the  last  10  amino  acids  abolished 
activity,  while  deleting  the  last  28  amino  acids  did  not.  These  conflicting  results  could  not 
initially  be  explained.  The  only  difference  between  these  two  mutants  was  the  stop  codon 
mutation  used  for  mutagenesis.  In  C810  TAA  encoded  the  stop  codon,  whereas  in  C828 
TGA  was  used.  It  has  been  suggested  previously  that  stop  codon  suppressors  exist  in  yeast, 
which  could  possibly  explain  this  different  result  in  the  interaction  with  hMLH1.  It  was 
proposed  that  TGA  stop  codon  suppressors  exist  in  Y190.  Therefore  the  stop  codon  was 
changed  in  C028  to  TAA  as  well.  This  change  resulted  in  the  loss  of  a  positive  interaction 
between  this  mutant  form  of  c-MYC  and  hMLH1.  Thus  deleting  10  and  28  amino  acids 
from  the  C-terminal  end  was  consistent.  From  these  results  it  was  concluded  that  the 
region  of  c-MYC  required  for  the  interaction  with  hMLH1  is  the  leucine  zipper  domain. 
In  summary  a  C-terminal  fragment  (F4)  of  hMLH1  (amino  acids  514-756)  was  found  to 
interact  with  c-MYC.  This  region  of  hMLH1  has  also  previously  been  found  to  contain  a 
hPMS2  interaction  domain.  The  leucine  zipper  domain  of  c-MYC  is  required  for  this 
interaction  with  hMLH1.  This  region  of  c-MYC  is  involved  in  the  binding  of  c-MYC  to 
other  proteins.  In  particular  it  is  required  for  the  c-MYC-MAX  interaction.  However  a 
mutation  in  the  second  helix  of  the  helix-loop-helix  domain  of  c-MYC  also  knocks  out  the 
interaction  of  this  protein  with  MAX  but  has  no  effect  on  the  hMLH1  interaction.  This 
would  suggest  that  the  interaction  domains  for  this  protein  with  MAX  and  hMLH1  differ 
slightly.  The  demonstration  of  the  ability  of  hMLH1  full  length  and  fragment  4  to  interact 144 
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Figure  13:  Schematic  diagram  representing  the  domains  incorporated  by  the  C- 
terminal  half  of  avian  c-MYC. 
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Region  (amino  acids)  Full  Length  MLH1 
as  1-756 
MLH1-F4 
as  514-756 
Human  c-MYC  aa245-439  +  + 
Avian  v-MYC  aa244-438  +  + 
Avian  c-MYC  aa222-416  +  + 
C/T  aa222-416  +  + 
H1  aa222-416  +  + 
H2  aa222-416  +  + 
C810  aa222-407  -  - 
C828  aa222-389  -  - 
Table  15:  Transformation  of  pGBT9-MLH1  and  pGBT9-MLH1  F4  with  pACT2 
expressing  the  C-terminal  half  of  avian  c-MYC,  v-MYC  and  mutants. 
ß-Galactosidase  assays  carried  out  on  the  transformed  Y190  cells  showed  that  both  full 
length  and  fragment  4  (aa514-756)  of  hMLH1  could  interact  with  avian  c-MYC  and  v- 
MYC  and  that  this  interaction  requires  the  leucine  zipper  region  of  c-MYC.  C810  and 
C628  are  leucine  zipper  domain  mutants  (10  and  28  amino  acids  deleted  at  the  C-terminal 
of  c-MYC  leucine  zipper  domain  respectively)  and  do  not  interact  with  hMLH1. 146 
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Figure  14:  ß-Galactosidase  assays  on  V190  co-transformed  with  pGBT9-hNILH  1  full 
length  and  fragment  4  with  wild  type  and  mutant  forms  of  avian  c-MYC  and  v- 
MYC. 
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with  this  region  of  avian  c-MYC,  v-MYC  and  mutants  of  c-MYC,  would  further  support 
this  interaction  is  real. 148 
3.7  Co-Immunoprecipitation  of  hMLH1  and  c-MYC. 
Protein-protein  interactions  identified  by  the  yeast  two-hybrid  system  may  not  be 
biologically  relevant.  Therefore  it  is  essential  that  secondary  evidence  for  a  physical 
association  is  obtained.  From  the  yeast  two-hybrid  data  the  question  must  be  asked,  do 
hMLH1  and  c-MYC  interact  in  vivo?  Co-immunoprecipitation  assays  were  carried  out  to 
look  for  in  vivo  evidence  for  an  interaction  between  c-MYC  and  hMLH1. 
Cell  extracts  from  a  number  of  mammalian  cell  lines  and  an  avian  cell  line  were  prepared 
(Blackwood  et  al.,  1992).  Specifically  extracts  were  made  from  the  human  A2780  ovarian 
carcinoma  cell  line,  from  the  K562  erythroleukaemia  cell  line  and  the  avian  cell  line 
MC29.  MC29  avian  cell  extracts  were  used  because  they  are  known  to  express  an  elevated 
level  of  c-MYC.  Therefore  the  co-immunoprecipitation  of  these  two  proteins  should  be 
more  easily  detectable  in  these  cell  lines.  MLH1  was  detected  in  MC29  crude  cell  extracts 
by  western  blot  using  anti-hMLH1,  thus  confirming  that  the  MLH1  antibodies  cross 
reacted  with  avian  MLH1. 
Extracts  were  also  made  from  A2780  and  K562  cells  treated  with  the  DNA  damaging  agent 
cis-diamminedichloroplatinum  (II),  (CDDP).  Cells  were  treated  with  CDDP  for  one  hour 
and  fresh  media  was  then  added  and  the  cells  left  for  a  further  24  hours  at  37°C  before 
extracts  were  made. 
Cell  pellets  were  washed  in  PBS,  re-suspended  in  lysis  buffer  at  4°C  and  sonicated  on  ice. 
Extracts  were  clarified  by  two  ultracentrifugation  steps  of  30  minutes  at  304,000  g  at  4°C. 
Extracts  were  immunoprecipitated  with  anti-c-MYC  polyclonal  antibody,  anti-hMLH1 
polyclonal  antibody  and  non  specific  rabbit  serum  (NIS)  and  collected  on  protein  A- 
Sepharose  beads.  The  beads  were  collected  by  centrifugation  and  washed  a  number  of 
times  in  low  stringency  buffer  and  denatured  samples  were  run  out  on  SDS-PAGE. 
Western  blots  were  performed  on  the  gels  and  probed  with  anti-c-MYC  and  anti-hMLH1 
monoclonal  antibodies  to  look  for  co-immunoprecipitation  of  the  two  proteins  (see  Figure 
15). 
It  is  clear  from  these  blots  that  hMLH1  and  c-MYC  co-immunoprecipitate  providing 
evidence  for  an  in  vivo  interaction  between  these  two  proteins.  The  first  two  western  blots 
represent  blots  probed  with  anti-hMLH1,  with  co-immunoprecipitation  assays  from  both 
A2780  and  K562  extracts.  Polyclonal  anti-hMLH1  antibody  is  clearly  able  to 149 
Anti-hMLH  I  Western  Blots 
1``,  \% 
A2780  ý"r 
K562  Will- 
Anti-e-MYC  Western  Blots 
MC  29  "iý  -,  . 
87Kd 
IiN1I  II  I 
-87  K& 
IhN1I  II  I 
Figure  15:  Western  Blots  of  Co-Ininiunopreeipitatiººn  1,  'xpcrinucnts  Nsith  poIN'clun:  ºI 
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immunoprecipitate  hMLH1  from  A2780  and  K562  extracts  (lane:  mlhi).  Polyclonal  anti- 
c-MYC  also  clearly  co-immunoprecipitates  hMLH1  as  shown  by  the  distinct  hMLIII  band 
on  both  blots  (lane:  myc).  The  level  of  hMLH1  protein  seen  in  these  lanes  are  clearly  not 
as  strong  as  those  with  polyclonal  anti-hMLH1.  This  is  an  expected  result  as  c-MYC  is  not 
an  abundant  protein,  forms  complexes  with  other  cellular  proteins  and  has  a  short  half  life. 
The  treatment  of  the  A2780  and  K562  cells  with  CDDP  does  not  effect  the  abundance  of 
hMLH1  co-immunoprecipitated  with  either  polyclonal  anti-hMLH1  or  anti-c-MYC 
antibodies  (lanes:  mlhl  +  cis,  myc  +  cis).  Non-specific  rabbit  serum  was  also  used  in  these 
assays  as  a  negative  control  for  non-specific  immunoprecipitation  of  the  proteins.  In 
A2780  and  K562  cells  (untreated  or  treated  with  CDDP),  this  pre-immune  rabbit  serum 
does  not  co-immunoprecipitate  hMLH1.  This  observation  supports  the  conclusion  that  the 
co-immunoprecipitation  of  hMLH1  with  polyclonal  anti-c-MYC  represents  a  specific 
interaction.  Crude  extracts  from  A2780  and  K562  cells  as  well  as  supernatant  taken  off  the 
protein-A  Sepharose  beads  were  also  included  on  these  blots  as  positive  controls.  hMLH1 
was  readily  detectable  in  these  samples  (lanes  not  shown). 
The  reciprocal  experiments,  detecting  c-MYC  on  the  western  blots  proved  much  more 
challenging.  Numerous  repeat  experiments  were  carried  out,  varying  the  amount  of  protein 
extracts  and  antibodies  in  the  immunoprecipitation  assays.  However  these  attempts  and 
alteration  of  the  immunoprecipitation  conditions  proved  unsuccessful.  The  fundamental 
problem  with  these  experiments  was  the  lack  of  a  good  anti-c-MYC  monoclonal  antibody. 
This  factor  along  with  the  relative  instability  of  the  c-MYC  protein  are  the  most  likely 
explanation  for  the  difficulties  encountered.  Problems  detecting  c-MYC  by  western  blot 
techniques  was  not  limited  to  the  co-immunoprecipitation  assays  but  also  in  crude  extracts 
from  A2780  and  K562  cell  extracts.  Therefore  extracts  were  made  from  the  MC29  avian 
cell  line.  hMLH1  was  shown  to  interact  with  avian  c-MYC  in  the  yeast  two  hybrid  system, 
and  both  MLH1  and  c-MYC  were  detected  with  anti-hMLH1  and  anti-c-MYC  from  MC29 
cell  extracts.  These  co-immunoprecipitation  experiments  with  MC29  cell  extracts  and 
subsequent  probing  of  the  western  blot  with  anti-c-MYC  proved  successful.  Polyclonal 
anti-hMLH1  immunoprecipitates  avian  c-MYC  (lane:  mlhl)  and  polyclonal  c-MYC  also 
immunoprecipitates  avian  c-MYC  (lane:  myc).  No  avian  c-MYC  is  seen  in  the  pre- 
immune  rabbit  serum  immunoprecipitate  (lane:  nis).  c-MYC  is  clearly  detected  in  the 
MC29  crude  cell  extract.  Overall  these  results  provide  evidence  for  an  in  vivo  interaction 
between  hMLH1  and  c-MYC. 151 
3.8  GST  Pull  Down  Assays  (work  done  in  collaboration 
with  Dr.  E.  Homer) 
A  criterion  for  biological  relevance  for  the  hMLH1-c-MYC  interaction  described,  is  the 
demonstration  of  an  interaction  between  these  proteins  using  other  systems.  GST  fusion 
proteins  were  prepared  with  full  length  hMLH1  and  the  four  overlapping  fragments  1-4 
described  for  the  yeast  two-hybrid  experiments.  GST-MYC  and  GST-MAX  were  also 
prepared.  However  the  GST-MYC  fusion  proteins  degraded  rapidly  upon  expression  and 
were  therefore  not  available  for  these  assays.  The  original  aim  of  these  experiments  was  to 
demonstrate  a  specific  interaction  between  hMLH1  in  cell  extracts  and  the  full  length  GST- 
c-MYC  fusion  protein,  as  the  interaction  studies  in  the  yeast  two-hybrid  experiments 
involve  the  C-terminal  half  of  c-MYC.  Unfortunately  this  was  not  possible.  These  assays 
however  provide  important  evidence  corroborating  the  yeast  two-hybrid  observations. 
As  described,  GST  fusion  proteins  were  expressed  from  pGex4T  plasmids  in  BL21  E.  coli 
cells.  The  fusion  proteins  were  collected  on  glutathione  sepharose  beads.  The  pull  down 
assays  were  carried  out  by  incubating  the  GST  fusion  proteins  on  the  beads  with  cell 
extracts  from  both  the  human  A2780  ovarian  carcinoma  cell  line,  and  from  the  K562 
erythroleukaemia  cell  line.  Following  this  incubation,  the  beads  bound  to  the  GST  fusion 
proteins  along  with  any  proteins  from  the  cell  extracts  that  bound  the  fusion  proteins  were 
precipitated.  These  samples  were  denatured  and  resolved  by  SDS-PAGE.  Western  blots  of 
these  gels  were  subsequently  probed  with  anti-hMLH1  and  anti-c-MYC  antibodies. 
c-MYC  clearly  binds  the  GST  fusion  proteins  with  full  length  hMLH1,  fragment  4  (F4)  of 
hMLH1  and  MAX.  An  example  of  a  western  blot  gel  demonstrating  an  interaction 
between  hMLH1  and  c-Myc  is  shown  (  see  Figure  16).  From  this  gel,  it  is  demonstrated 
that  GST  alone  and  GST  fusion  proteins  with  hMLH1-Fl  (GST  Fl),  hMLH1-F2  (GST-F2) 
and  hMLH1-F3  (GST-F3)  do  not  interact  and  hence  do  not  pull  down  cellular  c-MYC  from 
cell  extracts.  However  both  fragment  4  (aa514-756)  of  hMLH1,  hMLH1-F4  (GST-F4) 
and  full  length  hMLH1  (GST  MLH1)  clearly  interact  with  and  pull  down  cellular  c-MYC 
from  the  K562  cell  extracts.  As  a  positive  control,  MAX  a  known  c-MYC  binding  partner 
was  expressed  as  a  GST-fusion  protein,  GST-MAX 
,  which  clearly  binds  and  pulls  down 
cellular  c-MYC  in  this  assay  system.  The  same  binding  patterns  have  been  shown  with  this 
assay  using  cell  extracts  from  the  A2780  cell  line. 1')1 
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Figure  16:  GST  Pull  Down  Assays 
GST  pull  clown,  with  the  GST  fusion  proteins  listed  in  the  gel  lanes  aho  e.  and  eyIr,  ýct. 
from  K562  cells  were  resolved  by  SOS-NAGE:  and  the  subsequent  western  blot  probed 
with  anti-c-MYC.  CST-MAX,  GST-MLHI  and  GST-F4  each  hind  c-I  II('  from  K.  02 
extracts  as  shown  by  probing  the  western  blot  with  anti  c-MYC. 153 
This  study  provides  further  support  to  the  observations  from  the  yeast  two-hybrid 
experimental  results  and  the  co-immunoprecipitation  studies.  c-MYC  and  hMLII1  have 
been  shown  in  a  second  independent  assay  to  bind.  Using  these  two  assays  to  detect  an 
interaction  however  does  not  define  whether  this  hMLH1-c-MYC  interaction  is  specific. 
Demonstrating  that  this  interaction  is  specific  is  a  significant  obstacle,  due  to  the  fact  that 
c-MYC  is  such  an  unstable  protein  and  difficult  to  express  for  example  as  a  GST  fusion 
protein.  However,  even  though  these  attempts  to  use  full  length  c-MYC  in  this  GST-pull 
down  assay  were  unsuccessful,  some  hints  that  this  is  a  specific  interaction  have  come  from 
the  studies  with  the  site  directed  mutagenesis  of  avian  c-MYC.  In  these  studies  the 
demonstration  of  loss  of  an  interaction  between  hMLH1  and  specific  mutants  of  the  avian 
c-MYC  protein  have  been  shown  in  the  yeast  two-hybrid  system  and  identify  the  leucine 
zipper  domain  of  c-MYC  as  being  crucial  for  this  interaction. 
Recent  studies  have  demonstrated  an  interaction  between  hMSH2  and  MAX  (pers.  comm. 
Dr.  E.  Homer).  GST  pull  down  assays  with  GST-MAX  and  extracts  from  A2780  cells 
were  carried  out,  and  the  western  blot  on  assay  samples  probed  with  an  anti-hMSH2 
antibody.  These  experiments  clearly  demonstrated  that  hMSH2  in  A2780  cells  is  binding 
and  therefore  pulled  down  with  the  GST-MAX  fusion  protein. 154 
3.9  MYC/MAX/MLH1  Electrophoretic  Mobility  Shift  DNA 
Binding  Assays. 
c-MYC  and  MAX  proteins  dimerise  and  bind  DNA  through  their  basic-helix-loop-helix- 
leucine  zipper  motifs  (b-HLH-LZ)  (Blackwood  and  Eisenman,  1991).  c-MYC-MAX 
heterodimer  binds  with  highest  affinity  to  the  consensus  sequence  CACG/ATG,  the  E-box 
sequence  (Prendergast  and  Ziff,  1991).  c-MYC-MAX  and  MAX-MAX  complexes  can 
form  and  bind  to  this  E-box  DNA  core  sequence.  However  c-MYC  does  not  form  homo- 
oligomers  or  bind  this  DNA  sequence  except  at  very  high  concentrations  in  vivo  (Dang  et 
al.,  1991).  This  binding  of  c-MYC-MAX  heterodimers  can  be  observed  using 
electrophoretic  mobility  shift  DNA  binding  assays  (EMSA). 
The  gel  shift  system  has  been  used  in  the  past  to  identify  proteins  which  bind  to  specific 
sequences  involved  in  control  of  gene  transcription.  This  system  is  based  on  the  fact  that 
the  movement  of  DNA  through  a  non-denaturing  polyacrylamide  gel  is  retarded  when  a 
protein  binds  to  it.  The  DNA  is  32P  labelled  so  the  complexes  formed  can  be  visualised  by 
autoradiography.  Using  electrophoretic  mobility  shift  DNA  binding  assays  it  was 
investigated  whether  hMLH1  can  form  a  ternary  complex  with  the  c-Myc-Max  heterodimer 
or  if  indeed  it  can  compete  with  Max  for  binding  to  c-Myc.  The  requirement  for  the 
leucine  zipper  domain  of  c-MYC  for  an  interaction  with  both  MAX  and  hMLH1  (yeast 
two-hybrid  studies)  would  suggest  that  the  hMLH1  interaction  with  c-MYC  could  affect  c- 
MYC-MAX  binding. 
Purified  GST-MYC,  GST-MLH1  and  HIS-MAX  were  used  to  test  the  effect  of  hMLH1  on 
Myc-Max  heterodimerisation  and  DNA-binding  function.  Using  a  32P  radiolabelled 
oligonucleotide  incorporating  the  consensus  DNA  binding  sequence,  the  E-box  sequence,  a 
shift  in  mobility  of  the  oligonucleotide  using  gel  electrophoresis  is  visible  when  purified 
Max  is  added  to  the  reaction  (at  a  concentration  of  0.15µg).  A  further  shift  is  seen  upon 
the  addition  of  both  c-MYC  (in  excess  at  a  concentration  of  1.2µg)  and  MAX  (0.15µg)  to 
the  reaction  (see  Figure  17).  However  the  addition  of  hMLH1  had  no  effect  on  the 
formation  of  this  complex. 
Numerous  repeat  experiments  were  carried  out  to  try  and  determine  whether  hMLH1  could 
effect  the  formation  or  DNA  binding  ability  of  the  c-MYC-MAX  heterodimer.  hMLH1 
was  added,  to  the  reactions  with  c-MYC  and  MAX,  at  a  range  of  concentrations 155 
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Figure  17:  EMSA  with  purified  GST-MYC,  HIS-MAX  and  (:  ST-hNII,  H  I 
MAX  binds  the  E-box  oligo  causing  a  mobility  shift  as  seen  from  the  complex  furnned. 
MYC  and  MAX  binding  as  a  heterodimer  to  the  oligo  cause  a  further  shift.  hMLH  I  had 
no  effect  on  complex  formation  by  MYC  and  MAX  nor  did  it  form  a  ternary  complex  with 
these  proteins  under  these  conditions.  Gel  shifts  were  also  performed  with  a  range  of 
hMLH  I  and  MAX  concentrations. 156 
(from  5µg  down  to  0.5µg  ).  Addition  of  hMLH1  to  reactions  with  a  range  of 
concentrations  of  c-MYC  and  MAX  also  had  no  effect  on  the  formation  of  the  c-MYC- 
MAX  heterodimer.  hMLH1  and  c-MYC  were  added  to  the  reactions  alone  to  test  whether 
under  these  conditions  a  heterodimer  of  these  two  proteins  could  itself  bind  the  E-box 
recognition  sequence.  No  binding  was  observed.  The  order  of  additions  of  each  protein 
was  varied,  with  time  gaps  between  additions,  to  test  whether  order  of  addition  could  affect 
ternary  complex  formation  or  if  formation  of  hMLH1-c-MYC  complexes  before  the 
addition  of  MAX  could  prevent  c-MYC-MAX  complex  formation.  The  affinity  of  hMLHI 
for  c-MYC  may  not  be  high  enough  to  disrupt  the  formation  of  c-MYC-MAX  complexes 
under  these  experimental  conditions.  None  of  these  variations  in  the  protocol  had  any 
effect  on  the  binding  patterns  observed.  Max  alone  can  form  heterodimers  and  bind  the  E- 
box  oligonucleotide.  Upon  addition  of  c-MYC  to  the  reaction,  a  shift  in  mobility  is  seen, 
demonstrating  the  formation  of  a  c-MYC-MAX  heterodimer  capable  of  binding  this  E-box 
oligonucleotide.  Addition  of  hMLH1  to  the  reaction  however  had  no  effect  on  these 
observations.  No  shift  in  mobility  of  the  complex  band  or  indeed  loss  of  the  band  on  any 
of  the  gels  was  observed  upon  addition  of  hMLH1. 
From  these  in  vitro  studies  hMLH1  does  not  appear  to  form  a  ternary  complex  with  the  c- 
MYC-MAX  heterodimer  or  effect  the  ability  of  this  heterodimer  to  bind  the  E-box 
recognition  sequence.  However  as  these  are  in  vitro  studies  carried  out  with  fusion 
proteins,  a  negative  result  is  somewhat  difficult  to  interpret.  There  is  a  possibility  that 
under  these  conditions  the  native  conformation  of  the  protein  could  be  effected  through 
expression  of  the  individual,  proteins  as  fusion  proteins.  Although  this  does  not  seem  to 
effect  the  c-MYC-MAX  interaction  and  binding  to  DNA,  this  does  not  rule  out  the 
possibility  in  terms  of  formation  of  a  ternary  complex.  These  in  vitro  studies  may  also  lack 
other  factors  that  could  facilitate  the  formation  of  such  a  complex  or  indeed  a  role  for 
hMLH1  in  disrupting  binding  of  the  heterodimer  to  DNA.  In  conclusion,  the  addition  of 
hMLH1  to  these  assays  at  a  range  of  concentrations,  does  not  affect  the  ability  of  c-MYC- 
MAX  heterodimer  formation  or  binding  to  DNA  under  these  in  vitro  conditions. 157 
3.10  Electrophoretic  Mobility  Shift  Assays  with  a 
Mismatched  Substrate  (In  Collaboration  with  Prof.  D. 
Gillespie,  Beatson  Institute). 
DNA  mismatch  repair  proteins  recognise  and  bind  mismatched  DNA  substrates.  A  number 
of  studies  utilising  gel  shift  assays  have  shown  proteins  contained  within  nuclear  cell 
extracts  can  bind  single  mismatched  base  pairs  on  short  fragments  of  DNA  causing  the 
delayed  migration  of  these  oligos  through  polyacrylamide  gels  (Jiricny  et  al.,  1988; 
Stephenson  and  Karran,  1989).  Purified  yeast  proteins  yMSH2,  yMLH1  and  yPMS1 
(homologous  to  human  PMS2)  have  been  shown  by  gel  shift  analysis  to  interact  with 
heteroduplex  DNA  (Prolla  et  al.,  1994).  hMLH1  has  also  been  shown  to  be  able  to  co- 
immunoprecipitate  heteroduplex  DNA  (Matton  et  al.,  2000). 
The  aim  of  this  experiment  was  to  elucidate  whether  c-MYC  expression  could  affect 
mismatch  recognition  and  binding.  The  experiments  utilised  nuclear  extracts  from  Rat-1 
fibroblasts  expressing  c-MYCERTM  in  gel  shift  assays  with  an  oligonucleotide  carrying  a 
GT  mismatch  (Littlewood  et  al.,  1995).  These  constructs  were  first  made  to  elucidate  the 
biochemical  function  of  the  human  proto-oncogene  c-MYC  (Eilers  et  al.,  1989).  A  number 
of  proteins  have  been  rendered  functionally  hormone-dependent  by  fusing  them  with  the 
hormone  binding  domain  (HBD)  of  steroid  receptors  such  as  the  human  oestrogen  receptor 
(ER)  (Picard,  1993).  The  original  c-MYCER  construct  made  was  induced  by  addition  of 
either  oestrogen  or  4-hydroxytamoxifen  (4-OHT)  (Eilers  et  al.,  1989),  but  as  most  in  vitro 
experimental  systems  use  media  containing  phenol  red,  a  weak  agonist  of  ER  and  also 
serum  which  usually  contains  oestrogens,  this  system  had  a  number  of  practical  drawbacks. 
To  overcome  these  drawbacks  a  mutant  murine  oestrogen  receptor(G525R)  was  utilised, 
that  no  longer  binds  oestrogen,  but  continues  to  be  responsive  to  activation  by  the  synthetic 
steroid  4-OHT  (Danielian  et  al.,  1993).  The  mitogenic  effects  of  this  conditionally 
expressed  allele  of  c-Myc  are  dependent  on  the  presence  of  4-OHT  but  in  no  way  respond 
to  oestrogen. 
The  gel  shift  experiments  were  performed  with  nuclear  extracts  prepared  as  described 
(Jiricny  et  al.,  1988),  from  Rat-1  c-MYCER  cells  grown  in  the  absence  of  4-OHT  or 
grown  in  the  presence  of  4-OHT  for  between  2  and  24  hours.  The  first  experiment  used 
extracts  (made  from  2x  108  cells)  from  cells  at  0  hours  (no  4-OHT  added),  2  and  24  hours 
(plus  4-OHT).  The  second  experiment  used  extracts  from  0,2,4,8  and  24  hours.  A2780 158 
nuclear  cell  extracts  were  used  as  a  positive  control  for  the  assay.  Experiments  were 
performed  using  a  34  base  oligonucleotide,  with  aG  at  position  16,  annealed  to  a 
complementary  strand,  aC  at  position  16,  or  a  non-complementary  strand  with  aT  at 
position  16,  giving  a  GT  mismatch. 
Specific  binding  of  the  mismatch  recognition  complex  to  the  mismatched  substrate  was 
clearly  demonstrated  in  these  extracts.  However  no  significant  difference  in  this  specific 
binding  ability  was  observed  in  cell  extracts  after  the  addition  of  4-OHT  to  the  Rat-1  c- 
MYCER  cells  over  a  range  of  time  points  (see  Figure  18).  In  gel  A  extracts  from  0,2,4, 
8  and  24  hours  were  incubated  with  olignonucleotides  with  either  GC  at  position  16  or  GT. 
In  both  cases  i.  e.  GC  and  GT  a  non-specific  band  is  observed.  However  in  the  case  of  the 
mismatch,  GT,  a  clear  specific  bandshift  is  observed.  These  results  were  observed  in  the 
first  experiment  as  well,  where  extracts  were  made  at  0,2  and  24  hours.  This  pattern  was 
also  seen  in  the  A2780  extracts  (data  not  shown).  No  bands  were  observed  where  the 
oligonucleotide  probe  was  incubated  alone  in  the  absence  of  cell  extract  (data  not  shown). 
It  is  concluded  therefore  that  this  specific  bandshift  represents  a  shift  in  mobility  of  the 
oligonucleotide  due  to  mismatch  recognition  by  an  MMR  protein  complex. 
SP1  (Specificity  protein  1)  is  a  transcription  factor  which  can  bind  and  act  through  GC- 
boxes,  which  are  G-rich  elements  found  in  the  regulatory  region  of  many  genes  (Suske, 
1999).  SP1  belongs  to  a  family  of  proteins  which  include  SP3.  SP3  exists  in  a  number  of 
isoforms  and  as  can  be  seen  in  gel  B  can  recognise  and  bind  the  same  DNA  recognition 
sequence  as  SP1(see  Figure  18).  These  proteins  recognise  these  GC-box  sequences  in  a 
wide  variety  of  genes  and  therefore  an  oligonucleotide  incorporating  such  a  sequence  was 
used  for  EMSA  experiments  with  the  same  Ratl  c-MYCER  and  A2780  extracts.  The 
reason  for  this  was  to  identify  whether  there  was  any  difference  in  binding  intensity 
between  the  different  extracts.  By  comparison  to  the  experiments  with  the  mismatch 
oligonucleotide  it  is  concluded  that  any  differences  in  band  intensity  between  extracts  is 
purely  due  to  extract  quality.  As  seen  from  these  two  gels  any  differences  in  intensity  for  a 
particular  extract  is  seen  in  both  gels.  Therefore  the  elevated  expression  of  c-MYC  in  these 
cells  does  not  affect  the  binding  activity  of  an  MMR  protein  complex  to  the  mismatched 
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Figure  18:  A.  EMSA  with  a  Mismatched  Substrate 
Extracts  from  Rat  1  c-MYCFR  1  ý"  plus  4-UHT  at  0,2,4.8  and  24  hr 
in  the  gel  shift  assay  with  the  34mer  complementary  oligonueleutide 
(GC)  or  that  with  a  GT  mismatch  at  position  16. 
B.  EMSA  with  an  Oligo  carrying  an  SPI  Consensus  Binding  Site. 
Extracts  from  Rat  l  c-MYCER  IM  plus  tamoxilen  at  0,2.4,8  and 
24hr  in  the  gel  shift  assay  with  an  oligo  carrying  an  SP  I  consensus 
binding  site. 
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3.11  Mutator  Phenotype  Assay 
Resistance  to  the  chemotherapeutic  agent  6-thioguanine  (6-TG)  arises  due  to  mutations  in 
the  hypoxanthine-guanine  phosphoribosyl  transferase  (HPRT)  gene.  The  mechanism  of  6- 
TG  cytotoxicity  begins  by  the  metabolic  processing  of  6-TG  by  HPRT,  the  product  of  the 
HPRT  gene,  to  yield  6-thioguanosine  monophosphate.  This  product  is  then  phosphorylated 
to  give  6-thioguanosine  triphosphate  which  can  be  incorporated  into  genomic  DNA.  This 
incorporation  step  is  the  key  to  the  cytotoxicity  induced  by  this  agent. 
Loss  of  mismatch  repair  is  known  to  lead  to  an  increased  mutation  rate  at  HPRT  and 
consequently  increased  resistance  to  6-TG  (Bhattacharyya  et  al.,  1994;  Eshleman  et  al., 
1995;  Glaab  et  al.,  1998).  In  an  MMR  deficient  background  acquired  resistance  to  6- 
thioguanine  has  been  found  to  be  associated  with  hotspot  mutations  in  the  HPRT  gene 
(Bhattacharyya  et  al.,  1994;  Kat  et  al.,  1993).  In  particular  a  specific  frameshift  hotspot  at  a 
run  of  six  guanine  residues  in  exon  3  of  the  HPRT  gene,  accounted  for  a  high  proportion  of 
HPRT  mutations  in  an  MMR  deficient  cell  line  background. 
The  aim  of  this  experiment  was  to  use  the  Rat-1  MYCERTM  system  (described  earlier)  to 
look  at  the  effect  of  elevated  c-MYC  expression  on  the  mutation  rate  at  the  HPRT  gene,  as 
measured  by  resistance  to  6-TG.  Mutation  rate  was  measured  by  doing  a  fluctuation 
analysis.  Luria-Delbruck  fluctuation  analysis  involves  growing  a  number  of  cell  cultures 
from  single  colonies,  treating  these  with  a  mutagen,  in  this  case  activation  of  elevated  c- 
MYC  expression  by  addition  of  4-OHT  to  Rat-1  MYCERTM  cells,  and  estimating  the 
number  of  mutants  that  arise  in  each  culture  replicate  by  selecting  for  resistance  to  the  anti- 
metabolite  6-TG  (Delbruck,  1943).  It  is  the  number  of  plates  with  zero  colonies  that  is 
used  to  determine  the  mutant  number,  thus  avoiding  the  complication  of  daughter  colonies 
in  mutant  frequency  determinations. 
Rat-1  MYCER  cells  were  plated  out  on  9cm  plates  at  a  density  of  1x  103  cells/plate  and 
left  in  a  10%  CO2  incubator  at  37°C  for  two  weeks  to  allow  growth  of  colonies.  Individual 
colonies  were  picked  from  these  plates  onto  6  well  plates.  These  single  colonies  were 
allowed  to  grow  up  and  expanded  up  into  T75  flasks.  Flasks  grown  from  one  single 
original  colony  were  split  into  two  halves,  one  half  grown  in  the  presence  and  one  half  in 
the  absence  of  4-hydroxy  tamoxifen  (4-OHT).  Cells  were  exposed  to  fresh  media  +/-  4- 
OHT  twice,  after  48hr  intervals. 161 
At  this  point  the  cells  were  collected  and  plated  out  onto  10cm  plates  at  a  density  of  2x  106 
cells  per  plate  in  media  containing  5  µg/ml  6-TG.  Based  on  preliminary  experiments  and 
on  other  studies  this  concentration  of  6-TG  was  deemed  appropriate  for  use.  Control  plates 
were  also  setup  from  these  flasks,  plating  out  1x  103  cells  per  plate  in  media  without  6- 
TG.  The  plates  were  incubated  again  in  a  10%  CO2  incubator  at  37°C  for  two-three  weeks. 
The  number  of  colonies  were  counted  on  the  control  plates  (taken  and  stained  after  2 
weeks)  for  calculation  of  the  plating  efficiency.  All  plates  grown  in  the  presence  of  6-TG 
were  carefully  examined  for  the  growth  of  resistant  clones.  Any  colonies  on  these  plates 
were  picked  as  before  into  6-well  plates  and  grown  up. 
From  this  experiment  the  mutation  rate  was  calculated.  To  measure  the  induced  mutation 
frequency  in  these  cultured  mammalian  cells  the  population  was  treated  with  the  proposed 
mutagen  as  described,  in  this  case  elevated  expression  of  c-MYC  induced  by  the  addition 
of  4-OHT.  The  clones  were  then  grown  in  selective  media  (media  +  6-TG)  to  estimate  the 
number  of  variants.  Survival  was  measured  by  growing  the  clones  in  non  selective  media 
(control  plates). 
Luria-Delbruck  fluctuation  analysis  was  used  to  estimate  the  spontaneous  mutation  rate  per 
viable  cell  in  cultured  cells  (Delbruck,  1943).  Because  this  is  a  non-Poisson  distribution  of 
data,  tests  based  upon  actual  values  for  the  number  of  mutants  per  clone  are  not  used. 
Instead  the  appropriate  analysis  utilised  rank  ordering  of  the  number  of  mutants  per  plate 
(replicate).  The  lowest  rank  was  given  to  the  replicate  with  the  highest  number  of  resistant 
colonies,  where  there  were  tied  ranks  a  mean  rank  was  given.  The  significance  of  the 
difference  between  the  two  groups,  replicates  from  cells  +/-  4-OHT  were  analysed  using  a 
t-test. 
The  mutation  rates  were  calculated  from  the  combined  results  of  four  individual 
experiments  carried  out  as  described.  Rat-1  MYCER  cells  grown  in  the  absence  of  4- 
OHT  will  be  described  first.  In  total  482  replicates  (plates)  were  available  for  the 
fluctuation  analysis,  originating  from  31  single  clones.  The  plating  efficiency  of  each  clone 
was  calculated  by  dividing  the  average  number  of  colonies  on  the  control  plates  for  each 
clone  by  the  number  of  cells  plated  (1  x103).  The  number  of  colonies  on  the  selective 
plates  (mutants)  were  multiplied  by  the  plating  efficiency  and  these  numbers  were  used  for 
the  fluctuation  analysis.  Of  the  482  replicates  218  had  mutant  colonies  growing,  264  had 162 
none.  The  mutation  rate  was  calculated  with  the  following  equation,  the  Po  method  of 
Luria  and  Delbruck  (Delbruck,  1943); 
m=  loge2(-logePQ) 
Nt 
m=  mutation  rate,  Nt  =  number  of  cells  plated, 
Po  =  number  of  replicates  with  no  mutants/total  number  of  replicates. 
For  the  Rat-1  MYCER  cells  grown  in  the  absence  of  4-OHT  the  calculation  is: 
m=  loge2  -loge264/482)  =  1.52  x  10"6  mutants  per  viable  cell 
2x  106 
There  were  310  replicates  from  Rat-1  MYCERTM  cells  grown  in  the  presence  of  4-OHT, 
therefore  with  increased  c-MYC  expression,  originating  from  29  individual  clones.  These 
were  used  for  the  mutation  rate  and  fluctuation  analysis  calculations.  Of  these  310 
replicates  171  had  mutant  colonies  growing  on  them,  139  had  none.  The  mutation  rate,  m, 
was  calculated  with  the  equation  shown  and  found  to  be  3.47  x  10"6  mutants  per  viable  cell. 
Cells  and  Treatment  Phenotype  Mutation  Rate  (m)  t-Test  on  the 
numbers 
mutants/viable  cell  from  the 
Fluctuation 
Analysis 
Rat-1  MYCER  no  elevated  c-MYC  1.52  x  10-6  p-value<0.001 
Rat-i  MYCER  +  4-OHT  elevated  c-MYC  3.47  x  10" 
A  t-test  was  carried  out  on  the  two  groups  of  rank  numbers  from  the  fluctuation  analysis 
and  a  p-value<0.001,  a  highly  significant  number  was  shown.  This  result  demonstrates  that 
the  difference  in  the  mutation  rates  between  cells  exposed  to  elevated  c-MYC  expression 
through  addition  of  4-OHT  tö  the  Rat-1  MYCERTM  cells  and  cells  grown  without  4-OHT 163 
i.  e.  no  elevated  c-MYC  expression  is  significant.  Therefore  elevated  c-MYC  expression 
results  in  a  mutator  phenotype  in  this  cell  system. 
A  control  experiment  was  carried  out  with  both  Rat-1  cells  (without  the  MYCERTM 
construct)  and  Rat-1  MYCERTM  cells  both  treated  as  described  above  and  the  mutation 
frequency  measured.  Mutation  frequencies  were  calculated  because  in  the  Rat-1  cells  no 
replicates  had  zero  colonies  and  therefore  fluctuation  analysis  was  impossible.  The 
mutation  frequencies  were  measured  as  follows: 
1x  average  no.  of  colonies  on  replicates  from  a  clone 
plating  efficiency/1000  x  (2  x  106) 
A  t-test  was  used  to  compare  the  mutations  frequencies  from  Rat-1  with  or  without 
tamoxifen  and  also  to  compare  the  mutation  frequencies  from  Rat-1  MYCER  with  or 
without  4-hydroxy  tamoxifen.  In  all,  mutation  frequencies  were  calculated  from  44 
replicates  from  10  original  clones  for  Rat-1  cells  and  from  50  replicates  from  8  original 
clones  for  Rat-1  cells  plus  4-OHT.  The  p-value  from  the  t-test  comparing  the  two  groups 
of  mutation  frequencies  was  found  to  be  0.34,  which  shows  that  the  mutation  frequencies 
between  the  two  groups  are  not  significantly  different.  For  the  Rat-1  MYCERTM  cells 
mutation  frequencies  were  calculated  from  89  replicates  from  10  original  clones  and  from 
78  replicates  from  10  original  clones  for  Rat-1  MYCERTM  cells  plus  4-OHT.  The  p-value 
from  this  t-test  comparing  the  two  groups  of  mutation  frequencies  was  found  to  be  0.001, 
which  shows  that  the  mutation  frequencies  between  these  two  groups  are  significantly 
different.  These  results  demonstrate  that  the  4-hydroxy  tamoxifen  (4-OHT)  does  not  have 
a  mutagenic  effect,  as  treating  Rat-1  cells  in  the  same  manner  with  4-OHT  does  not 
produce  a  mutator  phenotype  in  these  cells. 
To  associate  this  discovery  of  a  c-MYC  induced  mutator  phenotype  specifically  to  a  defect 
in  MMR  (for  example  elevated  c-MYC  expression  having  an  inhibitory  effect  on  MMR), 
genomic  DNA  was  prepared  from  resistant  clones  that  were  isolated  and  grown  up  from 
these  experiments.  A  specific  frameshift  hotspot  at  a  run  of  six  guanine  residues  in  exon  3 
of  the  HPRT  gene,  was  previously  shown  to  account  for  a  high  proportion  of  HPRT 
mutations  in  an  MMR  deficient  cell  line  background  (Bhattacharyya  et  al.,  1994).  PCR 
across  a  160bp  fragment  of  exon  3  of  the  HPRT  gene  was  carried  out  using  specifically 
designed  oligonucleotide  primers  (HPRT-F  and  HPRT-R).  These  PCR  products  were 
sequenced  and  examined  for  frameshift  mutations  at  a  run  of  six  G  residues  at  position  206 164 
bp  of  the  HPRT  gene.  DNA  from  22  mutant  clones  from  Rat-1  MYCERTM  cells  grown  in 
the  absence  of  4-OHT  and  DNA  from  25  Rat-1  MYCERTM  mutant  clones  from  cells  grown 
in  the  presence  of  4-OHT  was  examined  by  this  method.  None  of  the  21  mutant  clones 
from  Rat-1  MYCERTM  cells  grown  without  4-OHT  had  any  frameshift  mutations  at  this 
run  of  guanines.  However  4  out  of  the  25  mutants  clones  from  Rat-1  MYCERTM  cells 
grown  in  the  presence  of  4-OHT  each  had  a  frameshift  mutation,  5  instead  of  6  guanines  at 
this  position  in  the  HPRT  gene.  The  significance  of  these  4  mutant  clones  from  Rat-1 
MYCERTM  cells  grown  in  the  presence  of  4-OHT  with  a  frameshift  mutation  at  this  run  of 
six  guanines  was  tested  using  Fisher's  Exact  Test.  From  this  a  p-value  of,  p=0.071,  was 
obtained.  A  p-value  of  p=0.05  and  below  is  taken  as  significant.  Therefore  this  small 
number  of  frameshift  mutants  observed  is  not  significant. 
The  large  numbers  of  replicates  used  for  these  experiments  and  the  relatively  lengthy 
incubation  time  led  to  a  number  of  problems  with  these  experiments.  In  particular  a  large 
proportion  of  replicates  were  lost  in  each  experimental  set  due  to  contamination.  Picking 
the  mutant  colonies  and  growing  them  up  from  six  well  plates  into  flasks  also  proved 
difficult.  However  from  the  replicates  which  survived,  it  is  shown  that  elevated  expression 
of  c-MYC  in  this  cell  system  clearly  leads  to  a  mutator  phenotype.  From  the  47  mutants 
grown  up,  genomic  DNA  was  isolated  and  a  previously  identified  mutation  hotspot  in  the 
HPRT  gene  in  MMR  deficient  cell  lines  was  examined  for  mutations  in  a  run  of  6  guanine 
residues.  In  DNA  from  22  mutant  clones  from  Rat-1  MYCERTM  cells  grown  in  the 
absence  of  4-OHT  no  frameshifts  at  this  mutation  hotspot  were  observed.  In  DNA  from 
mutant  clones  from  Rat-1  MYCERm  cells  grown  in  the  presence  of  4-OHT,  i.  e.  with 
elevated  c-MYC  expression,  4  out  of  the  25  mutants  had  frameshift  mutations  at  this 
mutation  hotspot.  Although  this  number  of  frameshift  mutants  in  the  Rat-1  MYCERTM 
cells  grown  in  the  presence  of  4-OHT  is  not  significant,  it  does  strongly  suggest  a  possible 
link  between  elevated  c-MYC  expression  and  loss  of  functional  MMR.  Because  of  the 
small  numbers  of  mutants  examined,  due  to  the  problems  described,  the  power  of  analysis 
from  these  experiments  is  quite  low.  However  these  encouraging  results  would  suggest 
further  study  of  such  mutants  may  prove  fruitful. 165 
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4.1  Introduction 
The  exact  function  of  hMLH1  in  MMR  is  not  fully  understood,  although  it  has  been  shown 
to  be  essential  for  in  vitro  MMR  activity.  Loss  of  hMLH1  expression  is  seen  in  a  number 
of  tumour  cell  lines  resistant  to  cytotoxic  drugs  such  as  cisplatin,  and  restoration  of  MMR 
leads  to  restoration  of  drug  sensitivity  (Brown  et  al.,  1997).  This  has  led  to  the  hypothesis 
that  MMR  is  involved  in  coupling  DNA  damage  to  an  apoptotic  response.  Signalling  to  a 
number  of  downstream  cellular  response  pathways  (c-Abl,  p53  and  p73)  in  response  to 
DNA  damage  has  been  shown  to  be  lost  in.  MMR  deficient  cells  (Duckett  et  al.,  1999; 
Gong  et  al.,  1999;  Nehme  et  al.,  1997).  Exactly  how  MMR  couples  to  these  apoptotic 
pathways  is  unclear.  The  aim  of  this  study  was  to  identify  proteins,  using  the  yeast  two- 
hybrid  system,  that  interact  with  hMLH1,  to  attempt  to  further  elucidate  it's  role  in  MMR 
and  the  engagement  of  downstream  damage  response  pathways. 
The  yeast  two-hybrid  system  is  an  in  vivo  system  used  to  identify  protein-protein 
interactions  (Fields  and  Song,  1989).  The  protein  of  interest  is  expressed  as  a  hybrid 
protein  and  can  be  tested  directly  for  an  interaction  with  other  candidate  hybrid  proteins. 
Alternatively  the  hybrid  protein  can  be  used  to  screen  a  high  complexity  yeast  two-hybrid 
cDNA  library,  to  identify  a  gene  encoding  a  novel  protein  that  interacts  with  it.  Using  a 
library  screen  large  numbers  of  interacting  proteins  can  be  identified.  The  advantages  of 
this  system  include  the  fact  that  the  identification  of  interacting  proteins  is  relatively  simple 
as  plasmid  DNA  can  be  isolated  from  positive  interacting  clones  and  the  inserts  sequenced. 
Therefore  purified  proteins  or  antibodies  to  the  protein  of  interest  are  not  required.  The 
interacting  domains  of  the  individual  proteins  can  also  be  identified  within  this  system 
through  site  directed  mutagenesis  or  deletion  analysis. 167 
4.2  The  Yeast  Two-Hybrid  System:  hMLH1-hPMS2 
Interaction 
The  aim  of  this  thesis  was  to  identify  novel  proteins  capable  of  interacting  with  the  human 
MMR  protein,  MLH1.  Therefore  making  a  yeast  two-hybrid  construct  expressing  a 
functional  hMLH1  hybrid  protein  was  required.  The  yeast  two  hybrid  system  is  an  in  vivo 
system  for  detecting  protein-protein  interactions.  Proteins  of  interest  are  expressed  as 
hybrid  proteins  with  the  DNA  binding  domain  and  activation  domain  of  a  transcription 
factor,  in  this  study  GAL4,  and  tested  for  an  interaction  within  yeast.  Interactions  between 
two-hybrid  proteins  results  in  reconstitution  of  the  transcription  factor  which  activates  the 
expression  of  a  reporter  gene  (LACZ  in  this  study)  which  is  under  the  transcriptional 
control  of  the  particular  transcription  factor  being  utilised  by  the  system. 
hMLH1  protein  has  been  shown  to  co-purify  with  hPMS2  as  a  heterodimer  (Umar  et  al., 
1996).  The  yeast  two-hybrid  system  was  also  used  to  identify  an  interaction  between 
yMlhip  and  yPmslp  (hPMS2  homologue)  (Prolla  et  al.,  1994).  Therefore  it  was  believed 
that  a  yeast  two-hybrid  interaction  between  hMLH1  and  hPMS2  would  be  detectable, 
providing  a  positive  control  for  using  the  hMLH1  hybrid  protein  for  further  studies. 
Constructs  expressing  full  length  and  overlapping  fragments  of  hMLH1  and  hPMS2  hybrid 
proteins  were  made  for  use  in  this  system.  This  study  would  also  allow  mapping  of  the 
domains  involved  in  the  hMLH1-hPMS2  interaction. 
hMLH1  and  hPMS2  clearly  interacted  in  the  yeast  two-hybrid  system.  In  particular, 
hMLH1  full  length  (amino  acids  1-756)  and  fragment  4  (amino  acids  514-756)  hybrid 
proteins  both  interacted  with  hPMS2  fragment  3  (F3,  amino  acids  430-647)  and  4  (F4, 
amino  acids  630-862)  hybrid  proteins  in  the  yeast  two-hybrid  system.  These  observations 
are  in  agreement  with  earlier  studies  with  the  yeast  homologues  of  these  proteins  which 
implicate  the  C-termini  of  the  proteins  in  this  interaction  (Pang  et  al.,  1997).  The  C- 
termini  of  the  yeast  proteins  are  highly  homologous  to  the  human  proteins  (see  Figure  19 
and  20).  yMlhlp  amino  acids  501-769  and  full  length  hybrid  protein  were  shown  in  the 
yeast  two-hybrid  system  to  interact  with  C-terminal  fragments  of  yPmslp. 
A  second  study  was  reported  during  the  present  study,  examining  the  interactions  of 
hMLH1  and  hPMS2,  using  GST-fusion  protein  binding  assays  (Guerrette  et  al.,  1999).  In 
the  yeast  two-hybrid  studies  described  in  this  thesis  hMLH1-F4  (F4,  amino  acids-514-756) 
and  full  length  hMLH1  could  interact  with  hPMS2-F3  (F3,  amino  acids  430-647)  and 168 
ymlhl  469  QPKKKQKLGDYKVPSIADDEKNALPISKD(;  YI  VPKERVNVNL'I':;  IP;  P:  I,  I'f:  F;  )D:;  IIIRI"; 
hmlhl  468  NPRKRHR.  EDSDVEMVEDDSRKEMTAA.....  'TPRRRI.  INI.  'I':;  VI.:;  I,,  I;  h;  I  JEQ(HEV 
ymlhl  529  LTDIFANLNYVGWDEERRLAAIQHDLKLFLIDYGSVCYELFYQLGLTUF'ANE'LKINC,  ý,  ):; 
hmlhl  521  LREMLHNHSFVGCVNPQWALA..  QHQTKLYLLNTTKLSEELFYQILIYDFANFGVLRLSE 
ymlhl  589  TNVSDDIVLYNLLS.  EFDELNDDASKEKIISKIWDM....  SSMLNEYYSIELVNDGLDND 
hmlhl  579  PAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLADYFSLEIDEE(.... 
ymlhl  644  LKSVKLKSLPLLLKGYIPSLVKLPFFIYRLGKEVDWEDEQECLDGILREIALLYIPDMVP 
hmlhl  635 
.... 
NLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAMFY..  SIRK 
ymlhl  704  KVDTSDASLSEDEKAQFINRKEHISSLLEHVLFPCIKRRFLAPRHILKD..  VVEIANLPD 
hmlhl  689  QYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNILQLANLPD 
ymlhl  762  LYKVFER 
hmlhl  749  LYKVFER 
Figure  19:  Alignment  of  the  C-terminal  End  of  yMlh  1p  (ymlh  1)  and  hMI.  H  I  (hmlh  1) 
Proteins. 
The  C-termini  of  both  proteins  are  highly  homologous.  The  C-terminal  fragment  of 
yMlh  lp  which  interacts  with  yPms  1p  is  enclosed  by  [..  I.  The  C-terminal  tiragnment  of' 
hMLH  I  which  interacts  with  hMLHI  is  enclosed  by  [..  ).  The  C-terminal  fragments  of' 
both  proteins  identified  in  this  protein-protein  interaction  include  the  sane  regions  in  both 
proteins  which  are  highly  homologous  to  each  other. 169 
hpms2  390  ADL.  EKPMVEKQDQSPSLRTGEEKKDVSISRLREAFSLRHT  ENKPHSPKTPEPRR: 
_; 
PLk; 
ypmsl  412  TEVFDDRSTTHESDNENYHTARSESNQS  ... 
NHAHFNSTTG  IDKSNGTELTSVMDGNYT 
hpms2  449  QKRGMLSSSTSGAISDKGVLRSQKEAVSSSHGPSDPTDRAEVEKDSGHGSTSVDSEGFSI 
ypmsl  469  NVTDVIGSECEVSVDSSVVLDEGNSSTPTKKLPSIKTDSQNLSDLNLNNFSNPEFQNIT'; 
4 
hpms2  509  PDTGSHCSSEYAASSP......  GDRGSQEHVDSQ.........  EKAPETDDSF.....  SD 
ypmsl  529  PDKAR..  SLEKVVEEPVYFDIDGEKFQEKAVLSQADGLVFVDNECHEHTNDCCHQERRGS 
hpms2  549  VDCHSNQEDTGCKFRVLPQPTNLATP...  NTKRFKKEEILSSSD.  ICQKLVNTQDMSASQ 
ypmsl  587  TDTEQDDEADSIYAEIEPVEINVRTPLKNSRKSISKDNYRSLSDG,  LTHRKFEDEIL...  E 
hpms2  605  VDVAVKIN  VVPLDFSMSSLAKR  KQLHHEAQQSEGEQNYRKFRAKICPGENQAAFDET 
ypmsl  644  YNLSTKNF  ISKNGKQMSSIISK 
....... 
RKSEAQENIIKNKDEL..  EDFEQGIKYY1, 
hpms2  665  RKEISKTMFAEMEIIGQFNLGFIIT..  KLNE..  DIFIVDQHATDEKYNFEMLQQHTVLQG 
ypmsl  694  TLTVSKNDFKKMEVVGQFNLGFIIVTRKVDNKYDLFIVDQEiASDEKYNFETLQAVTVFKS 
t 
735 
hpms2  721  QRLIAPQTLNLTAVNEAVLIENLEIFRKNGFDFVIDENAPVTERAKLISLPTSKNWTFGP 
ypmsl  754  QKLIIPQPVELSVIDELVVLDNLPVFEKNGFKLKIDEEEEFGSRVKLLSLPTSKQTLFDL 
hpms2  781  QDVDELIFMLSDSPGVM 
... 
CRPSRVKQMFASRACRKSVMIGTALNTSEMKKLITHMGEM 
ypmsl  814  GDFNELIHLIKEDGGLRRDNIRCSKIRSMFAMRACRSSIMI(3KPLNKKTMTRVVHNLSEL 
hpms2  838  DHPWNCPHGRPTMRHIANLGVISQ 
ypms1  874  DKPWNCPHGRPTMRHLMELRDWSS  KDYEI 
Figure  20:  Alignment  of  the  C-terminal  End  of  yPmslp  (ypmsl)  and  hPNIS2  (hpms2) 
Proteins. 
Again  the  C-termini  of  both  proteins  are  highly  homologous.  The  two  regions  of  hPMS2 
identified  from  the  yeast  two-hybrid  interaction  studies  with  hMLH  I  are  amino  acids  430- 
613  [..  ]  and  hPMS2-F4,  amino  acids  630-862  [..  ].  The  C-terminal  half  of  the  first 
fragment,  amino  acids  430-613  and  hPMS2-F4  are  highly  homologous  to  the  yeast 
protein,  yPms  I  p.  narks  the  region  of  hPMS2  between  amino  acids  547  and 
613.  Also  marked  on  the  alignment  is  amino  acids  692  and  735  which  Hawk  .i  region  of 
yPms  lp  which  has  been  shown  to  be  required  for  the  interaction  with  yMIh  I  p. 170 
hPMS2-F4  (F4,  amino  acids  630-862).  This  observation  is  supported  by  the  GST-fusion 
protein  assays  carried  out  with  hMLH1  and  hPMS2,  which  identified  an  interaction 
between  hMLH1  amino  acids  506-756  and  full  length  hPMS2,  and  also  between  full  length 
hMLH1  and  hPMS2  amino  acids  675-862  (Guerrette  et  al.,  1999). 
Because  of  the  overlapping  nature  of  F3  (amino  acids  430-647)  and  F4  (amino  acids  630- 
862)  of  hPMS2,  found  to  interact  with  hMLH1,  deletion  constructs  of  hPMS2  F3  were 
made  expressing  hybrid  proteins  with  gradual  deletions  from  the  C-terminus  of  hPMS2-F3. 
From  this  study  it  was  shown  that  loss  of  a  specific  domain  on  hPMS2  that  lies  between 
amino  acids  547  and  613,  led  to  loss  of  the  interaction  with  hMLH1.  This  was  shown  by 
the  observation  that  hPMS2-F3-102  (amino  acids  430-613)  interacts  with  hMLH1  but 
hPMS2-F3-300  (amino  acids  430-547)  does  not.  The  overall  charge  of  this  fragment  of 
hPMS2  is  also  not  dramatically  effected  through  these  deletions.  Loss  of  this  66  amino 
acid  domain  (amino  acids  547-613),  may  result  in  either  loss  of  an  essential  hMLH1 
interaction  domain  or  affect  the  conformation  of  this  hPMS2  fragment,  resulting  in  loss  of 
the  interaction  with  hMLH1. 
GCG  was  used  to  search  for  conserved  motifs  in  the  hMLH1  and  hPMS2  sequences,  in 
particular  the  motifs  command  was  used,  which  looks  for  sequence  motifs  by  searching 
through  the  protein  sequence  for  patterns  defined  in  the  PROSITE  dictionary  of  protein 
sites  and  patterns.  A  number  of  websites  which  allow  searches  of  protein  sequences  for 
known  motifs  such  as,  http:  //www.  bioweb.  pastuer.  fr/seqanal/interfaces/pscan.  html,  were 
also  utilised  to  examine  the  sequences  of  hMLH1  and  hPMS2  for  conserved  motifs.  In 
particular  the  interaction  domains  on  these  two  proteins  were  examined.  However  no 
conserved  motifs  were  identified  through  these  searches,  other  than  the  conserved  N- 
terminal  GFREAL,  ATP-binding  domain. 
GST-fusion  protein  studies  with  GST-hMLH1  and  GST-hPMS2,  full  length  and  fragments, 
identified  two  hPMS2  regions  capable  of  interacting  with  hMLH1,  amino  acids  602-862 
and  amino  acids  675-862  (Guerrette  et  al.,  1999).  These  observations  correlate  with  the 
yeast  two-hybrid  results  demonstrating  an  interaction  between  hMLH1  and  hPMS2-F3  (F3, 
amino  acids  430-647)  and  hPMS2-F4  (F4,  amino  acids  630-862).  Also  observations  of 
interactions  between  yMlhlp  and  yPmslp  using  the  yeast  two-hybrid  system  identified  an 
interaction  between  yMlhlp  and  yPmslp,  amino  acids  524-904,  and  amino  acids  692-904 
but  not  with  yPmslp  amino  acids  735-904  (Pang  et  al.,  1997).  The  loss  of  a  highly 
conserved  region  (between  yPmslp  and  hPMS2)  of  yPmslp,  between  amino  acids  692  and 171 
735  apparently  effects  the  ability  of  the  two  proteins  to  interact  (see  Figure  20).  However, 
these  studies  do  not  rule  out  the  possibility  that  a  second  domain  on  hPMS2  exists  that 
facilitates  an  interaction  with  hMLH1.  Therefore  the  observation  of  an  interaction  between 
hMLH1  and  two  separate  regions  of  hPMS2,  amino  acids  430-613  and  amino  acids  630- 
862  could  outline  two  separate  domains  involved  in  this  protein-protein  interaction. 
No  interaction  was  seen  between  hMLH1  full  length  or  F4  with  full  length  hPMS2. 
Although  the  entire  sequence  of  the  hPMS2  construct  was  not  sequenced  the  protein  is 
expressed  in  frame  and  restriction  enzyme  digests  would  suggest  the  sequence  is  correct. 
The  expression  of  the  full  length  hPMS2  protein  as  a  hybrid  protein  may  effect  its  ability  to 
interact  with  hMLH1.  A  low  level  of  interaction  between  full  length  yMlhlp  and  yPmslp 
was  observed  as  measured  by  ß-galactosidase  activity  in  a  quantitative  assay  compared  to 
the  strong  interaction  of  yMlhlp  with  a  C-terminal  fragment  of  yPmslp  (Pang  et  al.,  1997). 
The  interaction  between  the  two  full  length  proteins  in  these  studies,  is  undetectable  with 
the  full  length  human  proteins,  or  in  the  case  of  the  yeast  study  which  used  a  quantitative 
measurement  of  transcriptional  activation,  is  very  low.  Therefore  in  both  studies 
expressing  full  length  hPMS2  or  yPmslp'  as  hybrid  proteins  may  effect  the  native 
conformation  of  these  proteins  resulting  in  loss  of  an  interaction  with  hMLH1  or  yMlhlp 
respectively. 
Overall  this  yeast  two-hybrid  study  clearly  identified  an  interaction  between  hMLH1  and 
hPMS2.  It  was  shown  that  hMLH1-F4  (F4,  amino  acids  514-756)  and  full  length  hMLH1 
could  interact  with  hPMS2-F3  (F3,  amino  acids  430-647)  and  hPMS2-F4  (F4,  amino  acids 
630-862).  Deletion  analysis  demonstrated  two  separate  regions  of  hPMS2,  amino  acids 
430-613  and  amino  acids  630-862  which  can  interact  with  both  full  length  hMLH1  and 
hMLH1-F4  (F4,  amino  acids  514-756).  Loss  of  a  specific  domain  on  hPMS2  that  lies 
between  amino  acids  547  and  613,  led  to  loss  of  the  interaction  with  hMLH1.  This  was 
shown  by  the  observation  that  hPMS2-F3-102  (amino  acids  430-613)  interacts  with 
hMLH1  but  hPMS2-F3-300  (amino  acids  430-547)  does  not. 172 
4.3  Yeast  Two-Hybrid  cDNA  Library  Screening  with  a 
hMLH1  Hybrid  Protein. 
The  pGBT9-hMLH1  construct  had  been  shown  to  produce  a  hybrid  hMLH1  protein  with 
the  GAI4  binding  domain  that  did  not  activate  LACZ  transcription  autonomously  or  when 
expressed  with  other  unrelated  hybrid  proteins  (AD  hybrid  proteins).  hMLH1  protein  was 
also  detected  by  western  blot  in  extracts  made  from  yeast  cells  transformed  with  this 
construct.  The  interaction  studies  with  hPMS2  hybrid  proteins  demonstrates  that  this  full 
length  hMLH1  hybrid  protein  can  interact  with  a  known  binding  partner,  hPMS2,  in  this 
system.  Therefore  this  hMLH1  hybrid  protein  is  clearly  functional  for  binding  activity.  The 
pGBT9-hMLH1  construct  used  in  the  interaction  studies  with  hPMS2  hybrid  proteins  was 
therefore  deemed  suitable  for  use  in  further  yeast  two-hybrid  studies. 
This  functional  hMLH1  hybrid  protein  was  used  to  screen  a  MATCHMAKERTM  human 
normal  mammary  gland  yeast  two  hybrid  cDNA  library  (Clontech,  UK).  1x  105  colonies 
were  screened  in  this  screen  and  a  total  of  15  novel  clones  were  identified  as  interacting 
with  hMLH1.  Five  of  the  fifteen  clones  identified  are  unknown,  i.  e.  encode  sequences  that 
have  not  yet  been  assigned  a  function.  From  this  screen  the  interaction  of  hMLH1  with  c- 
MYC  was  particularly  interesting.  Identification  of  proteins  interacting  with  hMLH1  that 
have  known  roles  in  signal  transduction  pathways  was  the  main  aim  of  this  study.  c-MYC 
is  known  to  be  involved  in  a  number  of  pathways  including  signalling  to  apoptotic  cell 
death  pathways.  This  interaction  will  be  discussed  later.  However  a  number  of  other 
proteins  shown  to  interact  with  hMLH1  in  the  yeast  two-hybrid  system  are  also  potentially 
important  (see  Table  16). 
This  screen  was  relatively  small  and  would  not  be  fully  representative  of  the  range  of 
possible  interactions  that  hMLH1  may  be  involved  in.  Therefore  a  second  construct  was 
made,  pGBKT7-hMLH1.  This  construct  expressed  a  hMLH1  hybrid  protein  which  could 
also  interact  with  hPMS2-F3  and  hPMS2-F4  and  the  c-MYC  construct  pulled  out  from  the 
first  cDNA  library  screen.  This  hybrid  protein  did  not  autonomously  activate  LACZ 
expression  in  the  yeast  two-hybrid  system.  It  was  therefore  also  deemed  suitable  for  use  in 
a  second  yeast  two-hybrid  cDNA  library  screen,  this  time  using  a  pre-transformed 
MATCHMAKERTh  normal  ovary  cDNA  library.  This  second  system  from  Clontech, 
MATCHMAKERTM  3,  is  a  more  advanced  system,  with  much  fewer  false  positives  coming 
through  the  screen  and  also  easier  isolation  of  the  library  constructs  and  hence 
identification  of  the  interacting  proteins.  From  this  screen  an  estimated  5.3  x  106  clones 173 
Table  16:  Summary  of  Proteins  Identified  as  Interacting  with  hMLH1  with  the  Yeast 
Two-Hybrid  Screens. 
hMLH1  Function  Comment 
Interacting  Protein 
PMS1,  MLH3,  PMS1  and  MLH3  are  human  Previously  identified  interacting 
MED1  MutL  homologues  which  may  proteins. 
play  a  role  in  MMR. 
MED1  is  a  mismatch  specific  T/U 
DNA  glycosylase. 
c-Myc  c-MYC  protein  has  a  number  of  Potential  role  in  signalling 
functions  including  regulation  of  pathways  involving  hMLII1. 
cellular  proliferation  and 
apoptosis 
Polypeptide  chain  Elongation  factor  with  a  role  in  Predicted  to  have  a  role  in 
elongation  factor  1-  protein  synthesis,  also  plays  a  role  apoptosis,  may  also  be  involved 
alpha  in  cytoskeletal  organisation  in  signalling  pathways  involving 
hMLH1. 
Ribosomal  protein  Ribosomal  protein.  Possible  false  positive. 
L26 
U4/U6  small  nuclear  snRNP,  splicing  factor.  Possible  false  positive. 
ribonucleoprotein 
(hPrp3) 
-Fr-o-te-in--pho  ssphatase  A  methylesterase,  demethylates  Possible  false  positive,  as 
methylesterase  1  protein  phosphatase  2A.  identified  in  another  screen  with 
(PME1)  a  completely  unrelated  protein. 
Endothelial  PAS  Homologue  of  HIF-la,  both  Interaction  with  hMLH1  may 
domain  protein  1  hypoxia  inducible.  Also  can  block  transcriptional  activation 
(EPAS1)  activate  expression  of  VEGF.  properties  of  this  protein  under 
some  conditions. 
Alpha-L  iduronidase  A  lysosomal  hydrolase,  a  - 
gene  deficiency  in  which  results  in  the 
lysosomal  storage  disorder 
mucopolysaccharidosis  type  I 174 
Dc3  Function  not  known. 
RIGUI  putative  Function  not  known,  possible  role 
mammalian  ortholog  in  circadian  rhythm  regulation. 
of  PER 
Uncoupling  protein  Function  unknown,  may  act  in 
2  (UCP2)  similar  way  to  its  murine 
homologue  which  acts  as  an 
uncoupler  of  oxidative 
phosphorylation. 
FHL2  A  LIM  domain  protein 
preferentially  expressed  in  human 
heart. 
ELPIN  Cytoskeletal  protein  preferentially 
expressed  in  human  epithelial 
cells.  Expression  of  this  protein 
has  been  shown  to  be  lost  in  a 
number  of  cancer  cell  lines  (Maul 
and  Chang,  1999). 
KIAA09134,  Unknown  functions. 
KIAA0167,  mRNA 
from  chromosome 
5q  21-22,  mRNA 
full  length  insert 
cDNA  clone,  cDNA 
DKFZp434E2321 175 
were  screened.  Ten  different  clones  were  identified  from  this  screen  as  interacting  with 
hMLH1  which  included  three  known  binding  partners  of  hMLH1.  These  were  hML113, 
hPMS1  and  MED1. 
Although  the  c-MYC-hMLH1  interaction  is  the  only  interaction  that  has  been  examined 
further,  a  number  of  other  protein-protein  interactions  were  discovered  from  these  screens 
(see  Table  16).  These  protein-hMLH1  interactions  would  have  to  be  verified  with 
additional  assays  such  as  co-immunoprecipitation  assays,  as  shown  for  the  c-MYC-hMLH1 
interaction,  before  concluding  that  they  are  real.  However  the  initial  observations  from 
these  yeast  two-hybrid  cDNA  library  screens  are  indicative  of  the  capacity  of  these  proteins 
to  interact  with  hMLH1.  Some  of  the  proteins  pulled  out  from  these  screens  such  as  the 
ribosomal  protein  L26  and  the  ribonucleoprotein  hPrp3  could  be  false  positives  even 
though  they  do  not  fill  the  criteria  for  false  positives  in  this  system.  These  types  of  proteins 
have  been  reported  as  common  false  positives  in  this  system.  This  web  page  from  the 
Golemis  lab,  which  has  utilised  the  yeast  two-hybrid  screening  system  on  numerous 
occasions,  lists  a  range  of  proteins  commonly  found  as  false  positives  in  the  yeast  two- 
hybrid  system:  http:  //www.  fccc.  edu/research/labs/golemis/Tablel.  html. 
A  few  of  the  proteins  described  have  been  relatively  well  characterised  functionally.  These 
include  elongation  factor  1  alpha  and  EPAS1.  Elongation  factor  1  alpha  (EF-1  alpha)  was 
shown  to  interact  with  hMLH1  in  both  yeast  two-hybrid  library  screens.  EF-1  alpha  is  an 
enzyme  that  catalyses  the  GTP-dependent  binding  of  aminoacyl-tRNA  to  acceptor  sites  of 
ribosomes  during  protein  synthesis.  This  protein  has  also  more  recently  been  discovered  to 
play  a  role  in  cytoskeletal  organisation.  In  particular  EF-1  alpha  functions  in  microtublule 
severing  (Shiina  et  al.,  1994).  Translation  of  the  protein  is  also  selectively  activated  upon 
mitogenic  stimulation  demonstrating 
,  regulation  of  protein  expression  (Jefferies  and 
Thomas,  1994).  The  observation  that  EF-1  alpha  plays  a  key  role  in  both  protein  synthesis 
and  cytoskeletal  organisation,  led  to  further  studies  as  to  whether  EF-1  alpha  expression 
levels  could  affect  apoptosis  levels.  Apoptosis  was  induced  in  cells  by  serum  deprivation. 
Addition  of  antisense  EF-1  alpha  to  these  cells  led  to  a  significant  protection  from 
apoptotic  cell  death  (Duttaroy  et  al.,  1998).  In  addition  overexpression  of  EF-1  alpha 
increased  the  rate  of  cell  death:  These  observations  suggest  that  EF-1  alpha  levels  could  be 
a  global  regulator  modulating  the  rate  of  apoptosis.  Increased  expression  of  EF-1  alpha 
leads  to  an  increased  protein  synthesis  rate,  which  would  include  specific  pro-apoptotic 
proteins  and  also  could  play  a  role  in  the  cytoskeletal  changes  associated  with  apoptosis. 
Support  for  this  model  came  from  a  study  which  demonstrated  up-regulation  of  EF-1  alpha 176 
by  p53  in  murine  cells  (Kato,  1999).  p53  is  known  to  play  a  role  in  a  number  of  apoptotic 
pathways.  These  studies  suggesting  a  role  for  EF-1  alpha  in  regulating  apoptosis  are 
particularly  interesting  in  light  of  the  hMLH1-EF-1  alpha  interaction  seen  in  the  yeast  two- 
hybrid  system.  hMLH1  has  been  implicated  in  mediating  sensitivity  to  a  range  of  anti- 
cancer  agents  such  as  cisplatin  (Aebi  et  al.,  1996;  Anthoney  et  al.,  1996).  Loss  of  hMLII1 
in  cells  is  associated  with  the  emergence  of  resistance  to  treatment  with  such  drugs, 
suggesting  hMLH1  somehow  signals  apoptosis  in  response  to  treatment.  This  interaction 
therefore  could  possibly  represent  one  mechanism  through  which  hMLH1  exerts  this  effect. 
hMLH1  was  also  demonstrated  to  interact  with  EPAS1  and  RIGUI  in  the  yeast  two-hybrid 
system.  Endothelial  PAS-1  (EPAS1)  protein  is  a  basic  helix-loop-helix  and  PAS  domain 
transcription  factor.  This  protein  shares  48%  sequence  identity  with  hypoxia  inducible 
factor  (HIF-la)  (Tian  et  al.,  1997).  EPAS1  can  also,  like  HIF-1a,  activate  transcription  of 
VEGF  through  the  HIF-1a  binding  site  (Maemura  et  al.,  1999).  Activation  of  both  proteins 
is  stimulated  by  hypoxic  conditions.  The  acronym  PAS  derives  from  the  first  three 
members  of  the  family:  the  period  gene  (PER),  the  arylhydrocarbon  receptor  nuclear 
translocator  (ARNT)  gene  and  the  single  minded  gene.  RIGUI  is  a  putative  mammalian 
orthologue  of  the  Drosophila  PER  gene  (Sun  et  al.,  1997).  This  protein  also  has  a  basic 
helix-loop-helix  and  a  PAS  domain.  However,  in  both  cases,  the  C-terminal  region  of  the 
two  proteins  involved  in  the  interaction  with  hMLH1  does  not  include  these  domains. 
EPAS1  has  a  C-terminal  transactivation  domain,  which  does  not  seem  to  effect  its  use  in 
the  yeast  two-hybrid  system  as  the  construct  expressing  this  protein  did  not  autonomously 
activate  LACZ  expression  alone  or  when  co-transformed  into  yeast  with  a  lamin  expressing 
construct.  Within  this  domain  a  number  of  di-leucine  repeats  have  been  identified,  and 
such  repeats  are  important  for  the  interaction  of  co-activators  such  as  p300  with 
transcription  factors  (O'Rourke  et  al.,  1999).  p300  has  been  shown  to  bind  this  domain  in 
HIF-1.  The  identification  of  the  hMLH1  interaction  with  the  C-terminal  leucine  zipper 
domain  of  c-MYC  would  suggest  that  perhaps  hMLH1  could  also  interact  with  EPAS1 
through  this  leucine  rich  region  and  perhaps  block  binding  of  p300  and  effect  the 
transactivation  function  of  this  protein. 
The  observed  interactions  between  hMLH1  and  three  known  binding  partners  hPMS1, 
hMLH3  and  MED1  act  as  excellent  internal  controls  for  the  binding  function  of  the  hybrid 
hMLH1  protein  (Bellacosa  et  al.,  1999;  Leung  et  al.,  2000;  Lipkin  et  al.,  2000;  Raschle  et 
al.,  1999).  The  constructs  isolated  expressing  hMLH3  and  hPMS1  contain  the  C-terminal 
regions  of  these  proteins  previously  shown  to  be  required  for  this  interaction  with  hMLH1. 177 
Overall  a  range  of  proteins  have  been  identified  as  interacting  with  hMLH1  in  the  yeast 
two-hybrid  system.  These  include  known  binding  partners  as  well  as  novel  interacting 
proteins.  The  identification  of  proteins  that  could  play  a  role  in  signalling  from  DNA 
damage  ,  via  hMLH1,  to  downstream  cellular  response  pathways  was  the  main  aim  of  this 
project.  Therefore  the  identification  of  an  interaction  with  c-MYC,  a  protein  known  to 
have  a  number  of  functions  including  signalling  apoptosis,  was  intriguing.  However  some 
of  the  other  interactions  identified  were  also  particularly  interesting.  One  protein,  EF-1 
alpha  was  identified  in  both  screens.  In  the  second  yeast  two-hybrid  screen  numerous 
clones  were  also  identified  as  interacting  with  hMLH1.  Therefore  this  EF-1  alpha-hMLH1 
interaction  represents  another  potentially  interesting  study.  The  recent  identification  of  a 
link  between  EF-1  alpha  expression  and  apoptosis  also  signals  the  possible  role  of  this 
interaction  in  damage  response  pathways. 178 
4.4  c-MYC  Interacts  with  hMLH1 
From  the  first  yeast  two-hybrid  cDNA  library  screen  an  interaction  between  hMLH1  and  c- 
MYC  was  clearly  demonstrated.  c-MYC  is  a  protein  with  diverse  roles,  a  putative 
transcription  factor  which  plays  a  role  in  cell  growth  control,  regulation  of  the  cell  cycle, 
differentiation,  and  apoptosis.  The  aim  of  the  screen  was  to  identify  possible  pathways 
through  which  MMR  via  hMLH1,  signals  downstream  cellular  responses  after  DNA 
damage  occurs.  The  identification  of  a  hMLH1-c-MYC  interaction  could  represent  a 
specific  route  through  which  hMLH1  signals  from  DNA  damage  to  various  response 
pathways,  such  as  cell  death,  in  response  to  treatment  with  DNA-damaging  agents.  The 
hMLH1-c-MYC  interaction  observed  was  an  exciting  observation  but  needed  to  be 
confirmed  through  additional  independent  methods. 
The  pACT2  (GAL4  AD  plasmid)  library  construct  expressing  c-MYC  encodes  the  C- 
terminal  half  of  the  protein.  c-MYC  consists  of  439  amino  acids,  amino  acids  245-stop 
codon  are  expressed  from  this  pACT2  library  plasmid.  This  C-terminal  half  of  the  protein 
encodes  the  basic  helix-loop-helix  (bHLH)  leucine  zipper  domains.  These  domains  are 
known  to  be  required  for  the  biological  activity  of  c-MYC.  The  leucine  zipper  domain  of 
the  protein  facilitates  protein-protein  interactions  and  is  a  domain  seen  in  a  range  of  other 
proteins  such  'as  FOS  and  JUN.  The  bHLH  domain  is  required  for  binding  DNA.  An 
essential  function  of  c-MYC  is  to  forma  complex  with  MAX,  which  binds  a  conserved 
DNA  recognition  sequence  and  is  proposed  to  activate  the  transcription  of  certain  genes. 
Confirmation  of  the  specificity  of  the  hMLH1-c-MYC  interaction  within  this  system  was 
facilitated  through  using  c-MYC  mutants  and  testing  whether  they  could  still  interact  with 
hMLH1. 
Mutants  of  avian  c-MYC  were  available  from  Dr.  D.  Crouch  (University  of  Dundee)  and 
were  used  in  the  yeast  two-hybrid  system.  The  region  of  c-MYC  involved  in  the 
interaction  with  hMLH1  is  highly  conserved  from  chicken  to  human  cells.  Yeast  two- 
hybrid  pACT-2  constructs  were  made  expressing  the  same  C-terminal  region  of  avian  c- 
MYC,  v-MYC  and  also  mutants  of  avian  c-MYC.  These  constructs  were  all  tested  for 
autonomous  activation  of  the  yeast  two-hybrid  reporter  gene  and  none  were  positive. 
Therefore  the  constructs  were  tested  for  an  interaction  with  hMLH1. 
Both  avian  c-MYC  and  v-MYC  interacted  with  hMLH1  in  the  yeast  two-hybrid  system. 
Mutations  in  both  the  basic  region  and  the  two  helices  of  the  HLH  domain  of  avian  c-MYC 179 
had  no  effect  on  the  interaction  with  hMLH1.  However  deletion  of  the  C-terminal  10  and 
28  amino  acids  of  avian  c-MYC  led  to  the  loss  of  an  interaction  between  avian  c-MYC  and 
hMLH1.  This  region  of  c-MYC  encodes  the  leucine  zipper  domain  of  the  protein,  a 
domain  previously  identified  as  being  crucial  for  protein-protein  interactions.  The  original 
human  c-MYC  construct  from  the  library  screen  was  shown  to  specifically  interact  with 
hMLH1  F4,  the  same  domain  of  hMLH1  required  for  an  interaction  with  hPMS2.  The 
avian  c-MYC  and  v-MYC  constructs  were  also  tested  for  an  interaction  with  hMLH1  F4 
and  showed  the  same  pattern  of  interactions  as  with  full  length  hMLH1. 
From  these  experiments  the  critical  region  of  c-MYC  for  the  interaction  with  hMLH1  is 
shown  to  be  the  very  C-terminal  sequence  encompassing  the  leucine  zipper  domain.  The 
use  of  mutants  of  c-MYC  in  the  yeast  two-hybrid  system  demonstrating  this  specific  region 
of  the  protein  required  for  the  interaction  with  hMLH1  lends  further  support  for  this  being 
a  functionally  relevant  interaction.  Use  of  specific  mutants  of  c-MYC  in  these  assays 
eliminates  the  possibility  of  this  hMLH1-c-MYC  being  a  non-specific  interaction  due  to 
charge.  However  alternative  assays  should  -be  used  to  demonstrate  this  interaction 
independently.  Therefore  co-immunoprecipitation  assays  were  utilised  to  confirm  this 
interaction. 
These  co-immunoprecipitation  assays  utilise  cell  extracts  and  specific  polyclonal 
antibodies  against  the  proteins  of  interest.  Saturating  amounts  of  the  antibodies  were 
incubated  with  cell  extract  and  the  immunoprecipitates  collected  on  sepharose  beads. 
From  these  assays  hMLH1  was  clearly  shown  to  co-immunoprecipitate  with  c-MYC 
polyclonal  antibody.  hMLH1  did  not  co-immunoprecipitate  with  the  non-specific  rabbit 
pre-immune  serum.  Unfortunately  the  monoclonal  c-MYC  antibodies  available  are  not 
very  effective  and  the  reciprocal  detection  of  c-MYC  co-immunoprecipitating  with  the 
hMLH1  polyclonal  antibody  proved  more  difficult.  Avian  cell  extracts  (from  MC29  cells) 
were  prepared,  which  have  elevated  c-MYC  expression,  and  used  in  these  assays.  In  these 
experiments  hMLH1  polyclonal  antibody  was  shown  to  be  able  to  co-immunoprecipitate 
both  avian  MLH1  and  avian  c-MYC.  Again  these  associations  are  specific,  as  these 
proteins  did  not  co-immunoprecipitate  with  pre-immune  serum.  This  demonstration  of  co- 
immunoprecipitation  of  the  two  proteins  provides  additional  evidence  for  an  interaction 
between  c-MYC  and  hMLH1. 
Finally,  further  confirmation  for  an  interaction  between  hMLH1  and  c-MYC  came  from  the 
GST  pull  down  assays  done  in  collaboration  with  Dr.  E.  Homer.  In  these  assays  hMLH1 180 
full  length  and  F1-F4  (corresponding  to  the  fragments  of  hMLH1  used  in  the  yeast  two- 
hybrid  system)  were  expressed  as  fusion  proteins  with  GST.  MAX,  a  known  binding 
partner  of  c-MYC,  was  also  expressed  as  a  GST  fusion  protein.  In  a  similar  manner  to  the 
co-immunoprecipitation  protocol  the  GST  fusion  proteins  were  incubated  with  cell  extract 
and  the  proteins  bound  to  these  GST  fusion  proteins  examined  by  western  blot.  From  these 
assays,  as  in  the  co-immunoprecipitation  assays,  hMLH1  was  clearly  demonstrated  to  bind 
c-MYC.  c-MYC  is  shown  in  these  assays  to  bind  GST-MAX,  GST-hMLH1  and  hMLH1- 
F4  but  not  GST  alone.  The  demonstration  of  endogenous  c-MYC  being  pulled  down  with 
F4  of  hMLH1  as  well  as  full  length  hMLH1  supports  the  observations  from  the  yeast  two- 
hybrid  system. 
In  summary,  the  observed  interaction  between  hMLH1  and  c-MYC  in  the  yeast  two  hybrid 
system  has  been  confirmed  by  demonstrating  this  interaction  in  a  number  of  other 
independent  systems.  The  specific  domains  on  the  two  proteins  required  for  this 
interaction  have  been  elucidated  using  the  yeast  two-hybrid  system.  Co- 
immunoprecipitation  assays  and  GST  pull  down  assays  have  both  demonstrated  a  specific 
interaction  between  hMLH1  and  c-MYC  under  the  experimental  conditions  used  in  these 
assays. 
Preliminary  studies  have  also  demonstrated  an  interaction  between  hMSH2  and  MAX 
(pers.  comm.  Dr.  E.  Homer).  This  interaction  between  hMSH2  and  MAX  was  shown 
using  GST  pull  down  assays  and  further  verified  using  co-immunoprecipitation  assays. 
These  observations  further  substantiate  the  potential  importance  of  the  c-MYC-hMLH1 
interaction,  as  this  known  c-MYC  binding  partner  MAX  binds  a  second  MMR  protein 
hMSH2. 
Within  the  yeast  two  hybrid  system  and  also  from  the  GST  pull  down  assays  the  interaction 
region  on  hMLH1  for  binding  c-MYC  has  been  localised  to  hMLH1  F4,  the  C-terminal 
fragment  of  hMLH1  (amino  acids  514-756).  This  C-terminal  fragment  of  hMLH1  also 
contains  the  binding  domain  for  hPMS2.  Therefore  this  interaction  between  hMLH1  and 
c-MYC  could  be  competing  with  this  binding  of  hMLH1  to  hPMS2.  Interactions  between 
hMLH1  and  other  MutL  homologues,  hMLH3  and  hPMS1  recently  discovered,  are  also 
mediated  through  the  C-terminal  of  hMLH1  (Leung  et  al.,  2000;  Lipkin  et  al.,  2000; 
Raschle  et  al.,  1999).  c-MYC  could  be  competing  with  these  other  proteins  for  binding  to 
hMLH1  (see  Figure  21).  It  will  therefore  be  of  interest  to  define  more  specifically  the 181 
u 
hMI.  H  I  -hPMS2 
(hMutLu> 
hML.  HI-hPMSI 
(hMutL(3) 
hNII  H1 
, 4r-ý 
hMLH  I  -hM  LH; 
El 
HH 
hlII,  HI-c-NIY('  c-NIY(' 
r-  N1  Y  C'+ 
CD 
YYI 
A  P2 
TI-11-I 
Nil/-I 
BRCA 
Figure  21:  hNILH  I  and  c-N'IYC  Protein-Protein  Interactions. 
hMLH  I  binds  to  three  other  MutL  homologues,  hPMS2,  hPMS  I  and  hM  LH  3.  Complex 
formation  is  through  the  C-terminal  half  of  the  protein,  the  same  region  involved  in  the 
interaction  of  hMLH  I  with  c-MYC.  c-MYC  interacts  with  its  major  binding  partner 
MAX  through  its  C-terminal  half.  Interaction  between  c-MYC  and  a  range  of  other 
proteins  (listed)  have  also  been  identified  which  are  also  mediated  through  the  C-terminal 
of  the  protein. 182 
interaction  domain  on  hMLH1.  The  c-MYC  clone  pulled  out  of  the  yeast  two-hybrid 
screen  that  interacts  with  hMLH1  does  not  interact  with  hPMS2  F3  or  R.  This  would 
suggest  that  although  the  C-termini  of  the  MutL  homologues  are  relatively  homologous, 
the  interaction  of  the  C-terminal  half  of  c-MYC  with  hMLH1  is  specific. 
The  leucine  zipper  C-terminal  domain  of  c-MYC  has  been  shown  to  be  required  for  the 
interaction  with  hMLH1.  This  was  demonstrated  by  using  mutants  of  avian  c-MYC  in  the 
yeast  two-hybrid  system.  These  mutants  have  been  previously  tested  for  their  interaction 
with  MAX  (Crouch  et  al.,  1993).  The  leucine  zipper  domain  of  c-MYC  is  also  required  for 
the  interaction  with  MAX.  However  the  mutation  in  helix  2  of  the  HLH  domain  also  leads 
to  loss  of  binding  to  MAX.  Therefore  this  region  of  c-MYC  is  required  for  the  interaction 
between  c-MYC  and  MAX  but  not  for  the  interaction  between  c-MYC  and  hMLH1.  The 
mutation  in  helix  1  of  c-MYC  does  not  affect  the  binding  of  MAX  to  c-MYC.  However  it 
does  affect  the  ability  of  the  c-MYC-MAX  complex  binding  its  specific  DNA  recognition 
sequence  and  activating  transcription  from  a  reporter  gene  under  its  control.  hMLH1 
binding  to  c-MYC  could  be  in  competition  with  MAX. 
A  number  of  other  proteins  have  also  been  identified  that  can  bind  the  C-terminal  of  c- 
MYC.  These  include  YY1,  TFII-I,  BRCA1,  MIZ-1  and  AP2.  Both  MIZ-1  and  BRCA1 
specifically  bind  the  HLH  domain  of  c-MYC  and  do  not  require  the  leucine  zipper  domain 
of  this  protein  for  binding  (Peukert  et  al.,  1997;  Wang  et  al.,  1998).  MIZ-1  is  known  to 
bind  the  Inr  element  of  a  number  of  genes  including  cyclin  D1,  activating  transcription  of 
these  genes  (Peukert  et  al.,  1997).  Overexpression  of  the  MIZ-1  protein  leads  to  growth 
arrest.  However  co-expression  of  c-MYC  leads  to  inhibition  of  this  arrest  and  is dependent 
on  formation  of  the  MIZ-1-c-MYC  heterodimer  and  also  on  a  functional  POZ  domain  in 
MIZ-1.  This  has  led  to  the  proposal  that  c-MYC  somehow  activates  the  repression 
function  of  this  POZ  domain  and  inhibits  the  normal  transactivation  function  of  MIZ-1. 
The  interaction  of  MIZ1  with  the  HLH  domain  of  c-MYC  would  support  this  model,  as  it 
has  been  shown  that  it  is  through  this  domain  that  c-MYC  as  part  of  a  heterodimer  (c- 
MYC-MAX)  binds  DNA.  BRCA1  when  overexpressed  can  inhibit  the  transactivation 
function  of  c-MYC  and  also  c-MYC/RAS  co-transformation,  again  demonstrating  the 
importance  of  the  HLH  domain  of  c-MYC  and  the  interaction  with  MAX  for  its  different 
roles  (Wang  et  al.,  1998).  However  the  full  implications  of  this  interaction  with  BRCA1 
are  yet  to  be  elucidated. 183 
The  region  of  c-MYC  required  for  interaction  with  both  YY1  and  TFII-I  has  also  been 
examined  (Roy  et  al.,  1993;  Shrivastava  et  al.,  1993).  Although  these  studies  were  not 
conclusive  these  interactions  are  unlikely  to  require  the  leucine  zipper  domain  but  instead 
the  HLH  domain  of  c-MYC.  YY1  can  bind  c-MYC  to  the  exclusion  of  MAX  binding  c- 
MYC  (Shrivastava  et  al.,  1993;  Shrivastava  et  al.,  1996).  YY1  acts  to  both  activate  and 
repress  transcription  and  also  is  found  to  be  involved  in  transcription  initiation.  The  in  vivo 
interaction  between  these  two  proteins  occurs  mostly  in  cells  that  express  elevated  levels  of 
c_MYC.  These  two  proteins  appear  to  have  a  reciprocal  effect  on  each  other.  YYI  can 
compete  with  MAX  for  binding  to  c-MYC,  but  has,  also  been  found  to  affect  the  TAD 
(transactivation  domain)  of  c-MYC  although  not  through  a  direct  interaction.  YY1  can 
also  inhibit  the  co-transformation  activity  of  c-MYC/RAS  (Austen  et  al.,  1998).  The 
reciprocal  effect  of  c-MYC  on  YY1,  acts  to  interfere  with  the  ability  of  YY1  to  interact 
with  basal  transcription  factors  such  as  TBP  and/or  TFII-B.  c-MYC  can  again  block 
initiation  of  transcription  by  the  transcription  factor  TFII-l  which  can  bind  two  types  of 
promoter  element,  an  initiator  (Inr)  element  and  also  an  E-box  site,  by  preventing  co- 
operation  between  TFII-I  and  TBP  through  binding  to  TFII-I  (Roy  et  al.,  1993;  Roy  et  al., 
1993). 
AP2  also  interacts  with  the  C-terminal  of  c-MYC  but  the  specific  domains  of  c-MYC 
involved  in  this  interaction  have  not  been  elucidated  (Gaubatz  et  al.,  1995).  It  was 
demonstrated  that  binding  of  c-MYC  by  AP2  does  not  preclude  binding  of  MAX  to  c- 
MYC.  However  AP2  binding  of  c-MYC  does  impair  DNA  binding  of  this  complex  to 
DNA. 
hMLH1  is  therefore  also  competing  with  these  proteins  for  binding  to  c-MYC.  Is  it 
possible  that  like  some  of  these  other  proteins,  hMLH1  through  its  interaction  with  c-MYC 
can  effect  this  proteins  functions,  such  as  its  ability  to  activate  transcription  of  certain 
genes  or  its  co-transformation  activity  with  activated  RAS.  c-MYC  through  its  interaction 
with  hMLH1  could  also  exert  an  effect  on  the  functions  of  this  protein  in  MMR  or  its  role 
in  signalling  downstream  cellular  responses  after  treatment  with  a  range  of  DNA-damaging 
agents.  These  two  proteins  clearly  interact,  the  next  challenge  therefore  is  elucidating  the 
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4.5  Elucidating  the  Functional  Significance  of  the  hMLH1- 
c-MYC  Interaction 
The  interaction  between  hMLH1  and  c-MYC  has  been  demonstrated  utilising  a  number  of 
independent  assay  systems.  hMLH1  requires  the  leucine  zipper  domain  of  c-MYC  for  the 
formation  of  a  hMLH1-c-MYC  complex.  This  was  demonstrated  using  mutants  of  avian  c- 
MYC  in  the  yeast  two-hybrid  system.  The  leucine  zipper  domain  has  been  shown  to  be 
required  for  the  transforming  ability  of  c-MYC,  specifically  through  its  interaction  with 
MAX'  This  region  of  c-MYC  was  also  previously  shown  to  be  required  for  the  c-MYC- 
MAX  interaction,  but  unlike  the  hMLH1  interaction,  MAX  also  requires  helix  2  of  the 
HLH  domain  of  c-MYC  for  complex  formation  (Crouch  et  al.,  1993). 
Binding  to  MAX  is  required  for  both  the  oncogenic  and  transactivation  functions  of  the  c- 
MYC  Protein  (Amati  et  al.,  1993;  Amati  et  al.,  1992).  As  described  earlier  c-MYC  can  co- 
operate  with  activated  RAS  leading  to  cellular  transformation.  The  identification  of  an  N- 
terminal  transactivation  domain  and  also  a  C-terminal  bHLH-Zip  domain  (which  is 
commonly  found  in  a  number  of  transcription  factors)  in  the  c-MYC  protein  also  suggested 
a  role  for  this  protein  in  transcriptional  control.  c-MYC  through  an  interaction  with  MAX 
can  bind  a  consensus  DNA  recognition  binding  sequence  and  activate  transcription  of  a 
reporter  gene  in  a  number  of  in  vivo  reporter  gene  expression  systems  (Amati  et  al.,  1992; 
Kretzner  et  al.,  1992).  The  interaction  of  c-MYC-MAX  with  TRRAP  and  the  subsequent 
recruitment  of  the  histone  acetyltransferase  GCN5  provided  a  direct  link  between  c-MYC 
and  modes  of  transcription  activation  (McMahon  et  al.,  1998;  McMahon  et  al.,  2000).  c- 
MYC  has  also  been  shown  to  repress  transcription  of  certain  genes  through  its  interactions 
with  proteins  such  as  YY1  and  TFII-I. 
MAX  is  a  protein  that  is  central  to  two  opposing  networks  of  protein-protein  interactions. 
MAX  can  bind  other  proteins  such  as  MAD  and  MX11  (Ayer  et  al.,  1993;  Zervos  et  al., 
1993).  These  complexes  can  compete  with  the  c-MYC-MAX  heterodimer  for  binding  to 
the  E-box  recognition  sequences  and  can  inhibit  both  the  transactivation  and  oncogenic 
potential  of  c-MYC  (Ayer  et  al.,  1993).  Could  hMLH1  be  in  competition  with  MAX  for 
binding  to  c-MYC?  If  this  were  the  case,  loss  of  hMLHJ  would  lead  to  loss  of  this 
competition  and  therefore  increased  formation  of  c-MYC-MAX  heterodimer  through 
which  c-MYC  exerts  many  of  its  functions.  For  example  if  in  the  absence  of  hMLH1,  such 
an  increase  in  c-MYC-MAX  complex  formation  did  result,  this  could  have  an  effect  on  the 
balance  of  the  proposed  dual  control  that  c-MYC  has  on  the  cell,  Le.  proliferation  versus 185 
cell  death.  Loss  of  hMLH1  is  associated  with  loss  of  sensitivity  in  response  to  DNA 
damaging  agents.  Therefore  one  possible  model  for  the  function  of  this  hML111-c-MYC 
interaction  is  that  it  acts  to  mediate  the  response  from  DNA  damage  recognition  to 
downstream  effector  pathways. 
To  address  whether  the  association  of  hMLH1  with  C-MYC  can  preclude  binding  of  c. 
MYC  to  MAX,  electrophoretic  mobility  shift  DNA  binding  assays  (EMSA)  were  utiliscd. 
c-MYC  and  MAX  proteins  dimerise  and  bind  DNA  through  their  basic-helix-loop-helix- 
leucine  zipper  motifs  (b-HLH-LZ)  (Blackwood  and  Eisenman,  1991;  Blackwood  et  al., 
1992).  c_MYC-MAX  heterodimer  binds  with  highest  affinity  to  the  consensus  sequence 
CACG/ATG,  the  E-box  sequence  (Prendergast  and  Ziff,  1991).  c-MYC-MAX  and  MAX- 
MAX  complexes  can  form  and  bind  to  this  E-box  DNA  core  sequence.  However  c-MYC 
alone-does  not  bind  this  sequence.  Electrophoretic  mobility  shift  DNA  binding  assays  were 
carried  out  with  purified  GST-MYC,  HIS-MAX  and  GST-MLH1.  From  these  assays  using 
a  wide  range  of  GST-hMLH1  concentration's,  'hMLH1  did  not  have  an  effect  on  c-MYC- 
MAX  binding  to  its  recognition  E-box  sequence.  Furthermore,  no  ternary  complex 
formation  was  observed,  supporting  the  observed  overlapping  nature  of  the  regions  of 
interaction  on  c-MYC  for  these  two  proteins. 
hMLH1  in  these  bandshift  assays  could  not  inhibit  the  formation  of  c-MYC-MAX 
complexes  or  the  binding  of  these  complexes  to  their  recognition  DNA  binding  sequence, 
the  E-box  recognition  sequence.  Under  these  experimental  conditions  therefore  it  is 
concluded  that  the  affinity  of  hMLH1  for  c-MYC  is  not  high  enough  to  disrupt  a  c-MYC- 
MAX  complex.  Using  purified  proteins  not  expressed  as  fusions  could  prove  more  useful 
in  this  type  of  experiment.  Interpretation  of  the  results  would  not  be  complicated  by  the 
possible  distortions  in  protein  structure  introduced  through  the  fusion  protein.  This  would 
require  expression  and  purification  of  functional  full  length  c-MYC.  Alternatively,  to 
determine  whether  hMLH1  precludes  binding  of  c-MYC  to  MAX,  GST-hMLH1  could  be 
incubated  with  purified  c-MYC,  c-MYC  and  MAX  and  MAX  alone  and  subsequently  test 
which  proteins  co-immunoprecipitated  with  hMLH1. 
Although  a  negative  result  in  this  assay  is  somewhat  difficult  to  interpret  it  is  unlikely  that 
hMLH1  can  actively  compete  with  MAX  for  binding  to  c-MYC  in  a  similar  way  to,  for 
example  to  the  competition  for  binding  to  MAX  by  c-MYC  and  the  other  MAX  binding 
partners  such  as  MAD.  It  has  been  previously  reported  that  much  of  the  c-MYC  expressed 
in  the  cell  is  in  complex  with  MAX  (Blackwood  et  al.,  1992).  hMLH1  also  forms 186 
complexes  with  a  number  of  proteins  specifically  involved  in  MMR,  the  MutL 
homologues,  hPMS2,  hPMS1  and  hMLH3  (Leung  et  al.,  2000;  Li  and  Modrich,  1995; 
Lipkin  et  al.,  2000;  Raschle  et  al.,  1999).  Another  interaction  between  hMLII1  and  a  novel 
mismatch  specific  TIU  DNA  glycosylase  MED1  has  also  been  described  (Bellacosa  ct  al., 
1999). 
it  is  possible  therefore  that  the  interaction  between  hMLH1  and  c-MYC  acts  at  another 
specific  junction  in  cellular  activity.  For  example  hMLH1  is  specifically  involved  in 
MMR.  However  following  exposure  of  cells  to  DNA-damaging  agents  this  protein  is 
clearly  involved  in  signalling  from  the  DNA  damage  site  to  downstream  cellular  responses. 
Is  it  possible  that  this  pathway  through  hMLH1  co-operates  with  a  second  signal 
transduction  pathway  acting  via,  c-MYC  which  together,  through  the  hML111-c-MYC 
interaction,  signal  a  single  response  element  such  as  cell  cycle  arrest  or  apoptosis. 
4.5.1  . 
Could  Elevated  c-MYC  Expression  Ablate  hMLH1  Function? 
The  proto-oncogene  c-MYC  was  first  discovered  through  its  homology  with  the 
transforming  gene,  v-MYC,  of  avian  myelocytornatosis  virus,  MC29  (Vennstrom  et  al., 
1982).  The  v-MYC  retroviral  gene  causes  the  development  of  a  variety  of  turnours  in 
infected  chickens,  supporting  the  idea  that  c-MYC  would  have  oncogenic  activity  in  human 
cells  (Bishop,  1982).  Subsequently  the  c-MYC  oncogene  has  been  found  to  be  activated  in 
many  animal  and  human  turnours  (Nesbit  et  al.,  1999).  The  c-Myc,  L-Myc  and  N-Myc 
family  members  have  each  been  implicated  in  the  onset  of  human  neoplasia. 
Activation  of  human  c-MYC  genes  occurs  through  several  mechanisms  leading  to  the  onset 
of  cancer.  An  early  observation  of  a,  link  between  c-MYC  and  cancer  was  the  observed 
translocation  of  c-MYC  on  chromosome  8  so  that  it  is  juxtaposed  with  the  regulatory 
elements  of  one  of  three  immunoglobulin  genes  on  chromosome  2,44  or  22  in  Burkitt's 
lymphoma  (BL)  (Cole,  1986;  Nesbit  et  al.,  1999).  This  leads  to  the  activation  of  c-MYC 
and  subsequent  onset  of  the  BL  lymphoid  malignancy.  Elevated  expression  of  the  c-MYC 
gene  has  been  associated  with  a  number  of  cancers,  including  breast,  lung,  prostate, 
gastrointestinal,  some  melanomas  and  myeloid  leukaemia.  How  this  amplification  of  c- 
MYC  expression  arises  and  its  links  to  disease  progression  are  yet  to  be  clearly  elucidated. 
The  coincidence  of  elevated  c-MYC  expression  and  oncogenesis  is  clearly  a  common 
occurrence.  Is  it  possible  that  part  of  the  oncogenic  effect  of  this  elevated  c-MYC 187 
expression  acts  through  inhibition  of  functional  MMR,  perhaps  through  sequestration  of 
hMLH1?  Under  normal  cellular  conditions  this  interaction  between  hMLII1  and  c-MYC 
may  have  a  specific  role  in  mediating  cellular  responses  to  DNA  damage  which  are  ablated 
in  transformed  cells.  To  address  the  possibility  that  elevated  C-MYC  expression  can  act  to 
impair  functional  MMR,  the  Rat-1  c-MYCEem  system  was  utilised.  As  described  earlier 
this  system  allows  inducible  expression  of  c-MYC.  Therefore  the  effect  of  normal 
expression  versus  elevated  c-MYC  expression  on  MMR  can  be  examined. 
The  first  experiments  carried  out  to  address  the  possible  effect  of  elevated  c-MYC  on 
MMR  utilising  this  system  were  bandshift  experiments  with  a  mismatched  oligonucleotide. 
Mismatch  repair  protein  complexes  can  specifically  bind  heteroduplex  DNA  for  example 
in  the  form  of  a  GT  mismatch  within  a  short  oligonucleotide  sequence  (Branch  et  al.,  1993; 
Jiricny  et  al.,  1988).  Recognition  of  the  mismatch  and  initial  binding  is  mediated  through 
the  MutS  proteins  (Fishel  et  al.,  1994;  Miret  et  al.,  1993;  Modrich,  1989;  Su  and  Modrich, 
1986).  MutL  proteins  have  also  been  shown  to  be  part  of  this  complex  (Grilley  ct  al., 
1989;  Matton  et  al.,  2000;  Prolla  et  al.,  1994).  Formation  of  a  mismatch  specific 
retardation  complex.  was  shown  to  be  reduced  in  the  hMLH1  deficient  cell  line 
A2780/cp7O  compared  to  the  mismatch  repair,  hMLH1  proficient  A2780  parental  cell  line 
(Anthoney  et  al.,  1996).  Therefore  in  the  presence  of  elevated  c-MYC  expression,  if  c- 
MYC  can  sequester-  hMLH1  and  effect  its  function  in  MMR,  a  reduction  in  binding  of  a 
mismatch  specific  protein  complex  may  be  observed. 
Experiments  were  carried  out  with  nuclear  extracts  from  Rat-1  c-MYCEIjm  cells  without 
elevated  c-MYC  expression  and  at  time  points  ranging  between  2  and  24  hours  after 
treatment  with  4-hydroxy  tarnoxifen  (4-OHT).  These  extracts  were  incubated  with  a  32P 
end  labelled  34  bp  oligonucleotide  with  a  GC  base  pair  or  a  GT  mismatch  at  position  16. 
In  extracts  from  both  A2780  and  Rat-1  c-MYCERTm  (without  activation  of  c-MYC 
expression  by  4-OHT)  a  mismatch  specific  protein-DNA  complex  was  observed  in  the  gel 
shift  assays.  In  this  study  the  elevated  c-MYC  expression  in  extracts  made  from  Rat-1  c- 
MYCERTm  cells  at  2,4,8  and  24  hours  after  treatment  with  4-OHT  did  not  effect  the 
formation  of  this  mismatch  specific  complex.  Any  differences  in  intensity  of  the  mismatch 
specific  bands  were  found  to  be  due  to  extract  quality,  as  shown  by  performing  bandshift 
experiments  with  these  extracts  using  an  oligonucleotide  with  an  SP1  binding  site. 
Therefore  in  this  system  under  these  experimental  conditions  the  increased  expression  of  c- 
MYC  does  not  effect  the  formation  of  a  mismatch  specific  protein  complex  on  the 188 
heteroduplex  DNA.  c-MYC  may  require  other  co-factors  to  exert  any  effect  on  the 
formation  of  this  complex.  However  the  possible  effect  exerted  by  c-MYC  on  MMR 
through  binding  to  hMLH1  may  not  act  at  this  step  of  the  repair  process.  The  MutL  protein 
in  bacteria  is  known  to  be  involved  in  generating  a  signal  between  mismatch  recognition 
and  other  components  of  the  repair  pathway  in  particular  recruitment  of  the  MutH 
endonuclease  (Hall  et  al.,  1998;  Hall  and  Matson,  1999).  hMLH1  has  also  been 
demonstrated  to  play  a  crucial  role  in  signalling  downstream  cellular  responses  in  response 
to  DNA  damaging  agents  for  example  cisplatin  leading  to  the  activation  of  c-ABL,  JNK 
and  p73  (Duckett  et  al.,  1999;  Gong  et  al.,  1999;  Nehme  et  al.,  1997).  The  effect  of 
overexpression  of  c-MYC  on  hMLH1  and  MMR  may  therefore  materialise  at  a  later  point 
in  this  process,  when  perhaps  hMLH1  is  available  to  bind  and  is  no  longer  in  complex  with 
the  MutS  proteins.  The  actual  effect  of  this  proposed  sequestration  of  hMLHI  by  c-MYC 
may  be  more  easily  measured  using  alternative  systems. 
Utilising  the  MYCER  system  to  induce  expression  of  c-Myc  in  cells,  it  has  been  shown 
that  elevated  c-MYC  levels  can  result  in  genomic  instability  (Felsher  and  Bishop,  1999; 
Mai  et  al.,  1996).  Transient  induction  of  elevated  c'-MYC  gene  expression  led  to  a 
significant  increase  in  the  tumorigenicity  "of  Ratla  cells  as  measured  in  xenograft 
experiments  (Felsher  and  Bishop,  1999).  This  effect  was  seen  even  in  cells  30  days  after 
the  return  of  normal  c-MYC  levels.  Genomic  instability,  including  karyotypic  anomalies 
and  gene  amplification,  was  seen  upon  elevated  c-MYC  expression  in  this  system.  This 
instability  may  be  the  result  of  c-MYC  elevated  expression  leading  to  an  accelerated 
passage  of  the  cells  through  G,  and  only  arresting  at  G2.  This  study  has  led  to  the  proposal 
that  elevated  c-MYC  expression  may  contribute  to  a  neoplastic  phenotype  through  a 
dominant  mutator  effect  (Felsher  and  Bishop,  1999). 
it  was  decided  to  test  whether  this  effect  of  overexpressing  c-MYC  in  the  Rat-1  c- 
MYCER:  rm  cell  system  could  induce  a  mutator  phenotype.  More  specifically,  testing 
whether  overexpression  of  c-MYC  could  induce  a  mutator  phenotype  which  can  be  directly 
linked  to  MMR  inhibition.  Mutation  rates  at  a  selectable  gene,  HPRT,  were  measured  in 
response  to  treatment  with  6-thioguanine.  These  cells  were  grown  up  from  single  colonies 
in  the  presence  or  absence  of  4-hydroxy  tarnoxifen  i.  e.  the  presence  or  absence  of  elevated 
c-MYC  expression.  Cells  were  subsequently  plated  out  at  a  high  density  in  the  presence  of 
the  anti-metabolite  6-thioguanine.  Fluctuation  analysis  was  carried  out  by  the  Luria- 
Delbruck  method  and  the  mutation  rates  calculated  for  the  untreated  cells  and  the  cells 
treated  with  4-OHT  and  hence  with  elevated  expression  of  c-MYC  (Delbruck,  1943).  Cells 189 
with  elevated  c-MYC  expression  were  clearly  shown  to  possess  a  significantly  higher 
mutation  rate  compared  to  those  with  normal  c-MYC  expression.  Therefore  elevated  c- 
MYC  expression  in  this  system  also  induces  a  mutator  phenotype. 
Resistance  to  the  chemotherapeutic  agent  6-thioguanine  (6-TG)  arises  due  to  mutations  in 
the  hypoxanthine-guanine  phosphoribosyl  transferase  (HPR7)  gene.  Loss  of  mismatch 
repair  is  known  to  lead  to  an  increased  mutation  rate  at  HPRT  and  consequently  increased 
resistance  to  6-TG  (Bhattacharyya  et  al.,  1994;  Eshleman  et  al.,  1995;  Glaab  et  al.,  1998). 
In  an  MMR  deficient  background  acquired  resistance  to  6-thioguanine  has  been  found  to  be 
associated  with  hotspot  mutations  in  the  HPRT  gene  (Bhattacharyya  et  al.,  1994;  Kat  ct  al., 
1993).  In  particular  a  specific  frameshift  hotspot  at  a  run  of  six  guanine  residues  in  exon  3 
of  the  HPRT  gene,  accounted  for  a  high  proportion  of  HPRT  mutations  in  an  MMR 
deficient  cell  line  background. 
To  examine  whether  the  mutator  phenotype  induced  by  overexpression  of  c-MYC  can  be 
specifically  linked  to  inhibition  of  MMR,  mutant  colonies  which  grew  on  platcs  from  cells 
grown  both  in  the  presence  and  the  absence  of  elevated  c-MYC  expression  (+/-  4-OHT) 
were  picked  and  expanded  for  further  examination.  Genomic  DNA  was  extracted  from 
these  mutant  clones  and  tested  for  the  presence  of  mutations  at  a  specific  run  of  six  guanine 
(G)  bases  in  exon  3  of  the  HPRT  gene.  Comparison  of  mutant  clones  from  cells  treated  or 
not  with  4-OHT  and  hence  with  or  without  elevated  c-MYC  expression  showed  differences 
with  respect  to  mutations  at  this  run  of  G  residues.  All  22  mutant  clones  from  cells  grown 
in  the  absence  of  4-OHT  had  no  frameshift  mutations.  However  4  out  of  the  25  mutant 
clones  from  cells  treated  with  4-OHT,  i.  e.  with  elevated  c-MYC  expression,  had  frameshift 
mutations  at  this  run  of  six  G  bases.  Although  due  to  the  small  numbers  involved,  this 
number  of  mutants  in  the  cells  grown  in  the  presence  of  4-OHT  is  not  significant,  as 
measured  by  Fisher's  Exact  Test,  p-value=0.071  (p-value  of  less  than  0.05  is  taken  as 
significant).  However,  these  results  do  suggest  the  possibility  that  there  may  be  a  link 
between  the  mutator  phenotype,  induced  through  overexpression  of  c-MYC,  and  loss  of 
MMR.  Larger  numbers  of  mutant  clones  would  have  to  be  examined  to  strengthen  the 
power  of  the  analysis. 
An  elevated  mutation  rate  has  previously  been  identified  at  this  run  of  G  residues  to  be 
associated  with  loss  of  MMR  in  particular  loss  of  hMLH1  expression.  The  fact  that 
elevated  c-MYC  expression  leading  to  an  increased  mutation  rate  at  this  selectable  gene, 
HPRT,  also  results  in  mutations  in  a  number  of  mutant  clones  at  this  frameshift  mutation 190 
hotspot  seen  in  hMLH1  deficient  cells,  suggests  the  possibility  that  the  mutator  phenotype 
seen  in  this  assay  could  be  due  to  inhibition  of  MMR.  The  relatively  small  number  of 
mutants  examined  due  to  the  fact  that  mutant  numbers  were  small  and  also  the  difficulties 
encountered  growing  up  mutant  clones  means  that  only  22  mutant  colonies  from  cells  not 
treated  with  4-OHT  (i.  e.  no  elevated  c-MYC  expression)  were  examined  and  only  25 
mutants  from  4-OHT  treated  cells.  Therefore  the  possibility  remains  that  if  a  larger 
number  of  mutants  had  been  available  for  examination  this  outcome  may  have  differed.  A 
significant  number  of  the  mutant  clones  from  cells  treated  with  4-OHT,  i.  e.  elevated  c- 
MYC  expression,  with  a  frameshift  mutation  at  this  mutation  hotspot  similar  to  that  seen  in 
the  hMLH1  deficient  cell  lines  described  earlier,  may  have  been  observed. 
Overall  this  set  of  experiments  testing  Ahe  possibility  that  elevated  c-MYC  expression 
could  lead  to  inhibition  of  MMR  are  somewhat  inconclusive.  In  the  case  of  the  mismatch 
specific  gel  shift  experiments,  the  contents  of  the  mismatch  specific  protein-DNA  retarded 
complex  has  not  been  fully  defined.  It  is  known  that  MutL  and  its  eukaryotic  homologues 
are  capable  of  binding  MutS  (and  homologues)  bound  to  the  mismatch  and  in  fact  can 
enhance  the  binding  capacity  of  the  MutS  proteins  to  the  mismatched  DNA  (Grilley  et  al., 
1989;  Habraken  et  al.,  1997;  Prolla  et  al.,  1994).  However  these  observation  come  from 
experiments  utilising  purified  proteins,  demonstrating  recognition  and  binding  of  the 
mismatch  by  the  MutS  proteins  followed  by  ternary  complex  formation  with  the  MutL 
proteins.  One  inherent  problem  with  these  experiments  is  that  they  do  not  account  for  the 
possible  additional  factors  involved  in  MMR  that  could  also  bind  at  this  point  of  the  repair 
pathway.  Therefore  although  a'mismatch  specific  retardation  complex  is  clearly  visible 
upon  addition  of  nuclear  cell  extracts  the  actual  components  of  this  complex  have  not  been 
defined.  A  recent  study  involving  immunoprecipitation  of  proteins  crosslinked  specifically 
to  heteroduplex  DNA  revealed  the  presence  of  both  human  MutS  and  MutL  proteins  bound 
in  this  complex  (Matton  et  al.,  2000). 
Acknowledging  the  caveats  of  using  purified  proteins  for  such  mismatch  specific  gel  shift 
experiments,  it  is  possible  that  a  more  definitive  answer  as  to  the  effect  of  c-MYC  on 
mismatch  specific  complex  binding  may  be  more  forthcoming  through  experiments 
utilising  purified  proteins.  However  such  experiments  would  be  a  considerable 
undertaking  as  the  production  of  the  various  proteins  especially  c-MYC  is  not  trivial.  If 
such  experiments  were  to  be  considered,  the  inclusion  of  MAX  may  also  be  useful  as  it  is 
known  that  many  functions  of  c-MYC  are  facilitated  through  the  c-MYC-MAX  complex. 
The  recent  discovery  of  an  interaction  between  MAX  and  hMSH2  may  also  suggest  that 191 
the  inclusion  of  hMSH2  in  these  experiments  could  also  prove  worthwhile.  It  has  also  not 
been  shown  that  the  binding  of  c-MYC  to  hMLH1  and  MAX  is  mutually  exclusive. 
Interestingly  many  recently  defined  protein-protein  interactions  have  been  found  to  be  part 
of  a  bigger  multi-protein  complex,  one  example  being  the  discovery  of  the  BASC  complex 
(Wang  et  al.,  2000).  ý  BASC  is  a  super  complex  of  proteins  associated  with  BRCA1,  which 
is  believed  to  be  involved  in  the  recognition  and  repair  of  DNA  adducts.  Interestingly  both 
hMLH1  and  human  MutS  proteins  have  been  identified  as  components  of  this  multi- 
protein  complex.  It  is  possible  that  the  interaction  between  MMR  proteins  and  c-MYC  is 
representative  of  such  a  multi-protein  complex. 
The  anti-cancer  agent  cisplatin  (CDDP)  is  used  to  treat  a  range  of  cancers.  The 
development  of  tumour  resistance  to  treatment  with  platinum  drug  therapies  is  a  primary 
reason  why  treatment  fails.  Aberrant  oncogene  expression,  e.  g.  c-MYC,  differentiates 
between  malignant  and  normal  cells.  Since  a  number  of  studies  have  shown  a  correlation 
between  de-regulated  c-MYC  gene  expression  and  poor  prognosis,  it  was  thought  possible 
that  high  levels  of  c-MYC  expression  could  also  play  a  role  in  the  emergence  of  platinum 
drug  resistance. 
In  vitro  reporter  gene  assays  where  the  reporter  gene  is  under  the  control  of  the  c-MYC 
promoter  were  used  to  demonstrate  that  in  a  number  of  cell  lines  treated  with  CDDP,  c- 
MYC  gene  expression  was  stimulated  (Eliopoulos  et  al.,  1995).  Using  a  solid 
transplantable  turnour  model  in  rats,  c-MYC  expression  was  examined  after  turnours  were 
treated  intravenously  with  cisplatin  (Walker  et  al.,  1996).  The  tumour  cells  that  survived 
treatment  demonstrated  elevated  c-MYC  expression.  Additional  studies  with  both 
xenograft  and  cell  line  models  from  cancers  with  associated  c-MYC  oncogene 
amplification  were  carried  out.  From  these  it  was  shown  that  the  treatment  of  cells  with 
antisense  c-MYC  in  combination  with  CDDP,  -  was  able  to  restore  CDDP  sensitivity  to  these 
CDDP  resistant  models  (Citro  et  al.,  1998;  Leonetti  et  al.,  1999;  Mizutani  et  al.,  1994;  Van 
Waardenburg  et  al.,  1997).  This  restoration  of  sensitivity  through  the  synergistic  effect  of 
CDDP  and  antisense  c-MYC'specifically  led  to  an  increased  apoptotic  response  (Leonetti  et 
al.,  1999;  Van  Waardenburg  et  al.,  1997).  One  such  study  examined  the  effect  of  c-MYC 
expression  levels  on  sensitivity  to  both  CDDP  and  ionising  radiation  (IR).  Elevated  c-MYC 
expression  led  to  increased  CDDP  resistance  but  had  no  effect  on  the  sensitivity  of  cells  to 
IR  treatment.  It  has  been  proposed  from  this  study  that  c-MYC  acts  either  in  a  direct  or 
indirect  manner  on  a'DNA  repair  pathway  involved  in  recognising  DNA  damage  induced 
by  treatment  with  CDDP. 192 
These  observations  suggest  that  it  may  be  worthwhile  extending  the  mismatch  specific 
bandshift  studies  to  similar  studies  utilising  oligonucleotides  which  instead  of  a 
mismatched  base  pair  carry  the  major  CDDP  induced  adduct  a  1,2-intrastrand  d(GpG) 
crosslink.  The  human  MutSct  complex  has  been  shown  to  recognise  and  bind  such  adducts 
as  well  as  base  pairs  between  06  -methylguanine  and  thymine  or  cytosine  (Duckett  ct  al., 
1996).  Loss  of  functional  MMR  leads  to  resistance  to  a  range  of  DNA-damaging  agents 
including  CDDP  (Aebi  et  al.,  1996;  Anthoney  et  al.,  1996).  Both  hMS112  and  hMLIII 
have  been  implicated  in  the  signalling  of  downstream  response  pathways  in  response  to 
treatment  with  CDDP  (Gong  et  al.,  1999;  Nehme  et  al.,  1997).  One  model  would  suggest 
that  recognition  and  binding  of  CDDP  induced  adducts,  by  the  human  MutS  proteins  and 
binding  of  these  complexes  by  the  human  MutL  proteins  is  vitally  important  for  signalling 
a  cellular  response  to  the  DNA  damage  induced  by  CDDP.  The  most  likely  candidate  for 
the  specific  signalling  function  being  the  hMLH1  protein.  Therefore  the  observed 
increased  resistance  to  CDDP  treatment  in  cells  with  elevated  c-MYC  presents  the 
intriguing  possibility  that  in  these  cells  resistance  could  possibly  be  induced  through  the 
possible  effect  of  elevated  c-MYC  expression  on  the  MMR  pathway. 
4.5.2  `  Model  for  the  Role  of  a  hMLH1-c-MYC  Complex 
c-MYC  is  required  for  signalling  both  proliferation  and  apoptosis,  two  opposing  pathways. 
A  'dual  signal  model'  has  been  proposed  to  explain  these  paradoxical  roles  for  the  protein 
(Harrington  et  al.,  1994;  Prendergast,  1999).  This  model  proposes  that  c-MYC  acts  to 
regulate  both  cell  division  and  cell  death.  However  these  functions  of  c-MYC  cannot  be 
separated  as  distinct  entities.  Therefore  this  proposal  has  been  re-modelled  to  suggest  that 
c-MYC  can  co-ordinately  prime  both  cell  death  and  drive  proliferation  (Prendergast,  1999). 
Priming  of  cell  death  for  example  could  involve  the  transcriptional  regulation  of  c-MYC 
target  genes.  Triggering  of  cell  death  is  proposed  to  subsequently  act  through  an  additional 
pathway. 
An  interaction  between  c-MYC  and  the  BIN1  protein  was  recently  identified  (Elliott  et  al., 
1999;  Sakamuro,  et  al.,  1996).  BIN1  is  able  to  inhibit  the  transactivation  properties  of  c- 
MyC_MAX  on  a  number  of  artificial  promoters  examined  in  vivo  and  also  on  c-MYC 
endogenously  activated  promoters  such  as  ODC  (Elliott  et  al.,  1999).  These  studies  also 
demonstrated  the  ability  of  BIN1  to  suppress  c-MYC/RAS  co-transformation.  BIN1  is 
found  on  chromosome  2q14  which  localises  to  a  region  often  found  deleted  in  metastatic 
prostate  cancer  (Sakamuro  and  Prendergast,  1999).  Re-introduction  of  BIN1  into  tumour 193 
cell  lines  lacking  the  endogenous  protein  results  in  inhibition  of  cell  growth  which  is 
mediated  by  an  apoptotic  cell  death.  Binl  has  been  proposed  to  act  as  a  'cell  fate  adaptor 
protein'  which  acts  to  co-ordinate  various  pathways  upon  exit  from  the  cell  cycle 
(Prendergast,  1999;  Sakamuro  and  Prendergast,  1999).  An  example  of  this  role  is  the  fact 
that  Binl  seems  to  play  a  role  in  mediating  a  c-MYC  dependent  apoptotic  response 
(Prendergast,  1999).  The  interaction  between  c-MYC  and  BINI  is  required  to  trigger 
apoptosis  but  is  not  necessary  to  drive  proliferation  or  transformation.  The  transition  from 
dpriming'  cell  death  to  actually  'triggering'  cell  death  by  c-MYC  could  therefore  involve 
for  example,  interactions  between  BIN1  and  the  c-MYC  target  gene  products  (Prendergast, 
1999). 
This  'dual  control'  exerted  by  c-MYC  is  intriguing  with  respect  to  the  interaction  of  this 
protein  with,  hMLH1.  In  some  ways  hMLH1  could  be  considered  as  a  specific  cell  fate 
adaptor  protein  in  response  to  certain  types  of  DNA  damage.  DNA  damage  is  recognised 
by  the  MMR  system  and  where  possible  repaired.  However  upon  treatment  with  DNA- 
damaging  agents  which  cause  major  DNA  adducts,  the  MMR  system  can  recognise  and 
bind  such  adducts  but  cannot  repair  them  (Duckett  et  al.,  1996).  Therefore  the  MMR 
system  through  proteins  such  as  hMLH1  are  proposed  to  signal  from  the  DNA  damage  site 
to  downstream  effector  molecules  which  are  involved  in  signal  transduction  pathways  that 
lead  to  cell  death  through  apoptosis  (Duckett  et  al.,  1999;  Gong  et  al.,  1999;  Nehme  et  al., 
1997).  The  interaction  with  c-MYC  could  be  therefore  potentially  critical  in  the 
differentiation  between  successful  adduct  repair  and  hence  continued  cell  cycle  progression 
and  proliferation  compared  to  recognition  of  an  adduct  which  cannot  be  repaired  by  MMR 
followed  by  signalling  for  an  apoptotic  response  in  response  to  the  DNA-damaging  agent 
in  question. 
The  MMR  system  is  able  to  recognise  and  bind  the  adducts  that  result  from  treatment  with 
a  number  of  DNA  damaging  agents  (Duckett  et  al.,  1996).  A  number  of  models  have  been 
proposed  to  suggest  how  MMR  mediates  sensitivity  to  treatment  with  these  agents.  One 
early  model  proposed  to  explain  the  methylation  tolerance  phenotype  seen  in  the  absence  of 
functional  MMR  is  the  'futile  repair'  model.  This  proposes  that  MMR  recognises  the  DNA 
adduct  produced,  and  triggers  double  strand  breaks  through  futile  attempts  at  repair.  This 
model  suggests  that  these  double  strand  breaks  are  recognised  by  other  damage  sensors 
which  signal  the  downstream  response  pathways.  The  observations  that  MMR  is  in  fact 
involved  in  mediating  sensitivity  to  a  broad  range  of  DNA-damaging  agents  led  to  the 
proposal  that  the  MMR  system  may  be  directly  involved  in  the  signalling  of  downstream 194 
pathways.  Support  for  this  model  came  from  the  observations  that  the  up-regulation  of 
expression  of  some  downstream  effectors,  for  example  c-ABL,  in  response  to  treatment 
with  cisplatin  is  MMR  dependent.  Some  suggestions  have  been  made  that  the  mutation 
avoidance  role  of  MMR  and  the  role  in  signalling  downstream  pathways  in  response  to 
DNA  damaging  agents  may  be  separable.  These  have  been  proposed  because  of  the 
observation  that  some  alkylation  tolerant  cell  -lines  have  mild  or  undetectable  mutator 
phenotypes  (Hampson  et  al.,  1997). 
The  MMR  system  has  been  clearly  implicated  in  signalling  downstream  events  in  response 
to  treatment  with  DNA-damaging  agents  such  as  the  methylating  agents  MNU  and  MNNG 
or  platinum  drugs  such  as  cisplatin.  Treatment  of  MMR  proficient  and  deficient  cell  lines 
with  cisplatin,  have  shown  an  MMR  dependent  activation  of  c-ABL  and  c-ABL  induced 
stimulation  of  p73  in  response  to  cisplatin  (Nehme  et  al.,  1997).,  Cisplatin  also  stimulates 
expression  of  p53  but  this-is  independent  of  MMR  status.  Similar  experiments  have  been 
carried  out  with  MMR  deficient  and  proficient  cell  lines  treated  with  the  methylating 
agents  MNU  and  MNNG  (Duckett  et  al.,  1999).  In  these  experiments  phosphorylation  of 
p53  at  serine  15  and  392  in  response  to  treatment  with  these  drugs  was  shown  to  be 
dependent  on  functional  MMR.  Triggering  of  MMR  dependent  cell  death  pathways  in 
response  to  treatment  with  such  methylating  agents  has  also  been  shown  independent  of 
functional  p53.  Cell  death  is  observed  in  p53  deficient  HeLa  cells  and  also  methylation 
tolerant  cell  lines  defective  in  MMR  have  been  isolated  in  this  genetic  background 
(Aquilina  et  al.,  1997;  Aquilina  et  al.,  1995;  Duckett  et  al.,  1999).  This  p53  independent 
cell  death  pathway  in  response  to  treatment  with  methylating  agents  may  also  occur 
through  c_ABL  and  p73,  however  this  remains  undetermined. 
MMR  through  hMLH1  therefore  signals  more  than  one  cell  death  signalling  pathway,  in 
response  to  DNA  damage,  after  treatment  with  anti-cancer  drugs.  Drug  resistance  is  a 
major  problem  in  the  treatment  of  cancer.  Resistance  to  the  drug  cisplatin  has  been  linked 
to  both  loss  of  functional  MMR  but  also  to  elevated  levels  of  c-MYC  expression.  c-MYC 
is  an  enigmatic  protein  with  many  cellular  roles  not  all  of  which  are  fully  understood.  This 
protein  was  once  described  as  a  'citadel  of  incomprehensibility',  but  over  the  past  decade 
with  further  study  the  multiple  roles  which  intricately  cross  different  and  apparently 
opposing  pathways  are  beginning  to  be  understood  (Luscher  and  Eisenman,  1990).  The 
observed  interaction  of  hMLH1  with  c-MYC  in  the  studies  described  in  this  thesis  pose  the 
intriguing  possibility  that  hMLH1  as  part  of  the  MMR  system  may  act  through  this 195 
interaction  with  c-MYC  to  trigger  cellular  responses  after  treatment  with  agents,  like 
cisplatin,  that  are  known  to  cause  DNA  damage. 
A  number  of  possibilities  of  how  such  a  relationship  could  be  mediated  exist.  This 
interaction  may  act  as  a  decisive  step  for  C-MYC  function  i.  e.  maintenance  of  cellular 
proliferation  or  apoptotic  cell  death.  The  'dual  control'  model  proposed  to  explain  the 
opposing  functions  of  c-MYC  suggests  that  c-MYC  can  co-ordinatcly  prime  both  cell  death 
and  drive  proliferation.  In  response  to  suitable  signals  c-MYC  is  proposed  to  trigger 
apoptosis  through  downstream  pathways.  Therefore  the  interaction  with  hMLH1  may 
actively  link  the  priming  of  cell  death  to  the  triggering  of  cell  death.  This  would  suggest 
that  the  interaction  of  these  two  proteins  occurs  specifically  in  response  to  treatment  with 
DNA-damaging  agents.  Because  c-MYC  expression  is  known  to  be  upregulated  in 
response  to  treatment  with  cisplatin,  this  interaction  may  only  therefore  occur,  or  at  least 
preferably  occur  when  c-MYC  expression  is  high.  This  model  is  especially  plausible  when 
one  considers  the  relatively  low  levels  of  c-MYC  expression  in  normal  cells.  hMLH1  may 
interact  with  c-MYC  and  directly  trigger  an  apoptotic  response  through  proteins  such  as 
BIN1.  Alternatively  this  interaction  may  form  part  of  the  MMR  dependent  activation  of 
the  p53  or  p73  dependent  apoptotic  pathways.  The  observation  that  in  a  number  of  human 
turnours  c-MYC  expression  is  elevated,  and  this  is  associated  with  resistance  to  cisplatin, 
would  also  have  to  be  accounted  for  by  such  a  model.  A  fine  balance  obviously  exists 
between  the  various  functions  of  the  c-MYC  protein.  Upon  treatment  of  cells  with 
cisplatin,  the  increased  level  of  c-MYC  expression  proposed  here  to  act  in  concert  with 
MMR  to  trigger  cell  death  is  different  to  the  c-MYC  activation  seen  in  some  cancer  cells. 
This  represents  a  transient  effect  versus  a  more  permanent  effect  mediated  through  for 
example  APC  mutations  in  colon  cancer  cells  which  lead  to  loss  of  c-MYC  regulation. 
Further  studies  will  be  needed  to  address  the  functional  significance  of  this  interaction  and 
more  specifically  address  the  possible  scenarios  proposed  above. 196 
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Appendix  1  Human  MLH1  Details  of  the  Sequence  from  the 
National  Centre  for  Biotechnology  Information 
LOCUS 
DEFINITION 
ACCESSION 
VERSION 
KEYWORDS 
SOURCE 
ORGANISM 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
MEDLINE 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
FEATURES 
source 
gene 
CDS 
BASE  COUNT 
ORIGIN 
1 
61 
121 
181 
241 
301 
361 
421 
481 
541 
601 
661 
HSHMLHI  2503  bp  MRNA  PRI  31-MAR-1994 
Human  DNA  mismatch  repair  (hmlhl)  mRNA,  complete  cda. 
U07418 
U07418.1  GI:  466461 
Lman. 
Homo  sapiens 
Eukaryota;  Metazoa;  Chordata;  Craniata;  Vertebrata;  Euteleostomi; 
Mammalia;  Eutheria;  Primates;  Catarrhini;  Hominidae;  Homo. 
1  (bases  1  to  2503) 
Papadopoulos,  N.,  Nicolaides,  N.  C.,  Wei,  Y.  F.,  Ruben,  S.  M., 
Carter,  K.  C.,  Rosen,  C.  A.,  Haseltine,  W.  H.,  Fleischmann,  R.  D., 
Fraser,  C.  M.,  Adams,  M.  D.,  Venter,  J.  C.,  Hamilton,  S.  R.,  Petersen,  G.  M., 
Watson,  P.,  Lynch,  H.  T.,  Peltomaki,  P.,  Mecklin,  J.  P.,  Chapelle,  A.  D., 
Kinzler,  K.  W.  and  VogelBtein,  B. 
Mutation  of  a  mutL  Homolog  is  Associated  with  Hereditary  Colon 
Cancer 
Science  263,1625-1629  (1994) 
94174309 
2  (bases  1  to  2503) 
Wei,  Y.  F. 
Direct  Submission 
Submitted  (04-MAR-1994)  Ying-rei  Wei,  Molecular  Biology,  Human 
Genome  Sciences,  Inc.,  9620  Medical  Center  Drive,  Rockville,  MD 
20850,  USA 
Location/QualifierB 
J..  2503 
/organiBM="HOMO  sapiens" 
/db  xref="taxon:  9606" 
/chr-omosome="3" 
/map=11p2l" 
/tissue_type="gall  bladder" 
/deV  Btage="adult" 
42..  'h12 
/gene="hmlhl" 
42..  2312 
/gene="hmlhl" 
/function="DNA  mismatch  repair" 
/note="human  homolog  of  E.  coli  mutL  gene  product, 
Swiss-Prot  Accession  Number  P23367" 
/codon_Btart=l 
/protein 
- 
id="AAA17374.1" 
/db_xref="GI:  466462" 
/translation="MSFVAGVIRRLDETVVNRIAAGEVIQRPANAIKEMIENCLDAKS 
TSIQVIVKEGGLKLIQIQDNGTGIRKEDLDIVCERFTTSKLQSFEDLASISTYGFRGE 
ALASISHVAHVTITTKTADGKCAYRASYSDGKLKAPPKPCAGNOGTQITVEDLFYNIA 
TRRKALKNPSEEYGKILEVVGRYSVHNAGISFSVKKQGETVADVRTLPNASTVDNIRS 
VFGNAVSRELIEIGCEDKTLAFKMNGYISNANYSVKKCIFLLPINHRLVESTSLRKAI 
ETVYAAYLPKNTHPFLYLSLEISPQNVDVNVHPTKHEVHFLHEESILERVQQHIESKL 
LGSNSSRMYFTQTLLPGLAGPSGEMVKSTTSLTSSSTSGSSDKVYAHQMVRTDSREQK 
LDAFLQPLSKPLSSQPQAIVTEDKTDISSGRARQQDEEMLELPAPAEVAAKNOSLEGD 
TTKGTSEMSEKRGPTSSNPRKRHREDSDVEMVEDDSRKEMTAACTPRRRIINLTSVLS 
LQEEINEQGHEVLREMLHNHSFVGCVNPQWALAQHQTKLYLLNTTKLSEELFYQILIY 
DFANFGVLRLSEPAPLFDLAMLALDSPESGWTEEDGPKEGLAEYIVEFLKKKAEMLAD 
YFSLEIDEEGNLIGLPLLIDNYVPPLEGLPIFILRLATEVNWDEEKECFESLSKECAM 
FYSIRKQYISEESTLSGQQSEVPGSIPNSWKWTVEHIVYKALRSHILPPKHFTEDGNI 
LQLANLPDLYKVFERC" 
723  a  539  c  599  g  642  t 
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tacccaatgc  ctcaaccgtg  gacaatattc  gctccgtctt  tggaaatgct  gttagtcgag 198 
721  aactgataga  aattggatgt  gaggataaaa  ccctagcctt  caaaatgaat  ggttacatat 
781  ccaatgcaaa  ctactcagtg  aagaagtgca  tcttcttact  cttcatcaac  catcgtctgg 
841  tagaatcaac  ttccttgaga  aaagccatag  aaacagtgta  tgcagcctat  ttgcccaaaa 
gol  acacacaccc  attcctgtac  ctcagtttag  aaatcagtcc  ccagaatgtg  gatgttaatg 
961  tgcaccccac  aaagcatgaa  gttcacttcc  tgcacgagga  gagcatcctg  gagcgggtgc 
1021  agcagcacat  cgagagcaag  ctcctgggct  ccaattcctc  caggatgtac  ttcacccaga 
1081  ctttgctacc  aggacttgct  ggcccctctg  gggagatggt  taaatccaca  acaagtctga 
1141  cctcgtcttc  tacttctgga  agtagtgata  aggtctatgc  ccaccagatg  gttcgtacag 
1201  attcccggga  acagaagctt  gatgcatttc  tgcagcctct  gagcaaaccc  ctgtccagtc 
1261  agccccaggc  cattgtcaca  gaggataaga  cagatatttc  tagtggcagg  gctaggcagc 
1321  aagatgagga  gatgcttgaa  ctcccagccc  ctgctgaagt  ggctgccaaa  aatcagagct 
1381  tggaggggga  tacaacaaag  gggacttcag  aaatgtcaga  gaagagagga  cctacttcca 
1441  gcaaccccag  aaagagacat  cgggaagatt  ctgatgtgga  aatggtggaa  gatgattccc 
1501  gaaaggaaat  gactgcagct  tgtacccccc  ggagaaggat  cattaacctc  actagtgttt 
1561  tgagtctcca  ggaagaaatt  aatgagcagg  gacatgaggt  tctccgggag  atgttgcata 
1621  accactcctt  cgtgggctgt  gtgaatcctc  agtgggcctt  ggcacagcat  caaaccaagt 
1681  tataccttct  caacaccacc  aagcttagtg  aagaactgtt  ctaccagata  ctcatttatg 
1741  attttgccaa  ttttggtgtt  ctcaggttat  cggagccagc  accgctcttt  gaccttgcca 
1801  tgcttgcctt  agatagtcca  gagagtggct  ggacagagga  agatggtccc  aaagaaggac 
1861  ttgctgaata  cattgttgag  tttctgaaga  agaaggctga  gatgcttgca  gactatttct 
1921  ctttggaaat  tgatgaggaa  gggaacctga  ttggattacc  ccttctgatt  gacaactatg 
1981  tgcccccttt  ggagggactg  cctatcttca  ttcttcgact  agccactgag  gtgaattggg 
2041  acgaagaaaa  ggaatgtttt  gaaagcctca  gtaaagaatg  cgctatgttc  tattccatcc 
2101  ggaagcagta  catatctgag  gagtcgaccc  tctcaggcca  gcagagtgaa  gtgcctggct 
2161  ccattccaaa  ctcctggaag  tggactgtgg  aacacattgt  ctataaagcc  ttgcgctcac 
2221  acattctgcc  tcctaaacat  ttcacagaag  atggaaatat  cctgcagctt  gctaacctgc 
2281  ctgatctata  caaagtcttt  gagaggtgtt  aaatatggtt  atttatgcac  tgtgggatgt 
2341  gttcttcttt  ctctgtattc  cgatacaaag  tgttgtatca  aagtgtgata  tacaaagtgt 
2401  accaacataa  gtgttggtag  cacttaagac  ttatacttgc  cttctgatag  tattccttta 
2461  tacacagtgg  attgattata  aataaataga  tgtgtcttaa  cat 199 
Appendix  2.  Human  MLH1  Nucleotide  Sequence  and  Peptide 
Sequence  with  Primers  used  to  make  the  yeast 
Two-Hybrid  Constructs. 
F1 
GTTGAACATCTAGACGTTTCCTTGGCTCTTCTGGCGCCAAAATGTCGTTCGTGGCAGGGG 
---------+---------+---------+---------+---------+---------+  60 
MSFVAGV 
TTATTCGGCGGCTGGACGAGACAGTGGTGAACCGCATCGCGGCGGGGGAAGTTATCCAGC 
61  ---------+---------+---------+---------+---------+---------+ 
120 
IRRLDETVVNRIAA  G"  EVIQR 
GGCCAGCTAATGCTATCAAAGAGATGATTGAGAACTGTTTAGATGCAAAATCCACAAGTA 
121  ---------+---------+---------+---------+---------+---------+  180 
PANAIKEMIENCLDAKSTSI 
TTCAAGTGATTGTTAAAGAGGGAGGCCTGAAGTTGATTCAGATCCAAGACAATGGCACCG 
181  ---------+---------+---------+---------+---------+---------+  240 
QVIVKEGGLKLIQIQDNGTG 
GGATCAGGAAAGAAGATCTGGATATTGTATGTGAAAGGTTCACTACTAGTAAACTGCAGT 
241  ---------+---------+---------+---------+---------+---------+  300 
IRKEDLDIVCERFTTSKL0S 
CCTTTGAGGATTTAGCCAGTATTTCTACCTATGGCTTTCGAGGTGAGGCTTTGGCCAGCA 
301  ---------+---------+---------+---------+---------+---------+  360 
FEDLASISTYGFRGEALASI 
TAAGCCATGTGGCTCATGTTACTATTACAACGAAAACAGCTGATGGAAAGTGTGCATACA 
361  ---------+---------+---------+---------+---------+---------+  420 
SHVAHVTITTKTADGKCAYR 
GAGCAAGTTACTCAGATGGAAAACTGAAAGCCCCTCCTAAACCATGTGCTGGCAATCAAG 
421  ---------+---------+---------+---------+---------+---------+  480 
ASYSDGKLKAPPKPCAGN0G 
GGACCCAGATCACGGTGGAGGACCTTTTTTACAACATAGCCACGAGGAGAAAAGCTTTAA 
481  ---------+---------+---------+---------+---------+---------+  540- 
TQITVEDLFYNIATRRKALK 
AAAATCCAAGTGAAGAATATGGGAAAATTTTGGAAGTTGTTGGCAGGTATTCAGTACACA 
541  ------------------------------------------------------------  600 
NPSEEYGKILEVVGRYSVHN 
ATGCAGGCATTAGTTTCTCAGTTAAAAAACAAGGAGAGACAGTAGCTGATGTTAGGACAC 
601  ---------+---------+---------+---------+---------+---------+  660 
AGISFSVKKQGETVADVRTL 
TACCCAATGCCTCAACCGTGGACAATATTCGCTCCGTCTTTGGAAATGCTGTTAGTCGAG 
661  ---------+---------+---------+---------+---------+---------+  720 
PNASTVDNIRSVFGNAVSRE 200 
R2 
,  AACTGATAGAAATTGGATGTGAGGATAAAACCCTAGCCTTCAAAATGAATGGTTACATAT 
721  ------------------------------------------------------------  780 
LIEIGCEDKTLAFKMNGYIS 
CCAATGCAAACTACTCAGTGAAGAAGTGCATCTTCTTACTCTTCATCAACCATCGTCTGG 
781  ---------+---------+---------+---------+---------+---------+  840 
NANYSVKKCIFLLFINHRLV 
TAGAATCAACTTCCTTGAGAAAAGCCATAGAAACAGTGTATGCAGCCTATTTGCCCAAAA 
841  ------------------------------------------------------------  900 
ESTSLRKAIETVYAAYLPKN 
ACACACACCCATTCCTGTACCTCAGTTTAGAAATCAGTCCCCAGAATGTGGATGTTAATG 
901  ---------+---------+---------+---------+---------+---------+  960 
THPFLYLSLEISPQNVDVNV 
F3  10 
TGCACCCCACAAAGCATGAAGTTCACTTCCTGCACGAGGAGAGCATCCTGGAGCGGGTGC 
961  ---------+---------+---------+---------+---------+---------+  1020 
HPTRHEVHFLHEESILERVQ 
4  R2 
AGCAGCACATCGAGAGCAAGCTCCTGGGCTCCAATTCCTCCAGGATGTACTTCACCCAGA 
1021  ------------------------------------------------------------  1080 
QHIESKLLGSNSSRMYrT0T 
CTTTGCTACCAGGACTTGCTGGCCCCTCTGGGGAGATGGTTAAATCCACAACAAGTCTGA 
1081  ---------+---------+---------+---------+---------+---------+  1140 
LLPGLAGPSGEMVKSTTSLT 
CCTCGTCTTCTACTTCTGGAAGTAGTGATAAGGTCTATGCCCACCAGATGGTTCGTACAG 
1141  ---------+---------+---------+---------+---------+---------+  1200 
SSSTSGSSDKVYAH0MVRTD 
ATTCCCGGGAACAGAAGCTTGATGCATTTCTGCAGCCTCTGAGCAAACCCCTGTCCAGTC 
1201  ---------+---------+---------+---------+---------+---------+  1260 
SREQRLDAFLQPLSKPLSSQ 
AGCCCCAGGCCATTGTCACAGAGGATAAGACAGATATTTCTAGTGGCAGGGCTAGGCAGC 
1261  ---------+---------+---------+---------+---------+---------+  1320 
P0AIVTEDKTDISSGRARQQ 
AAGATGAGGAGATGCTTGAACTCCCAGCCCCTGCTGAAGTGGCTGCCAAAAATCAGAGCT 
1321  ---------+---------+---------+---------+---------+---------+  1380 
DEEMLELPAPAEVAAKN0SL 
TGGAGGGGGATACAACAAAGGGGACTTCAGAAATGTCAGAGAAGAGAGGACCTACTTCCA 
1381  ---------+---------+---------+---------+---------+---------+  1440 
EGDTTKGTSEMSEKRGPTSS 
GCAACCCCAGAAAGAGACATCGGGAAGATTCTGATGTGGAAATGGTGGAAGATGATTCCC 
1441  ---------+---------+---------+---------+---------+---------+  1500 
NPRRRHREDSDVEMVEDDSR 
GAAAGGAAATGACTGCAGCTTGTACCCCCCGGAGAAGGATCATTAACCTCACTAGTGTTT 
1501  ---------+---------+---------+---------+---------+---------+  1560 
KEMTAACTPRRRIINLTSVL 
40 
TGAGTCTCCAGGAAGAAATTAATGAGCAGGGACATGAGGTTCTCCGGGAGATGTTGCATA 
1561  ------------------------------------------------------------  1620 
SLQEEINE0GHEVLREMLHN 201 
ACCACTCCTTCGTGGGCTGTGTGAATCCTCAGTGGGCCTTGGCACAGCATCAAACCAAGT 
1621  ------------------------------------------------------------  1680 
HSFVGCVNPQWALAQHQTKL 
TATACCTTCTCAACACCACCAAGCTTAGTGAAGAACTGTTCTACCAGATACTCATTTATG 
1681  ------------------------------------------------------------  1740 
YLLNTTKLSEELPY01LIYD 
4,  R3 
ATTTTGCCAATTTTGGTGTTCTCAGGTTATCGGACCCAGCACCGCTCTTTGACCTTGCCA 
1741  ------------------------------------------------------------  1800 
FANFGVLRLSEPAPLFDLAM 
TGCTTGCCTTAGATAGTCCAGAGAGTGGCTGGACAGAGGAAGATGGTCCCAAAGAAGGAC 
1801  ------------------------------------------------------------  1860 
LALDSPESGWTEEDGPKEGL 
TTGCTGAATACATTGTTGAGTTTCTGAAGAAGAAGGCTGAGATGCTTGCAGACTATTTCT 
1861  ------------------------------------------------------------  1920 
AEYIVEFLKKKAEMLADYFS 
CTTTGGAAATTGATGAGGAAGGGAACCTGATTGGATTACCCCTTCTGATTGACAACTATG 
1921  ------------------------------------------------------------  1980 
LEIDEEGNLIGLPLLIDNYV 
TGCCCCCTTTGGAGGGACTGCCTATCTTCATTCTTCGACTAGCCACTGAGGTGAATTGGG 
1981  ------------------------------------------------------------  2040 
PPLEGLPIFILRLATEVNWD 
ACGAAGAAAAGGAATGTTTTGAAAGCCTCAGTAAAGAATGCGCTATGTTCTATTCCATCC 
2041  ------------------------------------------------------------  2100 
EEKECFESLSKECAMFYSIR 
GGAAGCAGTACATATCTGAGGAGTCGACCCTCTCAGGCCAGCAGAGTGAAGTGCCTGGCT 
2101  ------------------------------------------------------------  2160 
KQYISEESTLSGQQSEVPGS 
CCATTCCAAACTCCTGGAAGTGGACTGTGGAACACATTGTCTATAAAGCCTTGCGCTCAC 
2161  ------------------------------------------------------------  2220 
IPNSWKWTVEHIVYKALRSH 
ACATTCTGCCTCCTAAACATTTCACAGAAGATGGAAATATCCTGCAGCTTGCTAACCTGC 
2221  ------------------------------------------------------------  2280 
ILPPKHFTEDGNIL0LANLP 
R4 
CTGATCTATACAAAGTCTTTGAGAGGTGTTAA 
2281  ---------+---------+---------+-- 
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cds. 
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REFERENCE  2  (bases  1  to  2697) 
AUTHORS  Morrison,  P.  T. 
TITLE  Direct  Submission 
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MA  002115,  USA 
FEATURES  Location/Qualifiers 
source  1..  2697 
/organism--"Homo  sapiens" 
/db  xref="taxon:  9606" 
gene  3..  i591 
/gene="hPMS2" 
CDS  3..  2591 
/gene="hPMS2" 
/function="DNA  mismatch  repair" 
/note="similar  to  S.  cereviBiae  PMS1  Swiss-Prot  Accession 
Number  P14242,  S.  cerevisiae  MLHl  GenBank  Accession  Number 
U07187,  E.  coli  MUTL  Swiss-Prot  Accession  Number  P23367, 
Salmonella  typhimurium.  MUTL  Swiss-Prot  Accession  Number 
P14161,  Streptococcus  pneumoniae  Swiss-Prot  Accession 
Number  P14160" 
/codon_start=l 
/protein 
- 
id="AAA50390.1" 
/db_xref="GI:  557470" 
/translation="MERAESSSTEPAKAIKPIDRKSVHQICSGQVVLSLSTAVKELVE 
NSLDAGATNIDLKLKDYGVDLIEVSDNGCGVEEENFEGLTLKHHTSKIQEFADLTOVE 
TFGFRGEALSSLCALSDVTISTCHASAKVGTRLMFDHNGKIIQKTPYPRPRGTTVSVO 
QLFSTLPVRHKEFORNIKKEYAKMVQVLHAYCIISAGIRVSCTNQLGQGKRQPvvCTG 
GSPSIKENIGSVFGQKQLQSLIPFVQLPPSDSVCEEYGLSCSDALHNLFYISGFISOC 
THGVGRSSTDRQFFFINRRPCDPAKVCRLVNEVYHMYNRHOYPFVVLNISVDSECVDI 
NVTPDKRQILLQEEKLLLAVLKTSLIGMFDSDVNKLNVSQQPLLDVEGNLIKMHAADL 
EKPMVEKQDQSPSLRTGEEKKDVSISRLREAFSLRHTTENKPHSPKTPEPRRSPLGQK 
RGMLSSSTSGAISDKGVLRSQKEAVSSSHGPSDPTDRAEVEKDSGHGSTSVDSEGFSI 
PDTGSHCSSEYAASSPGDRGSQEHVDSQEKAPETDDSFSDVDCHSNQEDTGCKFRVLP 
QPTNLATPNTKRFKKEEILSSSDICQKLVNTQDMSASQVDVAVKINKKVVPLDFSMSS 
LAKRIKQLHHEAQQSEGEQNYRKFRAKICPGENQAAEDELRKEISKTMFAEMEIICQF 
NLGFIITKLNEDIFIVDQHATDEKYNFEMLQQHTVLQGQRLIAPQTLNLTAVNEAVLI 
ENLEIFRKNGFDFVIDENAPVTERAKLISLPTSKNWTFGPQDVDELIFMLSDSPGVMC 
RPSRVKQMFASRACRKSVMIGTALNTSEMKKLITHMGEMDHPWNCPHGRPTMRHIANL 
GVISQN" 
BASE  COUNT  797  a  588  c  653  g  659  t 
ORIGIN 
1  ccatggagcg  agctgagagc  tcgagtacag  aacctgctaa  ggccatcaaa  cctattgatc 
61  ggaagtcagt  ccatcagatt  tgctctgggC  aggtggtact  gagtctaagc  actgcggtaa 
121  aggagttagt  agaaaacagt  ctggatgctg  gtgccactaa  tattgatcta  aagcttaagg 
181  actatggagt  ggatcttatt  gaagtttcag  acaatggatg  tggggtagaa  gaagaaaact 
241  tcgaaggctt  aactctgaaa  catcacacat  ctaagattca  agagtttgCC  gacctaactc 
301  aggttgaaac  ttttggcttt  cggggggaag  ctctgagcto  actttgtgca  ctgagcgatg 
361  tcaccatttc  tacctgccac  gcatcggcga  aggttggaac  tcgactgatg  tttgatcaca 
421  atgggaaaat  tatccagaaa  accccctacc  cccgccccag  agggaccaca  gtcagcgtgc 
481  agcagttatt  ttccacacta  cctgtgcgcc  ataaggaatt  tcaaaggaat  attaagaagg 
541  agtatgccaa  aatggtccag  gtcttacatg  catactgtat  catttcagca  ggcatccgtg 203 
601  taagttgcac  caatcagctt  ggacaaggaa  aacgacagcc  tgtggtatgc  acaggtggaa 
661  gccccagcat  aaaggaaaat  atcggctctg  tgtttgggca  gaagcagttg  caaagcctca 
721  ttccttttgt  tcagctgccc  cctagtgact  ccgtgtgtga  agagtacggt  ttgagctgtt 
781  cggatgctct  gcataatctt  ttttacatct  caggtttcat  ttcacaatgc  acgcatggag 
841  ttggaaggag  ttcaacagac  agacagtttt  tctttatcaa  ccggcggcct  tgtgacccag 
gol  caaaggtctg  cagactcgtg  aatgaggtct  accacatgta  taatcgacac  cagtatccat 
961  ttgttgttct  taacatttct  gttgattcag  aatgcgttga  tatcaatgtt  actccagata 
1021  aaaggcaaat  tttgctacaa  gaggaaaagc  ttttgttggc  agttttaaag  acctctttga 
1081  taggaatgtt  tgatagtgat  gtcaacaagc  taaatgtcag  tcagcagcca  ctgctggatg 
1141  ttgaaggtaa  cttaataaaa  atgcatgcag  cggatttgga  aaagcccatg  gtagaaaagc 
1201  aggatcaatc  cccttcatta  aggactggag  aagaaaaaaa  agacgtgtcc  atttccagac 
1261  tgcgagaggc  cttttctctt  cgtcacacaa  cagagaacaa  gcctcacagc  ccaaagactc 
1321  cagaaccaag  aaggagccct  ctaggacaga  aaaggggtat  gctgtcttct  agcacttcag 
1381  gtgccatctc  tgacaaaggc  gtcctgagat  ctcagaaaga  ggcagtgagt  tccagtcacg 
1441  gacccagtga  ccctacggac  agagcggagg  tggagaagga  ctcggggcac  ggcagcactt 
1501  ccgtggattc  tgaggggttc  agcatcccag  acacgggcag  tcactgcagc  agcgagtatg 
1561  cggccagctc  cccaggggac  aggggctcgc  aggaacatgt  ggactctcag  gagaaagcgc 
1621  ctgaaactga  cgactctttt  tcagatgtgg  actgccattc  aaaccaggaa  gataccggat 
1681  gtaaatttcg  agttttgcct  cagccaacta  atctcgcaac  cccaaacaca  aagcgtttta 
1741  aaaaagaaga  aattctttcc  agttctgaca  tttgtcaaaa  gttagtaaat  actcaggaca 
1801  tgtcagcctc  tcaggttgat  gtagctgtga  aaattaataa  gaaagttgtg  cccctggact 
1861  tttctatgag  ttctttagct  aaacgaataa  agcagttaca  tcatgaagca  cagcaaagtg 
1921  aaggggaaca  gaattacagg  aagtttaggg  caaagatttg  tcctggagaa  aatcaagcag 
1981  ccgaagatga  actaagaaaa  gagataagta  aaacgatgtt  tgcagaaatg  gaaatcattg 
2041  gtcagtttaa  cctgggattt  ataataacca  aactgaatga  ggatatcttc  atagtggacc 
2101  agcatgccac  ggacgagaag  tataacttcg  agatgctgca  gcagcacacc  gtgctccagg 
2161  ggcagaggct  catagcacct  cagactctca  acttaactgc  tgttaatgaa  gctgttctga 
2221  tagaaaatct  ggaaatattt  agaaagaatg  gctttgattt  tgttatcgat  gaaaatgctc 
2281  cagtcactga  aagggctaaa  ctgatttcct  tgccaactag  taaaaactgg  accttcggac 
2341  cccaggacgt  cgatgaactg  atcttcatgc  tgagcgacag  ccctggggtc  atgtgccggc 
2401  cttcccgagt  caagcagatg  tttgcctcca  gagcctgccg  gaagtcggtg  atgattggga 
2461  ctgctctcaa  cacaagcgag  atgaagaaac  tgatcaccca  catgggggag  atggaccacc 
2521  cctggaactg  tccccatgga  aggccaacca  tgagacacat  cgccaacctg  ggtgtcattt 
2581  ctcagaactg  accgtagtca  ctgtatggaa  taattggttt  tatcgcagat  ttttatgttt 
2641  tgaaagacag  agtcttcact  aacctttttt  gttttaaaat  gaaacctgcg  gccttcg 204 
Appendix  4.  Human  PMS2  Nucleotide  Sequence  and  Peptide 
Sequence  with  Primers  used  to  make  the  yeast 
Two-Hybrid  Constructs. 
Fl  0 
CCATGGAGCGAGCTGAGAGCTCGAGTACAGAACCTGCTAAGGCCATCAAACCTATTGATC 
------------------------------------------------------------  60 
MERAESSSTEPAKAIKPIDR 
GGAAGTCAGTCCATCAGATTTGCTCTGGGCAGGTGGTACTGAGTCTAAGCACTGCGGTAA 
61  ------------------------------------------------------------  120 
KSVHQICSGQVVLSLSTAVK 
AGGAGTTAGTAGAAAACAGTCTGGATGCTGGTGCCACTAATATTGATCTAAAGCTTAAGG 
121  ------------------------------------------------------------  180 
ELVENSLDAGATNIDLKLKD 
ACTATGGAGTGGATCTTATTGAAGTTTCAGACAATGGATGTGGGGTAGAAGAAGAAAACT 
181  ------------------------------------------------------------  240 
YGVDLIEVSDNGCGVEEENr 
TCGAAGGCTTAACTCTGAAACATCACACATCTAAGATTCAAGAGTTTGCCGACCTAACTC 
241  ------------------------------------------------------------  300 
EGLTLKHHTSKIQEFADLT0 
AGGTTGAAACTTTTGGCTTTCGGGGGGAAGCTCTGAGCTCACTTTGTGCACTGAGCGATG 
301  -------------------------------------------------------------  360 
VETFGFRGEALSSLCALSDV 
TCACCATTTCTACCTGCCACGCATCGGCGAAGGTTGGAACTCGACTGATGTTTGATCACA 
361  ------------------------------------------------------------  420 
TISTCHASAKVGTRLHFDHN 
ATGGGAAAATTATCCAGAAAACCCCCTACCCCCCCCCCAGAGGGACCACAGTCAGCGTGC 
421  ------------------------------------------------------------  480 
GKI10KTPYPRPRGTTVSV0 
AGCAGTTATTTTCCACACTACCTGTGCGCCATAAGGAATTTCAAAGGAATATTAAGAAGG 
481  ------------------------------------------------------------  540 
QLFSTLPVRHKEFQRNIKKE 
AGTATGCCAAAATGGTCCAGGTCTTACATGCATACTGTATCATTTCAGCAGGCATCCGTG 
541  ------------------------------------------------------------  600 
YAKMV0VLHAYcIISAGIRV 
TAAGTTGCACCAATCAGCTTGGACAAGGAAAACGACAGCCTGTGGTATGCACAGGTGGAA 
601  ------------------------------------------------------------  660 
SCTNQLG0GKRQPVVCTGGS 
GCCCCAGCATAAAGGAAAATATCGGCTCTGTGTTTGGGCAGAAGCAGTTGCAAAGCCTCA 
661  ------------------------------------------------------------  720 
PSIKENIGSVFGQKQLQSLI 
F'2 
ý__ 
TTCCTTTTGTTCAGCTGCCCCCTAGTGACTCCGTGTGTGAAGAGTACGGTTTGAGCTGTT 
721  ------------------------------------------------------------  780 
pFVQLPPSDSVCEEYGLSCS 205 
R1 
CGGATCCTCTGCATAATCTTTTTTACATCTCAGGTTTCATTTCACAATGCACGCATGGAG 
781  ------------------------------------------------------------  840 
DAL,  H  NLr.  y  iSGFISQCTHGV 
TTGGAAGGAGTTCAACAGACAGACAGTTTTTCTTTATCAACCGGCGGCCTTGTGACCCAG 
841  ------------------------------------------------------------  900 
GRS.  S  TDRQFPFINRRPCDPA 
CAAAGGTCTGCAGACTCGTGAATGAGGTCTACCACATGTATAATCGACACCAGTATCCAT 
gol  ------------------------------------------------------------  960 
KVCRLVNEVYHMYNRH0YPF 
TTGTTGTTCTTAACATTTCTGTTGATTCAGAATGCGTTGATATCAATGTTACTCCAGATA 
961  ------------------------------------------------------------  1020 
VVLNISVDSECVDINVTPDK 
AAAGGCAAATTTTGCTACAAGAGGAAAAGCTTTTGTTGGCAGTTTTAAAGACCTCTTTGA 
1021  ------------------------------------------------------------  1080 
RQILLQEEKLLLAVLKTSLI 
TAGGAATGTTTGATAGTGATGTCAACAAGCTAAATGTCAGTCAGCAGCCACTGCTGGATG 
1081  ------------------------------------------------------------  1140 
GMFDSDVNKLNVSQQPLLDV 
TTGAAGGTAACTTAATAAAAATGCATGCAGCGGATTTGGAAAAGCCCATGGTAGAAAAGC 
1141  ------------------------------------------------------------  1200 
EGNLIKMHAADLEKPMVEK0 
AGGATCAATCCCCTTCATTAAGGACTGGAGAAGAAAAAAAAGACGTGTCCATTTCCAGAC 
1201  ------------------------------------------------------------  1260 
D0SPSLRTGEEKKDVSISRL 
F3  0 
TGCGAGAGGCCTTTTCTCTTCGTCACACAACAGAGAACAAGCCTCACAGCCCAAAGACTC 
1261  ------------------------------------------------------------  1320 
REAFSLRHTTENKPHSPKTP 
4  R2 
CAGAACCAAGAAGGAGCCCTCTAGGACAGAAAAGGGGTATGCTGTCTTCTAGCACTTCAG 
1321  ------------------------------------------------------------  1380 
EPRRS,  P  LGQKRGMLSSSTSG 
GTGCCATCTCTGACAAAGGCGTCCTGAGATCTCAGAAAGAGGCAGTGAGTTCCAGTCACG 
1381  ------------------------------------------------------------  1440 
AISDKGVLRSQKEAVSSSHG 
GACCCAGTGACCCTACGGACAGAGCGGAGGTGGAGAAGGACTCGGGGCACGGCAGCACTT 
1441  ------------------------------------------------------------  1500 
PSDPTDRAEVEKDSGHGSTS 
CCGTGGATTCTGAGGGGTTCAGCATCCCAGACACGGGCAGTCACTGCAGCAGCGAGTATG 
1501  ------------------------------------------------------------  1560 
VDSEGFSIPDTGSHCSSEYA 
CGGCCAGCTCCCCAGGGGACAGGGGCTCGCAGGAACATGTGGACTCTCAGGAGAAAGCGC 
1561  ------------------------------------------------------------  1620 
ASSPGDRGSQEHVDSQEKAP 
CTGAAACTGACGACTCTTTTTCAGATGTGGACTGCCATTCAAACCAGGAAGATACCGGAT 
1621  ------------------------------------------------------------  1680 
ETDDSFSDVDCHSNQEDTGC 206 
GTAAATTTCGAGTTTTGCCTCAGCCAACTAATCTCGCAACCCCAAACACAAAGCGTTTTA 
1681  ------------------------------------------------------------ 
1740 
KFRVLPQPTNLATPNTKRPK 
AAAAAGAAGAAATTCTTTCCAGTTCTGACATTTGTCAAAAGTTAGTAAATACTCAGGACA 
1741  ------------------------------------------------------------  1800 
KEEILSSSDICQKLVNTQDM 
TGTCAGCCTCTCAGGTTGATGTAGCTGTGAAAATTAATAAGAAAGTTGTGCCCCTGGACT 
1801  ------------------------------------------------------------ 
1860 
SASQVDVAVKINKKVVPLDF 
F4 
TTTCTATGAGTTCTTTAGCTAAACGAATAAAGCAGTTACATCATGAAGCACAGCAAAGTG 
1861  ------------------------------------------------------------ 
1920 
SMSSLAKRIK0LHHEA00SE 
4  R3 
AAGGGGAACAGAATTACAGGAAGTTTAGGGCAAA.  GATTTGTCCTGGAGAAAATCAAGCAG 
1921  ------------------------------------------------------------ 
1980 
GEQNYRKrRAKICPGEN0AA 
CCGAAGATGAACTAAGAAA,  AGAGATAAGTAAAACGATGTTTGCAGAAATGGAAATCATTG 
1981  ------------------------------------------------------------  2040 
EDELRKEISKTMPAEMEIIG 
GTCAGTTTAACCTGGGATTTATAATAACCAAACTGAATGAGGATATCTTCATAGTGGACC 
2041  ------------------------------------------------------------  2100 
0FNLGFIITKLNEDIFIVD0 
AGCATGCCACGGACGAGAAGTATAACTTCGAGATGCTGCAGCAGCACACCGTGCTCCAGG 
2101  ------------------------------------------------------------  2160 
HATDEKYNFEMLQQHTVLQG 
GGCAGAGGCTCATAGCACCTCAGACTCTCAACTTAACTGCTGTTAATGAAGCTGTTCTGA 
2161  ------------------------------------------------------------  2220 
QRLIAPQTLNLTAVNEAVLI 
TAGAAAATCTGGAAATATTTAGAAAGAATGGCTTTGATTTTGTTATCGATGAAAATGCTC 
2221  ------------------------------------------------------------  2280 
ENLEIFRKNGFDFVIDENAP 
CAGTCACTGAAAGGGCTAAACTGATTTCCTTGCCAACTAGTAAAAACTGGACCTTCGGAC 
2281  ------------------------------------------------------------  2340 
VTERAKLISLPTSKNWTFGP 
CCCAGGACGTCGATGAACTGATCTTCATGCTGAGCGACAGCCCTGGGGTCATGTGCCGGC 
2341  ------------------------------------------------------------  2400 
QDVDELIFMLSDSPGVMCRP 
CTTCCCGAGTCAAGCAGATGTTTGCCTCCAGAGCCTGCCGGAAGTCGGTGATGATTGGGA 
2401  ------------------------------------------------------------  2460 
SRVK0MFASRACRKSVMIGT 
CTGCTCTCAACACAAGCGAGATGAAGAAACTGATCACCCACATGGGGGAGATGGACCACC 
2461  ------------------------------------------------------------  2520 
ALNTSEHKKLITHMGEMDHP 
CCTGGAACTGTCCCCATGGAAGGCCAACCATGAGACACATCGCCAACCTGGGTGTCATTT 
2521  ------------------------------------------------------------  2580 
WNCPHGRPTMRHIANLGVIS 207 
R4 
CTCAGAACTGA 
2581  ---------+- 
QN* 208 
Appendix  5  Human  c-MYC  Details  of  the  Sequence  from  the 
National  Centre  for  Biotechnology  Information 
LOCUS  HSMYCl  2121  bp  MRNA  PRI  17-FEB-1997 
DEFINITION  Human  MRNA  encoding  the  c-myc  oncogene. 
ACCESSION  V00568 
VERSION  V00568.1  GI:  34815 
KEYWORDS  complementary  DNA;  oncogene. 
SOURCE  human. 
ORGANISM  Homo  sapiens 
Eukaryota;  Metazoa;  Chordata;  Vertebrata;  Mammalia;  Eutheria; 
Primates;  Catarrhini;  Hominidae;  Homo. 
REFERENCE  1  (bases  I  to  2121) 
AUTHORS  Watt,  R.,  Stanton,  L.  W.,  Marcu,  K.  B.,  Gallo,  R.  C.,  Croce,  C.  M.  and 
Rovera,  G. 
TITLE  Nucleotide  sequence  of  cloned  CDNA  of  human  c-myc  oncogene 
JOURNAL  Nature  303  (5919),  725-728  (1983) 
MEDLINE  83219310 
REFERENCE  2  (bases  833  to  834) 
AUTHORS  Watt,  R. 
TITLE  Direct  Submission 
JOURNAL  Submitted  (18-JUL-1983)  to  the  EMBL/GenBank/DDBJ  databases 
COMMENT  Data  kindly  reviewed  (18-JUL-1983)  by  Watt  R. 
The  germ  line  c-myc  oncogene  given  in  <HSCMYC>  differs  in  its 
5'  noncoding  sequence  from  the  sequence  reported  here,  but  the 
protein  coding  regions  are  the  same. 
FEATURES  Location/Qualifiers 
source  1-2121 
/organism="Homo  sapiens" 
/db  xref="taxon:  9606" 
CDS  559..  1878 
/note="c-myc  oncogene" 
/codon_start=l 
/protein 
- 
id="CAA23831.1" 
/db  xref="GI:  34816" 
/db-xref="SWISS-PROT:  PO1106" 
/translation="MPLNVSFTNRNYDLDYDSVQPYFYCDEEENFYQQQQQSELQPPA 
PSEDIWKKFELLPTPPLSPSRRSGLCSPSYVAVTPFSLRGDNDGGGGSFSTADQLEMV 
TELLGGDMVNQSFICDPDDETFIKNIIIQDCMWSGFSAAAKLVSEKLASYQAARKDSG 
SPNPARGHSVCSTSSLYLQDLSAAASECIDPSVVFPYPLNDSSSPKSCASQDSSAFSP 
SSDSLLSSTESSPQGSPEPLVLHEETPPTTSSDSEEEQEDEEEIDVVSVEKRQAPGKR 
SESGSPSAGGHSKPPHSPLVLKRCHVSTHQHNYAAPPSTRKDYPAAKRVKLDSVRVLR 
QISNNRKCTSPRSSDTEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPK 
VVILKKATAYILSVQAEEQKLISEEDLLRKRREQLKHKLEQLRNSCA" 
old_sequence  832..  835 
/citation=[l] 
/replace="acgt" 
old_sequence  1439..  1441 
/citation=[11 
/replace="ccc" 
BASE  COUNT  503  a  648  c  565  g  405  t 
ORIGIN 
l  ctgctcgcgg  ccgccaccgc  cgggccccgg  ccgtccctgg  ctcccctcct  gcctcgagaa 
61  gggcagggct  tctcagaggc  ttggcgggaa  aaaagaacgg  agggagggat  cgcgctgagt 
121  ataaaagccg  gttttcgggg  ctttatctaa  ctcgctgtag  taattccagc  gagaggcaga 
181  gggagcgagc  gggcggccgg  ctagggtgga  agagccgggc  gagcagagct  gcgctgcggg 
241  cgtcctggga  agggagatcc  ggagcgaata  gggggcttcg  cctctggccc  agccctcccg 
301  cttgatcccc  caggccagcg  gtccgcaacc  cttgccgcat  ccacgaaact  ttgcccatag 
361  cagcgggcgg  gcactttgca  ctggaactta  caacacccga  gcaaggacgc  gactctcccg 
421  acgcggggag  gctattctgc  ccatttgggg  acacttcccc  gccgctgcca.  ggacccgctt 
481  ctctgaaagg  ctctccttgc  agctgcttag  acgctggatt  tttttcgggt  agtggaaaac 
541  cagcagcctc  ccgcgacgat  gcccctcaac  gttagcttca  ccaacaggaa  ctatgaccte 
601  gactacgact  cggtgcagcc  gtatttctac  tgcgacgagg  aggagaactt  ctaccagcag 
661  cagcagcaga  gcgagctgca  9ccccc9gcg  cccagcgagg  atatctggaa  gaaattcgag 
721  ctgctgccca  ccccgcccct  gtcccctagc  cgccgctccg  ggctctgctc  gccctcctac 
781  gttgcggtca  cacccttctc  Ccttcgggga  gacaacgacg  gcggtggcgg  gagcttctcc 
841  acggccgacc  agctggagat  ggtgaccgag  ctgctgggag  gagacatggt  gaaccagagt 
901  ttcatctgcg  acccggacga  cgagaccttc  atcaaaaaca,  tcatcatcca  ggactgtatg 
961  tggagcggct  tctcg9ccgc  cgccaagctc  gtctcagaga  agctggcctc  ctaccaggct 
1021  gcgcgcaaag  acagcggcag  cccgaacccc  gcccgcggcc  acagcgtctg  ctccacctcc 
1081  agcttgtacc  tgcaggatct  gagcgccgcc  gcctcagagt  gcatcgaccc  ctcggtggtc 
1141  ttcccctacc  ctctcaacga  cagcagctcg  cccaagtcct  gcgcctcgea  agactccagc 
1201  gccttctctc  cgtcctcgga  ttctctgctc  tcctcgacgg  agtcctcccc  gcagggcagc 
1261  cccgagcccc  tggtgctcca  tgaggagaca  ccgcccacca  ccagcagcga  Ctctgaggag 209 
1321.  gaacaagaag  atgaggaaga  aatcgatgtt,  gtttctgtgg  aaaagaggca  ggctcctgga 
1381  aaaaggtcag  agtctggatc  accttctgct  ggaggccaca  gcaaacctcc  tcacagccca 
1441  ctggtcctca  agaggtgcca  cgtctccaca  catcagcaca  actacgcagc  gcctccctcc 
1501  actcggaagg  actatcctgc  tgccaagagg  gtcaagttgg  acagtgtcag  agtcctgaga 
1561  cagatcagca  acaaccgaaa  atgcaccagc  cccaggtcct  cggacaccga  ggagaatgtc 
1621  aagaggcgaa  cacacaacgt  cttggagcgc  cagaggagga  acgagctaaa  acggagcttt 
1681  tttgccctgc  gtgaccagat  cccggagttg  gaaaacaatg  aaaaggcccc  caaggtagtt 
1741  atccttaaaa  aagccacagc  atacatcctg  tccgtccaag  cagaggagca  aaagctcatt 
1801  tctgaagagg  acttgttgcg  gaaacgacga  gaacagttga  aacacaaact  tgaacagcta 
1861  cggaactctt  gtgcgtaagg  aaaagtaagg  aaaacgattc  cttctaacag  aaatgtcctg 
1921  agcaatcacc  tatgaacttg  tttcaaatgc  atgatcaaat  gcaacctcac  aaccttggct 
1981  gagtcttgag  actgaaagat  ttagccataa  tgtaaactgc  ctcaaattgg  actttgggca 
2041  taaaagaact  tttttatgct  taccatcttt  tttttttctt  taacagattt  gtatttaaga 
2101  attgttttta  aaaaatttta  a 210 
Appendix  6  Chicken  (avian)  c-MYC  Details  of  the  Sequence 
from  the  National  Centre  for  Biotechnology 
Information 
LOCUS  CHKMYC  4984  bp  DNA  VRT  28-APR-1993 
DEFINITION  Chicken  cellular  myc  proto-oncogene,  complete  cda. 
ACCESSION  J00889 
VERSION  J00889.1  GI:  212354 
KEYWORDS  c-myc  proto-oncogene;  integration  site;  myc  oncogene; 
proto-oncogene. 
SOURCE  Chicken  (Rhode  Island  Red):  genomic  DNA  from  lambda  library  of 
R.  Axel;  and  normal  DNA. 
ORGANISM  Gallus  gallus 
Eukaryota;  Metazoa;  Chordata;  Craniata;  Vertebrata;  Euteleostomij 
Archosauria;  Aves;  Neognathae;  Galliformes;  Phasianidae; 
Phasianinae;  Gallus. 
REFERENCE  1  (bases  2205  to  4984) 
AUTHORS  Watson,  D.  K.,  Reddy,  P.  E.,  Duesberg,  P.  H.  and  Papas,  T.  S. 
TITLE  Nucleotide  sequence  analysis  of  the  chicken  c-myc  gene  reveals 
homologous  and  unique  coding  regions  by  comparison  with  the 
transforming  gene  of  avian  myelocytomatosis  virus  MC29, 
delta-gag-myc 
JOURNAL  Proc.  Natl.  Acad.  Sci.  U.  S.  A.  80,2146-2150  (1983) 
MEDLINE  83169838 
REFERENCE  2  (bases  1  to  2399) 
AUTHORS  Shih,  C.  -K.,  Linial,  M.  L.,  Goodenow,  M.  M.  and  Hayward,  W.  S. 
TITLE  Nucleotide  sequence  5'  of  the  chicken  c-myc  coding  region: 
Localization  of  a  noncoding  exon  that  is  absent  from  myc 
transcripts  in  most  avian  leukosis  virus-induced  lymphomas 
JOURNAL  Proc.  Natl.  Acad.  Sci.  U.  S.  A.  81,4697-4701  (1984) 
MEDLINE  84272700 
REFERENCE  3  (sites) 
AUTHORS  Linial,  M.  L.  and  GroudineM. 
TITLE  Transcription  of  three  c-myc  exons  is  enhanced  in  chicken  bursal 
jymphoma  cell  lines 
JOURNAL  Proc.  Natl.  Acad.  Sci.  U.  S.  A.  82,53-57  (1985) 
MEDLINE  85113170 
COMMENT  [3]  sites;  exon  1  boundaries. 
The  chicken  cellular  myc  10CUS  shows  a  great  deal  of  homology  to 
the  onc  locus  of  avian  myelocytomatosis  virus  MC-29,  differing  in 
only  9  base  pairs  (resulting  in  seven  amino  acid  substitutions) 
within  the  two  coding  exons. 
(2]  found  that  in  nearly  all  of  the  avian  leukosis  virus-induced 
chicken  lymphomas  that  they  examined,  proviral  sequences  were 
located  within  the  1  to  1.5  kb  region  upstream  of  the  coding  exons 
of  c-myc.  Neel  et  al.  (J.  Virol.  44,158-166  (1982)),  sequenced  the 
3'  proviral  integration  boundaries  in  two  chicken  tumors  (see 
separate  entry). 
(3]  found  that  the  myc  mRNA  in  cell  lines  derived  from  ALV-induced 
bursal  lymphomas  includes  this  non-coding  exon.  (3)  also  notes  a 
potential  TATA  box  at  1166-1171. 
complete  source  information: 
Chicken  (Rhode  Island  Red  [2]):  genomic  DNA  from  lambda  library  of 
R.  Axel  [2];  and  normal  DNA  [11,13). 
FEATURES  Location/Qualifiers 
source  l..  4984 
/organism--"Gallus  gallus" 
/db  xref="taxon:  9031" 
mRNA  120i..  4788 
/product="c-myc  mRNA" 
misc-feature  1461..  1462 
/note="ALV  proviral  integration  site  12]" 
intron  1540..  2252 
/note="c-myc  intron  A  (no  splice  consensus  at  1540); 
putative" 
misc-feature  2001..  2002 
/note="ALV  proviral  integration  site  121" 
variation  2195 
/note="g  in  one  clone;  a  in  another  clone  11)" 
exon  <2268..  2955 
/note="c-myc  protein" 
/number=l 211 
CDS  join(2268..  2955,3927..  4489) 
/note="c-myc  protein" 
/codon_start=l 
/protein 
- 
id-"AAA48963.1" 
Mb_xrefý"GI:  212355" 
/tranBlation="MPLSASLPSKNYDYDYDSVOPYFYFEEEEENFYLAAQQRGSELO 
PPAPSEDIWKKFELLPTPPLSPSRRSSLAAASCFPSTADOLEMVTELLGGDMVNQSFI 
CDPDDESFVKSIIIQDCMWSGFSAAAKLEKVVSEKLATYQASRREGGPAAASRPGPPP 
SGPPPPPAGPAASAGLYLHDLGAAAADCIDPSVVFPYPLSERAPRAAPPGANPAALLG 
VDTPPTTSSDSEEEQEEDEEIDVVTLAEANESESSTESSTEASEEHCKPHHSPLVLKR 
CHVNIHQHNYAAPPSTKVEYPAAKRLKLDSGRVLKQISNNRKCSSPRTSDSEENDKRR 
THNVLERQRRNELKLSFFALRDQIPEVANNEKAPKVVXLKKATEYVLSIQSDEHRLIA 
EKEQLRRRREQLKHKLEQLRNSRA" 
intron  2956..  3926 
/note="c-myc  intron  B" 
exon  3927..  >4489 
/note="c-myc  protein" 
/number=2 
BASE  COUNT  1000  a  1422  c  1524  g  1038  t 
ORIGIN  4  bp  upstream  of  SacII  site. 
1  ccgcggcgct  atcgggcgcc  gggagagggc  gcgatggccc  cacggtagcg  ttggccgtgg 
61  gaaagccggg  ccgcccccag  cgccggggaa  ccgcaacggg  gggatggatg  gggagggggg 
121  tgcgggggtc  ctcccgcccg  gcgatccgtg  ttcctccccg  agcttctacg  cttagaaatg 
181  atacaaatac  ttataagtcc  gtttggtgtg  cgtgtgtgtg  tggggaggag  ggggggggag 
241  gggggagggg  gtgaagaaat  aaatgcgaaa  taaataagaa  atgcatgaga  aataggaatg 
301  atatatatgt  atatatctta  gcggggtgcc  cgcaggtgcg  ggtattgcag  cgggaggggc 
361  gcagatagcg  gtcccgcggg  gccgggaaga  cgcgatgcgg  agcgccccgt  cgggtctcgg 
421  ctccgcgcac  ctccggggat  gggtaacggg  gaaggggtga  ccccggggtg  gggaaggagc 
481  cgctgggtga  ggggctgcgg  agcgagcggg  gggaggtgca  gagcccccgg  gggtcacctt 
541  gcagccgctc  cccccgcagc  ctcctcctcc  cgtttaatcc  tccgggataa  cgaagcagcg 
601  acacgggcgg  gggtgcgcga  gctacggacg  ctcctttgtg  ccggtagggt  agccggcaac 
661  cgccccgccc  gcagccgcgt  tacgggtgga  cacggagcgt  gaacctcccc  tgccgccgtc 
721  ggggggcagc  gggaggaggg  ggagcggaga  gcgaggaggg  aaggagggag  gggggaaggc 
781  agcgaggagg  gaagcagcga  ggagcgccct  tttcatcccc  gctcgtattt  tttttttttt 
841  tttactatgt  ttacttccga  cctctccttg  tagtaggaaa  aaaaaccaac  cgctgctccg 
901  catcgcctct  ccccg9cccc  tctccctccc  tccctccctc  ccgcccgccc  agctccggct 
961  cgcagtactc  gggggggggc  acggagcccc  tcggccgccc  cctcgcggcg  cgccctcccc 
1021  gctcacggag  cccgcgcgga  gccgggggcg  agcgggaggg  agatgaagcg  gcgacgcgca 
1081  ccgcgagagc  gcgcactcgc  9999cccc9c  cgtgccgctc  gtgctcccgc  ccccgctgca 
1141  tctcccgccc  gcccctcgcc  ggcgctttaa  agacagcaaa  gcaacttaac  ttctattgta 
1201  ccggacggag  cgcgccgcgc  cgccttggac  cgtacaatct  gccgcacgcc  gggaaggcga 
1261  gccctctccg  ctgtattttt  tttctcatcg  tggtgggagg  aagcgatcta  cgttctcccg 
1321  gcgttttggc  tccctttttt  cccccgtctt  ctccggcggt  tctttttata  tttttatctc 
1381  caatttcctg  attttgttgt  tccccgcacc  gcccgcaatt  attgcctcgc  tccgtctcgc 
1441  agccggcgcg  ttggaggagc  cggtgagtgg  cggggctccg  ctttacccat  cactcgatcc 
1501  gccgcggtcg  ggctgacagc  gcggggccgc  gggaccgccg  gtgcctcccg  ggggacgcgg 
1561  cgctgctccg  ggcacggcgc  gccccatcct  tctccgtgct  ctcggcttgg  atatataatt 
1621  ctattttttg  gagggggggg  ggggggtggg  ggagggcaag  aagcatttgc  ttctccagcg 
1681  tacgcacggc  aggttatgct  tattgcacat  atatacgtat  atatatgtgc  gtgtgtggat 
1741  atatatgtat  atatgataaa  tttggcaaag  tttgcccagc  tccgtgcacg  gccaggtggg 
1801  tggctgggga  gcagcceggc  tctgcgctgg  gagctaccgg  cccttctcgc  ccggttcccg 
1861  gtgccggagc  tgggcaccgg  ctgagcgcgg  cggctgcggg  agctgtgccc  gagcggagcc 
1921  cctccggaga  gtcgcgggga  gagcgctccg  ggcgtccccg  ggcgctgacc  cctcgatgga 
1981  cggggtcgcg  actcccggtc  gcccgctgag  ctggggaggg  ggtgaggcgg  ggggctcacg 
2041  aggggtcgtg  ctttttatta  ttattattat  tttattatta  ttattagttt  atatatatat 
2101  atatatatat  aaatcaatct  gacggcgcgg  ggtgccggag  gagcgctgcg  tgccgagggt 
2161  cgatctcccc  cgctataggg  gccgggggga  gcgggcctcg  cggccccgag  cgcggctcac 
2221  ccggcccccc  cgtgtccccc  tcccgcccgc  aggcagcagc  cgccgcgatg  ccgctcagcg 
2281  ccagcctccc  cagcaagaac  tacgattacg  actacgactc  ggtgcagccc  tacttctact 
2341  tcgaggagga  ggaggagaac  ttctacctgg  cggcgcagca  gcggggcagc  gagctgcagc 
2401  ctcccgcccc  gtccgaggac  atctggaaga  agtttgagct  cctgcccacg  ccgcccctct 
2461  cgcccagccg  ccgctccagc  ctggccgccg  cctcctgctt  cccttccacc  gccgaccagc 
2521  tggagatggt  gacggagctg  ctcggggggg  acatggtcaa  ccagagcttc  atctgcgacc 
2581  cggacgacga  atccttcgtc  aaatccatca  tcatccagga  ctgcatgtgg  agcggcttct 
2641  ccgccgccgc  caagctggag  aaggtggtgt  cggagaagct  cgccacctac  caagcctccc 
2701  gccgggaggg  gggccccgcc  gccgcctccc  gacccggccc  gccgccctcg  gggccgccgc 
2761  ctcctcccgc  cggccccgcc  gcctcggccg  gcctctacct  gcacgacctg  ggagccgcgg 
2821  ccgccgactg  catcgacccc  tcggtggtct  tcccctaccc  gctcagcgag  cgcgccccgc 
2881  gggccgcccc  gcccggcgcc  aaccccgcgg  ctctgctggg  ggtcgacacg  ccgcccacga 
2941  ccagcagcga  ctcgggtgag  cggcgcccac  tcgtgtcggg  gacccgagcg  ttcctccttc 
3001  ccgctgctcg  cgggacctca  ccctgcttct  ccccccttgc  gcgcaccgct  ctgttaaatg 
3061  ccacgttagc  gaggcgctct  gcgagtttat  ttcctggaaa  agcagttttc  cctccaccct 
3121  tttggaggaa  aaaaaggagt  caaaagggga  aaaaaaaaaa  aaaaaaaaaa  agggagggag 
3181  ggagaaactt  tcataacggg  gtcagagcca  gaggtcccca  gcgcgggagc  ggagggagcg 
3241  cttcccggtg  acacccgagg  gtcgggaagg  ggttaactgc  agcccgagaa  ccgcggggag 
3301  aatgcgggcg  ggggaggtgc  cagtgaaagt  ggctgcgagg  agcgagtgaa  tgggactcgg 
3361  aaagttttag  aaatgcttcc  ttaggtattt  gacagcgtgt  tccgctcgct  cataaatttg 
3421  ggttgaaagc  gagttgctac  cttcgggttt  ctcagttttt  taaggttttt  tttttttttt 212 
3481 
, 
ctgcttagat  tttccacaaa  ttagcagatc  aagagagatt  gagaaaatgt  ctctgaatac 
3541  acatgtgtgt  taagtaagct  ttcttttgag  gcgtggccaa  agccttctaa  atccttaatt 
3601  aagggcagct  tgagtctggg  agctttattg  cgctgcgttg  ctgacagccg  aggttaaact 
3661  ttgctgctat  ctctgtgctc  gcagttacgc  aagagctgtg  caacttttga  aatcagggag 
3721  ccagagttcc  gagggcagtc  cttgaaacgc  tgcttcctta  agggaagggc  tcttgggtag 
3781  ggaatgggga  gtcttgcaga  gtcggatggt  ttgaaagtag  gtttgtcaat  gggttccttg 
3841  cttcgtggct  tggagtaacc  ccttgttggg  ctgtcctgag  agtttttgca  cagatcagct 
3901  catgatgcta  tttttttcct  gtgcagaaga  agaacaagaa  gaagatgagg  aaatcgatgt 
3961  cgttacatta  gctgaagcga  acgagtctga  atccagcaca  gagtccagca  cagaagcatc 
4021  agaggagcac  tgtaagcccc  accacagtcc  gctggtcctc  aagcggtgtc  acgtcaacat 
4081  ccaccaacac  aactacgctg  ctcctccctc  caccaaggtg  gaatacccag  ccgccaagag 
4141  gctaaagttg  gacagtggca  gggtcctcaa  acagatcagc  aacaaccgaa  aatgctccag 
4201  tccccgcacg  tcagactcag  aggagaacga  caagaggcga  acgcacaacg  tcttggagcg 
4261  ccagcgaagg  aatgagctga  agctgagttt  ctttgccctg  cgtgaccaga  tacccgaggt 
4321  ggccaacaac  gagaaggcgc  ccaaggttgt  catcctgaaa  aaagccacgg  agtacgttct 
4381  gtctatccaa  tcggacgagc  acagactaat  cgcagagaaa  gagcagttga  ggcggaggag 
4441  agaacagttg  aaacacaaac  ttgagcagct  aaggaactct  cgtgcatagg  aactcttgga 
4501  catcacttag  aataccccaa  actagactga  aactatgata  aaatattagt  gtttctaata 
4561  tcactcatga  actacatcag  tccattgagt  atggaactat  tgcaactgca  tgctgtgcga 
4621  cttaacttga  gactacacaa  ccttggccga  atctccgaac  ggtttggcca  gaacctcaaa 
4681  actgcctcat  aattgatact  ttgggcataa  gggatgatgg  gacattcttc  atgcttgggg 
4741  atgaactctt  caactttttt  tcttttaaaa  ttttgtattt  aaggcatttt  ttcttagcga 
4801  gaattccaaa  tagagttgtc  cccagattgc  tgtatatatt  tacacatctt  cttgccatgt 
4861  aaataccttt  aataaagtct  ttatagaaaa  atgtgcaaca  ttaatacaca  gcagttgtgg 
4921  gaactggatt  tatacttgtc  ttgaacttgt  gtgccataac  atttcacagt  tttgtttttt 
4981  attt 213 
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